title,url,time_published,summary,ticker,relevance_score,ticker_sentiment_score,ticker_sentiment_label
Eisai files for approval of Alzheimer's drug in Europe,https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-files-approval-alzheimers-drug-europe-2023-01-10/,2023-01-10 23:46:00,"Jan 10 ( Reuters ) - Japanese drugmaker Eisai Co Ltd ( 4523.T ) said on Tuesday it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States.",BIIB,0.327366,-0.121403,Neutral
FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer's Drug Aduhelm,https://www.wsj.com/articles/fda-commissioner-denies-wrongdoing-in-approval-process-for-biogen-alzheimers-drug-aduhelm-11673385441,2023-01-10 21:48:00,Robert Califf acknowledged the agency made mistakes when it failed to properly document interactions with the company.,BIIB,0.250386,0.077397,Neutral
Globant acquired Vertic to consolidate its digital marketing global network and start operations in Denmark,https://www.prnewswire.com/news-releases/globant-acquired-vertic-to-consolidate-its-digital-marketing-global-network-and-start-operations-in-denmark-301718075.html,2023-01-10 16:38:00,Globant acquired Vertic to consolidate its digital marketing global ... PR ...,BIIB,0.045482,0.075662,Neutral
Globant acquired Vertic to consolidate its digital marketing global network and start operations in Denmark,https://www.prnewswire.com/news-releases/globant-acquired-vertic-to-consolidate-its-digital-marketing-global-network-and-start-operations-in-denmark-301718062.html,2023-01-10 16:21:00,Globant acquired Vertic to consolidate its digital marketing global ... PR ...,BIIB,0.045482,0.075662,Neutral
Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day,https://www.zacks.com/stock/news/2037184/campbell-soup-and-eli-lilly-have-been-highlighted-as-zacks-bull-and-bear-of-the-day,2023-01-10 13:27:00,"Chicago, IL - January 10, 2023 - Zacks Equity Research shares Campbell Soup Company ( CPB Quick QuoteCPB - ) as the Bull of the Day and Eli Lilly & Co. ( LLY Quick QuoteLLY - ) as the Bear of the Day.",BIIB,0.030543,-0.034821,Neutral
McDonald's Former C.E.O. Pays for a Workplace Scandal,https://www.nytimes.com/2023/01/10/business/dealbook/mcdonalds-ceo-sec-firing.html,2023-01-10 13:24:24,The Securities and Exchange Commission fined Steve Easterbrook for lack of disclosure about the circumstances behind his firing in 2019.,BIIB,0.016249,0.28449,Somewhat-Bullish
Bear of the Day: Eli Lilly  ( LLY ) ,https://www.zacks.com/commentary/2037063/bear-of-the-day-eli-lilly-lly,2023-01-10 11:20:00,Guidance for this year drags down analyst EPS estimates by nearly 10% to just 9% growth ...,BIIB,0.122581,0.033023,Neutral
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?,https://www.fool.com/investing/2023/01/10/should-you-buy-biogen-stock-after-its-alzheimers-d/,2023-01-10 10:55:00,There's more to the story with Biogen after receiving good news for Leqembi.,BIIB,0.545618,0.317131,Somewhat-Bullish
New Alzheimer's drug may have limited real-world impact,https://www.axios.com/2023/01/10/alzheimers-drug-patients-doctors-tradeoffs,2023-01-10 10:30:38,"Leqembi, a new Alzheimer's drug developed by Eisai and Biogen, may have passed muster with the FDA last week, but experts say it's still an open question how much it will improve the quality of patients' lives.",BIIB,0.059488,0.096999,Neutral
"Most Alzheimer's patients would pay up to $26,500 per year for new treatment Leqembi",https://www.cnbc.com/2023/01/09/most-alzheimers-patients-would-pay-up-to-26500-per-year-for-leqembi.html,2023-01-09 23:46:55,Most seniors who are eligible for the treatment will have to pay for it out of pocket because Medicare has limited coverage to people participating in studies.,BIIB,0.075635,0.013427,Neutral
Biogen Inc.  ( BIIB )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2037053/biogen-inc-biib-dips-more-than-broader-markets-what-you-should-know,2023-01-09 23:15:20,"Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day.",BIIB,0.587962,0.189375,Somewhat-Bullish
Eli Lilly has spent years and billions of dollars in search of an effective Alzheimer's drug. But success is not all or nothing for the stock,https://www.cnbc.com/2023/01/09/eli-lilly-search-for-effective-alzheimers-drug-may-be-close-to-success.html,2023-01-09 21:29:46,Eli Lilly's latest Alzheimer's drug may be next to receive FDA approval. But investors should know about some of the hurdles ahead.,BIIB,0.29234,0.656843,Bullish
"Investors Look to Steer Friday's Rally Around Expected Q4 Earnings Headwinds - Citigroup  ( NYSE:C ) , Bank of America  ( NYSE:BAC ) ",https://www.benzinga.com/markets/23/01/30337651/investors-look-to-steer-fridays-rally-around-expected-q4-earnings-headwinds,2023-01-09 17:36:59,( Monday Market Open ) Investors kept Friday's jobs rally rolling this morning despite warning signs that Q4 earnings season could be anything but a party. Major stock futures indexes were all up slightly.,BIIB,0.104797,0.089878,Neutral
6 Favorite Biotech Bets For 2023,https://www.forbes.com/sites/moneyshow/2023/01/09/6-favorite-biotech-bets-for-2023/,2023-01-09 15:48:07,"Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception. here's a six-pack of favorite biotech ideas for the coming year.",BIIB,0.020266,0.006596,Neutral
"Biogen  ( BIIB ) , Eisai's Lecanemab Gets FDA Nod for Alzheimer's",https://www.zacks.com/stock/news/2036807/biogen-biib-eisais-lecanemab-gets-fda-nod-for-alzheimers,2023-01-09 15:04:00,FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.,BIIB,0.29234,0.102134,Neutral
The FDA Approved The New Anti-Alzheimer's Drug Leqembi. What You Need To Know,https://www.forbes.com/sites/howardgleckman/2023/01/09/the-fda-approved-the-new-anti-alzheimers-drug-leqembi-what-you-need-to-know/,2023-01-09 15:01:21,A trial found the drug slowed the progression of early-stage Alzheimer's Disease.,BIIB,0.047749,0.10863,Neutral
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis' Genetic Medicines and Commercial Readiness,https://www.globenewswire.com/news-release/2023/01/09/2585361/0/en/Royalty-Pharma-and-Ionis-Enter-Into-Royalty-Agreement-for-Up-to-1-1-Billion-to-Further-Advance-Ionis-Genetic-Medicines-and-Commercial-Readiness.html,2023-01-09 14:15:00,"NEW YORK and CARLSBAD, Calif., Jan. 09, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) and Ionis Pharmaceuticals, Inc. ( Nasdaq: IONS ) today announced that Royalty Pharma has acquired an interest in Ionis' royalty in Biogen's SPINRAZAÂ® ( nusinersen ) and Novartis' pelacarsen for ...",BIIB,0.061263,0.120206,Neutral
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness,https://www.prnewswire.com/news-releases/ionis-and-royalty-pharma-enter-into-royalty-agreement-for-up-to-1-1-billion-to-further-advance-ionis-genetic-medicines-and-commercial-readiness-301716470.html,2023-01-09 14:05:00,Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 ... PR ...,BIIB,0.061684,0.120235,Neutral
"Eisai, Biogen's Alzheimer's drug price should not dent demand, analysts say",https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-biogens-alzheimers-drug-price-should-not-dent-demand-analysts-2023-01-09/,2023-01-09 13:19:00,"Eisai, Biogen's Alzheimer's drug price should not dent demand ... ...",BIIB,0.241684,0.37366,Bullish
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases - Denali Therapeutics  ( NASDAQ:DNLI ) ,https://www.benzinga.com/pressreleases/23/01/g30331041/denali-therapeutics-announces-key-anticipated-2023-milestones-for-its-therapeutic-portfolio-for-ne,2023-01-09 13:00:44,"Four programs expected to progress in late-stage clinical studies for MPS II ( Hunter syndrome ) , ALS, and Parkinson's disease",BIIB,0.047607,0.035893,Neutral
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases,https://www.globenewswire.com/news-release/2023/01/09/2585204/0/en/Denali-Therapeutics-Announces-Key-Anticipated-2023-Milestones-for-Its-Therapeutic-Portfolio-for-Neurodegeneration-and-Lysosomal-Storage-Diseases.html,2023-01-09 13:00:00,"SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 ( GLOBE NEWSWIRE ) -- Denali Therapeutics Inc. ( Nasdaq: DNLI ) , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ( BBB ) for neurodegenerative diseases and lysosomal storage ...",BIIB,0.0484,0.035921,Neutral
"Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill - Berkshire Hathaway Inc. Common Stock  ( NYSE:BRK/A ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/large-cap/23/01/30322685/barrons-top-weekend-stock-picks-tesla-snowflake-delta-and-why-warren-buffetts-berkshire-hathaway-m,2023-01-07 23:31:08,"Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read. In ""Tech's Bill Is Coming Due.",BIIB,0.227007,0.274386,Somewhat-Bullish
EXPLAINER: New drug slows Alzheimer's but comes with caveats,https://apnews.com/article/health-medication-b42dc8b32d71f1b6892b07d85e0e7da0,2023-01-07 14:14:29,"EXPLAINER: New drug slows Alzheimer's but comes with caveats This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimer's drug that modestly slows the ...",BIIB,0.040011,0.063949,Neutral
New Alzheimer's Drug Leqembi Will Be Out of Reach for Most Patients,https://www.wsj.com/articles/new-alzheimers-drug-leqembi-will-be-out-of-reach-for-most-patients-11673055252,2023-01-07 14:00:00,Medicare won't pay for the drug unless patients are enrolled in government-sanctioned trials-and no such studies are under way or planned.,BIIB,0.401331,0.0845,Neutral
Eisai Submits SBLA To FDA For Traditional Approval Of Leqembi For Alzheimer's Disease Treatment,https://markets.businessinsider.com/news/stocks/eisai-submits-sbla-to-fda-for-traditional-approval-of-leqembi-for-alzheimer-s-disease-treatment-1032005249,2023-01-07 04:52:28,"( RTTNews ) - Eisai has submitted a supplemental biologics license application to the U.S. Food and Drug Administration for traditional approval of leqembi ( lecanemab-irmb ) for the treatment of alzheimer's disease, Eisai Co., Ltd. and Biogen Inc. ( BIIB ) said in a statement on Friday.",BIIB,0.678673,0.538344,Bullish
FDA Approves Eisai And Biogen's Leqembi For Alzheimer's Disease Treatment,https://markets.businessinsider.com/news/stocks/fda-approves-eisai-and-biogen-s-leqembi-for-alzheimer-s-disease-treatment-1032005248,2023-01-07 04:31:17,"( RTTNews ) - The U.S. Food and Drug Administration approved Eisai Co., Ltd. and Biogen Inc.'s ( BIIB ) Leqembi ( lecanemab-irmb ) via the Accelerated Approval pathway for the treatment of Alzheimer's disease.",BIIB,0.338582,0.429004,Bullish
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBIâ¢  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease,https://markets.businessinsider.com/news/stocks/eisai-submits-supplemental-biologics-license-application-to-fda-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimer-s-disease-1032005246,2023-01-07 04:30:00,Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBIâ¢ (lecanemab-irmb) for the Treatment of Alzheimer's Disease ...,BIIB,0.208096,0.076295,Neutral
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBIâ¢  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease,https://www.prnewswire.com/news-releases/eisai-submits-supplemental-biologics-license-application-to-fda-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease-301715905.html,2023-01-07 04:30:00,Eisai Submits Supplemental Biologics License Application to FDA ... PR ...,BIIB,0.19661,0.076224,Neutral
"US Market closes on upbeat note as jobs, services data calm rate hike concerns",https://www.business-standard.com/article/news-cm/us-market-closes-on-upbeat-note-as-jobs-services-data-calm-rate-hike-concerns-123010700124_1.html,2023-01-07 03:32:00,"US Market closes on upbeat note as jobs, services data calm rate ... Business Standard ...",BIIB,0.116914,0.008523,Neutral
"Wall St rallies as jobs, services data calm rate hike worries",https://www.moneycontrol.com/news/business/markets/wall-st-rallies-as-jobs-services-data-calm-rate-hike-worries-9824601.html,2023-01-07 02:58:14,"The Dow Jones Industrial Average rose 700.53 points, or 2.13%, to 33,630.61. the SP 500 gained 86.98 points, or 2.28%, at 3,895.08. and the Nasdaq Composite added 264.05 points, or 2.56%, at 10,569.29.",BIIB,0.104455,0.168424,Somewhat-Bullish
AbbVie cuts earnings forecast due to milestone payments,https://www.marketwatch.com/story/abbvie-cuts-earnings-forecast-due-to-milestone-payments-11673048665,2023-01-06 23:52:00,AbbVie Inc. lowered its outlook for the quarter and year late Friday for research and development expenses and milestone payments to partners.,BIIB,0.132368,0.096377,Neutral
Factbox: Who can get the newly approved Eisai and Biogen Alzheimer's drug?,https://www.reuters.com/business/healthcare-pharmaceuticals/who-can-get-newly-approved-eisai-biogen-alzheimers-drug-2023-01-06/,2023-01-06 22:39:00,Factbox: Who can get the newly approved Eisai and Biogen ... ...,BIIB,0.081001,-0.019696,Neutral
"FDA approves Biogen, Eisai Alzheimer's drug",https://www.foxbusiness.com/markets/fda-approves-biogen-eisai-alzheimers-drug,2023-01-06 22:33:08,"An Alzheimer's drug from Biogen and Eisai has received accelerated approval from the Food and Drug Administration ( FDA ) , the companies and agency announced Friday.",BIIB,0.211806,0.153885,Somewhat-Bullish
"Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer",https://www.prnewswire.com/news-releases/intergalactic-therapeutics-appoints-theresa-gh-heah-md-mba-as-chief-executive-officer-301715778.html,2023-01-06 22:00:00,"Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A. ... PR ...",BIIB,0.047278,0.023588,Neutral
"Dow Jones Rallies On This; Tesla Stock Fights Back, Elon Musk Jokes; WWE Stock 'Gorilla Presses' Higher",https://www.investors.com/market-trend/stock-market-today/dow-jones-rallies-on-this-tesla-stock-fights-back-elon-musk-jokes-wwe-stock-vince-mcmahon-return-world-wrestling-entertainment/,2023-01-06 21:22:00,"Dow Jones Rallies On This. Tesla Stock Fights Back, Elon Musk ... Investor's Business Daily ...",BIIB,0.08282,0.138102,Neutral
US Approves New Drug To Treat Alzheimer's Disease,https://www.barrons.com/news/us-approves-new-drug-totreat-alzheimer-s-01673037009,2023-01-06 20:31:05,US Approves New Drug To Treat ...,BIIB,0.25168,0.181702,Somewhat-Bullish
Why Longeveron  ( LGVN )  Shares Are Trading Higher Today - Longeveron  ( NASDAQ:LGVN ) ,https://www.benzinga.com/markets/penny-stocks/23/01/30316507/longeveron-shares-surge-following-fda-decision-on-biogen-alzheimers-drug,2023-01-06 20:17:32,Shares of Longeveron LGVN are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen BIIB's Leqembi. The FDA on Friday granted approval to Biogen and Eisai's Leqembi via the Accelerated Approval pathway for the treatment of ...,BIIB,0.504646,0.785617,Bullish
"Afternoon update: Soft-landing market rally, Alzheimer's drug approval, time to sell a winner",https://www.cnbc.com/2023/01/06/soft-landing-market-rally-alzheimers-drug-approval-time-to-sell-a-winner.html,2023-01-06 20:05:16,"""The Homestretch,"" exclusively for Club members, helps get you ready for the final hour of trading on Wall Street. We hit all the big stories and look ahead to next week.",BIIB,0.080188,0.107413,Neutral
"New Alzheimer's Drug Approved by FDA, Promises to Slow Disease",https://www.wsj.com/articles/new-alzheimers-drug-approved-by-fda-promises-to-slow-disease-11673032312,2023-01-06 20:02:00,Eisai and Biogen's Leqembi is the first drug to show that reducing a protein linked to Alzheimer's helped patients.,BIIB,0.345674,0.212385,Somewhat-Bullish
"SAVA, LLY, IBB: Why The Alzheimer's Related Stocks Are Volatile On Friday - Eli Lilly  ( NYSE:LLY ) , Biogen  ( NASDAQ:BIIB ) , Cassava Sciences  ( NASDAQ:SAVA ) ",https://www.benzinga.com/general/biotech/23/01/30316142/sava-lly-ibb-why-the-alzheimers-related-stocks-are-volatile-on-friday,2023-01-06 19:47:16,"Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. SAVA and Eli Lilly And Company LLY, spiked on Friday after the FDA granted accelerated approval to Biogen BIIB's Leqembi.",BIIB,0.59972,0.609124,Bullish
FDA approves treatment for people with mild forms of Alzheimer's,https://www.marketwatch.com/story/fda-approves-treatment-for-people-with-mild-forms-of-alzheimers-11673034098,2023-01-06 19:47:00,"Leqembi, which was developed by Eisai and Biogen, will cost about $26,000 a year ...",BIIB,0.488777,0.352696,Bullish
FDA Approves Eisai and Biogen's New Alzheimer's Therapy,https://www.barrons.com/articles/fda-eisai-biogen-lecanemab-alzheimer-drug-51673032642,2023-01-06 19:37:00,"The Food and Drug Administration on Friday approved Eisai and Biogen's Alzheimer's treatment lecanemab, clearing the way for the drug to be prescribed to patients and opening what will likely be a long debate over whether Medicare will pay for it.",BIIB,0.7887,0.272202,Somewhat-Bullish
"Why Biogen  ( BIIB )  Stock Is Gaining Today - Eisai Co  ( OTC:ESALY ) , Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/01/30316003/fda-approves-biogens-second-alzheimers-treatment-under-accelerated-pathway,2023-01-06 19:35:27,"The FDA has approved Biogen Inc's BIIB second Alzheimer's disease treatment, Leqembi ( lecanemab-irmb ) via the Accelerated Approval pathway. Leqembi is the second of a new category of medications approved for Alzheimer's disease that target the fundamental pathophysiology of the disease.",BIIB,0.43852,0.505086,Bullish
FDA Approves LEQEMBIâ¢  ( lecanemab-irmb )  Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease,https://www.prnewswire.com/news-releases/fda-approves-leqembi-lecanemab-irmb-under-the-accelerated-approval-pathway-for-the-treatment-of-alzheimers-disease-301715691.html,2023-01-06 19:30:00,FDA Approves LEQEMBIâ¢ ( lecanemab-irmb ) Under the ... PR ...,BIIB,0.169887,0.078491,Neutral
FDA grants fast-track approval to experimental Alzheimer's drug,https://www.axios.com/2023/01/06/fda-accelerated-approval-lecanemab-alzheimers,2023-01-06 19:26:10,The Food and Drug Administration on Friday granted fast-track approval to a new Alzheimer's drug that clinical trials showed can slow the progression of the disease.,BIIB,0.109956,-0.018277,Neutral
US approves Alzheimer's drug that modestly slows disease,https://apnews.com/article/health-medication-us-food-and-drug-administration-business-d2a155172735e00d2aa7baaeb8c24a9b,2023-01-06 19:18:32,Alzheimer's drug that modestly slows disease OK'd by FDA The Associated Press - en ...,BIIB,0.095771,-0.05185,Neutral
US approves Alzheimer's drug that modestly slows disease,https://apnews.com/article/health-medication-us-food-and-drug-administration-business-d2a155172735e00d2aa7baaeb8c24a9b,2023-01-06 19:18:32,Alzheimer's drug that modestly slows disease OK'd by FDA The Associated Press - en ...,BIIB,0.09245,-0.051342,Neutral
Alzheimer's drug that modestly slows disease OK'd by FDA,https://apnews.com/article/health-medication-us-food-and-drug-administration-business-d2a155172735e00d2aa7baaeb8c24a9b,2023-01-06 19:18:32,"WASHINGTON ( AP ) - U.S. health officials on Friday approved a closely watched Alzheimer's drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh.",BIIB,0.107978,-0.015938,Neutral
"U.S. FDA approves Eisai, Biogen's Alzheimer's drug",https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-eisai-biogens-alzheimers-drug-2023-01-06/,2023-01-06 19:18:00,"[1/2] The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato Jan 6 ( Reuters ) - The U.S.",BIIB,0.222838,0.124397,Neutral
FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial,https://www.cnbc.com/2023/01/06/alzheimers-disease-fda-decision-on-biogen-eisai-treatment-lecanemab.html,2023-01-06 19:10:09,The FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer's.,BIIB,0.169378,0.052516,Neutral
The Deal Worth Millions That Helped AbbVie Stock Briefly Break Out,https://www.investors.com/news/technology/abbvie-stock-briefly-breaks-out-on-a-new-cancer-deal/,2023-01-06 18:45:00,AbbVie Stock Briefly Breaks Out On A New $30 Million Cancer Deal ... Investor's Business Daily ...,BIIB,0.122269,-0.040195,Neutral
BIIB: 3 Value Stocks Worth Your Attention in 2023,https://stocknews.com/news/biib-dow-aci-3-value-stocks-worth-your-attention-in-2023/,2023-01-06 17:12:16,BIIB: 3 Value Stocks Worth Your Attention in ...,BIIB,0.362065,0.246849,Somewhat-Bullish
FDA Mulls Biogen's Second Alzheimer's Drug; Will Medicare Bite?,https://www.investors.com/news/technology/biogen-stock-fda-mulls-alzheimers-treatment-but-will-medicare-bite/,2023-01-06 15:41:00,"Biogen Stock: FDA Mulls Alzheimer's Treatment, But Will Medicare ... Investor's Business Daily ...",BIIB,0.595343,0.522652,Bullish
"1 Stock Defying the Downturn to Buy, and 1 to Avoid",https://www.fool.com/investing/2023/01/06/1-stock-defying-the-downturn-to-buy-and-1-to-avoid/,2023-01-06 14:53:00,These two stocks might go in different directions in the future.,BIIB,0.377958,0.0,Neutral
"CRISPR, Genetics And AI - Why 2023 Could Be Biotech's Year",https://www.investors.com/news/technology/biotech-stocks-how-crispr-genetics-and-ai-could-drive-a-2023-inflection/,2023-01-06 13:00:00,"Biotech Stocks: How CRISPR, Genetics And AI Could Drive A 2023 ... Investor's Business Daily ...",BIIB,0.07031,0.0,Neutral
Should iShares Morningstar MidCap Value ETF  ( IMCV )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2036057/should-ishares-morningstar-midcap-value-etf-imcv-be-on-your-investing-radar,2023-01-06 11:20:05,Style Box ETF report for ...,BIIB,0.120733,0.067941,Neutral
2023 could be a banner year for prescription drugs,https://www.axios.com/2023/01/06/prescription-drugs-alzheimers-obesity-health-costs,2023-01-06 10:30:11,A group of pricey breakthrough prescription drugs are poised to shake up the market this year - including an Alzheimer's treatment that could be approved today by the FDA.,BIIB,0.036532,0.009703,Neutral
Biogen  ( BIIB )  Inks Licensing Deal for Implantable Medical Device,https://www.zacks.com/stock/news/2035910/biogen-biib-inks-licensing-deal-for-implantable-medical-device,2023-01-05 19:14:00,Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.,BIIB,0.766141,0.275973,Somewhat-Bullish
Biogen splits R&D division ahead of key decision on Alzheimer's drug,https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-splits-rd-division-ahead-key-decision-alzheimers-drug-2023-01-05/,2023-01-05 13:18:00,Jan 5 ( Reuters ) - Biogen Inc ( BIIB.O ) said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug.,BIIB,0.451494,-0.032287,Neutral
"Biogen Names Priya Singhal as Executive Vice President, Head of Development - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/pressreleases/23/01/g30291349/biogen-names-priya-singhal-as-executive-vice-president-head-of-development,2023-01-05 12:30:00,"CAMBRIDGE, Mass., Jan. 05, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc.",BIIB,0.3986,0.201283,Somewhat-Bullish
Eisai Alzheimer's drug and clot buster seen as cause of brain hemorrhage death -analysis,https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-alzheimers-drug-clot-buster-seen-cause-brain-hemorrhage-death-analysis-2023-01-04/,2023-01-04 22:03:00,Eisai Alzheimer's drug and clot buster seen as cause of brain ... ...,BIIB,0.091509,-0.106102,Neutral
"Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies - Ionis Pharmaceuticals  ( NASDAQ:IONS ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/pressreleases/23/01/g30271378/biogen-and-alcyone-therapeutics-announce-license-and-collaboration-agreement-to-evaluate-a-novel-d,2023-01-04 12:30:00,"Alcyone's ThecaFlex DRxâ¢ System is an implantable medical device in development for intrathecal drug delivery CAMBRIDGE, Mass. and LOWELL, Mass., Jan. 04, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc.",BIIB,0.310004,0.2459,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2034871/biogen-inc-biib-dips-more-than-broader-markets-what-you-should-know,2023-01-03 23:00:19,"Biogen Inc. (BIIB) closed at $272.63 in the latest trading session, marking a -1.55% move from the prior day.",BIIB,0.640349,0.257249,Somewhat-Bullish
"Amid criticism for its handling of another Alzheimer's drug, FDA will decide this week whether to approve lecanemab",https://www.marketwatch.com/story/amid-criticism-for-its-handling-of-another-alzheimers-drug-fda-will-decide-this-week-whether-to-approve-lecanemab-11672775250,2023-01-03 19:47:00,A damning new congressional report found the regulator didn't follow the correct procedures when it approved Aduhelm in ...,BIIB,0.368773,0.135696,Neutral
"How Two Key Question In 2023 Could Spark, Or Slam, This Pharma",https://www.investors.com/research/ibd-stock-of-the-day/lly-stock-the-key-issues-in-2023-that-could-spark-or-topple-shares/,2023-01-03 17:45:00,"LLY Stock: The Key Issues In 2023 That Could Spark, Or Topple ... Investor's Business Daily ...",BIIB,0.226477,0.040827,Neutral
The FDA's Next Call on an Alzheimer's Drug Is Due This Week,https://www.barrons.com/articles/biogen-fda-alzheimer-decision-51672767410,2023-01-03 17:37:00,FDA's Call on Biogen and Eisai's New Alzheimer's Drug Is Due This Week ...,BIIB,0.674691,-0.481793,Bearish
FDA decision on experimental Alzheimer's drug expected this week,https://www.cnn.com/2023/01/02/health/lecanemab-fda-decision-expected/index.html,2023-01-02 11:21:00,"The US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental dementia drug lecanemab, according to Eisai and Biogen, the companies that make the drug.",BIIB,0.041901,0.153948,Somewhat-Bullish
BIIB: Sitting on Cash? These 3 Stocks Are Great Buys Right Now,https://stocknews.com/news/biib-an-asix-sitting-on-cash-these-3-stocks-are-great-buys-right/,2023-01-20 19:35:42,"The stock market ended 2022 as the worst year since the 2008 economic meltdown, with the Fed launching four consecutive 75-basis-point rate increases in 2022 before wrapping the year with a slightly lower 50-basis-point rate hike.",BIIB,0.381128,0.343928,Somewhat-Bullish
"FDA rejects Lilly's alzheimer's drug candidate, seeks more data",https://www.foxbusiness.com/healthcare/fda-rejects-lillys-alzheimers-drug-candidate-seeks-more-data,2023-01-20 19:07:53,"U.S. drug regulators rejected Eli Lilly & Co.'s proposed new Alzheimer's disease treatment, saying they need more data from clinical testing, according to the company.",BIIB,0.056143,0.203976,Somewhat-Bullish
FDA Rejects Accelerated Nod to Lilly's  ( LLY )  Alzheimer's Drug,https://www.zacks.com/stock/news/2042167/fda-rejects-accelerated-nod-to-lillys-lly-alzheimers-drug,2023-01-20 17:52:00,"The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.",BIIB,0.30021,0.216889,Somewhat-Bullish
Lilly Dives After FDA Delivers A Blow To Its Alzheimer's Drug,https://www.investors.com/news/technology/eli-lilly-stock-dips-after-fda-stuns-with-an-alzheimers-treatment-rejection/,2023-01-20 14:58:00,Eli Lilly Stock Dips After FDA Stuns With An Alzheimer's Treatment ... Investor's Business Daily ...,BIIB,0.452639,0.243543,Somewhat-Bullish
Why the FDA didn't grant an approval to Lilly's Alzheimer's drug,https://www.marketwatch.com/story/why-the-fda-didnt-grant-an-approval-to-lillys-alzheimers-drug-11674224605,2023-01-20 14:23:00,The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year ...,BIIB,0.199584,0.219581,Somewhat-Bullish
Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-alzheimers-drug-setback-extends-rival-biogens-lead-analysts-2023-01-20/,2023-01-20 12:29:00,"Jan 20 ( Reuters ) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said. The U.S.",BIIB,0.244109,0.225119,Somewhat-Bullish
"Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss",https://www.benzinga.com/news/earnings/23/01/30498229/tech-stocks-get-netflix-boost-amid-jittery-wider-market-on-friday-dow-stares-at-4th-straight-loss,2023-01-20 11:30:03,"U.S. stocks look set for a positive start on Friday, reversing course from the sell-off seen in the past three sessions. What Happened: Traders may have to contend with Fed speeches and housing market data, which could provide direction to the market.",BIIB,0.114956,0.05194,Neutral
Eli Lilly Stock Slips Lower As FDA Rejects Fast Track Approval For Alzheimer's Drug,https://www.thestreet.com/markets/eli-lilly-stock-slips-as-fda-rejects-quick-ok-for-alzheimers-drug,2023-01-20 10:34:00,"""We are committed to working with the FDA to ensure the fastest possible path to bring this potential medicine to patients in need,"" Eli Lilly said.",BIIB,0.185306,0.025239,Neutral
Why Eli Lilly  ( LLY )  Shares Are Trading Lower Today,https://www.benzinga.com/general/biotech/23/01/30497466/fda-rejects-eli-lillys-donanemab-for-alzheimers-disease-needs-more-data,2023-01-20 10:22:17,The FDA issued a complete response letter for the accelerated approval submission of Eli Lilly And Co's LLY donanemab for early symptomatic Alzheimer's disease due to the limited number of patients with at least 12 months of drug exposure data provided in the submission.,BIIB,0.329551,0.622277,Bullish
Futures: Market Rally Breaks Key Levels,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-netflix-jumps-on-subscribers-after-market-rally-breaks-key-levels/,2023-01-19 23:39:00,"Dow Jones Futures Rise, Netflix Jumps On Subscribers After Market ... Investor's Business Daily ...",BIIB,0.051386,0.010045,Neutral
Biogen Inc.  ( BIIB )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2041678/biogen-inc-biib-dips-more-than-broader-markets-what-you-should-know,2023-01-19 23:15:25,"Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session.",BIIB,0.686288,0.145975,Neutral
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today,https://www.benzinga.com/news/earnings/23/01/30491207/100-invested-in-biogen-20-years-ago-would-be-worth-this-much-today,2023-01-19 20:03:47,"Biogen BIIB has outperformed the market over the past 20 years by 4.04% on an annualized basis producing an average annual return of 11.92%. Currently, Biogen has a market capitalization of $40.62 billion.",BIIB,0.983605,0.387251,Bullish
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval,https://www.fool.com/investing/2023/01/19/why-biogens-stock-isnt-soaring-since-its-alzheimer/,2023-01-19 14:20:00,The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.,BIIB,0.465901,0.239075,Somewhat-Bullish
"Outlook TherapeuticsÂ® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence",https://www.globenewswire.com/news-release/2023/01/19/2591759/0/en/Outlook-Therapeutics-Strengthens-Medical-Affairs-and-Commercial-Expertise-with-Appointments-of-Surendra-Sharma-MD-Senior-Vice-President-of-Medical-Affairs-and-Glen-Olsheim-Executiv.html,2023-01-19 13:05:00,Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry from their various roles launching and commercializing ophthalmic products Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global ...,BIIB,0.029078,0.07201,Neutral
"If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today",https://www.fool.com/investing/2023/01/19/if-invested-25000-biogen-2018-how-much-today/,2023-01-19 10:25:00,"The stock hasn't been a great investment in recent years, but there's hope for a brighter future.",BIIB,0.444919,0.307014,Somewhat-Bullish
"Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen",https://www.benzinga.com/general/biotech/23/01/30462022/neurodegenerative-diseases-focused-company-goes-public-via-wilbur-ross-backed-spac-joins-alzheime,2023-01-18 15:10:09,"Neurodegenerative diseases-focused Aprinoia Therapeutics has announced a business combination with Ross Acquisition Corp II ROSS, a special-purpose acquisition company founded by former Commerce Secretary Wilbur Ross, at an equity value of $280 million.",BIIB,0.241684,0.372014,Bullish
3 Biotech Stocks Under $15 Worth a Second Look in 2023,https://www.fool.com/investing/2023/01/18/3-biotech-stocks-under-15-worth-look-in-2023/,2023-01-18 13:00:00,All three stocks have promising therapies that could drive revenue in the coming years.,BIIB,0.092569,0.044321,Neutral
"Stablix Appoints Douglas Williams, Ph.D., to Board of Directors",https://www.benzinga.com/pressreleases/23/01/g30458105/stablix-appoints-douglas-williams-ph-d-to-board-of-directors,2023-01-18 12:00:47,"NEW YORK, Jan. 18, 2023 ( GLOBE NEWSWIRE ) -- Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization ( TPS ) as a novel therapeutic modality, today announced the appointment of Douglas E. Williams, Ph.D. to its Board of Directors.",BIIB,0.063425,-0.038049,Neutral
APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases,https://www.prnewswire.com/news-releases/aprinoia-therapeutics-and-ross-acquisition-corp-ii-announce-business-combination-agreement-to-create-publicly-listed-company-focused-on-neurodegenerative-diseases-301724108.html,2023-01-18 11:50:00,APRINOIA Therapeutics and ROSS Acquisition Corp II Announce ... PR ...,BIIB,0.014462,0.111884,Neutral
APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases,https://www.benzinga.com/pressreleases/23/01/n30457858/aprinoia-therapeutics-and-ross-acquisition-corp-ii-announce-business-combination-agreement-to-crea,2023-01-18 11:50:00,"ROSS SPAC will issue $280 million of stock for APRINOIA Therapeutics Precision Neurology Company Focused on Developing a Pipeline of Highly Specific Central Nervous System ( ""CNS"" ) Diagnostics and Therapeutics, including CNS Protein Degraders",BIIB,0.014401,0.110941,Neutral
VRTX: The No. 1 Biotech Stock to Buy for 2023,https://stocknews.com/news/vrtx-gild-biib-uthr-the-no-1-biotech-stock-to-buy-for-2023/,2023-01-17 14:02:08,VRTX: The No. 1 Biotech Stock to Buy for ...,BIIB,0.083107,0.09299,Neutral
CMCSA: 3 Nasdaq Stocks You'll Regret Not Buying This Year,https://stocknews.com/news/cmcsa-hon-biib-3-nasdaq-stocks-youll-regret-not-buying-this-year/,2023-01-17 13:06:35,"Last year, macroeconomic uncertainties kept the stock market under pressure. Furthermore, tech stocks bore the brunt of the market sell-off, which led to the tech-heavy Nasdaq Composite to decline over 25% over the past year. However, inflation has come down significantly from its peak.",BIIB,0.289234,0.245635,Somewhat-Bullish
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich,https://www.fool.com/investing/2023/01/17/monumental-breakthrough-turn-the-world-upside-down/,2023-01-17 10:55:00,The fountain of youth might not be a myth in the future.,BIIB,0.090989,0.192995,Somewhat-Bullish
Leqembi's prospects in Alzheimer's disease market remain uncertain despite its advantages over Aduhelm: GlobalData | The Financial Express,https://www.financialexpress.com/healthcare/pharma-healthcare/leqembis-prospects-in-alzheimers-disease-market-remain-uncertain-despite-its-advantages-over-aduhelm-globaldata/2950678/,2023-01-17 05:49:51,Leqembi's prospects in Alzheimer's disease market remain uncertain despite its advantages over Aduhelm: GlobalData The Financial Express ...,BIIB,0.079392,0.216116,Somewhat-Bullish
Biogen  ( BIIB )  Partner Eisai Seeks Nod for Lecanemab in Japan,https://www.zacks.com/stock/news/2039800/biogen-biib-partner-eisai-seeks-nod-for-lecanemab-in-japan,2023-01-16 17:33:00,Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.,BIIB,0.394125,0.181589,Somewhat-Bullish
Eisai files for approval of Alzheimer's drug in Japan,https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-files-approval-alzheimers-drug-japan-2023-01-16/,2023-01-16 01:19:00,"Jan 16 ( Reuters ) - Japanese drugmaker Eisai Co Ltd ( 4523.T ) said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States.",BIIB,0.235823,-0.093215,Neutral
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN,https://www.prnewswire.com/news-releases/eisai-files-marketing-authorization-application-for-anti-amyloid-beta-protofibril-antibody-lecanemab-for-early-alzheimers-disease-in-japan-301721956.html,2023-01-16 00:30:00,EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ... PR ...,BIIB,0.140719,0.034266,Neutral
Prothena  ( PRTA )  Stock Gains 88.5% in 6 Months: What Lies Ahead?,https://www.zacks.com/stock/news/2039265/prothena-prta-stock-gains-885-in-6-months-what-lies-ahead,2023-01-13 19:47:00,Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.,BIIB,0.152983,0.028181,Neutral
Biogen Inc.  ( BIIB )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2038744/biogen-inc-biib-outpaces-stock-market-gains-what-you-should-know,2023-01-12 23:00:35,"Biogen Inc. (BIIB) closed at $288.08 in the latest trading session, marking a +1.07% move from the prior day.",BIIB,0.688096,0.334865,Somewhat-Bullish
VRTX: 3 Biotech Stocks to Help Boost Your Portfolio in January,https://stocknews.com/news/vrtx-biib-jazz-3-biotech-stocks-to-help-boost-your-portfolio-in-january/,2023-01-12 16:51:03,"President Joe Biden signed an executive order last year and launched a national initiative to invest more than $2 billion in the U.S. biotechnology sector. Additionally, the U.S. Department of Energy ( DOE ) is committed to taking key steps to advance the Biden-Harris Administration's National ...",BIIB,0.281018,0.167701,Somewhat-Bullish
Should You Invest in the SPDR S&P Biotech ETF  ( XBI ) ?,https://www.zacks.com/stock/news/2038279/should-you-invest-in-the-spdr-sp-biotech-etf-xbi,2023-01-12 11:20:07,Sector ETF report for ...,BIIB,0.128478,0.00358,Neutral
Biogen's  ( BIIB )  Partner Eisai Files MAA for Lecanemab in Europe,https://www.zacks.com/stock/news/2037886/biogens-biib-partner-eisai-files-maa-for-lecanemab-in-europe,2023-01-11 14:38:00,Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.,BIIB,0.359014,0.138184,Neutral
"1 Hot Growth Stock to Buy Now, and 1 to Avoid",https://www.fool.com/investing/2023/01/11/1-hot-growth-stock-to-buy-now-and-1-to-avoid/,2023-01-11 10:30:00,One company is gearing up for further growth while the other stumbles over itself.,BIIB,0.217346,-0.051259,Neutral
Biogen Inc.  ( BIIB )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2046598/biogen-inc-biib-dips-more-than-broader-markets-what-you-should-know,2023-01-30 23:00:23,"Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.",BIIB,0.638519,0.245834,Somewhat-Bullish
"With 14.1% CAGR, Monoclonal Antibody Therapy Market Size Worth USD 451.89 Billion by 2028",https://www.benzinga.com/pressreleases/23/01/g30618366/with-14-1-cagr-monoclonal-antibody-therapy-market-size-worth-usd-451-89-billion-by-2028,2023-01-30 10:54:18,"Pune, India, Jan. 30, 2023 ( GLOBE NEWSWIRE ) -- The global monoclonal antibody therapy market size was USD 157.33 billion in 2020. The market is projected to grow from USD 178.50 billion in 2021 to USD 451.89 billion in 2028 at a CAGR of 14.1% in the 2021-2028 period.",BIIB,0.035983,0.104395,Neutral
Lecanemab Receives Priority Review Status in Japan,https://www.benzinga.com/pressreleases/23/01/g30616334/lecanemab-receives-priority-review-status-in-japan,2023-01-29 23:30:00,"TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"" ) and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.",BIIB,0.278335,0.067188,Neutral
Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen,https://www.reuters.com/business/healthcare-pharmaceuticals/japan-grants-priority-review-status-alzheimers-treatment-eisai-biogen-2023-01-29/,2023-01-29 06:11:15,Japan grants priority review status to Alzheimer's treatment from ... ...,BIIB,0.407844,0.0,Neutral
Biogen  ( BIIB )  & Eisai's Lecanemab Secures EMA's MAA Acceptance,https://www.zacks.com/stock/news/2045510/biogen-biib-eisais-lecanemab-secures-emas-maa-acceptance,2023-01-27 14:57:00,"Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.",BIIB,0.352223,0.292167,Somewhat-Bullish
Eli Lilly  ( LLY )  to Report Q4 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2045353/eli-lilly-lly-to-report-q4-earnings-whats-in-the-cards,2023-01-27 13:23:00,Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.,BIIB,0.12023,0.16817,Somewhat-Bullish
EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review,https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-accepts-biogen-eisais-alzheimers-treatment-lecanemab-review-2023-01-26/,2023-01-26 23:47:00,EU regulator accepts Biogen-Eisai's Alzheimer's treatment ... ...,BIIB,0.546745,0.232799,Somewhat-Bullish
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency,https://www.globenewswire.com/news-release/2023/01/26/2596565/0/en/Marketing-Authorization-Application-for-Lecanemab-as-Treatment-for-Early-Alzheimer-s-Disease-Accepted-by-European-Medicines-Agency.html,2023-01-26 23:30:00,"TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"" ) announced today that the European ...",BIIB,0.369163,0.091047,Neutral
"This ""Golden"" Technical Indicator is Triggering Across the Market",https://www.zacks.com/commentary/2044315/this-golden-technical-indicator-is-triggering-across-the-market,2023-01-26 13:36:00,"A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.",BIIB,0.139669,0.153734,Somewhat-Bullish
Is Biogen Stock a Buy Now?,https://www.fool.com/investing/2023/01/26/is-biogen-stock-a-buy-now/,2023-01-26 12:30:00,Its new drug might succeed where the company faltered in 2021.,BIIB,0.218817,-0.069427,Neutral
"Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More",https://www.zacks.com/stock/news/2044175/biotech-stock-roundup-blue-down-on-share-issuance-cprx-falls-on-generic-filing-more,2023-01-25 15:53:00,Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.,BIIB,0.050679,0.077436,Neutral
"Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor",https://www.globenewswire.com/news-release/2023/01/25/2595175/0/en/Vir-Biotechnology-Announces-Retirement-of-CEO-George-Scangos-Ph-D-Appoints-Marianne-De-Backer-MSc-Ph-D-MBA-as-Successor.html,2023-01-25 13:29:00,- Dr. De Backer to assume CEO role on April ...,BIIB,0.026013,0.101624,Neutral
"Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor",https://www.benzinga.com/pressreleases/23/01/g30566644/vir-biotechnology-announces-retirement-of-ceo-george-scangos-ph-d-appoints-marianne-de-backer-msc-,2023-01-25 13:29:00,"- Dr. De Backer to assume CEO role on April 3, 2023 - - Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Directors -",BIIB,0.025487,0.111688,Neutral
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?,https://www.fool.com/investing/2023/01/25/is-biogen-stock-a-no-brainer-buy-after-eli-lillys/,2023-01-25 10:57:00,Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.,BIIB,0.568953,0.465098,Bullish
Biogen Inc.  ( BIIB )  Stock Moves -0.02%: What You Should Know,https://www.zacks.com/stock/news/2043655/biogen-inc-biib-stock-moves--002-what-you-should-know,2023-01-24 23:00:19,"In the latest trading session, Biogen Inc. (BIIB) closed at $291.88, marking a -0.02% move from the previous day.",BIIB,0.507932,0.189845,Somewhat-Bullish
Why Biogen Inc.  ( BIIB )  Could Beat Earnings Estimates Again,https://www.zacks.com/stock/news/2043482/why-biogen-inc-biib-could-beat-earnings-estimates-again,2023-01-24 17:10:11,Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,BIIB,0.407844,0.447464,Bullish
GILD: 1 High-Yield Dividend Stock You Can Count on in 2023,https://stocknews.com/news/gild-uthr-vrtx-biib-1-high-yield-dividend-stock-you-can-count-on-in-2023/,2023-01-24 14:55:48,GILD: 1 High-Yield Dividend Stock You Can Count on in ...,BIIB,0.100308,0.159969,Somewhat-Bullish
GILD: 3 Top-Rated Stocks to Buy for the Long Haul,https://stocknews.com/news/gild-biib-audc-3-top-rated-stocks-to-buy-for-the-long-haul/,2023-01-24 12:27:54,"Aggressive rate hikes by the Fed to curb sky-high inflation last year had resulted in massive selloffs, but it did have its intended effect. Inflation eased for the sixth consecutive time in December. CPI increased by 6.5% year-over-year and dipped 0.1% over the prior month, in line with the Dow ...",BIIB,0.32014,0.235416,Somewhat-Bullish
Is SPDR S&P Biotech ETF  ( XBI )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2042472/is-spdr-sp-biotech-etf-xbi-a-strong-etf-right-now,2023-01-23 11:20:06,Smart Beta ETF report for ...,BIIB,0.114409,0.003389,Neutral
"AbbVie  ( ABBV )  Beats Q4 Earnings Estimates, Misses on Sales",https://www.zacks.com/stock/news/2052457/abbvie-abbv-beats-q4-earnings-estimates-misses-on-sales,2023-02-09 16:37:00,"AbbVie's Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates.",BIIB,0.163354,0.05385,Neutral
"Bulls Back in Driver's Seat For Moment as Buyers Resurface Following Heavy Selloff - Lyft  ( NASDAQ:LYFT ) , Walt Disney  ( NYSE:DIS ) ",https://www.benzinga.com/markets/23/02/30837398/bulls-back-in-drivers-seat-for-moment-as-buyers-resurface-following-heavy-selloff,2023-02-09 16:11:39,"( Thursday Market Open ) Investors swooped back in and snapped up stocks early Thursday after yesterday's heavy sell-off, perhaps a sign that a decent pool of potential buyers is still out there for the time being. Upbeat earnings news from Walt Disney DIS and PepsiCo PEP didn't hurt, either.",BIIB,0.036926,0.0,Neutral
GILD: 1 Dividend Stock You'll Be Thankful to Own in 2023,https://stocknews.com/news/gild-vrtx-biib-uthr-1-dividend-stock-youll-be-thankful-to-own-in-2023/,2023-02-09 13:53:09,GILD: 1 Dividend Stock You'll Be Thankful to Own in ...,BIIB,0.074345,0.079659,Neutral
Still Parsing Powell: Market Dips as Investors Ponder Latest Musings from Fed Chairman,https://www.benzinga.com/federal-reserve/23/02/30821095/still-parsing-powell-market-dips-as-investors-ponder-latest-musings-from-fed-chairman,2023-02-08 19:34:04,"( Wednesday Market Open ) Wall Street's seesaw ride continued early Wednesday as investors continued to parse Federal Reserve Chairman Jerome Powell's statements, which could be taken as hawkish or dovish depending on how you read them.",BIIB,0.037358,0.0,Neutral
"Factbox: Bayer's new CEO: long-time Roche, Genentech executive, Bill Anderson",https://www.reuters.com/business/bayers-new-ceo-long-time-roche-genentech-executive-bill-anderson-2023-02-08/,2023-02-08 19:03:00,"Factbox: Bayer's new CEO: long-time Roche, Genentech executive ... ...",BIIB,0.261117,0.391659,Bullish
2 Top Biotech Stocks Defying the Bear Market,https://www.fool.com/investing/2023/02/08/2-top-biotech-stocks-defying-the-bear-market/,2023-02-08 19:00:00,These stocks soared in the double digits last year.,BIIB,0.432818,0.257831,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Reports Next Week: Wall Street Expects Earnings Growth,https://www.zacks.com/stock/news/2051719/biogen-inc-biib-reports-next-week-wall-street-expects-earnings-growth,2023-02-08 15:00:45,Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BIIB,0.29887,0.216673,Somewhat-Bullish
Will Biogen  ( BIIB )  Beat Estimates This Earnings Season?,https://www.zacks.com/stock/news/2051652/will-biogen-biib-beat-estimates-this-earnings-season,2023-02-08 14:47:00,Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.,BIIB,0.372757,0.247767,Somewhat-Bullish
Can the government's new ability to negotiate drug prices eliminate blockbuster price tags?,https://www.marketwatch.com/story/can-the-governments-new-ability-to-negotiate-drug-prices-eliminate-blockbuster-price-tags-11675809067,2023-02-08 11:02:00,"The drug companies want $26,500 per year for the newest Alzheimer's drug. negotiations might take it to $20,000.",BIIB,0.117774,0.271194,Somewhat-Bullish
James Abate's stock fund has nearly doubled its benchmark over 3 tumultuous years. Here's how he says investors should get ready for potential black swan events that could shape 2023.,https://markets.businessinsider.com/news/stocks/stock-market-investing-strategy-black-swan-event-recession-inflation-2023-2,2023-02-07 17:40:43,Stock Market in 2023: Black Swan Warning From the Best Fund ... - Markets Insider ...,BIIB,0.048425,0.13191,Neutral
Will a More Dovish or Hawkish Powell Show Up Today After Friday's Hot Jobs Report?,https://www.benzinga.com/federal-reserve/23/02/30771524/will-a-more-dovish-or-hawkish-powell-show-up-today-after-fridays-hot-jobs-report,2023-02-07 17:13:59,"( Tuesday Market Open ) Last week, Federal Reserve Chairman Jerome Powell let loose the doves. Now, following Friday's dramatically bullish January jobs data, today's scheduled comments from the Fed chief and other central bank speakers could indicate whether the hawks are back in charge.",BIIB,0.035582,0.0,Neutral
Sage and Biogen's NDA for Depression Drug Gets Priority Review,https://www.zacks.com/stock/news/2051039/sage-and-biogens-nda-for-depression-drug-gets-priority-review,2023-02-07 15:17:00,"Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.",BIIB,0.219477,0.015883,Neutral
James Abate's stock fund has nearly doubled its benchmark over 3 tumultuous years. Here's how he says investors should get ready for potential black swan events that could shape 2023.,https://www.businessinsider.com/stock-market-investing-strategy-black-swan-event-recession-inflation-2023-2,2023-02-07 10:45:00,Stock Market in 2023: Black Swan Warning From the Best Fund ... - Business Insider ...,BIIB,0.048425,0.13191,Neutral
Biogen Inc.  ( BIIB )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2050632/biogen-inc-biib-gains-as-market-dips-what-you-should-know,2023-02-06 23:00:26,"Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.",BIIB,0.640349,0.252484,Somewhat-Bullish
"Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive' - Sage Therapeutics  ( NASDAQ:SAGE ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/02/30734753/sage-therapeutics-biogen-partnered-depression-candidate-under-priority-fda-review-a,2023-02-06 17:14:46,The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc SAGE and Biogen Inc's BIIB zuranolone for major depressive disorder ( MDD ) and postpartum depression ( PPD ) . The FDA has assigned a Prescription Drug User Fee Act ( PDUFA ) action date of ...,BIIB,0.605937,0.290398,Somewhat-Bullish
"On Tap: Earnings from Disney, Powell Speech as Market Digests Blockbuster Jobs Data - Apple  ( NASDAQ:AAPL ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/earnings/23/02/30733494/on-tap-earnings-from-disney-powell-speech-as-market-digests-blockbuster-jobs-data,2023-02-06 16:05:39,"( Monday Market Open ) Friday's jobs report really put the Federal Reserve in a tough place. While recession fears haven't vanished, it's tough to forecast an economic downturn with half a million people hired, upward revisions for the two prior months, and confirmation of wide breadth of jobs ...",BIIB,0.039516,0.0,Neutral
ADM: 3 Fantastic Stocks to Get Bullish on Now,https://stocknews.com/news/adm-biib-mcft-3-fantastic-stocks-to-get-bullish-on-now/,2023-02-06 12:51:39,"Last week, the Federal Reserve raised interest rates by 25 basis points ( bps ) at its first meeting of 2023, taking it to a target range of 4.5% to 4.75%. This move marks a slowdown from the 50-bps hike in December and a string of four 75-bps hikes from June through November last year.",BIIB,0.294446,0.335478,Somewhat-Bullish
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression,https://www.globenewswire.com/news-release/2023/02/06/2601896/0/en/Biogen-and-Sage-Therapeutics-Announce-FDA-Accepts-Filing-of-New-Drug-Application-and-Grants-Priority-Review-of-Zuranolone-in-the-Treatment-of-Major-Depressive-Disorder-and-Postpart.html,2023-02-06 11:30:00,"CAMBRIDGE, Mass., Feb. 06, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) and Sage Therapeutics, Inc. ( Nasdaq: SAGE ) announced the U.S. Food and Drug Administration ( FDA ) has accepted the filing of a New Drug Application ( NDA ) for zuranolone in the treatment of major depressive ...",BIIB,0.190117,0.066763,Neutral
Sanofi  ( SNY )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/02/03/sanofi-sny-q4-2022-earnings-call-transcript/,2023-02-03 23:30:21,"SNY earnings call for the period ending December 31, 2022.",BIIB,0.003527,0.012889,Neutral
Biohaven Nabbed A Nearly $12 Billion Buyout - What's Next?,https://www.investors.com/news/technology/bhvn-stock-what-is-next-for-biohaven-after-a-buyout/,2023-02-02 17:52:00,BHVN Stock: What's Next For Biohaven After A $12 Billion Buyout ... Investor's Business Daily ...,BIIB,0.085022,0.16211,Somewhat-Bullish
"Depression treatments haven't changed much in decades. Here are the promising new drugs that could be more precise, work faster, and help more people.",https://www.businessinsider.com/new-drugs-depression-treatments-auvelity-zuranolone-biomarkers-psychedelics-2023-2,2023-02-02 16:43:38,Depression Drugs That Could Revolutionize Treatment: Auvelity ... - Business Insider ...,BIIB,0.217249,0.203965,Somewhat-Bullish
"New Alzheimer's drug shows some promise, but has big price tag",https://www.marketwatch.com/story/new-alzheimers-drug-shows-some-promise-but-has-big-price-tag-11675288239,2023-02-02 10:39:00,How to alleviate ravages of the disease without bankrupting individuals or Medicare program?,BIIB,0.180236,0.112954,Neutral
VRTX: 3 Biotech Stocks to Get in on Before It's Too Late,https://stocknews.com/news/vrtx-biib-jazz-3-biotech-stocks-to-get-in-on-before-its-too/,2023-02-01 16:33:13,The rising prominence of personalized medicine and an increasing number of orphan drug formulations are spurring the growth in the biotech sector.,BIIB,0.22792,0.165522,Somewhat-Bullish
An Increase In Investments In The R&D Of Autoimmune Disease Drugs Is Expected To Drive The Autoimmune Treatment Market As Per The Business Research Company's Autoimmune Treatment Global Market Report 2023,https://www.benzinga.com/pressreleases/23/02/g30671480/an-increase-in-investments-in-the-r-d-of-autoimmune-disease-drugs-is-expected-to-drive-the-autoimm,2023-02-01 16:30:00,"LONDON, Feb. 01, 2023 ( GLOBE NEWSWIRE ) -- The Business Research Company's research on the ""Autoimmune Treatment Market"" forecasts the global autoimmune treatment market size to grow from $6 billion in 2022 to $6.8 billion in 2023 at a compound annual growth rate ( CAGR ) of more than 12%.",BIIB,0.050572,-0.049564,Neutral
Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock,https://www.fool.com/investing/2023/02/01/why-fda-rejection-of-eli-lilly-drug-is-good-news/,2023-02-01 14:53:00,"Ironically, it was the drug's own effectiveness that led to the FDA not granting approval.",BIIB,0.063933,0.239507,Somewhat-Bullish
"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",https://www.benzinga.com/general/biotech/23/01/30648889/february-pdufa-catalysts-biotech-investors-must-know-sanofis-bleeding-disorder-drug-regenerons-tw,2023-01-31 19:33:01,"The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year. NME approvals assume importance as the metric is an indicator of ...",BIIB,0.067727,0.074462,Neutral
"Analyst Initiates Coverage of GE Healthcare, Says' Path To Greatness Well-Paved' - GE HealthCare Techs  ( NASDAQ:GEHC ) ",https://www.benzinga.com/news/23/02/30963475/analyst-initiates-coverage-of-ge-healthcare-says-path-to-greatness-well-paved,2023-02-17 18:08:03,"Mizuho Securities initiated coverage on GE Healthcare Technologies Inc GEHC with a Buy rating and a price target of $90. Last month, General Electric Company GE completed the previously announced spin-off of its healthcare unit.",BIIB,0.28387,0.437794,Bullish
"Stocks making the biggest moves midday: Deere, Airbnb, AutoNation, Moderna and more",https://www.cnbc.com/2023/02/17/stocks-making-the-biggest-moves-midday.html,2023-02-17 17:53:13,Deere shares popped on strong earnings.,BIIB,0.135347,0.143959,Neutral
Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights,https://www.prnewswire.com/news-releases/declining-ms-sales-for-historic-powerhouse-biogen-point-to-shifting-tides-in-the-multiple-sclerosis-market-according-to-spherix-global-insights-301749890.html,2023-02-17 17:30:00,Declining MS Sales for Historic Powerhouse Biogen Point to Shifting ... PR ...,BIIB,0.090816,0.133008,Neutral
Market Rally Extends Pause Amid Hot Inflation: Weekly Review,https://www.investors.com/market-trend/stock-market-today/stock-market-rally-extends-pause-amid-hot-inflation-tesla-shopify-airbnb/,2023-02-17 17:07:00,"The stock market rally continued to consolidate, with the major indexes falling to the bottom or below their recent ranges on Friday as Fed fears mounted. Consumer and wholesale inflation came in hotter than expected, along with retail sales. Earnings remained heavy.",BIIB,0.037504,0.042107,Neutral
Senators call on Medicare to offer broad coverage of Alzheimer's treatments as public pressure grows,https://www.cnbc.com/2023/02/17/senators-urge-medicare-to-cover-alzheimers-treatments.html,2023-02-17 15:56:16,"Eighteen Republicans and two Democrats, led by Sens. Susan Collins and Shelley Moore Capito, pushed Medicare to expand coverage for Alzheimer's treatments.",BIIB,0.03704,-0.061593,Neutral
GM: 3 No-Brainer Stocks to Buy Right Now Without Hesitation,https://stocknews.com/news/gm-biib-mcft-3-no-brainer-stocks-to-buy-right-now-without-hesitation/,2023-02-17 15:14:03,"Stocks have had a great start to 2023, with optimism fueled by the recent slowdown in the Fed's rate increases, moderating inflation, and the possibility of a pause in hikes in the second half of the year.",BIIB,0.279305,0.19728,Somewhat-Bullish
"Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage",https://www.cnbc.com/2023/02/17/maker-of-promising-alzheimer-drug-leqembi-expects-fdas-full-approval-this-summer.html,2023-02-17 13:28:42,"Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout of the treatment will take years.",BIIB,0.052397,0.022001,Neutral
"Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates",https://www.zacks.com/stock/news/2055515/biotech-stock-roundup-biibs-q4-results-ebs-and-bpmc-offer-updates,2023-02-16 16:48:00,Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.,BIIB,0.159218,0.048615,Neutral
CONTINUED INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Biogen Inc.'s Directors and Officers for Breach of Fiduciary Duties - BIIB - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/02/g30940471/continued-investigation-alert-scott-scott-attorneys-at-law-llp-investigates-biogen-inc-s-directors,2023-02-16 13:00:00,"NEW YORK, Feb. 16, 2023 ( GLOBE NEWSWIRE ) -- Scott+Scott Attorneys at Law LLP ( ""Scott+Scott"" ) , an international securities and consumer rights litigation firm, continues its investigation as to whether certain directors and officers of Biogen Inc. ( ""Biogen"" ) BIIB breached their fiduciary ...",BIIB,0.664882,0.387748,Bullish
"Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023",https://www.prnewswire.com/news-releases/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2022-and-provides-financial-expectations-for-2023-301748314.html,2023-02-16 12:00:00,Alkermes plc Reports Financial Results for the Fourth Quarter and ... PR ...,BIIB,0.012428,-0.020128,Neutral
Virtualware to be Listed on the Paris Stock Exchange,https://www.benzinga.com/pressreleases/23/02/g30937610/virtualware-to-be-listed-on-the-paris-stock-exchange,2023-02-16 07:51:43,"BILBAO, Spain, Feb. 16, 2023 ( GLOBE NEWSWIRE ) -- Spanish technology company Virtualware, one of the European leaders in the virtual reality industry, will be listed on the Paris Stock Exchange in the coming weeks.",BIIB,0.077343,0.051578,Neutral
Biogen  ( BIIB )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/02/15/biogen-biib-q4-2022-earnings-call-transcript/,2023-02-15 19:30:34,"BIIB earnings call for the period ending December 31, 2022.",BIIB,0.107636,0.107015,Neutral
Biogen Boss Turns Corner on Alzheimer's Miscues,https://www.wsj.com/articles/biogen-boss-turns-corner-on-alzheimers-miscues-56936d56,2023-02-15 18:16:00,The biotech company needs to embark on new growth path as former Sanofi CEO Chris Viehbacher takes the helm.,BIIB,0.371523,0.481383,Bullish
"Compared to Estimates, Biogen Inc.  ( BIIB )  Q4 Earnings: A Look at Key Metrics",https://www.zacks.com/stock/news/2054842/compared-to-estimates-biogen-inc-biib-q4-earnings-a-look-at-key-metrics,2023-02-15 17:26:00,"Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",BIIB,0.298567,0.053652,Neutral
"Biogen  ( BIIB )  Beats Q4 Earnings & Sales Estimates, Stock Up",https://www.zacks.com/stock/news/2054754/biogen-biib-beats-q4-earnings-sales-estimates-stock-up,2023-02-15 15:57:00,Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.,BIIB,0.295867,0.105481,Neutral
Why Biogen  ( BIIB )  Stock Is Falling Today - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/general/biotech/23/02/30925051/why-biogen-stock-is-falling-today,2023-02-15 14:47:59,"Biogen Inc BIIB posted Q4 sales of $2.54 billion, beating the consensus of $2.44 billion, down 7% Y/Y and 4% at constant currency ( CC ) . Multiple sclerosis revenue of $1.27 billion decreased by 17% ( down 14% CC ) . Multiple sclerosis drug Tysabri sales are down to $488.4 million from ...",BIIB,0.760593,0.286595,Somewhat-Bullish
Drugmaker Biogen tops 4Q forecasts despite sales slip,https://apnews.com/article/biogen-inc-business-earnings-multiple-sclerosis-691d987d3f49fb453bcc7af58358516f,2023-02-15 14:13:17,"Biogen closed 2022 with a better-than-expected fourth quarter, as more cost cutting helped counter sales declines for some key treatments. The drugmaker said Wednesday that total cost and expenses fell 17% in the quarter, and Biogen's bottom line grew nearly 50% to $550.4 million.",BIIB,0.550532,-0.017209,Neutral
Biogen Expects Alzheimer's Drug Leqembi To Face A Key 2023 Headwind,https://www.investors.com/news/technology/biogen-stock-biogen-earninga-q4-2022/,2023-02-15 13:54:00,"Biogen Stock Inches Higher On Quarterly Beat, Predicts 'Modest ... Investor's Business Daily ...",BIIB,0.941495,0.333639,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Q4 Earnings and Revenues Beat Estimates,https://www.zacks.com/stock/news/2054518/biogen-inc-biib-q4-earnings-and-revenues-beat-estimates,2023-02-15 13:25:08,"Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",BIIB,0.402403,0.174588,Somewhat-Bullish
Futures Fall Ahead Of Retail Sales; Tesla Rallies On Buy Rating,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-retail-sales-tesla-stock-races-higher-on-buy-rating/,2023-02-15 13:23:00,Futures Fall Ahead Of Retail Sales. Tesla Rallies On Buy Rating Investor's Business Daily ...,BIIB,0.027892,0.087498,Neutral
"Stocks making the biggest moves premarket: Kraft Heinz, Paramount, Airbnb, Tripadvisor and more",https://www.cnbc.com/2023/02/15/stocks-making-the-biggest-moves-premarket-khc-para-abnb.html,2023-02-15 13:15:41,Here are the companies making headlines before the bell on Monday.,BIIB,0.214937,0.03445,Neutral
Futures Fall After Market Shrugs Off Inflation; Hot Stock Crashes,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-shrugs-off-hot-inflation-tesla-runs-airbnb-flies-on-earnings/,2023-02-15 13:13:00,Futures Fall After Market Shrugs Off Inflation. Hot Stock Crashes Investor's Business Daily ...,BIIB,0.054669,0.0,Neutral
Yellow.ai strengthens its platform capabilities with Dynamic Conversation Designer to deliver faster time-to-market,https://www.prnewswire.com/ae/news-releases/yellowai-strengthens-its-platform-capabilities-with-dynamic-conversation-designer-to-deliver-faster-time-to-market-301747483.html,2023-02-15 13:00:00,Yellow.ai strengthens its platform capabilities with Dynamic ... PR ...,BIIB,0.05257,0.129958,Neutral
Yellow.ai strengthens its platform capabilities with Dynamic Conversation Designer to deliver faster time-to-market,https://www.prnewswire.com/in/news-releases/yellowai-strengthens-its-platform-capabilities-with-dynamic-conversation-designer-to-deliver-faster-time-to-market-301747483.html,2023-02-15 13:00:00,Yellow.ai strengthens its platform capabilities with Dynamic ... PR ...,BIIB,0.05257,0.129958,Neutral
Yellow.ai strengthens its platform capabilities with Dynamic Conversation Designer to deliver faster time-to-market,https://www.prnewswire.com/news-releases/yellowai-strengthens-its-platform-capabilities-with-dynamic-conversation-designer-to-deliver-faster-time-to-market-301747473.html,2023-02-15 13:00:00,Yellow.ai strengthens its platform capabilities with Dynamic ... PR ...,BIIB,0.05257,0.129958,Neutral
Yellow.ai strengthens its platform capabilities with Dynamic Conversation Designer to deliver faster time-to-market,https://www.newswire.ca/news-releases/yellow-ai-strengthens-its-platform-capabilities-with-dynamic-conversation-designer-to-deliver-faster-time-to-market-878483072.html,2023-02-15 13:00:00,Yellow.ai strengthens its platform capabilities with Dynamic ... Canada ...,BIIB,0.05257,0.129958,Neutral
Futures slip ahead of retail sales data,https://www.reuters.com/markets/us/futures-slip-ahead-retail-sales-data-2023-02-15/,2023-02-15 12:35:00,"Feb 15 ( Reuters ) - U.S. stock index futures slipped on Wednesday, as investors awaited retail sales data amid worries that elevated inflation and a tight labor market will keep the Federal Reserve on track for more interest rate increases this year.",BIIB,0.112008,-0.009406,Neutral
"Biogen Inc. Q4 Profit Increases, beats estimates",https://markets.businessinsider.com/news/stocks/biogen-inc-q4-profit-increases-beats-estimates-1032098624,2023-02-15 12:26:33,"( RTTNews ) - Biogen Inc. ( BIIB ) announced earnings for its fourth quarter that increased from the same period last year and beat the Street estimates. The company's earnings totaled $550.4 million, or $3.79 per share. This compares with $368.2 million, or $2.50 per share, in last year's ...",BIIB,0.693563,0.379946,Bullish
Biogen earnings beat estimates on boost from muscle disorder drug,https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-earnings-beat-estimates-boost-muscle-disorder-drug-2023-02-15/,2023-02-15 12:05:17,"Feb 15 ( Reuters ) - Biogen Inc ( BIIB.O ) beat Wall Street expectations for quarterly profit and sales on Wednesday, riding on strong demand for its spinal muscular atrophy drug, Spinraza, and forecast modest revenue from its Alzheimer's disease drug this year.",BIIB,0.33628,0.191774,Somewhat-Bullish
Should BNY Mellon US Mid Cap Core Equity ETF  ( BKMC )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2054439/should-bny-mellon-us-mid-cap-core-equity-etf-bkmc-be-on-your-investing-radar,2023-02-15 11:20:02,Style Box ETF report for ...,BIIB,0.128822,0.076992,Neutral
"Cisco, Analog Devices And 3 Stocks To Watch Heading Into Wednesday - Analog Devices  ( NASDAQ:ADI ) , Airbnb  ( NASDAQ:ABNB ) ",https://www.benzinga.com/news/earnings/23/02/30919646/cisco-analog-devices-and-3-stocks-to-watch-heading-into-wednesday,2023-02-15 09:03:13,"With US futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Cisco Systems, Inc. CSCO to post quarterly earnings at $0.85 per share on revenue of $13.42 billion before the opening bell.",BIIB,0.535653,0.590055,Bullish
"US Stocks Settle Mixed; Investor Optimism Improves - Analog Devices  ( NASDAQ:ADI ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/earnings/23/02/30919292/us-stocks-settle-mixed-investor-optimism-improves,2023-02-15 07:31:23,"The CNN Money Fear and Greed index showed an improvement in the overall sentiment among US investors. The Dow Jones recorded losses on Tuesday following the release of inflation data from the US. Consumer prices rose 0.5% month-over-month in January, the most in three months, coming in-line with ...",BIIB,0.345674,0.0,Neutral
"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings",https://www.barrons.com/articles/biogen-earnings-stock-price-6fa00d35,2023-02-14 22:23:00,Biogen Reports Earnings Wednesday. What to Expect. ...,BIIB,0.944494,-0.03849,Neutral
"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings",https://www.barrons.com/articles/biogen-stock-earnings-what-to-expect-6fa00d35,2023-02-14 21:18:00,Biogen Reports Earnings Wednesday. What to Expect ...,BIIB,0.944494,-0.03849,Neutral
Meh: It's Not All Candy and Flowers as Market Wavers on Still-Hot Inflation Report - Coca-Cola  ( NYSE:KO ) ,https://www.benzinga.com/markets/23/02/30904131/meh-its-not-all-candy-and-flowers-as-market-wavers-on-still-hot-inflation-report,2023-02-14 16:26:22,"( Tuesday market open ) Inflation isn't giving up easy, rising moderately in January and likely further reinforcing the Federal Reserve's rate hike plans. Investors didn't show much love for the January Consumer Price Index ( CPI ) data, initially sending stock index futures lower.",BIIB,0.035061,0.0,Neutral
The top doctor at a $2.7 billion pharma company developing a new depression drug says we may be 'on the cusp' of a new wave of mental-health treatments,https://www.businessinsider.com/zuranalone-sage-therapeutics-biogen-postpartum-depression-treatments-2023-2,2023-02-13 19:17:55,"Sage on Zuranolone: Treatment for Postpartum Depression, MDD - Business Insider ...",BIIB,0.050465,0.050549,Neutral
Price Check: Choppy Trading Seen Likely as Market Prepares for Possible Uptick in CPI Data,https://www.benzinga.com/markets/23/02/30882161/price-check-choppy-trading-seen-likely-as-market-prepares-for-possible-uptick-in-cpi-data,2023-02-13 17:24:33,"( Monday Market Open ) Between the excitement of the big game and the mystery of flying objects, it was an eventful weekend, to say the least. Wall Street gets back to work today after an active premarket and now appears focused on tomorrow's inflation data.",BIIB,0.038969,0.0,Neutral
Buying These 2 Under-the-Radar Stocks for 2023 Could Be a Smart Move,https://www.fool.com/investing/2023/02/13/buying-these-2-under-the-radar-stocks-for-2023-cou/,2023-02-13 15:00:00,Even a volatile market can be a great time to scoop up wonderful companies.,BIIB,0.046273,0.018818,Neutral
Are we on the brink of a corporate credit crisis? | Business,https://www.cnn.com/2023/02/13/investing/premarket-stocks-trading/index.html,2023-02-13 13:32:00,Are we on the brink of a corporate credit crisis? ...,BIIB,0.027257,0.132756,Neutral
"Marathon earnings, CPI and Fed speeches top week ahead",https://www.foxbusiness.com/markets/marathon-earnings-cpi-fed-speeches-top-week-ahead,2023-02-12 22:12:21,"Another busy week for investors is almost upon us with half a dozen Fed speeches, new CPI data and earnings across industries from energy to hospitality filling the week. The stock market is coming off a somber week with the Nasdaq Composite unable to escape the bear market it's been stuck in ...",BIIB,0.054359,0.0,Neutral
"Q4 Reporting Season Pushes Past Halfway Mark: Coca-Cola, Cisco Systems, Palantir, Roku Lead Earnings This Week - Cisco Systems  ( NASDAQ:CSCO ) , Coca-Cola  ( NYSE:KO ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/23/02/30870340/q4-reporting-season-pushes-past-halfway-mark-coca-cola-cisco-systems-palantir-roku-lead-earnings-th,2023-02-12 21:39:02,"The stock market pulled back in the week ended Feb. 10, dragged by some disappointing earnings and revised December inflation data. The Scorecard So Far: The fourth-quarter reporting season is well past the halfway mark, as almost 70% of the S&P 500 companies have announced their results so far, ...",BIIB,0.088472,0.0,Neutral
"Airbnb, Coca-Cola, Shopify, Deere, DoorDash, Paramount, and More Stocks for Investors to Watch This Week",https://www.barrons.com/articles/airbnb-coca-cola-shopify-deere-doordash-paramount-and-more-stocks-for-investors-to-watch-this-week-f6ffd7d1,2023-02-12 20:00:00,"A high-stakes inflation report and more fourth-quarter results will be this week's highlights. About 60 S&P 500 companies are scheduled to report. Airbnb Coca-Cola and Marriott International will present to shareholders on Tuesday, followed by Biogen Cisco Systems Kraft Heinz and Shopify on ...",BIIB,0.546745,0.0,Neutral
"Airbnb, Coca-Cola, Shopify, Deere, DoorDash, Paramount, and More Stocks for Investors to Watch This Week",https://www.barrons.com/articles/stocks-to-watch-this-week-airbnb-coca-cola-shopify-deere-doordash-paramount-f6ffd7d1,2023-02-12 20:00:00,"A high-stakes inflation report and more fourth-quarter results will be this week's highlights. About 60 S&P 500 companies are scheduled to report. Airbnb Coca-Cola and Marriott International will present to shareholders on Tuesday, followed by Biogen Cisco Systems Kraft Heinz and Shopify on ...",BIIB,0.546745,0.0,Neutral
"In a market that's gone mad, investors can embrace these dependable stocks | Business",https://www.cnn.com/2023/02/12/investing/stocks-week-ahead/index.html,2023-02-12 13:39:00,"In a market that's gone mad, investors can embrace these dependable stocks ...",BIIB,0.056607,-0.119935,Neutral
"Stock Market Week: Gold, Lithium, Steel, And Deere, Medpace Earnings",https://www.investors.com/research/investing-action-plan/stock-market-week-gold-lithium-steel-and-deere-medpace-earnings/,2023-02-10 23:03:00,"Stock Market Week: Gold, Lithium, Steel, And Deere, Medpace ... Investor's Business Daily ...",BIIB,0.04045,0.049248,Neutral
"Caution Returns as Investors Contemplate Rate Uncertainty, Geopolitical Tension",https://www.benzinga.com/markets/23/02/30857171/caution-returns-as-investors-contemplate-rate-uncertainty-geopolitical-tension,2023-02-10 16:26:09,"( Friday Market Open ) Caution stormed back into the markets this week after a tropical January vacation. Things went south for stocks in a hurry the last two days, while risk signals like bond yields and volatility rose sharply.",BIIB,0.038192,0.0,Neutral
Peering Into Biogen's Recent Short Interest - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/03/31136334/peering-into-biogens-recent-short-interest,2023-03-01 19:27:08,"Biogen's BIIB short percent of float has fallen 8.84% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 1.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their ...",BIIB,0.224903,0.085754,Neutral
"Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback",https://www.zacks.com/stock/news/2060596/biotech-stock-roundup-mrna-q4-earnings-regns-updates-cytk-receives-setback,2023-03-01 17:24:00,Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.,BIIB,0.116631,-0.046615,Neutral
Reata shares surge after surprise FDA nod for rare disease drug,https://www.reuters.com/business/healthcare-pharmaceuticals/reata-shares-surge-after-surprise-fda-nod-rare-disease-drug-2023-03-01/,2023-03-01 13:42:00,"March 1 ( Reuters ) - Shares of U.S. biotech firm Reata Pharmaceuticals Inc ( RETA.O ) more than doubled in premarket trading on Wednesday, a day after the Food and Drug Administration ( FDA ) approved its rare disease drug and ended years of uncertainty over its future.",BIIB,0.154455,0.043016,Neutral
"Denali  ( DNLI )  Q4 Earnings Beat Estimates, Pipeline in Focus",https://www.zacks.com/stock/news/2059770/denali-dnli-q4-earnings-beat-estimates-pipeline-in-focus,2023-02-28 14:01:00,"Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.",BIIB,0.162802,-0.023905,Neutral
"Henlius Swallows Bitter Pill In Watered-Down Licensing Deal - Abbott Laboratories  ( NYSE:ABT ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/small-cap/23/02/31090323/henlius-swallows-bitter-pill-in-watered-down-licensing-deal,2023-02-28 13:41:25,"Henlius Biotech will receive up to $11 million less than originally agreed under a licensing agreement due to higher-than-expected R&D costs Such alterations aren't uncommon to licensing deals, but can still undermine investor confidence in a company and slow its overseas expansion",BIIB,0.073659,-0.108217,Neutral
"These 13 beaten-down stocks offer a 'margin of safety' from a possible credit shock, according to a top-1% fund manager",https://www.businessinsider.com/13-cheap-stocks-to-buy-recession-interest-rates-credit-shock-2023-2,2023-02-28 13:05:00,13 Undervalued Stocks to Buy in a Recession: Top-1% Fund Manager - Business Insider ...,BIIB,0.071677,0.214791,Somewhat-Bullish
"Eisai, Biogen say Alzheimer's drug Lecanemab getting priority review in China",https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-biogen-say-alzheimers-drug-lecanemab-getting-priority-review-china-2023-02-28/,2023-02-28 00:16:28,"Eisai, Biogen say Alzheimer's drug Lecanemab getting priority ... ...",BIIB,0.371523,0.0,Neutral
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration,https://www.globenewswire.com/news-release/2023/02/27/2616587/0/en/Biologics-License-Application-for-Lecanemab-Designated-for-Priority-Review-by-China-National-Medical-Products-Administration.html,2023-02-27 23:30:00,"TOKYO and CAMBRIDGE, Mass., Feb. 27, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"" ) announced today that the Biologics ...",BIIB,0.285526,0.077118,Neutral
Why Reata Pharmaceuticals  ( RETA )  Shares Are Falling Today - Reata Pharmaceuticals  ( NASDAQ:RETA ) ,https://www.benzinga.com/general/biotech/23/02/31073435/why-reata-pharmaceuticals-shares-are-falling-monday,2023-02-27 17:39:43,"According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. Dunn presided over the controversial approval of Biogen Inc's BIIB Alzheimer's disease treatment, Aduhelm ( aducanumab ) .",BIIB,0.417995,0.189061,Somewhat-Bullish
3 Biotech Stocks To Watch Ahead Of March 2023,https://stockmarket.com/featured/3-biotech-stocks-to-watch-ahead-of-march-2023-2023-02-25,2023-02-25 20:44:12,"Biotech stocks represent shares of companies that specialize in the development and commercialization of drugs, therapies, and other medical products based on biological and chemical research. Biotech companies often focus on treating diseases that currently have no cure.",BIIB,0.30928,0.0023,Neutral
"Spherix Global Insights Continues Coverage of Biogen & Coherus Biosciences' Ranibizumab Biosimilars, Tracking Uptake and Perceptions of the First Commercially Available Biosimilars to Genentech's Lucentis",https://www.prnewswire.com/news-releases/spherix-global-insights-continues-coverage-of-biogen--coherus-biosciences-ranibizumab-biosimilars-tracking-uptake-and-perceptions-of-the-first-commercially-available-biosimilars-to-genentechs-lucentis-301755717.html,2023-02-24 20:00:00,Spherix Global Insights Continues Coverage of Biogen & Coherus ... PR ...,BIIB,0.053992,0.037839,Neutral
Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi,https://www.cnbc.com/2023/02/23/medicare-rejects-alzheimer-association-request-on-coverage-for-treatments-like-leqembi.html,2023-02-23 15:47:23,"The Alzheimer's Association, in a statement Wednesday, said it was ""appalled"" by CMS' decision.",BIIB,0.07423,-0.007159,Neutral
Is Anavex Life Sciences Stock a Buy Now?,https://www.fool.com/investing/2023/02/23/is-anavex-life-sciences-stock-a-buy-now/,2023-02-23 15:00:00,A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.,BIIB,0.067347,0.166735,Somewhat-Bullish
"Ionis  ( IONS )  Q4 Earnings Top Estimates, Sales Lag, Stock Down",https://www.zacks.com/stock/news/2058089/ionis-ions-q4-earnings-top-estimates-sales-lag-stock-down,2023-02-23 14:15:00,"Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.",BIIB,0.261584,0.073897,Neutral
"4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates",https://www.zacks.com/stock/news/2057943/4-drug-biotech-stocks-poised-to-beat-q4-earnings-estimates,2023-02-23 12:46:00,"We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.",BIIB,0.046907,0.097373,Neutral
U.S. Medicare says no change to Alzheimer's drug restrictions,https://www.reuters.com/business/healthcare-pharmaceuticals/us-medicare-says-no-change-alzheimers-drug-restrictions-2023-02-22/,2023-02-22 23:37:33,"Feb 22 ( Reuters ) - The U.S. government health plan for people over the age of 65 on Wednesday said it will not reconsider strict coverage limits put in place last year for new Alzheimer's treatments, rejecting a request from the Alzheimer's Association.",BIIB,0.185306,0.185489,Somewhat-Bullish
AMGN: 3 Biotech Stocks to Buy and Hold for the Next 20 Years,https://stocknews.com/news/amgn-biib-fold-3-biotech-stocks-to-buy-and-hold-for-the-next/,2023-02-22 15:21:22,"The biotech industry has witnessed significant growth in recent years, primarily driven by sustained demand amid an increasing prevalence of chronic diseases and an aging population. The COVID-19 pandemic has further catalyzed the industry with enormous breakthroughs.",BIIB,0.27432,0.069279,Neutral
How Are Biotech ETFs Reacting to Q4 Earnings Releases?,https://www.zacks.com/stock/news/2057067/how-are-biotech-etfs-reacting-to-q4-earnings-releases,2023-02-21 19:21:00,The latest earnings from some of the big biotech players came in at mixed this reporting season.,BIIB,0.096671,-0.078435,Neutral
Should iShares Morningstar Mid-Cap Value ETF  ( IMCV )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2063939/should-ishares-morningstar-mid-cap-value-etf-imcv-be-on-your-investing-radar,2023-03-10 11:20:09,Style Box ETF report for ...,BIIB,0.125789,0.063395,Neutral
"Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More",https://www.zacks.com/stock/news/2063653/biotech-stock-roundup-ptgx-gains-on-study-data-bmrn-faces-setback-more,2023-03-09 16:14:00,Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.,BIIB,0.038284,-0.071218,Neutral
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed,https://www.investors.com/news/technology/eli-lilly-stock-decade-long-effort-in-alzheimers-treatment-fails/,2023-03-09 14:37:00,Eli Lilly Stock: Decade-Long Effort In Alzheimer's Treatment Fails ... Investor's Business Daily ...,BIIB,0.59972,0.190453,Somewhat-Bullish
Lilly's  ( LLY )  Alzheimer Drug Fails Late-Stage Prevention Study,https://www.zacks.com/stock/news/2063562/lillys-lly-alzheimer-drug-fails-late-stage-prevention-study,2023-03-09 14:33:00,Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.,BIIB,0.302553,0.259817,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2063231/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know,2023-03-08 23:00:19,"Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session.",BIIB,0.666827,0.264956,Somewhat-Bullish
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors,https://www.globenewswire.com/news-release/2023/03/08/2622919/0/en/Caroline-Dorsa-to-Succeed-Stelios-Papadopoulos-as-Chair-of-Biogen-Board-of-Directors.html,2023-03-08 12:30:00,"CAMBRIDGE, Mass., March 08, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( NASDAQ: BIIB ) today announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company's 2023 Annual Meeting of Stockholders ( the ""Annual Meeting"" ...",BIIB,0.335864,0.355312,Bullish
Boston could be first city to make vendors donate leftovers,https://www.axios.com/local/boston/2023/03/08/boston-leftovers-donate-food-waste,2023-03-08 11:20:00,A new proposal would make Boston the first city in the country to require vendors to donate leftover food.,BIIB,0.064797,0.102112,Neutral
Why Shares of Anavex Life Sciences Rose 12.4% in February,https://www.fool.com/investing/2023/03/06/why-shares-of-anavex-life-sciences-rose-124-in-feb/,2023-03-07 01:21:53,The company's first-quarter earnings report detailed positive news regarding its pipeline.,BIIB,0.187463,-0.050135,Neutral
FDA Will Weigh Full Approval for Alzheimer's Drug. Why It Matters for Biogen Stock.,https://www.barrons.com/articles/biogen-fda-alzheimer-drug-approval-fff53cc3,2023-03-06 16:38:00,FDA to Weigh Full Approval for Alzheimer's Drug. It Matters for Biogen Stock. ...,BIIB,0.582526,0.426956,Bullish
"Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment - Eisai Co Ltd ADR  ( OTC:ESALY ) , Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/03/31216357/eisai-biogen-seek-complete-fda-approval-for-its-second-alzheimers-treatment,2023-03-06 15:46:54,"The FDA has accepted Eisai Co Ltd ESALY and Biogen Inc's BIIB supplemental Biologics License Application ( sBLA ) for Leqembi ( lecanemab-irmb ) 100 mg/mL injection, supporting the conversion of the accelerated approval of Leqembi to a traditional approval.",BIIB,0.615462,0.603838,Bullish
"Biogen  ( BIIB ) , Eisai Seek Full Nod for Alzheimer Drug Leqembi",https://www.zacks.com/stock/news/2061981/biogen-biib-eisai-seek-full-nod-for-alzheimer-drug-leqembi,2023-03-06 13:16:00,"The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.",BIIB,0.301686,0.223771,Somewhat-Bullish
"Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab",https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-biogen-say-fda-grants-priority-review-alzheimers-drug-lecanemab-2023-03-06/,2023-03-06 00:16:00,"Eisai, Biogen say FDA grants priority review for Alzheimer's drug ... ...",BIIB,0.495015,0.402985,Bullish
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBIâ¢  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease,https://www.prnewswire.com/news-releases/fda-accepts-eisais-filing-of-a-supplemental-biologics-license-application-and-grants-priority-review-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease-301762846.html,2023-03-05 23:30:00,FDA Accepts Eisai's Filing of a Supplemental Biologics License ... PR ...,BIIB,0.166169,0.057685,Neutral
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBIâ¢  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease,https://www.globenewswire.com/news-release/2023/03/05/2620647/0/en/FDA-Accepts-Eisai-s-Filing-of-a-Supplemental-Biologics-License-Application-and-Grants-Priority-Review-for-Traditional-Approval-of-LEQEMBI-lecanemab-irmb-for-the-Treatment-of-Alzhei.html,2023-03-05 23:30:00,Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval ...,BIIB,0.165978,0.066123,Neutral
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBIâ¢  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/03/g31210662/fda-accepts-eisais-filing-of-a-supplemental-biologics-license-application-and-grants-priority-revi,2023-03-05 23:30:00,"Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with a Prescription Drug User Fee Act ( PDUFA ) target action on July 6, 2023",BIIB,0.164375,0.062821,Neutral
Biotech Stocks Fell on Fear of Less Flexible FDA. This Analyst Isn't Worried.,https://www.barrons.com/articles/biotech-stocks-fda-drug-approvals-fff374d5,2023-03-03 17:11:00,"Wall Street may have overreacted to fears that the FDA could grow less flexible in approving certain new drugs. Biotech investors panicked on Monday when news broke that Dr. Billy Dunn, who ran the Food and Drug Administration office that decides whether to approve drugs for neurological ...",BIIB,0.110717,0.104071,Neutral
GILD: 1 Resilient Growth Stock to Buy Now and Hold Forever,https://stocknews.com/news/gild-vrtx-biib-incy-1-resilient-growth-stock-to-buy-now-and-hold-forever/,2023-03-03 17:05:02,"After a brutal 2022, growth stocks are expected to stage a recovery amid cooling inflation, the Fed's downshift on monetary policy tightening, and recent economic data, including strong retail sales and job growth, hinting at the possibility of the economy getting a soft landing.",BIIB,0.06623,0.091152,Neutral
AMGN: 3 Biotech Stocks With Potential to Be Big Winners in 2023,https://stocknews.com/news/amgn-biib-jazz-ibb-zyme-3-biotech-stocks-with-potential-to-be-big-winners-in/,2023-03-03 16:24:05,AMGN: 3 Biotech Stocks With Potential to Be Big Winners in ...,BIIB,0.212115,0.116747,Neutral
3 Generic Drug Stocks to Watch Amid Macro Headwinds,https://www.zacks.com/commentary/2061533/3-generic-drug-stocks-to-watch-amid-macro-headwinds,2023-03-03 16:01:00,"The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.",BIIB,0.03072,0.027859,Neutral
"Medicare just crushed the hopes of 750,000 Alzheimer's patients a year",https://www.marketwatch.com/story/medicare-just-crushed-the-hopes-of-750-000-alzheimers-patients-a-year-ce9da3c,2023-03-03 11:05:00,"Three years after Uncle Sam spent $4 trillion trying to fight a disease that ended up killing ( or helping kill ) one million Americans, the Centers for Medicare and Medicaid Services is refusing to spend 0.4% as much fighting a disease that is killing six times as many people-and rising.",BIIB,0.113329,-0.094771,Neutral
What Does Biogen's Debt Look Like? - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/03/31177603/what-does-biogens-debt-look-like,2023-03-02 18:33:36,"Shares of Biogen Inc. BIIB moved lower by 7.52% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.",BIIB,0.368773,0.058505,Neutral
Short Volatility Alert: Biogen Inc - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/23/03/31171329/short-volatility-alert-biogen-inc,2023-03-02 15:03:31,"On Wednesday, shares of Biogen Inc BIIB experienced volatile short activity. After the activity, the stock price went up +0.87% to $272.21. The overall sentiment for BIIB has been Neutral. The signal from the volatility alert is trending Bullish. Therefore, the recommendation is to Strong Buy.",BIIB,0.350564,0.017548,Neutral
Generics dominate lupus marketplace but new biologics will drive growth in coming years: GlobalData | The Financial Express,https://www.financialexpress.com/healthcare/pharma-healthcare/generics-dominate-lupus-marketplace-but-new-biologics-will-drive-growth-in-coming-years-globaldata/2997301/,2023-03-02 06:54:00,Generics dominate lupus marketplace but new biologics will drive ... The Financial Express ...,BIIB,0.064623,0.062043,Neutral
Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2068750/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know,2023-03-21 22:00:22,"Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.",BIIB,0.639942,0.276181,Somewhat-Bullish
Wall Street analysts predict approval for another ALS drug,https://www.marketwatch.com/story/wall-street-predicts-approval-for-another-als-drug-6268e03b,2023-03-21 15:00:00,An FDA advisory committee is set to meet this week to discuss a drug developed by Biogen and Ionis to treat a rare form of Lou Gehrig's disease.,BIIB,0.372912,0.319298,Somewhat-Bullish
"Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/03/31433167/despite-failed-phase-3-study-fda-staff-says-biogens-als-drug-may-have-clinical-benefit,2023-03-21 10:59:25,"FDA's Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc's BIIB ALS drug tofersen.",BIIB,0.481177,-0.06054,Neutral
FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease,https://www.cnbc.com/2023/03/20/fda-staff-says-biogens-als-drug-may-have-a-clinical-benefit-on-a-rare-form-of-the-disease.html,2023-03-20 18:53:03,"The FDA staff on Monday said Biogen's investigational ALS drug tofersen may have a ""clinical benefit"" on a rare and aggressive form of the disease.",BIIB,0.13459,-0.027269,Neutral
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo - Novartis  ( NYSE:NVS ) ,https://www.benzinga.com/general/biotech/23/03/31421168/two-big-pharma-companies-bow-out-of-neurology-drug-partnerships-with-sangamo,2023-03-20 14:25:22,"Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc SGMO over a few days. On Friday, the company filed an SEC document, Novartis AG NVS terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023.",BIIB,0.502207,0.470579,Bullish
US FDA staff flags no new safety concerns for Biogen's ALS drug,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-flags-no-new-safety-concerns-biogens-als-drug-2023-03-20/,2023-03-20 14:04:03,"March 20 ( Reuters ) - Staff reviewers of U.S. drug regulator on Monday did not raise any new safety concerns about Biogen Inc's ( BIIB.O ) experimental drug for treating a rare type of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.",BIIB,0.188193,0.027358,Neutral
Biogen  ( NASDAQ:BIIB )  Now Covered by StockNews.com,https://www.defenseworld.net/2023/03/20/biogen-nasdaqbiib-now-covered-by-stocknews-com.html,2023-03-20 11:05:00,StockNews.com started coverage on shares of Biogen ( NASDAQ:BIIB - Get Rating ) in a research report sent to investors on Thursday morning. The firm issued a strong-buy rating on the biotechnology company's stock.,BIIB,0.882787,0.439764,Bullish
Should You Buy Biogen Before a Big July Decision?,https://www.fool.com/investing/2023/03/19/should-you-buy-biogen-before-a-big-july-decision/,2023-03-19 09:30:00,Biogen stock has dropped about 40% from its record high.,BIIB,0.607669,0.448389,Bullish
Price Over Earnings Overview: Biogen - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/03/31404462/price-over-earnings-overview-biogen,2023-03-17 20:15:25,"Looking into the current session, Biogen Inc. BIIB shares are trading at $263.16, after a 0.79% drop. Over the past month, the stock decreased by 5.47%, but over the past year, it actually increased by 27.25%.",BIIB,0.401331,0.016774,Neutral
 ( BIIB )  - Analyzing Biogen's Short Interest - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/03/31400036/biib-analyzing-biogens-short-interest,2023-03-17 15:45:23,"Biogen's BIIB short percent of float has risen 8.21% since its last report. The company recently reported that it has 1.85 million shares sold short, which is 1.45% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their ...",BIIB,0.224903,0.158881,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Down 2.3% Since Last Earnings Report: Can It Rebound?,https://www.zacks.com/stock/news/2067425/biogen-inc-biib-down-23-since-last-earnings-report-can-it-rebound,2023-03-17 15:30:53,Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BIIB,0.49407,0.154915,Somewhat-Bullish
"Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/03/31385552/biogen-triumphs-in-legal-battle-regarding-tecfidera-delaying-eu-generic-erosion-for-another-year,2023-03-16 17:51:05,The Court of Justice of the European Union favored Biogen Inc BIIB regarding its appeal of a General Court decision annulling the European Medicines Agency's ( EMA ) refusal to evaluate a generic version of Tecfidera due to regulatory data and marketing protection.,BIIB,0.76367,0.516412,Bullish
"Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments - Eisai Co Ltd ADR  ( OTC:ESALY ) , Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/03/31380813/alzheimers-association-launches-grassroots-level-lobbying-for-medicare-coverage-of-alzheimers-tre,2023-03-16 16:00:51,"The Alzheimer's Association has launched a grassroots lobbying campaign while deploying 1,000 people, either patients or caring for someone with the disease, to meet with all 535 members of Congress across the U.S. and urge them to press Medicare program for the drugs starting with Biogen Inc ...",BIIB,0.582526,0.402711,Bullish
"Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More",https://www.zacks.com/stock/news/2066904/biotech-stock-roundup-acads-drug-approval-sgen-to-be-acquired-by-pfe-more,2023-03-16 15:20:00,"Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.",BIIB,0.046999,0.044897,Neutral
Biogen  ( BIIB )  Up 29% in a Year Despite Multiple Challenges,https://www.zacks.com/stock/news/2066604/biogen-biib-up-29-in-a-year-despite-multiple-challenges,2023-03-16 12:43:00,"Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.",BIIB,0.46648,0.162407,Somewhat-Bullish
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERAÂ®  ( dimethyl fumarate )  Regulatory Data and Marketing Protection - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/03/g31375808/biogen-receives-favorable-decision-from-court-of-justice-of-the-european-union-relating-to-tecfide,2023-03-16 10:30:14,"CAMBRIDGE, Mass., March 16, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc.",BIIB,0.336852,0.251878,Somewhat-Bullish
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERAÂ®  ( dimethyl fumarate )  Regulatory Data and Marketing Protection,https://www.globenewswire.com/news-release/2023/03/16/2628437/0/en/Biogen-Receives-Favorable-Decision-from-Court-of-Justice-of-the-European-Union-Relating-to-TECFIDERA-dimethyl-fumarate-Regulatory-Data-and-Marketing-Protection.html,2023-03-16 10:30:00,"CAMBRIDGE, Mass., March 16, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency ( EMA ) , and the European Commission in their appeal of a General Court decision ...",BIIB,0.302642,0.354213,Bullish
Should You Invest in the SPDR S&P Biotech ETF  ( XBI ) ?,https://www.zacks.com/stock/news/2066519/should-you-invest-in-the-spdr-sp-biotech-etf-xbi,2023-03-16 10:20:07,Sector ETF report for ...,BIIB,0.127456,0.003566,Neutral
Alzheimer's Association lobbies for Medicare coverage of Leqembi and other drugs,https://www.reuters.com/business/healthcare-pharmaceuticals/alzheimers-association-lobbies-medicare-coverage-leqembi-other-drugs-2023-03-16/,2023-03-16 10:11:00,Alzheimer's Association lobbies for Medicare coverage of Leqembi ... ...,BIIB,0.122062,0.055539,Neutral
Biogen Inc.  ( BIIB )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2066421/biogen-inc-biib-gains-as-market-dips-what-you-should-know,2023-03-15 22:00:23,"Biogen Inc. (BIIB) closed the most recent trading day at $262.37, moving +0.01% from the previous trading session.",BIIB,0.625937,0.269944,Somewhat-Bullish
Biogen's Debt Overview - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/03/31368708/biogens-debt-overview,2023-03-15 19:45:41,"Over the past three months, shares of Biogen Inc. BIIB decreased by 7.79%. Before having a look at the importance of debt, let's look at how much debt Biogen has. According to the Biogen's most recent balance sheet as reported on February 15, 2023, total debt is at $6.28 billion, with $6.28 ...",BIIB,0.406197,0.135037,Neutral
Biogen Inc.  ( BIIB )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2065781/biogen-inc-biib-gains-but-lags-market-what-you-should-know,2023-03-14 22:15:23,"In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day.",BIIB,0.661658,0.246575,Somewhat-Bullish
"Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity - Eisai Co Ltd ADR  ( OTC:ESALY ) , Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/03/31342277/analyst-says-biogen-eisais-alzheimers-treatment-leqembi-coverage-enables-access-to-over-2-5b-mark,2023-03-14 17:34:52,Eisai Co Ltd ESALY and Biogen Inc BIIB said the U.S. Department of Veteran Affairs ( VA ) would provide coverage of their Alzheimer's treatment Leqembi ( lecanemab ) to veterans at an early stage.,BIIB,0.401331,0.125513,Neutral
The VA Will Pay for Leqembi. It's a Step in Right Direction for Biogen.,https://www.barrons.com/articles/va-medicare-alzheimer-biogen-leqembi-8b190949,2023-03-14 15:00:40,"Biogen and its partner Eisai notched a win in their campaign to get U.S. government agencies to pay for their new Alzheimer's disease therapy, but their goal of full Medicare coverage remains a long way off.",BIIB,0.485711,0.098904,Neutral
"1 Reason to Buy Biogen Stock, and 1 Reason to Sell",https://www.fool.com/investing/2023/03/14/1-reason-to-buy-biogen-stock-and-1-reason-to-sell/,2023-03-14 14:23:00,It could be a make or break year for the biotech.,BIIB,0.558244,0.335416,Somewhat-Bullish
Biogen Appoints Chuck Triano as Head of Investor Relations,https://www.globenewswire.com/news-release/2023/03/14/2626506/0/en/Biogen-Appoints-Chuck-Triano-as-Head-of-Investor-Relations.html,2023-03-14 11:30:00,"CAMBRIDGE, Mass., March 14, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( NASDAQ: BIIB ) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief ...",BIIB,0.213423,0.30554,Somewhat-Bullish
Biogen Appoints Chuck Triano as Head of Investor Relations - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/03/g31336884/biogen-appoints-chuck-triano-as-head-of-investor-relations,2023-03-14 11:30:00,"CAMBRIDGE, Mass., March 14, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial Officer.",BIIB,0.210457,0.299159,Somewhat-Bullish
Veterans' Health will cover Alzheimer's treatment Leqembi for some patients,https://www.cnbc.com/2023/03/13/veterans-health-will-cover-alzheimers-treatment-leqembi-for-some-patients.html,2023-03-13 20:48:37,"Veterans with early Alzheimer's who meet certain VHA criteria can get the treatment covered, according to Eisai.",BIIB,0.06179,0.211173,Somewhat-Bullish
Veterans to get coverage of Alzheimer's drug Medicare won't pay for,https://www.axios.com/2023/03/13/veterans-alzheimers-drug-insurance-coverage,2023-03-13 20:18:11,"The Veterans Health Administration said Monday that it intends to pay for a $26,500-a-year experimental Alzheimer's drug that the Centers for Medicare and Medicaid Services has to date declined to cover.",BIIB,0.154455,0.24294,Somewhat-Bullish
"Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone - Sage Therapeutics  ( NASDAQ:SAGE ) ",https://www.benzinga.com/general/biotech/23/03/31326007/analyst-creates-bullish-pitch-for-sage-therapeutics-around-greater-enthusiasm-for-its-depression-,2023-03-13 17:25:29,"RBC Capital Markets has upgraded Sage Therapeutics Inc SAGE to Outperform from Sector Perform with a price target of $60, up from $40. The analyst sees a more substantial likelihood that depression candidate zuranolone will win FDA approval.",BIIB,0.666827,0.527218,Bullish
Yellow.ai recognized as a Challenger in the 2023 GartnerÂ® Magic Quadrantâ¢ for Enterprise Conversational AI Platforms,https://www.prnewswire.com/news-releases/yellowai-recognized-as-a-challenger-in-the-2023-gartner-magic-quadrant-for-enterprise-conversational-ai-platforms-301770337.html,2023-03-13 16:05:00,Yellow.ai recognized as a Challenger in the 2023 GartnerÂ® Magic ... PR ...,BIIB,0.062434,0.130339,Neutral
Yellow.ai recognized as a Challenger in the 2023 GartnerÂ® Magic Quadrantâ¢ for Enterprise Conversational AI Platforms,https://www.newswire.ca/news-releases/yellow-ai-recognized-as-a-challenger-in-the-2023-gartner-r-magic-quadrant-tm-for-enterprise-conversational-ai-platforms-820066622.html,2023-03-13 16:05:00,Yellow.ai recognized as a Challenger in the 2023 GartnerÂ® Magic ... Canada ...,BIIB,0.062434,0.130339,Neutral
AMGN: 2 Top Biotech Stocks to Buy in March,https://stocknews.com/news/amgn-biib-azn-2-top-biotech-stocks-to-buy-in-march/,2023-03-13 14:59:11,"Despite macroeconomic uncertainties, the biotech industry has performed relatively well over the last year, owing to breakthrough advancements and inelastic demand for healthcare products and services. So, investors could consider buying shares of Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ) now.",BIIB,0.326746,0.175461,Somewhat-Bullish
Price Over Earnings Overview: Biogen - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/03/31617427/price-over-earnings-overview-biogen,2023-03-31 20:30:23,"In the current session, the stock is trading at $278.03, after a 1.05% increase. Over the past month, Biogen Inc. BIIB stock increased by 2.87%, and in the past year, by 31.37%.",BIIB,0.43852,0.121907,Neutral
Lilly says experimental Alzheimer's drug reduces amyloid in small study,https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-says-experimental-alzheimers-drug-reduces-amyloid-small-study-2023-03-31/,2023-03-31 12:32:00,Lilly says experimental Alzheimer's drug reduces amyloid in small ... ...,BIIB,0.09186,0.129222,Neutral
"Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug - Eisai Co Ltd ADR  ( OTC:ESALY ) , Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/03/31606007/eisai-biogen-highlights-additional-data-from-recently-approved-alzheimers-drug,2023-03-31 11:57:51,Eisai Co Ltd ESALY and Biogen Inc BIIB announced that three additional detailed analyses from the Phase IIb clinical study ( Study 201 ) of lecanemab for mild cognitive impairment ( MCI ) due to Alzheimer's disease ( AD ) and mild AD were published in the peer-reviewed journals.,BIIB,0.414559,0.106674,Neutral
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PDâ¢ 2023 Annual Meeting,https://www.globenewswire.com/news-release/2023/03/30/2638301/0/en/Eisai-Presented-New-Analyses-of-ARIA-and-QOL-on-Lecanemab-in-Clarity-AD-at-the-AD-PD-2023-Annual-Meeting.html,2023-03-30 23:30:00,"TOKYO and CAMBRIDGE, Mass., March 30, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"" ) announced today that Eisai presented new ...",BIIB,0.227662,0.092905,Neutral
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/03/g31600926/additional-detailed-analyses-from-phase-2-study-201-of-lecanemab-published-as-three-papers-in-peer,2023-03-30 23:30:00,"TOKYO and CAMBRIDGE, Mass., March 30, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"" ) and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.",BIIB,0.195571,0.046062,Neutral
Novavax  ( NVAX )  Down 2.9% Since Last Earnings Report: Can It Rebound?,https://www.zacks.com/stock/news/2072516/novavax-nvax-down-29-since-last-earnings-report-can-it-rebound,2023-03-30 15:30:38,Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BIIB,0.21686,0.057505,Neutral
Amyotrophic Lateral Sclerosis Treatment Market Size to Hit USD 436.17 Million by 2027 at 5.52% CAGR Reported by Brandessence Market Research,https://www.prnewswire.com/news-releases/amyotrophic-lateral-sclerosis-treatment-market-size-to-hit-usd-436-17-million-by-2027-at-5-52-cagr-reported-by-brandessence-market-research-301785993.html,2023-03-30 14:20:00,Amyotrophic Lateral Sclerosis Treatment Market Size to Hit USD ... PR ...,BIIB,0.061473,0.156123,Somewhat-Bullish
Roundtable of Experts Discusses 50-year Rise of Intangible Assets as Dominant Source of Corporate Investment and Equity Market Value Creation,https://www.prnewswire.com/news-releases/roundtable-of-experts-discusses-50-year-rise-of-intangible-assets-as-dominant-source-of-corporate-investment-and-equity-market-value-creation-301785146.html,2023-03-30 13:35:00,Roundtable of Experts Discusses 50-year Rise of Intangible Assets ... PR ...,BIIB,0.09402,0.096229,Neutral
NRG Therapeutics Announces International Scientific Advisory Board,https://www.benzinga.com/pressreleases/23/03/g31574017/nrg-therapeutics-announces-international-scientific-advisory-board,2023-03-30 08:00:00,"STEVENAGE, United Kingdom, March 30, 2023 ( GLOBE NEWSWIRE ) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board ( SAB ) , to support and steer its R&D programmes to develop novel ...",BIIB,0.039944,0.04722,Neutral
Biogen Inc.  ( BIIB )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2072129/biogen-inc-biib-gains-but-lags-market-what-you-should-know,2023-03-29 22:00:23,"Biogen Inc. (BIIB) closed at $274.01 in the latest trading session, marking a +1.39% move from the prior day.",BIIB,0.600271,0.299305,Somewhat-Bullish
GILD: 3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry,https://stocknews.com/news/gild-vrtx-biib-crsp-sage-3-of-the-best-stocks-in-1-of-wall-streets/,2023-03-29 14:59:32,"The biotech industry thrived during the pandemic with rising demand for drugs, therapies, and vaccines. However, various macroeconomic and regulatory challenges have hampered the industry's growth since last year, prompting massive layoffs and shutdowns.",BIIB,0.290894,0.248232,Somewhat-Bullish
New Data Presented at AD/PDâ¢ 2023 Show Biogen's BIIB080  ( MAPT ASO )  Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease,https://www.globenewswire.com/news-release/2023/03/29/2636687/0/en/New-Data-Presented-at-AD-PD-2023-Show-Biogen-s-BIIB080-MAPT-ASO-Substantially-Reduced-Tau-Protein-Levels-in-Patients-with-Early-stage-Alzheimer-s-Disease.html,2023-03-29 12:45:00,"CAMBRIDGE, Mass., March 29, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) reported new promising Phase 1b clinical data showing that the investigational antisense oligonucleotide ( ASO ) therapy, BIIB080, reduced soluble tau protein in cerebrospinal fluid ( CSF ) in a dose-dependent ...",BIIB,0.355023,0.058958,Neutral
Is SPDR S&P Biotech ETF  ( XBI )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2071156/is-spdr-sp-biotech-etf-xbi-a-strong-etf-right-now,2023-03-28 10:20:06,Smart Beta ETF report for ...,BIIB,0.114137,0.003386,Neutral
Alzheimer's Breakthrough? Researchers Find New Omega-3 Acid That Could Reduce Vision Loss In Patients,https://www.forbes.com/sites/brianbushard/2023/03/27/alzheimers-breakthrough-researchers-find-new-omega-3-acid-that-could-reduce-vision-loss-in-patients/,2023-03-27 22:15:52,"Researchers say the omega-3 fatty acid, which is different from omega-3 found in fish oil supplements, can cross into the eye and potentially ward off visual decline.",BIIB,0.070935,-0.04473,Neutral
Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2071081/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know,2023-03-27 22:15:19,"Biogen Inc. (BIIB) closed at $269.98 in the latest trading session, marking a -0.02% move from the prior day.",BIIB,0.548363,0.258198,Somewhat-Bullish
Ionis  ( IONS )  Posts New Upbeat Data From Amyloidosis Drug Study,https://www.zacks.com/stock/news/2070884/ionis-ions-posts-new-upbeat-data-from-amyloidosis-drug-study,2023-03-27 15:42:00,"Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).",BIIB,0.429845,0.22999,Somewhat-Bullish
"Non-hodgkin lymphoma therapeutics market size to increase by USD 5,427.51 million between 2022 and 2027; Growing awareness about cancer as a key trend - Technavio",https://www.prnewswire.com/news-releases/non-hodgkin-lymphoma-therapeutics-market-size-to-increase-by-usd-5-427-51-million-between-2022-and-2027-growing-awareness-about-cancer-as-a-key-trend---technavio-301779830.html,2023-03-24 18:00:00,Non-hodgkin lymphoma therapeutics market size to increase by ... PR ...,BIIB,0.037387,-0.019406,Neutral
AbbVie  ( ABBV )  Provides Clinical Updates on Inflammatory Drugs,https://www.zacks.com/stock/news/2070329/abbvie-abbv-provides-clinical-updates-on-inflammatory-drugs,2023-03-24 16:56:00,AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus meet their primary endpoints.,BIIB,0.224383,0.075097,Neutral
US FDA moots more rigorous trials for accelerated nod of cancer therapy,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-seeks-more-rigorous-trials-cancer-drugs-accelerated-nod-2023-03-24/,2023-03-24 15:58:00,US FDA moots more rigorous trials for accelerated nod of cancer ... ...,BIIB,0.118647,0.015588,Neutral
FDA advisers give partial backing to ALS drug,https://www.axios.com/2023/03/23/fda-advisers-als-drug-tofersen,2023-03-24 02:43:13,"Food and Drug Administration advisers on Wednesday signaled openness to expediting an experimental drug from Biogen that targets a rare form of ALS, or Lou Gehrig's disease.",BIIB,0.159569,0.111998,Neutral
Biogen Unusual Options Activity - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/markets/options/23/03/31481763/biogen-unusual-options-activity,2023-03-23 19:45:41,"A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen BIIB we detected 12 strange trades. If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations ...",BIIB,0.688096,0.056509,Neutral
"Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval",https://www.zacks.com/stock/news/2069798/biotech-stock-roundup-alt-obesity-data-gild-exercises-option-incy-drug-approval,2023-03-23 17:51:00,Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.,BIIB,0.137083,0.038663,Neutral
Biogen  ( BIIB )  Gets Positive FDA Panel Vote for Tofersen NDA,https://www.zacks.com/stock/news/2069672/biogen-biib-gets-positive-fda-panel-vote-for-tofersen-nda,2023-03-23 14:53:00,The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.,BIIB,0.420608,0.278479,Somewhat-Bullish
Ionis Rockets As Biogen-Tied ALS Drug Wins Key Endorsement,https://www.investors.com/news/technology/ionis-stock-rockets-as-biogen-partnered-als-drug-wins-key-endorsement/,2023-03-23 13:25:26,"Ionis stock jumped Thursday after a Food and Drug Administration panel offered a mixed view of its Biogen ( BIIB ) -partnered treatment for a deadly neurodegenerative condition. The companies are hoping to win approval for tofersen, a potential treatment for a rare form of ALS, or amyotrophic ...",BIIB,0.655281,-0.1933,Somewhat-Bearish
"FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder - Ionis Pharmaceuticals  ( NASDAQ:IONS ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/03/31470034/fda-adcomm-says-benefit-risk-profile-favor-biogens-tofersen-for-inherited-neuro-disorder,2023-03-23 11:12:28,"The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 9 yes - 0 no, indicating sufficient evidence showing a reduction in plasma neurofilament light chain ( NfL ) concentration in tofersen-treated patients is reasonably likely to predict the clinical benefit of tofersen ...",BIIB,0.410059,0.441981,Bullish
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/03/g31468189/biogen-provides-update-on-fda-advisory-committee-meeting-on-tofersen-for-sod1-als,2023-03-23 00:31:57,"CAMBRIDGE, Mass., March 22, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB announced today the outcome of the U.S. Food and Drug Administration's ( FDA ) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide ...",BIIB,0.247838,0.18457,Somewhat-Bullish
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS,https://www.globenewswire.com/news-release/2023/03/23/2632800/0/en/Biogen-Provides-Update-on-FDA-Advisory-Committee-Meeting-on-Tofersen-for-SOD1-ALS.html,2023-03-23 00:31:00,SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States ...,BIIB,0.247523,0.235956,Somewhat-Bullish
FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease,https://www.cnbc.com/2023/03/22/fda-advisors-vote-against-effectiveness-of-biogen-als-drug.html,2023-03-22 22:55:25,"FDA advisors voted against the effectiveness of Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.",BIIB,0.178021,0.087198,Neutral
FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease,https://www.cnbc.com/2023/03/22/fda-advisors-reject-accelerated-approval-of-biogens-als-drug.html,2023-03-22 21:36:36,"FDA advisors voted against Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.",BIIB,0.182736,0.088862,Neutral
US FDA panel votes against effectiveness of Biogen's ALS drug,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-votes-against-effectiveness-biogens-als-drug-2023-03-22/,2023-03-22 21:16:00,March 22 ( Reuters ) - A panel of U.S. Food and Drug Administration ( FDA ) advisers on Wednesday voted against the effectiveness of Biogen Inc's ( BIIB.O ) experimental treatment for an inherited form of amyotrophic lateral sclerosis ( ALS ) .,BIIB,0.17715,0.079054,Neutral
Alzheimer's Blood Test That Could Help Diagnose Disease Earlier Is Being Developed By Eli Lilly And Roche,https://www.forbes.com/sites/roberthart/2023/03/22/alzheimers-blood-test-that-could-help-diagnose-disease-earlier-is-being-developed-by-eli-lilly-and-roche/,2023-03-22 13:09:30,"If approved, the test could streamline the diagnostic journey and help patients get earlier access to future Alzheimer's treatments, Roche said.",BIIB,0.064104,-0.002023,Neutral
"iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach - Eisai Co  ( OTC:ESAIY ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/03/31454627/imetabolic-biopharmas-alzheimers-disease-therapeutic-innovation-is-a-breakthrough-three-pronged-a,2023-03-22 12:14:13,"iMetabolic BioPharma ( iMBP ) , an early-stage TechBio drug discovery company blending technology with biotechnology, launched a crowdfunding campaign on StartEngine to raise capital from individual investors as it makes plans to move into the neurodegenerative disease space with its addition of ...",BIIB,0.061003,0.026333,Neutral
Veterans Health Administration will cover new Alzheimer's drug. Why won't Medicare?,https://www.marketwatch.com/story/veterans-health-administration-will-cover-new-alzheimers-drug-why-wont-medicare-af7f7855,2023-03-22 09:04:00,Rift opens in Biden administration over Alzheimer's drug ...,BIIB,0.185781,0.080624,Neutral
Roche teams up with Lilly to validate Alzheimer's blood test,https://www.reuters.com/business/healthcare-pharmaceuticals/roche-teams-up-with-lilly-validate-alzheimers-blood-test-2023-03-22/,2023-03-22 06:13:00,"[1/2] A 3D printed Lilly logo and test tubes are seen in this Illustration taken, October 18, 2022. REUTERS/Dado Ruvic/Illustration",BIIB,0.076847,-0.052876,Neutral
Pharma CEOs Say US Abortion Pill Ruling Threatens Drug Development,https://www.barrons.com/news/pharma-ceos-say-us-abortion-pill-ruling-threatens-drug-development-2b33898c,2023-04-10 20:05:35,"Hundreds of pharmaceutical executives on Monday condemned a US judicial ruling outlawing a leading abortion pill, saying it threatens the development of needed medications in the United States.",BIIB,0.115232,-0.104932,Neutral
Top-Notch Biotech Logs 'Solid Jump' In Sales; Shares Rocket,https://www.investors.com/news/technology/tgtx-stock-rockets-on-solid-jump-in-ms-drug-sales/,2023-04-10 17:23:00,TGTX Stock Rockets On 'Solid Jump' In MS Drug Sales | Investor's ... Investor's Business Daily ...,BIIB,0.156461,-0.033271,Neutral
US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-weigh-full-approval-eisai-biogens-alzheimers-drug-2023-04-10/,2023-04-10 14:01:00,US FDA advisers to weigh full approval for Eisai-Biogen's ... ...,BIIB,0.202366,0.109128,Neutral
"DNA: 2 Biotech Stocks That Are Screaming ""SELL ME!""",https://stocknews.com/news/dna-nvax-2-biotech-stocks-that-are-screaming-sell-me/,2023-04-10 13:14:29,"The biotech industry thrived during the pandemic. However, despite robust demand, the industry is currently pressured by macroeconomic headwinds and layoffs. Hence, let's take a look at biotech stocks Ginkgo Bioworks Holdings, Inc. ( DNA ) and Novavax, Inc. ( NVAX ) and discuss why it's best to ...",BIIB,0.101797,-0.084292,Neutral
"TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors",https://www.globenewswire.com/news-release/2023/04/10/2643534/0/en/TScan-Therapeutics-Announces-Appointment-of-Barbara-Klencke-M-D-to-its-Board-of-Directors.html,2023-04-10 11:00:00,Deepens the Board's clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance ...,BIIB,0.023464,-0.00089,Neutral
"TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors - TScan Therapeutics  ( NASDAQ:TCRX ) ",https://www.benzinga.com/pressreleases/23/04/g31723078/tscan-therapeutics-announces-appointment-of-barbara-klencke-m-d-to-its-board-of-directors,2023-04-10 11:00:00,"Deepens the Board's clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance Company also announces key leadership promotions WALTHAM, Mass., April 10, 2023 ( GLOBE NEWSWIRE ) -- TScan Therapeutics, Inc.",BIIB,0.023013,-0.001774,Neutral
"Alzheimer's patients retain the benefits of Leqembi even when they stop the drug, Eisai says",https://www.cnbc.com/2023/04/06/eisai-alzheimers-patients-retain-the-benefits-of-leqembi-when-they-stop-the-drug.html,2023-04-06 22:26:44,"Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.",BIIB,0.089462,0.055535,Neutral
"Alzheimer's patients retain the benefits of Leqembi even when they stop the drug, Eisai says",https://www.cnbc.com/2023/04/06/alzheimers-eisai-leqembi-patients-retain-benefits-when-they-stop-drug.html,2023-04-06 21:20:35,"Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.",BIIB,0.089462,0.055535,Neutral
Prothena  ( PRTA )  Gains 29% in One Year: Will the Momentum Continue?,https://www.zacks.com/stock/news/2075748/prothena-prta-gains-29-in-one-year-will-the-momentum-continue,2023-04-06 17:49:00,Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.,BIIB,0.133841,0.313221,Somewhat-Bullish
Club meeting recap: Jim Cramer says 'the existential threat is gone for J&J',https://www.cnbc.com/2023/04/05/jim-cramer-says-the-existential-threat-is-gone-for-jj-.html,2023-04-05 16:23:16,"The Investing Club holds its ""Morning Meeting"" every weekday at 10:20 a.m. ET.",BIIB,0.147366,0.057003,Neutral
Eli Lilly says experimental Alzheimer's drug reduces brain plaque in early study,https://www.cnbc.com/2023/04/05/eli-lilly-says-alzheimers-drug-reduces-brain-plaque-in-early-study.html,2023-04-05 14:21:31,"Eli Lilly said a higher dose of the up-and-coming Alzheimer's treatment, remternetug, had a larger effect on clearing amyloid plaque.",BIIB,0.064797,0.098623,Neutral
"Jim Cramer's top 10 things to watch in the stock market Wednesday: New dawn for JNJ, Disney push, Meta upgrade",https://www.cnbc.com/2023/04/05/cramers-things-to-watch-in-stock-market-wednesday.html,2023-04-05 12:51:53,"Big victory for an embattled Club name, positive analyst calls for META and Apple.",BIIB,0.127456,0.108139,Neutral
Biogen Inc.  ( BIIB )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2074589/biogen-inc-biib-dips-more-than-broader-markets-what-you-should-know,2023-04-04 22:15:20,"In the latest trading session, Biogen Inc. (BIIB) closed at $275.25, marking a -0.75% move from the previous day.",BIIB,0.654859,0.200378,Somewhat-Bullish
Biogen Appoints Adam Keeney as Head of Corporate Development - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/04/g31651697/biogen-appoints-adam-keeney-as-head-of-corporate-development,2023-04-04 11:30:00,"CAMBRIDGE, Mass., April 04, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen's Executive Committee reporting to Christopher A.",BIIB,0.268084,0.242802,Somewhat-Bullish
Biogen Appoints Adam Keeney as Head of Corporate Development,https://www.globenewswire.com/news-release/2023/04/04/2640516/0/en/Biogen-Appoints-Adam-Keeney-as-Head-of-Corporate-Development.html,2023-04-04 11:30:00,"CAMBRIDGE, Mass., April 04, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen's Executive Committee reporting to ...",BIIB,0.254751,0.296309,Somewhat-Bullish
A Look Into Biogen's Debt - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/04/31635294/a-look-into-biogens-debt,2023-04-03 14:30:45,"Shares of Biogen Inc. BIIB rose by 2.54% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials. One key aspect of a companies financials is its debt, but before we understand the importance of debt, ...",BIIB,0.277958,-0.021616,Neutral
"Top Stories Monday, Apr. 3: Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices - Activision Blizzard  ( NASDAQ:ATVI ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/04/31634317/tesla-manufactured-4-000-model-ys-in-one-week-ubs-prepping-for-massive-layoffs-mcdonalds-temporar,2023-04-03 14:01:48,"UBS Group AG UBS, which agreed to buy peer Credit Suisse AG CS in a central-bank-brokered deal, is preparing to eliminate about 20 to 30% of jobs worldwide. UBS is expected to announce up to 36,000 job cuts across its branches. As many as 11,000 employees in Switzerland would be laid off.",BIIB,0.076602,0.223333,Somewhat-Bullish
"National Institute on Aging Aims Building $300M Alzheimer's Research Database - Eisai Co Ltd ADR  ( OTC:ESALY ) , Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/04/31629876/national-institute-on-aging-aims-building-300m-alzheimers-research-database,2023-04-03 13:47:34,"The U.S. National Institute on Aging ( NIA ) , part of the government's National Institutes of Health ( NIH ) , aims to build an Alzheimer's research database.",BIIB,0.266828,0.413318,Bullish
Exclusive: US to build $300 mln database to fuel Alzheimer's research,https://www.reuters.com/business/healthcare-pharmaceuticals/us-build-300-mln-database-fuel-alzheimers-research-2023-04-03/,2023-04-03 10:07:00,"CHICAGO, April 3 ( Reuters ) - The U.S. National Institute on Aging ( NIA ) is funding a 6-year, up to $300 million project to build a massive Alzheimer's research database that can track the health of Americans for decades and enable researchers to gain new insights on the brain-wasting disease.",BIIB,0.063258,0.0,Neutral
Virtual Reality company Virtualware to start trading in Euronext Paris on April 20,https://www.benzinga.com/pressreleases/23/04/g31626457/virtual-reality-company-virtualware-to-start-trading-in-euronext-paris-on-april-20,2023-04-03 08:23:36,"BILBAO, Spain and PARIS, April 03, 2023 ( GLOBE NEWSWIRE ) -- European company Virtualware, one of the European leaders in the Virtual Reality industry, will start trading on Euronext Paris on April 20.",BIIB,0.136113,0.098444,Neutral
Better Big Biotech Buy: Biogen vs. Vertex,https://www.fool.com/investing/2023/04/20/better-big-biotech-buy-biogen-vs-vertex/,2023-04-20 18:00:00,One is slightly cheaper than the other.,BIIB,0.51159,0.393412,Bullish
Amgen  ( AMGN )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?,https://www.zacks.com/stock/news/2082079/amgen-amgn-expected-to-beat-earnings-estimates-can-the-stock-move-higher,2023-04-20 14:03:12,Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BIIB,0.173333,-0.001414,Neutral
What Does Biogen's Debt Look Like? - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/04/31902174/what-does-biogens-debt-look-like,2023-04-19 20:31:04,"Shares of Biogen Inc. BIIB increased by 0.12% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.",BIIB,0.377142,0.128531,Neutral
P/E Ratio Insights for Biogen - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/04/31896682/pe-ratio-insights-for-biogen,2023-04-19 16:45:31,"In the current market session, Biogen Inc. BIIB stock price is at $292.48, after a 0.46% decrease. However, over the past month, the company's stock spiked by 11.97%, and in the past year, by 33.92%.",BIIB,0.348919,0.009866,Neutral
"Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates",https://www.zacks.com/stock/news/2081528/biotech-stock-roundup-mdgl-pcvx-up-on-study-data-mrna-provides-updates,2023-04-19 15:36:00,"Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.",BIIB,0.046184,0.123433,Neutral
Biogen  ( BIIB )  to Report Q1 Earnings: Here's What to Expect,https://www.zacks.com/stock/news/2081377/biogen-biib-to-report-q1-earnings-heres-what-to-expect,2023-04-19 14:29:00,"Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.",BIIB,0.33884,0.205797,Somewhat-Bullish
"Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors",https://www.globenewswire.com/news-release/2023/04/19/2649959/0/en/Keros-Therapeutics-Appoints-Alpna-Seth-Ph-D-to-its-Board-of-Directors.html,2023-04-19 12:00:00,"LEXINGTON, Mass., April 19, 2023 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( ""Keros"" or the ""Company"" ) ( Nasdaq: KROS ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, ...",BIIB,0.243701,-0.043299,Neutral
Agios Appoints Jeffrey Capello to Board of Directors,https://www.globenewswire.com/news-release/2023/04/19/2649857/31990/en/Agios-Appoints-Jeffrey-Capello-to-Board-of-Directors.html,2023-04-19 11:00:00,- Board Member Paul Clancy Will Step Down at the End of His Term ...,BIIB,0.036532,0.044678,Neutral
Agios Appoints Jeffrey Capello to Board of Directors - Agios Pharmaceuticals  ( NASDAQ:AGIO ) ,https://www.benzinga.com/pressreleases/23/04/g31886205/agios-appoints-jeffrey-capello-to-board-of-directors,2023-04-19 11:00:00,"- Board Member Paul Clancy Will Step Down at the End of His Term - CAMBRIDGE, Mass., April 19, 2023 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Jeffrey Capello has been appointed ...",BIIB,0.035502,0.044479,Neutral
Global Biosimilars Business and Investment Opportunities 2023: Attractive Approval Numbers Present Fertile Ground for New Entrants,https://www.prnewswire.com/news-releases/global-biosimilars-business-and-investment-opportunities-2023-attractive-approval-numbers-present-fertile-ground-for-new-entrants-301800267.html,2023-04-18 17:45:00,Global Biosimilars Business and Investment Opportunities 2023 ... PR ...,BIIB,0.050894,0.076564,Neutral
Earnings Preview: Biogen Inc.  ( BIIB )  Q1 Earnings Expected to Decline,https://www.zacks.com/stock/news/2080440/earnings-preview-biogen-inc-biib-q1-earnings-expected-to-decline,2023-04-18 14:01:15,Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BIIB,0.29887,-0.024532,Neutral
Is Biogen Stock a Buy Now?,https://www.fool.com/investing/2023/04/18/is-biogen-stock-a-buy-now/,2023-04-18 13:53:00,The company's fascinating saga in the Alzheimer's disease drug market continues.,BIIB,0.741707,0.449295,Bullish
"Virtualware will start trading in Paris on Thursday, at 27.25 million valuation",https://www.benzinga.com/pressreleases/23/04/g31848161/virtualware-will-start-trading-in-paris-on-thursday-at-27-25-million-valuation,2023-04-18 09:10:15,"BILBAO, Spain and PARIS, April 18, 2023 ( GLOBE NEWSWIRE ) -- Virtualware, which develops industrial virtual reality platforms for the nuclear, medical, educational and defense industries, will be listed on Euronext Access Paris next Thursday, April 20, at a valuation of 27.25 million euros.",BIIB,0.129516,0.096012,Neutral
"Leqembi Sales To Propel Biogen Stock To New Heights, Says Bullish Analyst",https://markets.businessinsider.com/news/stocks/leqembi-sales-to-propel-biogen-stock-to-new-heights-says-bullish-analyst-1032237325,2023-04-17 18:08:00,"Piper Sandler analyst Christopher J. Raymond upgraded Biogen Inc ( NASDAQ:BIIB ) to Overweight, raising the price target to $346.",BIIB,0.414559,0.193946,Somewhat-Bullish
"Leqembi Sales To Propel Biogen Stock To New Heights, Says Bullish Analyst - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/23/04/31834905/leqembi-sales-to-propel-biogen-stock-to-new-heights-says-bullish-analyst,2023-04-17 18:07:59,"Piper Sandler analyst Christopher J. Raymond upgraded Biogen Inc BIIB to Overweight, raising the price target to $346.",BIIB,0.550532,0.240349,Somewhat-Bullish
Canada Infrastructure Bank invests $100 million with Noventa to decarbonize buildings,https://www.newswire.ca/news-releases/canada-infrastructure-bank-invests-100-million-with-noventa-to-decarbonize-buildings-856718257.html,2023-04-17 15:50:00,Canada Infrastructure Bank invests $100 million with Noventa to ... Canada ...,BIIB,0.059194,0.059274,Neutral
Should BNY Mellon US Mid Cap Core Equity ETF  ( BKMC )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2079427/should-bny-mellon-us-mid-cap-core-equity-etf-bkmc-be-on-your-investing-radar,2023-04-17 10:20:03,Style Box ETF report for ...,BIIB,0.129168,0.077091,Neutral
How The Texas Abortion Ruling Could Destroy Biotech Stocks,https://www.investors.com/news/technology/biotech-stocks-how-the-texas-abortion-ruling-could-be-their-undoing/,2023-04-14 12:15:00,"A federal judge's decision in Texas to outlaw a decades-old abortion drug undermines the foundation of all biotech stocks, warns a group of nearly 600 health care executives and experts. Chiefs of big medical names like Pfizer ( PFE ) , Biogen ( BIIB ) and Incyte ( INCY ) are uniting to oppose ...",BIIB,0.074926,0.020285,Neutral
"Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say",https://www.cnbc.com/2023/04/13/abortion-pill-blocking-fda-approval-could-harm-biopharma-innovation.html,2023-04-13 19:37:18,"A complicated legal fight over abortion pill mifepristone could reduce innovation in the biopharma industry, companies and experts in law and economics said.",BIIB,0.041039,0.086158,Neutral
Upcoming Boston special elections are all about housing,https://www.axios.com/local/boston/2023/04/13/boston-elections-all-about-housing,2023-04-13 10:22:00,"Voters in Boston want the state to do more to tackle the cost of living in the city, and they're making sure the candidates running for two open seats on Beacon Hill know where they stand. Why it matters: Gov.",BIIB,0.102888,0.030944,Neutral
"Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: ""Devastating Risks"" Ahead - VanEck Biotech ETF  ( NASDAQ:BBH ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/04/31752497/attorney-generals-of-over-20-states-sound-alarm-over-suspension-of-abortion-med-approval-devastat,2023-04-11 18:28:28,"In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone ""presents devastating risks to millions of people,"" including those in states where abortion remains legal.",BIIB,0.136888,0.177593,Somewhat-Bullish
Celebrating Canada's Global Leadership in Access to Biosimilars,https://www.newswire.ca/news-releases/celebrating-canada-s-global-leadership-in-access-to-biosimilars-882616997.html,2023-04-11 16:23:00,"TORONTO, April 11, 2023 /CNW/ - With Ontario, Newfoundland & Labrador and the Yukon each implementing new policies over the past few days, nearly 96% of Canadians now live in jurisdictions with expanded access to biosimilars.",BIIB,0.126784,0.165145,Somewhat-Bullish
"Top Stories Tuesday, Apr. 11: Twitter Inc Is Officially Defunct, Alibaba Plans to Integrate ChatGPT Like Chatbot Across Products - Alibaba Group Holding  ( NYSE:BABA ) , Boeing  ( NYSE:BA ) ",https://www.benzinga.com/general/biotech/23/04/31742441/twitter-inc-is-officially-defunct-alibaba-plans-to-integrate-chatgpt-like-chatbot-across-products,2023-04-11 13:16:37,"Twitter Inc, the parent company of the namesake social media platform, has ceased to exist, and it has now been merged into X Corp., court filings show. 'Chief Twit' Elon Musk also appeared to acknowledge the change early on Tuesday by tweeting out ""X.""",BIIB,0.076358,0.068808,Neutral
"Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension - Ovid Therapeutics  ( NASDAQ:OVID ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/04/31739346/drugmakers-stand-up-for-reproductive-rights-pfizer-and-biogen-among-300-condemning-abortion-pill-,2023-04-11 11:48:20,"Last week Friday, a U.S. judge suspended the FDA's approval of mifepristone, effectively banning sales. Executives from over 300 companies, including Pfizer Inc PFE and Biogen Inc BIIB, signed an open letter calling to reverse a federal judge's decision. The abortion pill has been available since ...",BIIB,0.362505,0.101557,Neutral
"Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease",https://www.cnbc.com/2023/04/30/alzheimers-treatment-patients-may-wait-years-for-new-drugs.html,2023-04-30 13:00:01,Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.,BIIB,0.029078,0.083295,Neutral
3 Biotech Buyout Targets to Watch,https://www.fool.com/investing/2023/04/29/3-biotech-buyout-targets-to-watch/,2023-04-29 12:25:00,The trio all have late-stage therapies with blockbuster potential.,BIIB,0.045918,0.070795,Neutral
AbbVie  ( ABBV )  Q1 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/04/28/abbvie-abbv-q1-2023-earnings-call-transcript/,2023-04-28 19:35:18,"ABBV earnings call for the period ending March 31, 2023.",BIIB,0.004719,0.117671,Neutral
Looking At Biogen's Recent Unusual Options Activity - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/markets/options/23/04/32090120/looking-at-biogens-recent-unusual-options-activity,2023-04-28 17:47:01,"A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen BIIB we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations ...",BIIB,0.760593,0.043082,Neutral
Market Rally Volatile And Tight Amid Big Earnings Moves,https://www.investors.com/news/market-rally-wobbles-amid-big-earnings-moves-from-microsoft-meta-crocs-cloudflare/,2023-04-28 16:36:00,Market Rally Wobbles Amid Big Earnings Moves From Microsoft ... Investor's Business Daily ...,BIIB,0.036532,-0.06261,Neutral
"AbbVie  ( ABBV )  Q1 Earnings Beat, Skyrizi Sales Underperform",https://www.zacks.com/stock/news/2086355/abbvie-abbv-q1-earnings-beat-skyrizi-sales-underperform,2023-04-27 16:33:00,"AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.",BIIB,0.042421,0.055312,Neutral
REGN: A Prescription for Success: Check Out This Strong Pharmaceutical Stock This Week,https://stocknews.com/news/regn-biib-gild-vnda-a-prescription-for-success-check-out-this-strong-pharmaceutical-stock/,2023-04-27 15:54:46,REGN: A Prescription for Success: Check Out This Strong ... ...,BIIB,0.150592,0.228145,Somewhat-Bullish
"The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio",https://www.zacks.com/stock/news/2085613/the-zacks-analyst-blog-highlights-biogen-incyte-morphic-therapeutic-and-bluebird-bio,2023-04-27 10:10:00,"Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.",BIIB,0.263535,0.029715,Neutral
"Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says",https://www.cnbc.com/2023/04/26/medicare-will-cover-alzheimers-treatment-leqembi-after-fda-approves.html,2023-04-26 17:44:14,"Medicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis.",BIIB,0.048621,0.112001,Neutral
Why Legend Biotech Stock Is Having Its Best Month Yet - Legend Biotech  ( NASDAQ:LEGN ) ,https://www.benzinga.com/general/biotech/23/04/32007247/why-legend-biotech-stock-is-having-its-best-month-yet,2023-04-26 16:37:45,"Legend Biotech Corporation LEGN is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that. On April 19th, a data leak revealed that Legend Biotech's Carvykti, a blood cancer therapy, performed extremely well in a recent ...",BIIB,0.045054,0.097348,Neutral
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/general/biotech/23/04/32011471/biogens-amyotrophic-lateral-sclerosis-drug-scores-conditional-approval-from-fda,2023-04-26 15:53:20,The FDA approved Biogen Inc's BIIB Qalsody ( tofersen ) for amyotrophic lateral sclerosis ( ALS ) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene.,BIIB,0.673107,0.212287,Somewhat-Bullish
"If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/earnings/23/04/32014291/if-you-invested-100-in-this-stock-15-years-ago-you-would-have-500-today,2023-04-26 15:30:21,"Biogen BIIB has outperformed the market over the past 15 years by 3.79% on an annualized basis producing an average annual return of 11.11%. Currently, Biogen has a market capitalization of $40.28 billion.",BIIB,0.983605,0.387251,Bullish
"Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More",https://www.zacks.com/stock/news/2084870/drugbiotech-stocks-q1-earnings-due-apr-27-lly-abbv-more,2023-04-26 13:28:00,Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.,BIIB,0.038407,0.106241,Neutral
"Alphabet To Rally Around 36%? Here Are 10 Other Analyst Forecasts For Wednesday - Apple  ( NASDAQ:AAPL ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/23/04/32009677/alphabet-to-rally-around-36-here-are-10-other-analyst-forecasts-for-wednesday,2023-04-26 12:55:02,Morgan Stanley raised the price target for Alphabet Inc. GOOGL from $135 to $140. Morgan Stanley analyst Brian Nowak maintained an Overweight rating. Alphabet shares fell 1% to $102.83 in pre-market trading. UBS cut the price target for Texas Instruments Incorporated TXN from $185 to $175.,BIIB,0.298264,0.356682,Bullish
These Analysts Revise Price Targets On Biogen Following Q1 Results - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/earnings/23/04/32009300/these-analysts-revise-price-targets-on-biogen-following-q1-results,2023-04-26 12:38:22,"Biogen reported first-quarter revenue of $2.46 billion, which beat average estimates of $2.34 billion. The company reported adjusted earnings of $3.40 per share, which beat estimates of $3.28 per share. The FDA approved Biogen and Ionis Pharmaceuticals' tofersen, which will be sold under the ...",BIIB,0.974346,0.081744,Neutral
"Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates",https://www.zacks.com/stock/news/2084747/biotech-stock-roundup-biibs-q1-results-arwr-up-on-data-incy-blue-offer-updates,2023-04-26 11:06:00,Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.,BIIB,0.237358,0.060323,Neutral
Alkermes plc Reports First Quarter 2023 Financial Results,https://www.prnewswire.com/news-releases/alkermes-plc-reports-first-quarter-2023-financial-results-301807602.html,2023-04-26 11:00:00,- First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio - - GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01 - - Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023 -,BIIB,0.01682,-0.020903,Neutral
Biogen wins accelerated FDA approval for treatment for rare form of ALS,https://www.marketwatch.com/story/fda-grants-accelerated-approval-to-biogens-treatment-for-rare-form-of-als-ddc291c7,2023-04-26 10:23:00,The FDA has deemed Biogen's torferson reasonably likely to produce a clinical benefit for patients.,BIIB,0.558244,0.513637,Bullish
"FDA Grants Accelerated Approval for QALSODYâ¢  ( tofersen )  for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS",https://www.globenewswire.com/news-release/2023/04/25/2654404/0/en/FDA-Grants-Accelerated-Approval-for-QALSODY-tofersen-for-SOD1-ALS-a-Major-Scientific-Advancement-as-the-First-Treatment-to-Target-a-Genetic-Cause-of-ALS.html,2023-04-25 19:04:00,"CAMBRIDGE, Mass., April 25, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced today that the U.S. Food and Drug Administration ( FDA ) has approved QALSODYâ¢ ( tofersen ) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis ( ALS ) in adults who have a mutation ...",BIIB,0.195137,0.185167,Somewhat-Bullish
What's Going On With Biogen Stock Tuesday? - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/earnings/23/04/31996374/whats-going-on-with-biogen-stock-tuesday,2023-04-25 18:36:30,"Biogen Inc BIIB shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon. Q1 Earnings: Biogen reported first-quarter revenue of $2.46 billion, which beat average estimates of $2.34 billion.",BIIB,0.917988,0.542391,Bullish
"Biogen isn't concerned about competing with Eli Lilly in the Alzheimer's drug space, CEO says",https://www.cnbc.com/2023/04/25/biogen-alzheimers-competition-eli-lilly.html,2023-04-25 17:40:18,Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.,BIIB,0.414559,0.204265,Somewhat-Bullish
Drug for rare form of Lou Gehrig's disease OK'd by FDA,https://apnews.com/article/als-drug-fda-approval-54ec2766f7fef61e68b715ca36a71755,2023-04-25 17:39:02,"WASHINGTON ( AP ) - Food and Drug Administration regulators on Tuesday approved a first-of-a-kind drug for a rare form of Lou Gehrig's disease, though they are requiring further research to confirm it truly helps patients.",BIIB,0.110973,-0.123127,Neutral
US FDA approves Biogen's ALS drug,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-biogens-als-drug-2023-04-25/,2023-04-25 17:28:00,"April 25 ( Reuters ) - The U.S. Food and Drug Administration has approved Biogen Inc's ( BIIB.O ) drug for treating an inherited form of amyotrophic lateral sclerosis ( ALS ) , the health regulator said on Tuesday.",BIIB,0.213048,0.134676,Neutral
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease,https://www.cnbc.com/2023/04/25/fda-grants-accelerated-approval-biogen-als-drug.html,2023-04-25 17:20:41,The FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits.,BIIB,0.110717,0.177693,Somewhat-Bullish
F.D.A. Approves Drug for Rare Form of A.L.S.,https://www.nytimes.com/2023/04/25/business/biogen-fda-als-drug.html,2023-04-25 17:15:52,"The Food and Drug Administration on Tuesday authorized the first drug for a rare genetic form of the neurological disorder A.L.S., despite uncertainty about the treatment's effectiveness.",BIIB,0.310843,0.28204,Somewhat-Bullish
"Biogen  ( BIIB )  Beats on Q1 Earnings, Ends Some Research Programs",https://www.zacks.com/stock/news/2084363/biogen-biib-beats-on-q1-earnings-ends-some-research-programs,2023-04-25 15:36:00,Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.,BIIB,0.450165,0.257701,Somewhat-Bullish
Experts Raise New Questions About The Safety Of Anti-Alzheimer's Drug Leqembi,https://www.forbes.com/sites/howardgleckman/2023/04/25/experts-raise-new-questions-about-the-safety-of-anti-alzheimers-drug-leqembi/,2023-04-25 14:22:51,"Most troubling, the condition that endangers these people is extremely hard to diagnose.",BIIB,0.093836,0.051745,Neutral
"Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/04/31987467/biogen-announces-additional-cost-cutting-initiatives-chops-certain-stroke-gene-therapy-programs,2023-04-25 14:02:07,"Biogen Inc BIIB posted Q1 FY23 sales of $2.46 billion, beating the consensus of $2.34 billion, down 3% Y/Y and flat% at constant currency ( CC ) . Multiple sclerosis revenue of $1.125 billion decreased by 19% ( down 17% CC ) . Multiple sclerosis drug Tysabri sales are down to $472.8 million ...",BIIB,0.716023,0.007684,Neutral
Biogen tops 1Q forecast despite sales slip for key products,https://apnews.com/article/biogen-leqembi-quarter-35df1bac843ad146310f4f5fccfcb89a,2023-04-25 13:57:56,"Biogen beat Wall Street's first-quarter expectations even as revenue from the drugmaker's biggest product group tumbled. Sales of Biogen's multiple sclerosis treatments, which include Tecfidera and Tysabri, fell 19% to $1.12 billion compared to last year's quarter, the company said Tuesday.",BIIB,0.685386,-0.034365,Neutral
Biogen Dips As Alzheimer's Drug Doesn't Save Its Falling Sales,https://www.investors.com/news/technology/biogen-stock-biogen-earnings-q1-2023/,2023-04-25 12:58:00,"Biogen ( BIIB ) stock dipped early Tuesday after the biotech company reported adjusted earnings of $3.40 per share and $2.46 billion in first-quarter sales. On average, analysts polled by FactSet expected Biogen earnings of $3.28 a share and $2.34 billion in sales.",BIIB,0.939207,0.24226,Somewhat-Bullish
3 Top Biotech Stocks Defying the Bear Market,https://www.fool.com/investing/2023/04/25/3-top-biotech-stocks-defying-the-bear-market/,2023-04-25 12:45:00,All three companies have therapies with strong sales potential.,BIIB,0.046907,-0.008928,Neutral
Biogen Inc.  ( BIIB )  Beats Q1 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2083943/biogen-inc-biib-beats-q1-earnings-and-revenue-estimates,2023-04-25 12:25:13,"Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",BIIB,0.402403,0.174588,Somewhat-Bullish
"Biogen Earnings Beat Expectations, but All Eyes Are on Alzheimer's Drug",https://www.barrons.com/articles/biogen-earnings-stock-price-55b2407d,2023-04-25 12:18:00,"Biogen reported earnings that beat Wall Street expectations on Tuesday, while announcing cost- saving efforts. The company reported first-quarter revenues of $2.5 billion, slightly better than the consensus estimate of $2.3 billion among analysts tracked by FactSet",BIIB,0.716023,0.466282,Bullish
"Nasdaq, S&P 500 Futures Slide Ahead Of Microsoft, Alphabet Earnings - Analyst Flags 3 Key Things That Could Impact May Fed Decision - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/23/04/31984803/nasdaq-s-p-500-futures-slide-ahead-of-microsoft-alphabet-earnings-analyst-flags-3-key-things-that-c,2023-04-25 11:30:45,"Trading in the index futures suggests a negative opening by Wall Street stocks on Tuesday ahead of earnings from tech behemoths Alphabet, Inc. GOOGL GOOG and Microsoft Corp. MSFT. Traders may also focus on a few house market readings and consumer confidence data as well as President Joe Biden's ...",BIIB,0.102668,0.0,Neutral
Biogen beats profit estimates on strong Spinraza sales,https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-beats-profit-estimates-strong-spinraza-sales-2023-04-25/,2023-04-25 11:06:15,"April 25 ( Reuters ) - Biogen Inc ( BIIB.O ) on Tuesday beat expectations for quarterly profit on strong sales of spinal muscular atrophy drug Spinraza, but said it would pause or discontinue some studies to cut costs.",BIIB,0.598621,-0.214159,Somewhat-Bearish
Morning Bid: Bank angst echo,https://www.reuters.com/markets/us/global-markets-view-usa-2023-04-25/,2023-04-25 10:02:00,"A look at the day ahead in U.S. and global markets from Mike Dolan Bombarded by incoming corporate earnings updates and increasingly wary of tense geopolitics, world markets appear to have turned sour again on financial stocks as the full extent of March bank stress unfolds.",BIIB,0.058615,0.089987,Neutral
"1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea  ( aflibercept ) , Presented at the 2023 Association for Research in Vision and Ophthalmology  ( ARVO )  Annual Meeting",https://www.benzinga.com/pressreleases/23/04/g31973964/1-year-outcomes-of-phase-3-study-for-sb15-proposed-biosimilar-to-eylea-aflibercept-presented-at-th,2023-04-24 22:30:00,"SB15 demonstrates comparable efficacy, safety, immunogenicity, and pharmacokinetics profiles to reference aflibercept up to Week 56 Switching group had similar efficacy and safety compared to the continuing groups without treatment-emergent issues such as loss of efficacy, increased adverse ...",BIIB,0.054483,0.11279,Neutral
Large Life Science Developer and Manufacturer to Digitize on Kneat's Platform,https://www.newswire.ca/news-releases/large-life-science-developer-and-manufacturer-to-digitize-on-kneat-s-platform-836716620.html,2023-04-24 21:05:00,Large Life Science Developer and Manufacturer to Digitize on ... Canada ...,BIIB,0.038101,0.152682,Somewhat-Bullish
Large Life Science Developer and Manufacturer to Digitize on Kneat's Platform - kneat.com  ( OTC:KSIOF ) ,https://www.benzinga.com/pressreleases/23/04/n31971634/large-life-science-developer-and-manufacturer-to-digitize-on-kneats-platform,2023-04-24 21:05:00,"Latest in string of wins underscores Kneat's market-leading position in digital validation for Life Science industry LIMERICK, Ireland, April 24, 2023 /CNW/ - kneat.com, inc.",BIIB,0.037213,0.426736,Bullish
"Alzheimer's, Depression Drugs Are in Focus as Biogen Reports Results",https://www.barrons.com/articles/biogen-stock-earnings-tuesday-what-to-expect-55b2407d,2023-04-24 20:21:00,Biogen Reports Earnings Tuesday. Here's What to Watch. ...,BIIB,0.997796,-0.055823,Neutral
"BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer",https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-strengthens-leadership-team-with-appointment-of-kirk-taylor-md-as-executive-vice-president-and-chief-medical-officer-301805136.html,2023-04-24 11:00:00,BrainStorm Cell Therapeutics Strengthens Leadership Team with ... PR ...,BIIB,0.033375,-0.001903,Neutral
"Investing Action Plan: Microsoft, Amazon, Boeing, Alphabet Earnings",https://www.investors.com/research/investing-action-plan/stock-trading-action-plan-inflation-gauges-and-microsoft-amazon-boeing-alphabet-earnings/,2023-04-21 22:24:00,"Stock Trading Action Plan: Inflation Gauges And Microsoft, Amazon ... Investor's Business Daily ...",BIIB,0.056451,0.055003,Neutral
Why Shares of Keros Therapeutics Jumped This Week,https://www.fool.com/investing/2023/04/21/why-shares-of-keros-therapeutics-jumped-this-week/,2023-04-21 17:55:00,The company appointed a new director and an analyst reiterated his position on the stock.,BIIB,0.11983,0.0,Neutral
"Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes! - Eisai Co Ltd ADR  ( OTC:ESALY ) , Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/04/31937862/will-us-medicare-fully-cover-alzheimers-drugs-eli-lilly-thinks-yes,2023-04-21 16:03:15,"Eli Lilly And Co LLY expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid brain plaques can help patients.",BIIB,0.390904,0.076101,Neutral
'It totally backfired': The pitfalls of Alzheimer's genetic testing,https://www.reuters.com/business/healthcare-pharmaceuticals/it-totally-backfired-pitfalls-alzheimers-genetic-testing-2023-04-21/,2023-04-21 10:12:21,"CHICAGO, April 21 ( Reuters ) - Wendy Nelson watched her mother slowly die of Alzheimer's disease, unable to move or swallow at the end. ""All her pleasures of life were gone,"" Nelson said.",BIIB,0.031529,0.033346,Neutral
"Exclusive: Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs",https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-expects-us-medicare-reverse-course-fully-cover-alzheimers-drugs-2023-04-21/,2023-04-21 10:07:57,"Exclusive: Lilly expects US Medicare to reverse course, fully cover ... ...",BIIB,0.16099,-0.008321,Neutral
 ( BIIB )  - Analyzing Biogen's Short Interest - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/05/32327721/biib-analyzing-biogens-short-interest,2023-05-10 20:30:32,"Biogen's BIIB short percent of float has risen 7.59% since its last report. The company recently reported that it has 2.00 million shares sold short, which is 1.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.4 days to cover their ...",BIIB,0.224903,0.158881,Somewhat-Bullish
"Global Hyper-Personalized Medicine Market Expected to Generate a Revenue of $5,886.50 Billion and Rise at a CAGR of 11.7% over the 2022-2031 Timeframe [280-Pages] | Information by Research Dive",https://www.benzinga.com/pressreleases/23/05/g32315607/global-hyper-personalized-medicine-market-expected-to-generate-a-revenue-of-5-886-50-billion-and-r,2023-05-10 13:05:00,"New York, USA, May 10, 2023 ( GLOBE NEWSWIRE ) -- According to a report published by Research Dive, the global hyper-personalized medicine market is anticipated to garner a revenue of $5,886.50 billion and rise at a CAGR of 11.7% during the analysis timeframe from 2022 to 2031.",BIIB,0.053153,0.269869,Somewhat-Bullish
"Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer",https://www.globenewswire.com/news-release/2023/05/10/2665341/0/en/Cerevel-Therapeutics-Appoints-Susan-Altschuller-Ph-D-as-Chief-Financial-Officer.html,2023-05-10 10:30:00,"Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to ...",BIIB,0.070621,0.062264,Neutral
"Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",https://www.benzinga.com/pressreleases/23/05/g32310471/cerevel-therapeutics-appoints-susan-altschuller-ph-d-as-chief-financial-officer,2023-05-10 10:30:00,"Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023",BIIB,0.069596,0.062213,Neutral
"Denali  ( DNLI )  Q1 Earnings Miss Estimates, Pipeline in Focus",https://www.zacks.com/stock/news/2092620/denali-dnli-q1-earnings-miss-estimates-pipeline-in-focus,2023-05-09 17:24:00,Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.,BIIB,0.376194,0.06953,Neutral
"Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors - Voyager Therapeutics  ( NASDAQ:VYGR ) ",https://www.benzinga.com/pressreleases/23/05/g32282893/voyager-therapeutics-announces-appointment-of-george-scangos-ph-d-to-board-of-directors,2023-05-09 10:55:00,"CAMBRIDGE, Mass., May 09, 2023 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos, Ph.D., to its Board of Directors.",BIIB,0.089965,0.089278,Neutral
"Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors",https://www.globenewswire.com/news-release/2023/05/09/2664203/36461/en/Voyager-Therapeutics-Announces-Appointment-of-George-Scangos-Ph-D-to-Board-of-Directors.html,2023-05-09 10:55:00,"CAMBRIDGE, Mass., May 09, 2023 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( NASDAQ: VYGR ) , a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos, Ph.D., to its Board of Directors.",BIIB,0.084871,0.089348,Neutral
P/E Ratio Insights for Biogen - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/05/32266928/pe-ratio-insights-for-biogen,2023-05-08 15:00:39,"In the current market session, Biogen Inc. BIIB stock price is at $314.35, after a 1.17% decrease. However, over the past month, the company's stock increased by 10.81%, and in the past year, by 61.20%.",BIIB,0.359014,-0.01009,Neutral
"The Zacks Analyst Blog Highlights Exxon Mobil, Costco Wholesale, Activision Blizzard, Biogen and Arista Networks",https://www.zacks.com/stock/news/2091538/the-zacks-analyst-blog-highlights-exxon-mobil-costco-wholesale-activision-blizzard-biogen-and-arista-networks,2023-05-08 12:54:00,"Exxon Mobil, Costco Wholesale, Activision Blizzard, Biogen and Arista Networks are part of the Zacks top Analyst Blog.",BIIB,0.165598,0.0,Neutral
"After weight loss, Alzheimer's may be next frontier for drugs like Ozempic",https://www.reuters.com/business/healthcare-pharmaceuticals/after-weight-loss-alzheimers-may-be-next-frontier-drugs-like-ozempic-2023-05-08/,2023-05-08 10:11:00,"After weight loss, Alzheimer's may be next frontier for drugs like ... ...",BIIB,0.042421,-0.036002,Neutral
Where Will Eli Lilly Be in 3 Years?,https://www.fool.com/investing/2023/05/08/where-will-eli-lilly-be-in-3-years/,2023-05-08 09:57:00,The pharmaceutical giant is likely to grow quickly as it is entering a new age of contested markets.,BIIB,0.054236,0.040003,Neutral
3 Things About Eli Lilly That Smart Investors Know,https://www.fool.com/investing/2023/05/08/3-things-about-eli-lilly-that-smart-investors-know/,2023-05-08 09:05:00,"There are quite a few details to keep track of with this company, and they all matter.",BIIB,0.063933,0.134318,Neutral
2 Top Healthcare Stocks Defying the Bear Market,https://www.fool.com/investing/2023/05/07/2-top-healthcare-stocks-defying-the-bear-market/,2023-05-07 12:14:00,"These pharmaceutical companies are expected to see a big rise in revenue, thanks to new therapies.",BIIB,0.043264,0.050951,Neutral
Access to New Alzheimer's Drugs Might Depend on Where You Live,https://www.wsj.com/articles/access-to-new-alzheimers-drugs-might-depend-on-where-you-live-4829caed,2023-05-07 09:30:00,Big clinics are giving Leqembi to some patients while rural providers said they would wait.,BIIB,0.451494,0.584783,Bullish
Biogen Unusual Options Activity - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/markets/options/23/05/32247224/biogen-unusual-options-activity,2023-05-05 19:31:01,"Someone with a lot of money to spend has taken a bearish stance on Biogen BIIB. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BIIB,0.802099,0.096141,Neutral
"Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32215612/analysts-say-eli-lillys-donanemab-in-alzheimers-is-encouraging-outline-potential-im,2023-05-04 19:06:03,"Wednesday, Eli Lilly And Co LLY announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of donanemab for Alzheimer's disease. Donanemab treatment slowed clinical decline by 35% compared to placebo and resulted in 40% less decline on the ability to perform activities of daily living.",BIIB,0.514619,0.444965,Bullish
"Ionis  ( IONS )  Q1 Earnings Surpass Estimates, Sales Match",https://www.zacks.com/stock/news/2089897/ionis-ions-q1-earnings-surpass-estimates-sales-match,2023-05-04 12:58:00,Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.,BIIB,0.369456,0.236254,Somewhat-Bullish
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2023/05/04/2661295/0/en/C4-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html,2023-05-04 11:00:00,Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDACâ¢ Degrader. Phase 1/2 Clinical Trial Enrolling Patients ...,BIIB,0.023861,0.051665,Neutral
Should You Buy Eli Lilly Stock Now?,https://www.fool.com/investing/2023/05/04/should-you-buy-eli-lilly-stock-now/,2023-05-04 09:13:00,An important clinical trial with Eli Lilly's Alzheimer's disease candidate just produced successful results.,BIIB,0.047654,0.032952,Neutral
"STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors",https://www.globenewswire.com/news-release/2023/05/03/2660895/0/en/STERIS-Appoints-Esther-M-Alegria-Ph-D-to-Board-of-Directors.html,2023-05-03 20:30:00,"DUBLIN, IRELAND, May 03, 2023 ( GLOBE NEWSWIRE ) -- STERIS plc ( NYSE: STE ) ( ""STERIS"" or the ""Company"" ) announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today.",BIIB,0.028388,0.062471,Neutral
"STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors",https://www.benzinga.com/pressreleases/23/05/g32198634/steris-appoints-esther-m-alegria-ph-d-to-board-of-directors,2023-05-03 20:30:00,"DUBLIN, IRELAND, May 03, 2023 ( GLOBE NEWSWIRE ) -- STERIS plc STE ( ""STERIS"" or the ""Company"" ) announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today.",BIIB,0.027892,0.062352,Neutral
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/earnings/23/05/32195089/1000-invested-in-biogen-15-years-ago-would-be-worth-this-much-today,2023-05-03 18:30:21,"Biogen BIIB has outperformed the market over the past 15 years by 4.42% on an annualized basis producing an average annual return of 11.92%. Currently, Biogen has a market capitalization of $45.30 billion.",BIIB,0.983605,0.387251,Bullish
Why Eli Lilly Stock Is Bolting Higher Today,https://www.fool.com/investing/2023/05/03/why-eli-lilly-stock-is-bolting-higher-today/,2023-05-03 17:59:00,Lilly's Alzheimer's disease candidate might be a best-in-class option for patients.,BIIB,0.114682,-0.107643,Neutral
"'Remarkable' Alzheimer's Drug Reduces Cognitive Decline, Study Shows",https://www.barrons.com/news/remarkable-alzheimer-s-drug-reduces-cognitive-decline-study-shows-dc8a890e,2023-05-03 15:41:44,"US pharmaceutical giant Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as ""remarkable"" by experts despite some patients experiencing serious side effects.",BIIB,0.121959,0.020743,Neutral
Biogen Recent Insider Activity - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/05/32190222/biogen-recent-insider-activity,2023-05-03 15:06:23,"Ginger Gregory, EVP at Biogen BIIB, reported a large insider sell on May 2, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Gregory sold 2,681 shares of Biogen. The total transaction amounted to $804,300.",BIIB,0.524949,0.296816,Somewhat-Bullish
Biogen Unusual Options Activity For May 03 - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/markets/options/23/05/32190027/biogen-unusual-options-activity-for-may-03,2023-05-03 15:02:17,"A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen BIIB we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations ...",BIIB,0.831658,0.161718,Somewhat-Bullish
Eli Lilly's Results Signal Arrival of Blockbuster New Drug Class,https://www.wsj.com/articles/eli-lillys-results-signal-arrival-of-blockbuster-new-drug-class-bf7802cd,2023-05-03 14:16:00,"The company's Alzheimer's drug results might look better than Biogen's, but both makers will likely benefit.",BIIB,0.388879,0.211359,Somewhat-Bullish
Eli Lilly Surges After Alzheimer's Drug Cuts Cognitive Decline,https://www.investors.com/news/technology/eli-lilly-stock-surges-after-alzheimers-treatment-succeeds-in-final-phase-study/,2023-05-03 13:16:00,Eli Lilly Stock Surges After Alzheimer's Treatment Succeeds In Final ... Investor's Business Daily ...,BIIB,0.382925,0.348681,Somewhat-Bullish
"Microsoft, Snap And 2 Other Stocks Insiders Are Selling - Microsoft  ( NASDAQ:MSFT ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/23/05/32185131/microsoft-snap-and-2-other-stocks-insiders-are-selling,2023-05-03 12:25:29,"The S&P 500 closed lower more than 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on ...",BIIB,0.358152,-0.074401,Neutral
Lilly drug slows Alzheimer's progression by 35% in trial,https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-drug-slows-alzheimers-progression-by-35-trial-2023-05-03/,2023-05-03 10:06:40,"[1/2] Dr. Seth Gale points out evidence of Alzheimer's disease on PET scans at the Center for Alzheimer Research and Treatment ( CART ) at Brigham And Women's Hospital in Boston, Massachusetts, U.S., March 30, 2023.",BIIB,0.119235,-0.034265,Neutral
"An experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly",https://www.businessinsider.com/alzheimers-treatment-eli-lilly-donanemab-clinical-trial-results-2023-5,2023-05-03 10:00:00,Eli Lilly's Alzheimer's Drug Donanemab Slows Cognitive Decline: Trial - Business Insider ...,BIIB,0.088799,0.113504,Neutral
"Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More",https://www.zacks.com/stock/news/2088427/biotechdrug-stocks-q1-earnings-due-may-3-uthr-pcrx-more,2023-05-02 17:32:00,"Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.",BIIB,0.04497,-0.053922,Neutral
Is Eli Lilly a Smart Dividend Stock to Buy Now?,https://www.fool.com/investing/2023/05/02/is-eli-lilly-a-smart-dividend-stock-to-buy-now/,2023-05-02 13:45:00,"The first quarter seems like it was brutal, but there's more to the story.",BIIB,0.065685,0.251864,Somewhat-Bullish
Biden will end Covid vaccine mandates for federal workers and international travelers on May 11,https://www.cnbc.com/2023/05/01/covid-biden-will-end-vaccine-mandates-for-federal-workers-travelers.html,2023-05-02 00:39:01,"The Biden administration will end Covid vaccine mandates for federal employees, contractors and air travelers on May 11.",BIIB,0.082677,0.285622,Somewhat-Bullish
Biotech Is Back With Guggenheim Upgrade: What You Need To Know - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32124655/biotech-is-back-with-guggenheim-upgrade-what-you-need-to-know,2023-05-01 16:54:12,"Guggenheim Partners upgraded shares of Biogen Inc BIIB to Buy, citing the company's potential for growth driven by its Alzheimer's disease ( AD ) and major depressive disorder ( MDD ) operations. The BIIB Analyst: Yatin Suneja upgraded Biogen to a Buy from a Neutral rating, with a $350 ...",BIIB,0.726873,0.47111,Bullish
"Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock",https://moneymorning.com/investing/despite-its-falling-92-cathie-wood-is-buying-more-of-this-growth-stock/,2023-05-01 13:17:19,Portfolio manager Cathie Wood's ARK Innovation ETF ( NYSEMKT: ARKK ) is known for making bets on growth-stage businesses that have the potential to disrupt their industries with new technologies.,BIIB,0.08183,0.187177,Somewhat-Bullish
"Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock",https://www.fool.com/investing/2023/05/01/despite-falling-92-cathie-wood-buy-growth-stock/,2023-05-01 13:17:19,Wood is betting that Ginkgo Bioworks' biofoundry can scale up enough to become profitable.,BIIB,0.06179,0.183113,Somewhat-Bullish
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments,https://www.cnbc.com/2023/05/01/states-medicare-alzheimers-treatments.html,2023-05-01 13:00:01,"Attorneys general from 23 states, Washington D.C., and two U.S. territories called on Medicare to cover Alzheimer's treatments without restrictions.",BIIB,0.041181,0.274564,Somewhat-Bullish
"We're taking profits on a drugmaker, raising its price target; adding to cybersecurity stock",https://www.cnbc.com/2023/05/01/taking-profits-on-a-drugmaker-raising-its-price-target-adding-to-cybersecurity-stock.html,2023-05-01 12:51:46,"Eli Lilly has been on an absolute tear lately, rallying about 28% from its lows on March 7 to new all-time highs above $400 per share this past Friday.",BIIB,0.084423,0.077331,Neutral
Clinical Project Manager  ( CPM )  Beginner Training Course,https://www.prnewswire.com/news-releases/clinical-project-manager-cpm-beginner-training-course-301829578.html,2023-05-20 00:00:00,"DUBLIN, May 19, 2023 /PRNewswire/ -- The ""Clinical Project Manager ( CPM ) Beginner"" training has been added to ResearchAndMarkets.com's offering. If you are looking to enter the field of clinical research, this CPD-accredited is for you.",BIIB,0.072655,0.033182,Neutral
"If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/earnings/23/05/32491391/if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-5-500-today,2023-05-19 18:00:24,"Biogen BIIB has outperformed the market over the past 15 years by 4.24% on an annualized basis producing an average annual return of 11.87%. Currently, Biogen has a market capitalization of $44.53 billion.",BIIB,0.983605,0.387251,Bullish
"Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential - Ultragenyx Pharmaceutical  ( NASDAQ:RARE ) , Denali Therapeutics  ( NASDAQ:DNLI ) ",https://www.benzinga.com/general/biotech/23/05/32483099/analysts-say-these-2-mid-cap-biotechs-have-2x-potential,2023-05-19 17:56:26,"On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel narrowly recommended approval for the company's gene therapy for Duchenne Muscular Dystrophy ( DMD ) .",BIIB,0.049424,0.09267,Neutral
"Global Pharma, Biotech and Diagnostics Co-development Partnering Deals Analysis Report 2023 with a Directory of Deals - Comprehensive Access to Actual Co-development Contracts",https://www.prnewswire.com/news-releases/global-pharma-biotech-and-diagnostics-co-development-partnering-deals-analysis-report-2023-with-a-directory-of-deals---comprehensive-access-to-actual-co-development-contracts-301829437.html,2023-05-19 14:15:00,"Global Pharma, Biotech and Diagnostics Co-development ... PR ...",BIIB,0.035138,0.0,Neutral
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market,https://www.fool.com/investing/2023/05/19/1-major-advantage-biogen-may-have-over-eli-lilly/,2023-05-19 12:15:00,"Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.",BIIB,0.43789,-0.11496,Neutral
Canadian Solar Reports First Quarter 2023 Results,https://www.prnewswire.com/news-releases/canadian-solar-reports-first-quarter-2023-results-301828321.html,2023-05-18 10:00:00,"GUELPH, ON, May 18, 2023 /PRNewswire/ -- Canadian Solar Inc. ( ""Canadian Solar"" or the ""Company"" ) ( NASDAQ: CSIQ ) today announced financial results for the first quarter ended March 31, 2023. â¢ 66% increase in solar module shipments year-over-year ( ""yoy"" ) to 6.1 GW, in line with guidance of ...",BIIB,0.01101,0.155397,Somewhat-Bullish
The War Over Whether Medicare Should Pay For The New Anti-Alzheimer's Drugs,https://www.forbes.com/sites/howardgleckman/2023/05/17/the-war-over-whether-medicare-should-pay-for-the-new-anti-alzheimers-drugs/,2023-05-17 19:26:46,"Unless Medicare widely covers anti-Alzheimer's drugs, they will be unaffordable for the vast majority of consumers.",BIIB,0.046184,0.084539,Neutral
We're starting a new position in one of the Big 3 global medical imaging and diagnostics companies,https://www.cnbc.com/2023/05/17/were-starting-a-new-position-in-a-medical-imaging-and-diagnostics-leader.html,2023-05-17 17:30:53,This company operates in an $84 billion total addressable market that the company sees growing to around $100 billion by 2024.,BIIB,0.073209,0.110168,Neutral
"Virtualware rewards its employees with more than 52,000 shares during its first month as a listed company on the Paris Stock Exchange",https://www.globenewswire.com/news-release/2023/05/17/2671266/0/en/Virtualware-rewards-its-employees-with-more-than-52-000-shares-during-its-first-month-as-a-listed-company-on-the-Paris-Stock-Exchange.html,2023-05-17 15:13:00,"PARIS and BILBAO, Spain, May 17, 2023 ( GLOBE NEWSWIRE ) -- Virtual reality company Virtualware ( EPA:MLVIR ) has distributed in its first month of trading a total of 52,602 shares among most of its employees, with a total value of more than 315,612 euros.",BIIB,0.115232,0.132715,Neutral
CENTOGENE Reports Full Year 2022 Financial Results,https://www.globenewswire.com/news-release/2023/05/16/2670546/0/en/CENTOGENE-Reports-Full-Year-2022-Financial-Results.html,2023-05-16 22:25:00,"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 16, 2023 ( GLOBE NEWSWIRE ) -- Centogene N.V. ( Nasdaq: CNTG ) ( ""we"" or the ""Company"" ) , the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal ...",BIIB,0.016738,0.121407,Neutral
Here's Why Biogen  ( BIIB )  Stock is Up 12.6% This Year So Far,https://www.zacks.com/stock/news/2095822/heres-why-biogen-biib-stock-is-up-126-this-year-so-far,2023-05-16 13:56:00,"Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.",BIIB,0.557075,0.02096,Neutral
Alcami Appoints Laurent Boer as General Manager of Biostorage and Pharmaceutical Support Services.,https://www.prnewswire.com/news-releases/alcami-appoints-laurent-boer-as-general-manager-of-biostorage-and-pharmaceutical-support-services-301825973.html,2023-05-16 13:30:00,Alcami Appoints Laurent Boer as General Manager of Biostorage ... PR ...,BIIB,0.098255,-0.017051,Neutral
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease,https://www.globenewswire.com/news-release/2023/05/15/2669467/0/en/Health-Canada-Accepts-New-Drug-Submission-for-Lecanemab-as-Treatment-for-Early-Alzheimer-s-Disease.html,2023-05-15 23:30:00,"TOKYO and CAMBRIDGE, Mass., May 15, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"" ) announced today that Health Canada has ...",BIIB,0.285249,0.072732,Neutral
Why Shares of Denali Therapeutics Are Up Monday,https://www.fool.com/investing/2023/05/15/why-shares-of-denali-therapeutics-are-up-monday/,2023-05-15 20:31:43,Analysts maintained their buy ratings on the clinical-stage biotech company.,BIIB,0.13459,-0.029706,Neutral
Eli Lilly Is On Track For A Blockbuster Alzheimer's Drug; What's Next?,https://www.investors.com/news/technology/eli-lilly-stock-why-version-alzheimers-treatment-could-become-a-blockbuster-in-2025/,2023-05-15 17:50:00,Eli Lilly Stock: Why Version 1.0 In Alzheimer's Treatment Could ... Investor's Business Daily ...,BIIB,0.33628,0.125055,Neutral
Nature Publishes Work Demonstrating Clinical ink Technology Sensitivity to Parkinson's Disease,https://www.benzinga.com/pressreleases/23/05/g32401310/nature-publishes-work-demonstrating-clinical-ink-technology-sensitivity-to-parkinsons-disease,2023-05-15 17:30:43,"Winston Salem, NC, May 15, 2023 ( GLOBE NEWSWIRE ) -- Clinical ink, a global life science technology company, announces the publication of ""Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study"" in npj Parkinson's Disease.",BIIB,0.109956,0.021888,Neutral
Recurrent Energy Signs Aggregation Deal for 100 MW of Solar Energy in Texas with Industry Consortium,https://www.prnewswire.com/news-releases/recurrent-energy-signs-aggregation-deal-for-100-mw-of-solar-energy-in-texas-with-industry-consortium-301824300.html,2023-05-15 11:00:00,Recurrent Energy Signs Aggregation Deal for 100 MW of Solar ... PR ...,BIIB,0.140896,0.206224,Somewhat-Bullish
BiomX Reports First Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/15/2668546/0/en/BiomX-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-05-15 10:30:00,"Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis ( ""CF"" ). Results from Part 2 Expected in Third Quarter of ...",BIIB,0.023533,0.030946,Neutral
Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research,https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html,2023-05-15 09:32:00,Report Forecasts Promising Future for Alzheimer's Disease Market ... PR ...,BIIB,0.069495,0.0,Neutral
Promising new Alzheimer's drugs present patients with tough choices,https://www.axios.com/2023/05/15/alzheimers-drugs-patients-risks-medicare-fda,2023-05-15 06:34:42,"Promising clinical trial results from another new Alzheimer's drug haven't put to bed questions about how much the treatments actually benefit patients, and whether their strong points outweigh their safety risks.",BIIB,0.040622,0.072431,Neutral
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win,https://www.fool.com/investing/2023/05/14/these-2-pharma-stocks-might-face-off-soon-but-they/,2023-05-14 12:15:00,There's no rule that says a market must have only one winner.,BIIB,0.103778,-0.080198,Neutral
"Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates",https://www.cnbc.com/2023/05/12/alzheimers-disease-leqembi-could-cost-medicare-5-billion-per-year.html,2023-05-12 18:53:57,"The authors said the estimated cost of Leqembi to Medicare are conservative, and spending on the Alzheimer's treatment may increase more than anticipated.",BIIB,0.121959,0.075092,Neutral
3 Reasons to Buy Biogen Stock  ( and 1 to Sell ) ,https://www.fool.com/investing/2023/05/12/3-reasons-to-buy-biogen-stock-and-1-to-sell/,2023-05-12 14:15:00,"The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.",BIIB,0.596433,0.389816,Bullish
"Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds",https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-biogen-alzheimers-drug-leqembi-would-cost-us-medicare-up-5-bln-year-study-2023-05-11/,2023-05-11 19:42:00,"Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up ... ...",BIIB,0.127795,0.007203,Neutral
BIIB: 3 Biotech Stocks to Buy Now,https://stocknews.com/news/biib-alks-vnda-3-biotech-stocks-to-buy-now/,2023-05-11 15:08:16,"The biotech industry was at the forefront of vaccine development and helped tide over the pandemic. Government initiatives, rapid advancements in agricultural biotechnology, and the inelastic demand for healthcare are the main drivers of the biotech industry's growth.",BIIB,0.343543,0.159905,Somewhat-Bullish
Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal,https://www.fool.com/investing/2023/05/11/heres-why-eli-lillys-alzheimers-drug-could-be-the/,2023-05-11 14:07:00,"Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.",BIIB,0.199584,0.048343,Neutral
Should iShares Morningstar Mid-Cap Value ETF  ( IMCV )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2093943/should-ishares-morningstar-mid-cap-value-etf-imcv-be-on-your-investing-radar,2023-05-11 10:20:08,Style Box ETF report for ...,BIIB,0.121343,0.068087,Neutral
Cassava  ( SAVA )  Up on Progress With Alzheimers Disease Study,https://www.zacks.com/stock/news/2101565/cassava-sava-up-on-progress-with-alzheimers-disease-study,2023-05-30 16:06:00,"Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.",BIIB,0.123209,0.282067,Somewhat-Bullish
Global Recombinant DNA Technology Market Report 2023: Increasing Number of Chronic Diseases Drives Growth,https://www.prnewswire.com/news-releases/global-recombinant-dna-technology-market-report-2023-increasing-number-of-chronic-diseases-drives-growth-301835829.html,2023-05-27 01:45:00,Global Recombinant DNA Technology Market Report 2023 ... PR ...,BIIB,0.033006,0.110153,Neutral
Biogen Unusual Options Activity For May 26 - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/markets/options/23/05/32598541/biogen-unusual-options-activity-for-may-26,2023-05-26 16:02:57,"Someone with a lot of money to spend has taken a bullish stance on Biogen BIIB. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BIIB,0.767792,0.267763,Somewhat-Bullish
Alkermes  ( ALKS )  Up 3.7% Since Last Earnings Report: Can It Continue?,https://www.zacks.com/stock/news/2100372/alkermes-alks-up-37-since-last-earnings-report-can-it-continue,2023-05-26 15:31:41,Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BIIB,0.251032,0.064733,Neutral
"New Alzheimer's drug could bring hope to patients, but could be out of reach for people on Medicare",https://www.marketwatch.com/story/new-alzheimers-drug-could-bring-hope-to-patients-but-could-be-out-of-reach-for-people-on-medicare-8b128e70,2023-05-25 15:50:00,The Food and Drug Administration is set to announce soon whether it will grant full approval to lecanemab for the treatment of Alzheimer's.,BIIB,0.069094,0.0,Neutral
Biogen Inc.  ( BIIB )  Up 4.7% Since Last Earnings Report: Can It Continue?,https://www.zacks.com/stock/news/2099759/biogen-inc-biib-up-47-since-last-earnings-report-can-it-continue,2023-05-25 15:31:00,Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BIIB,0.541149,0.235743,Somewhat-Bullish
"Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical",https://www.zacks.com/stock/news/2098801/zacks-industry-outlook-highlights-amphastar-dr-reddys-and-teva-pharmaceutical,2023-05-24 08:34:00,"Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.",BIIB,0.029113,0.060772,Neutral
3 Generic Drug Stocks to Watch Amid Macro Headwinds,https://www.zacks.com/commentary/2098340/3-generic-drug-stocks-to-watch-amid-macro-headwinds,2023-05-23 12:01:00,"The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.",BIIB,0.030292,0.051993,Neutral
Biogen  ( NASDAQ:BIIB )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/05/22/biogen-nasdaqbiib-coverage-initiated-at-stocknews-com.html,2023-05-22 11:43:02,StockNews.com began coverage on shares of Biogen ( NASDAQ:BIIB - Get Rating ) in a report released on Thursday. The firm issued a strong-buy rating on the biotechnology company's stock. A number of other research analysts have also recently commented on the company.,BIIB,0.801457,0.455986,Bullish
Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic,https://www.prnewswire.com/news-releases/marketing-authorisation-application-for-lecanemab-submitted-in-great-britain-bioarctic-301830416.html,2023-05-22 03:03:00,Marketing Authorisation Application for lecanemab submitted in ... PR ...,BIIB,0.067727,0.150516,Somewhat-Bullish
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBIÂ®  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/06/g32805841/fda-advisory-committee-votes-unanimously-to-confirm-the-clinical-benefit-of-leqembi-lecanemab-irmb,2023-06-09 22:45:00,"Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's disease The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with ...",BIIB,0.14835,0.034087,Neutral
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBIÂ®  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease,https://www.prnewswire.com/news-releases/fda-advisory-committee-votes-unanimously-to-confirm-the-clinical-benefit-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease-301847597.html,2023-06-09 22:45:00,FDA Advisory Committee Votes Unanimously to Confirm the Clinical ... PR ...,BIIB,0.144131,0.033499,Neutral
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBIÂ®  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease,https://www.globenewswire.com/news-release/2023/06/09/2685832/0/en/FDA-Advisory-Committee-Votes-Unanimously-to-Confirm-the-Clinical-Benefit-of-LEQEMBI-lecanemab-irmb-for-the-Treatment-of-Alzheimer-s-Disease.html,2023-06-09 22:45:00,Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's disease ...,BIIB,0.140821,0.031662,Neutral
"Bullish Market Trend, But Fed Meeting Looms; 7 Stocks To Watch",https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-bullish-market-trend-but-fed-meeting-looms-tesla-nvidia-lead-stocks-to-watch/,2023-06-09 21:19:00,"Bullish Market Trend, But Fed Meeting Looms. 7 Stocks To Watch Investor's Business Daily ...",BIIB,0.065987,0.09945,Neutral
FDA advisers vote in favor of Biogen and Eisai's collaborative Alzheimer's treatment,https://www.marketwatch.com/story/eisai-shares-jump-on-fda-advisers-vote-on-alzheimers-treatment-bed17402,2023-06-09 21:12:00,"If granted full FDA approval, which could come in early July, treatment could boost annual Medicare spending by nearly $9 billion, analysis shows.",BIIB,0.24289,0.233057,Somewhat-Bullish
Experimental Alzheimer's drug endorsed for full approval by FDA advisers,https://www.axios.com/2023/06/09/alzheimers-drug-leqembi-fda-endorse,2023-06-09 20:01:48,Experimental Alzheimer's drug endorsed for full approval by FDA ... ...,BIIB,0.046724,0.191455,Somewhat-Bullish
"Alzheimer's drug gets FDA panel's backing, setting the stage for broader use",https://apnews.com/article/leqembi-alzheimers-drug-fda-f438cd0d1df98d1df0677a219cee6fa7,2023-06-09 19:53:17,"Alzheimer's drug gets FDA panel's backing, setting the stage for ... The Associated Press ...",BIIB,0.044222,0.260786,Somewhat-Bullish
Biogen Halted As It Faces Make-Or-Break Moment In Alzheimer's,https://www.investors.com/news/technology/biogen-stock-halted-as-fda-panelists-mull-alzheimers-treatment/,2023-06-09 16:08:00,Biogen Stock Halted As FDA Panelists Mull Alzheimer's Treatment ... Investor's Business Daily ...,BIIB,0.644856,0.401051,Bullish
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval,https://www.cnbc.com/2023/06/09/fda-advisors-review-alzheimers-drug-leqembi-for-full-approval.html,2023-06-09 14:07:03,"Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment.",BIIB,0.266101,0.108745,Neutral
FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen,https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-debate-us-approval-alzheimers-drug-eisai-biogen-2023-06-09/,2023-06-09 11:06:15,FDA panel to debate US approval for Alzheimer's drug from Eisai ... ...,BIIB,0.073773,0.040826,Neutral
"Biogen  ( BIIB ) , Eisai's Alzheimer Drug Likely to Get Full FDA Nod",https://www.zacks.com/stock/news/2105996/biogen-biib-eisais-alzheimer-drug-likely-to-get-full-fda-nod,2023-06-08 16:41:00,"Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.",BIIB,0.3038,0.200188,Somewhat-Bullish
"Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More",https://www.zacks.com/stock/news/2105968/biotech-stock-roundup-gsk-provides-updates-biogen-to-discontinue-study-more,2023-06-08 16:38:00,Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.,BIIB,0.148961,-0.025128,Neutral
"Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/06/32780854/bernie-sanders-takes-on-high-costs-of-alzheimers-treatment-leqembi-calls-price-tag-unconscionable,2023-06-08 15:27:15,Senator Bernie Sanders urged the U.S. Department of Health and Human Services ( HHS ) to immediately address the exorbitant cost of Eisai Co Ltd ESALY/Biogen Inc BIIB Alzheimer's treatment Leqembi ( lecanemab ) .,BIIB,0.512093,-0.101001,Neutral
Jim Cramer's top 10 things to watch in the stock market Thursday,https://www.cnbc.com/2023/06/08/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html,2023-06-08 13:10:38,"Wall Street little changed heading into the open as the Dow, S&P 500 and Nasdaq track modestly lower for the week.",BIIB,0.055236,0.157032,Somewhat-Bullish
"FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/06/32776205/fda-signals-support-for-eisai-biogen-alzheimers-drug-data-confirms-benefits-for-complete-approval,2023-06-08 12:34:50,"FDA Peripheral and Central Drugs Advisory Committee is meeting Friday ( June 9 ) to discuss a supplemental marketing application for Leqembi ( lecanemab ) submitted by Eisai Co Ltd ESALY for Alzheimer's disease, initiated in patients with mild cognitive impairment or mild dementia stage of the ...",BIIB,0.392948,0.237019,Somewhat-Bullish
Why This Cathie Wood Holding Is On An 8-Month Hot Streak,https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/,2023-06-08 12:00:00,"The market for colon cancer screening is massive - and underserved - says Exact Sciences ( EXAS ) Chief Medical Officer Paul Limburg. And that might be why EXAS stock is on an eight-month hot streak. Exact Sciences makes Cologuard, a stool-based detection test for colorectal cancer.",BIIB,0.044222,0.370369,Bullish
Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation,https://www.prnewswire.com/news-releases/alkermes-publishes-investor-presentation-detailing-companys-transformation-and-value-creation-301846055.html,2023-06-08 11:00:00,Alkermes Publishes Investor Presentation Detailing Company's ... PR ...,BIIB,0.043539,-0.097648,Neutral
Tokyo Stocks Trade Modestly Higher,https://www.barrons.com/amp/news/tokyo-stocks-open-modestly-higher-b7777e1,2023-06-08 00:21:38,Tokyo Stocks Open Modestly Higher ...,BIIB,0.126119,0.108773,Neutral
Mastering the Double-Bottom Pattern  ( Unveiling 3 Intriguing Setups in Today's Market ) ,https://www.zacks.com/commentary/2105410/mastering-the-double-bottom-pattern-unveiling-3-intriguing-setups-in-todays-market,2023-06-07 22:14:00,A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils 3 juicy setups.,BIIB,0.407844,0.350821,Bullish
What To Do Now As Market Rally Turns Upside Down; Two Big Losers Late,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-what-to-do-as-market-rally-turns-upside-down-gamestop-dives-late/,2023-06-07 21:56:00,What To Do Now As Market Rally Turns Upside Down Investor's Business Daily ...,BIIB,0.12455,0.154746,Somewhat-Bullish
"Nasdaq Skids, But These Stocks Keep Running; What To Do Now",https://www.investors.com/market-trend/stock-market-today/nasdaq-skids-but-these-areas-run-meme-stock-gamestop-dives-on-miss-ceo-ouster/,2023-06-07 20:44:00,Nasdaq Skids But These Areas Run. Meme Stock GameStop Dives ... Investor's Business Daily ...,BIIB,0.12455,0.154746,Somewhat-Bullish
"Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action",https://www.cnbc.com/2023/06/07/sanders-condemns-alzheimers-treatment-price-calls-for-hhs-action.html,2023-06-07 18:30:23,"Sen. Bernie Sanders said the $26,500 annual price for Alzheimer's treatment Leqembi would financially burden on Medicare and increase premiums for seniors.",BIIB,0.237668,0.052195,Neutral
"Biogen Is Eyeing A Repeat Alzheimer's Approval, But No Drama",https://www.investors.com/news/technology/biogen-stock-rises-on-the-fda-uncontroversial-take-on-alzheimers-treatment/,2023-06-07 17:37:00,Biogen Stock Rises On The FDA's Uncontroversial Take On ... Investor's Business Daily ...,BIIB,0.46898,0.194353,Somewhat-Bullish
Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day,https://www.zacks.com/stock/news/2104904/novo-nordisk-and-golden-entertainment-have-been-highlighted-as-zacks-bull-and-bear-of-the-day,2023-06-07 11:32:00,Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.,BIIB,0.327366,0.076479,Neutral
Merck lawsuit opens new effort to cripple drug price negotiations,https://www.axios.com/2023/06/07/merck-lawsuit-cripple-drug-price-talks,2023-06-07 09:30:00,"Merck's lawsuit challenging drug price negotiations established by the Inflation Reduction Act is the likely start of a flurry of litigation to undo Democrats' signature effort to tackle pharmaceutical costs. Why it matters: At a minimum, the IRA's drug pricing provisions probably won't start on ...",BIIB,0.069697,-0.070655,Neutral
Biogen  ( BIIB )  to End One of Two Parkinson's Studies on BIIB122,https://www.zacks.com/stock/news/2104520/biogen-biib-to-end-one-of-two-parkinsons-studies-on-biib122,2023-06-06 14:58:00,"Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for ...",BIIB,0.656041,0.112768,Neutral
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/general/biotech/23/06/32721144/biogen-and-denali-realign-parkinsons-disease-research-priorities-amidst-r-d-restructure,2023-06-05 20:15:15,The Phase 2b LUMA study in participants with early-stage Parkinson's disease commenced in May 2022. The Phase 3 LIGHTHOUSE study in participants with Parkinson's disease related to LRRK2 mutations commenced in September 2022 and was slated for completion in 2031.,BIIB,0.524949,0.0,Neutral
Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.,https://www.marketwatch.com/story/biotech-stocks-could-soon-get-a-m-a-boost-here-are-3-likely-takeover-plays-206b79c3,2023-06-05 19:05:00,Big pharma will be looking to acquire companies with promsing new medicines.,BIIB,0.097193,0.061044,Neutral
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/earnings/23/06/32721701/100-invested-in-biogen-15-years-ago-would-be-worth-this-much-today,2023-06-05 18:00:23,"Biogen BIIB has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 11.92%. Currently, Biogen has a market capitalization of $43.65 billion.",BIIB,0.983605,0.387251,Bullish
Autoinjectors Global Market Report 2023: Increasing Prevalence of Chronic Disease Drives Growth,https://www.prnewswire.com/news-releases/autoinjectors-global-market-report-2023-increasing-prevalence-of-chronic-disease-drives-growth-301841281.html,2023-06-03 01:00:00,Autoinjectors Global Market Report 2023: Increasing Prevalence of ... PR ...,BIIB,0.03853,0.12297,Neutral
Why The Biotech Buying Bonanza Will Likely Continue,https://www.investors.com/news/technology/biotech-stocks-are-in-blistering-ma-climate-ftc-could-change-that/,2023-06-02 17:17:00,Biotech Stocks Are In A 'Blistering' M&A Climate. The FTC Could ... Investor's Business Daily ...,BIIB,0.031529,0.0,Neutral
Autoinjectors Market worth $1.7 billion | MarketsandMarkets,https://www.prnewswire.com/news-releases/autoinjectors-market-worth-1-7-billion--marketsandmarkets-301840949.html,2023-06-02 17:00:00,"CHICAGO, June 2, 2023 /PRNewswire/ -- The autoinjectors industry is set to experience significant growth in the near future as a result of several factors. With the rise in chronic diseases and the increasing need for self-administration of medication, autoinjectors have emerged as a convenient ...",BIIB,0.021937,0.013872,Neutral
Ionis  ( IONS )  Posts Two-Year Upbeat Data From HAE Drug Study,https://www.zacks.com/stock/news/2103417/ionis-ions-posts-two-year-upbeat-data-from-hae-drug-study,2023-06-02 16:35:00,Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.,BIIB,0.331765,0.220693,Somewhat-Bullish
Ionis Pharmaceuticals  ( IONS )  Up 19.3% Since Last Earnings Report: Can It Continue?,https://www.zacks.com/stock/news/2103298/ionis-pharmaceuticals-ions-up-193-since-last-earnings-report-can-it-continue,2023-06-02 15:31:40,Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BIIB,0.054114,0.100757,Neutral
BioNTech Is Taking On Bristol In Cancer Treatment - Could It Win?,https://www.investors.com/news/technology/bntx-stock-pops-as-it-takes-on-bristol-in-hard-to-treat-cancer-treatment/,2023-06-02 15:11:00,BNTX Stock Pops As It Takes On Bristol In Hard-To-Treat Lung ... Investor's Business Daily ...,BIIB,0.076115,0.378713,Bullish
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease,https://www.investors.com/news/technology/biogen-stock-jumps-into-buy-zone-on-a-key-win-in-alzheimers-treatment/,2023-06-01 20:09:00,Biogen ( BIIB ) stock jumped into a buy zone Thursday after Medicare officials said they would reimburse patients for the cost of Alzheimer's treatments that target an abnormal protein called beta amyloid.,BIIB,0.605266,0.3945,Bullish
Top 2% Biotech Comes 'Out Of Stealth Mode' On A Four-Day Sprint,https://www.investors.com/news/technology/bhvn-stock-runs-up-for-the-fourth-day-as-it-comes-out-of-stealth-mode/,2023-06-01 20:08:00,BHVN Stock Exits 'Stealth Mode' And Hits A Record High Investor's Business Daily ...,BIIB,0.11894,0.086748,Neutral
"US to require patient data for payment of Leqembi, similar Alzheimer's drugs",https://www.reuters.com/business/healthcare-pharmaceuticals/medicare-cover-new-alzheimers-drug-after-full-approval-2023-06-01/,2023-06-01 18:33:00,"US to require patient data for payment of Leqembi, similar ... ...",BIIB,0.059935,0.086307,Neutral
BNGO: Is Now the Time to Buy Bionano Genomics  ( BNGO ) ?,https://stocknews.com/news/bngo-alks-biib-gild-is-now-the-time-to-buy-bionano-genomics-bngo/,2023-06-01 17:56:05,"Bionano Genomics, Inc. ( BNGO ) is a genome analysis software provider that enables genomics labs to analyze and interpret data across a range of platforms. The company's revenue saw a significant jump in the recent past, increasing at CAGRs of 46.4% and 25.3% over the past three and five years, ...",BIIB,0.140485,0.219421,Somewhat-Bullish
Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer,https://www.prnewswire.com/news-releases/abilita-bio-changes-name-to-abilita-therapeutics-and-appoints-joel-edwards-as-chief-business-officer-301839467.html,2023-06-01 11:00:00,Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel ... PR ...,BIIB,0.065685,0.033201,Neutral
Does This Signal Trouble for Biogen's New Alzheimer's Drug?,https://www.fool.com/investing/2023/06/19/does-this-signal-trouble-for-biogens-new-alzheimer/,2023-06-19 09:30:00,Biogen is counting on Leqembi to boost its revenue growth.,BIIB,0.370733,0.266196,Somewhat-Bullish
2 Market-Beating Stocks With Major Catalysts on the Way,https://www.fool.com/investing/2023/06/17/2-market-beating-stocks-with-major-catalysts-on/,2023-06-17 14:07:00,Can these companies keep climbing?,BIIB,0.327366,0.260878,Somewhat-Bullish
BNGO: Is Bionano Genomics  ( BNGO )  a Buy or Sell this Week?,https://stocknews.com/news/bngo-alks-smlr-biib-is-bionano-genomics-bngo-a-buy-or-sell-this-week/,2023-06-16 18:50:36,"Bionano Genomics, Inc. ( BNGO ) has garnered attention with its Saphyr system, a third-generation optical mapping solution offering quick, high-throughput, long-range genome mapping and structural variation detection capabilities critical for genomic research.",BIIB,0.103778,0.193065,Somewhat-Bullish
This Stock Crushed the Market Last Year. Here's Why It Could Do That Again.,https://www.fool.com/investing/2023/06/16/this-stock-crushed-the-market-last-year-heres-why/,2023-06-16 18:00:00,This small biotech could become much bigger in just a few years.,BIIB,0.057079,0.123958,Neutral
AbbVie's  ( ABBV )  Skyrizi Meets Ulcerative Colitis Study Goals,https://www.zacks.com/stock/news/2109293/abbvies-abbv-skyrizi-meets-ulcerative-colitis-study-goals,2023-06-16 11:45:00,AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.,BIIB,0.156461,0.060314,Neutral
Clene's ALS drug shows reduction in disease indicator levels in trial,https://www.reuters.com/business/healthcare-pharmaceuticals/clenes-als-drug-shows-reduction-disease-indicator-levels-trial-2023-06-15/,2023-06-15 22:55:00,June 15 ( Reuters ) - Clene ( CLNN.O ) said on Thursday its experimental amyotrophic lateral sclerosis ( ALS ) drug showed reduction in levels of an indicator believed to be tied with the disease progression in a mid-stage trial.,BIIB,0.167322,0.315938,Somewhat-Bullish
ISS backs election of Langer to replace former Biogen director Denner,https://www.reuters.com/business/healthcare-pharmaceuticals/iss-backs-election-langer-replace-former-biogen-director-denner-2023-06-15/,2023-06-15 18:32:00,"[1/2] Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration",BIIB,0.673107,-0.022353,Neutral
"Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More",https://www.zacks.com/stock/news/2108932/biotech-stock-roundup-kdny-up-on-nvs-buyout-biib-eisais-ad-drug-update-more,2023-06-15 14:21:00,Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.,BIIB,0.2317,0.142861,Neutral
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/general/biotech/23/06/32859749/senator-bernie-sanders-puts-brakes-on-health-agency-nominees-until-drug-pricing-issue-is-addresse,2023-06-14 17:52:39,"Senator Bernie Sanders vowed to oppose President Joe Biden's nominated candidate, Monica Bertagnolli, or any other current or future health agency nominee, to lead the National Institutes of Health until the administration delivers a plan to lower prescription drug prices.",BIIB,0.25168,-0.1685,Somewhat-Bearish
"The Biggest Barrier To New Anti-Alzheimer's Drugs May Be Cost, Not Medicare Rules",https://www.forbes.com/sites/howardgleckman/2023/06/14/the-biggest-barrier-to-new-anti-alzheimers-drugs-may-be-cost-not-medicare-rules/,2023-06-14 16:11:58,"CMS says the record-keeping will help provide important, real-world information about the benefits and risks of these new drugs.",BIIB,0.094576,0.066113,Neutral
What's Happening With Biogen Stock?,https://www.forbes.com/sites/greatspeculations/2023/06/14/whats-happening-with-biogen-stock/,2023-06-14 12:00:46,"After a 13% rise in Biogen stock (NASDAQ: BIIB) this year, aligning with the broader S&P500 index returns, we believe it has little room for growth.",BIIB,0.879764,0.299281,Somewhat-Bullish
BUSINESS LOCATION SWITZERLAND - A THRIVING HUB FOR HEALTH TECH,https://www.prnewswire.com/news-releases/business-location-switzerland--a-thriving-hub-for-health-tech-301850632.html,2023-06-14 12:00:00,"ZURICH, June 14, 2023 /PRNewswire/ -- Switzerland is home to a globally unique life science cluster.",BIIB,0.024648,0.127229,Neutral
3 Well-Known Stocks Hit 52-Week Lows Monday While The Overall Market Surged Higher - SPDR S&P 500  ( ARCA:SPY ) ,https://www.benzinga.com/news/23/06/32841170/3-well-known-stocks-hit-52-week-lows-monday-while-the-overall-market-surged-higher,2023-06-13 18:25:47,"The stock market ended Monday with the S&P 500 continuing to hit new 52-week highs. While many stocks have hit new 52-week highs in recent weeks, three well-known companies found themselves hitting new 52-week lows:",BIIB,0.064276,0.064038,Neutral
Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes,https://www.reuters.com/business/healthcare-pharmaceuticals/sarissas-denner-quits-biogen-board-firm-seeks-seats-alkermes-2023-06-13/,2023-06-13 17:52:00,"NEW YORK, June 13 ( Reuters ) - Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes ( ALKS.O ) when one of its candidates resigned from the board of a company that has a commercial relationship with the drugmaker.",BIIB,0.266828,-0.265805,Somewhat-Bearish
"Stocks making the biggest moves midday: JD.com, Biogen, Oracle and more",https://www.cnbc.com/2023/06/13/stocks-making-the-biggest-moves-midday-jdcom-biogen-oracle-and-more.html,2023-06-13 16:38:01,These are some of the stocks posting the largest moves in midday trading.,BIIB,0.261117,0.09744,Neutral
A 53-year-old biotech investor is set to be replaced by a 32-year-old exec on Biogen's board. No one disclosed that the new board member is his girlfriend and the mother of his child.,https://www.businessinsider.com/biogen-board-susan-langer-alex-denner-2023-6,2023-06-13 16:13:00,Biogen board: Susan Langer joining as partner Alex Denner departs - Business Insider ...,BIIB,0.824879,0.274152,Somewhat-Bullish
"Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday - Beneficient  ( NASDAQ:BENF ) , AvePoint  ( NASDAQ:AVPT ) ",https://www.benzinga.com/news/23/06/32837210/methode-electronics-brookfield-renewable-partners-and-other-big-stocks-moving-lower-on-tuesday,2023-06-13 14:36:27,"Methode Electronics, Inc. MEI shares dipped 15.7% to $37.98 after the company reported worse-than-expected preliminary fourth-quarter results. The company's outlook for FY24 lagged consensus. Cibus, Inc. CBUS declined 10.6% to $20.74. Chijet Motor Company, Inc. CJET fell 9.4% to $3.5880.",BIIB,0.47672,-0.508105,Bearish
"Top Stories Tuesday, June 13: FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business - Apple  ( NASDAQ:AAPL ) , Activision Blizzard  ( NASDAQ:ATVI ) ",https://www.benzinga.com/news/23/06/32835975/ftc-sues-to-block-microsoft-activision-blizzard-deal-netflixs-first-sports-streaming-debut-european,2023-06-13 14:02:10,"The U.S. Federal Trade Commission ( FTC ) has sued to block Microsoft Inc's MSFT acquisition of video game maker Activision Blizzard ATVI, stating that the deal will hurt consumer choice and competition. The FTC complaint comes when Microsoft has appealed the U.K.",BIIB,0.079392,-0.149065,Neutral
"Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/06/32830662/alzheimers-drug-leqembi-faces-hurdles-in-europe-concerns-over-health-risks-and-healthcare-resourc,2023-06-13 12:30:17,Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd ESALY and Biogen Inc BIIB say Leqembi ( lecanemab ) 's ability to slow cognitive decline may not outweigh its health risks or justify the strain it would place on limited healthcare ...,BIIB,0.340915,-0.19526,Somewhat-Bearish
Virtualware's VIROO set to support Mixed Reality capabilities upon its new release,https://www.benzinga.com/pressreleases/23/06/g32832191/virtualwares-viroo-set-to-support-mixed-reality-capabilities-upon-its-new-release,2023-06-13 11:38:50,"BILBAO, Spain, June 13, 2023 ( GLOBE NEWSWIRE ) -- Spanish listed company Virtualware MLVIR, a global leader in immersive technology solutions, today announced its readiness to support mixed reality ( MR ) capabilities on its VIROO 2.4 release coming in July.",BIIB,0.103331,0.128897,Neutral
Virtualware's VIROO set to support Mixed Reality capabilities upon its new release,https://www.globenewswire.com/news-release/2023/06/13/2687037/0/en/Virtualware-s-VIROO-set-to-support-Mixed-Reality-capabilities-upon-its-new-release.html,2023-06-13 11:38:00,"BILBAO, Spain, June 13, 2023 ( GLOBE NEWSWIRE ) -- Spanish listed company Virtualware ( EPA:MLVIR ) , a global leader in immersive technology solutions, today announced its readiness to support mixed reality ( MR ) capabilities on its VIROO 2.4 release coming in July.",BIIB,0.107495,0.130525,Neutral
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors - Alkermes  ( NASDAQ:ALKS ) ,https://www.benzinga.com/pressreleases/23/06/n32831446/alkermes-issues-letter-to-shareholders-highlighting-skills-and-experience-of-refreshed-board-of-di,2023-06-13 11:00:00,"Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote ""FOR"" Alkermes' Director Nominees on Company's WHITE Proxy Card",BIIB,0.009551,0.062837,Neutral
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors,https://www.prnewswire.com/news-releases/alkermes-issues-letter-to-shareholders-highlighting-skills-and-experience-of-refreshed-board-of-directors-301848944.html,2023-06-13 11:00:00,"Sarissa's Proposed Candidates Would Not Bring New Skills to the Board DUBLIN, June 13, 2023 /PRNewswire/ -- Alkermes plc ( Nasdaq: ALKS ) ( the Company ) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders ( the Annual ...",BIIB,0.014839,0.143356,Neutral
"European Alzheimer's experts unconvinced by new Eisai, Biogen drug",https://www.reuters.com/business/healthcare-pharmaceuticals/european-alzheimers-experts-unconvinced-by-new-eisai-biogen-drug-2023-06-13/,2023-06-13 07:16:00,"[1/5] A scientist looks at scans of grains at the Memory Centre at the Department of Readaptation and Geriatrics of the University Hospital ( HUG ) in Geneva, Switzerland, June 6, 2023. REUTERS/Denis Balibouse",BIIB,0.041682,-0.152658,Somewhat-Bearish
S&P 500 and Nasdaq close at highest since April 2022,https://www.moneycontrol.com/news/business/markets/sp-500-and-nasdaq-close-at-highest-since-april-2022-10785741.html,2023-06-13 00:38:55,"Lifted by gains in market heavyweights Amazon ( AMZN.O ) , Apple ( AAPL.O ) and Tesla ( TSLA.O ) , the SP 500 has now recovered 21% from its October 2022 lows. Some investors say Wall Street is the midst of a bull market.",BIIB,0.060085,0.124447,Neutral
Biogen Announces Changes to Its Board of Directors - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/06/g32825498/biogen-announces-changes-to-its-board-of-directors,2023-06-12 21:14:01,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023, to Give All Stockholders Sufficient Time to Review and Vote on Proposed Slate CAMBRIDGE, Mass., June 12, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB announced several changes to its Board of Directors today.",BIIB,0.279369,0.149238,Neutral
Biogen Announces Changes to Its Board of Directors,https://www.globenewswire.com/news-release/2023/06/12/2686722/0/en/Biogen-Announces-Changes-to-Its-Board-of-Directors.html,2023-06-12 21:14:00,"CAMBRIDGE, Mass., June 12, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced several changes to its Board of Directors today. The changes will refresh the composition of the Board and follow the Board's continual interaction with company stockholders to solicit their perspective ...",BIIB,0.252987,0.187488,Somewhat-Bullish
Nasdaq Jumps More Than 1%; Musk Mocks Short Sale,https://www.investors.com/market-trend/stock-market-today/dow-jones-up-as-oracle-earnings-stock-pops-on-upgrade-elon-musk-mocks-short-call-tesla-stock-gains/,2023-06-12 19:08:00,Dow Jones Up As Oracle Pops On Upgrade. Elon Musk Mocks Short ... Investor's Business Daily ...,BIIB,0.128592,0.069706,Neutral
"Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32818719/prospects-for-full-approval-of-eisai-and-biogens-leqembi-shine-brighter-after-fda-c,2023-06-12 18:01:11,"Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd ESALY and Biogen Inc BIIB Phase 3 Clarity AD trial confirms the clinical benefit of Leqembi ( lecanemab ) for Alzheimer's disease.",BIIB,0.465196,0.289262,Somewhat-Bullish
"TriNet, Nasdaq fall; Ballard Power, Chinook Therapeutics rise, Monday, 6/12/2023",https://apnews.com/article/financial-markets-stocks-wall-street-58a2518c3cc898958159a59e72f05038,2023-06-12 16:19:13,"TriNet, Nasdaq fall. Ballard Power, Chinook Therapeutics rise ... The Associated Press ...",BIIB,0.443626,0.0,Neutral
Stock Market Upbeat On Monday; IPO Stock Breaks Out,https://www.investors.com/market-trend/stock-market-today/stock-market-upbeat-ahead-of-cpi-fed-decision-ipo-stock-breaks-out/,2023-06-12 14:58:00,Stock Market Upbeat On Monday. IPO Stock Breaks Out Investor's Business Daily ...,BIIB,0.099476,0.07098,Neutral
Biotech Stock Launches Almost 60% On Novartis Takeover,https://www.investors.com/news/technology/biotech-stock-chinook-skyrockets-on-novartis-takeover/,2023-06-12 14:09:00,Biotech Stock Chinook Skyrockets On $3.5 Billion Novartis Takeover ... Investor's Business Daily ...,BIIB,0.295867,0.639223,Bullish
"Questex's Fierce Biotech Summit Returns to Boston in October, Gathering the Industry's Most Influential Leaders to Discuss the Future of Biotech",https://www.benzinga.com/pressreleases/23/06/g32816429/questexs-fierce-biotech-summit-returns-to-boston-in-october-gathering-the-industrys-most-influenti,2023-06-12 14:00:00,"NEW YORK, June 12, 2023 ( GLOBE NEWSWIRE ) -- Questex's Fierce Biotech, today announces the Fierce Biotech Summit, the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials, will take place October 16-18 in Boston. Register here.",BIIB,0.040145,-0.226958,Somewhat-Bearish
Did This CRISPR Company Just Cure A Rare Swelling Disease?,https://www.investors.com/news/technology/ntla-stock-surges-why-its-crispr-drug-could-cure-a-rare-swelling-disease/,2023-06-12 13:38:00,NTLA Stock Surges. Why Its CRISPR Drug Could Cure A Rare ... Investor's Business Daily ...,BIIB,0.072655,0.185636,Somewhat-Bullish
"Biogen  ( BIIB ) , Eisai Alzheimer Drug Gets FDA Panel Endorsement",https://www.zacks.com/stock/news/2107073/biogen-biib-eisai-alzheimer-drug-gets-fda-panel-endorsement,2023-06-12 13:25:00,An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.,BIIB,0.279015,0.292392,Somewhat-Bullish
Jim Cramer's top 10 things to watch in the stock market Monday,https://www.cnbc.com/2023/06/12/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html,2023-06-12 13:08:25,"The Magnificent Seven keep rolling, the cruise lines catch price target boosts and consumers stay strong.",BIIB,0.119235,0.102221,Neutral
"Goldman pushes back against bearish Morgan Stanley's Mike Wilson with new 4,500 S&P 500 target",https://www.marketwatch.com/story/goldman-pushes-back-against-bearish-morgan-stanleys-mike-wilson-with-new-4-500-s-p-500-target-e69059a8,2023-06-12 11:23:00,"Resilient economic growth and softening inflation will keep stocks supported, says Goldman Sachs, which has a new bullish S&P 500 target.",BIIB,0.076847,0.275576,Somewhat-Bullish
"Why Nasdaq, S&P 500 Futures Signal Strong Start To Week - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Illumina  ( NASDAQ:ILMN ) , Chinook Therapeutics  ( NASDAQ:KDNY ) , Oracle  ( NYSE:ORCL ) , Novartis  ( NYSE:NVS ) , SPDR S&P 500  ( ARCA:SPY ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/markets/equities/23/06/32812362/nasdaq-s-amp-p-500-futures-signal-strong-start-to-week-on-hopes-of-fed-pause-why-this-analyst-is,2023-06-12 11:00:46,"U.S. stocks are set to start the week on an upbeat note, as traders begin to bake in a pause by the Federal Reserve when it meets this week. Technology stocks could large the charge but oil's slide could weigh down on the space.",BIIB,0.113329,-0.056275,Neutral
"Futures rise as focus shifts to inflation data, Fed meet",https://www.reuters.com/markets/us/futures-rise-focus-shifts-inflation-data-fed-meet-2023-06-12/,2023-06-12 10:28:28,"June 12 ( Reuters ) - U.S. stock index futures rose on Monday ahead of inflation data and the Federal Reserve's interest rate decision this week, while Biogen shares gained in premarket trading after the U.S. FDA panel backed its Alzheimer's drug. Investors are on the watch for the U.S.",BIIB,0.192694,0.287585,Somewhat-Bullish
"Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns",https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-rises-fda-panel-backs-alzheimers-drug-easing-safety-concerns-2023-06-12/,2023-06-12 10:26:14,"Biogen rises as FDA panel backs Alzheimer's drug, easing safety ... ...",BIIB,0.305058,0.30554,Somewhat-Bullish
"Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move",https://www.marketwatch.com/story/biogen-stock-climbs-on-drug-approval-recommendation-oracle-shares-rise-ahead-of-earnings-and-other-stocks-on-the-move-b36703f1,2023-06-12 09:38:00,Here are some of the biggest movers of Monday.,BIIB,0.975551,0.771304,Bullish
FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBIÂ®  ( lecanemab-irmb )  for the treatment of early Alzheimer's disease,https://www.prnewswire.com/news-releases/fda-advisory-committee-votes-unanimously-to-confirm-clinical-benefit-of-leqembi-lecanemab-irmb-for-the-treatment-of-early-alzheimers-disease-301847722.html,2023-06-10 11:37:00,FDA Advisory Committee votes unanimously to confirm clinical ... PR ...,BIIB,0.029599,0.126184,Neutral
How Is The Market Feeling About Biogen? - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/06/33059937/how-is-the-market-feeling-about-biogen,2023-06-29 14:00:44,"Biogen's BIIB short percent of float has fallen 24.68% since its last report. The company recently reported that it has 2.23 million shares sold short, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.3 days to cover their ...",BIIB,0.224903,0.085754,Neutral
Can A Woman Be Respected If She's In The Same Industry As Her Boyfriend? We May Soon Find Out,https://www.forbes.com/sites/ikebrannon/2023/06/28/can-a-woman-be-respected-if-shes-in-the-same-industry-as-her-boyfriend-we-may-soon-find-out/,2023-06-28 16:21:35,"Sarissa Capital recently acquired a nine percent stake in another biotech company called Alkermes, which-like Biogen-has a focus on neuroscience, and partners with Bio...",BIIB,0.420316,0.193281,Somewhat-Bullish
A Look Into Biogen Inc's Price Over Earnings - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/06/33031168/a-look-into-biogen-incs-price-over-earnings,2023-06-27 18:02:02,"In the current market session, Biogen Inc. BIIB share price is at $281.65, after a 0.03% increase. Moreover, over the past month, the stock fell by 5.68%, but in the past year, spiked by 37.28%.",BIIB,0.344074,0.0,Neutral
BIIB: 3 Stocks to Own as Alzheimer's Drugs Bring Relief,https://stocknews.com/news/biib-esaly-lly-3-stocks-to-own-as-alzheimers-drugs-bring-relief/,2023-06-27 17:04:16,"Rapidly aging populations pose a huge challenge to society, governments and public services. Older populations put an immense strain on healthcare expenditure, and the financial costs of dementia are large and growing.",BIIB,0.439153,0.257919,Somewhat-Bullish
BNGO: Should You Watch Bionano Genomics  ( BNGO )  this Week?,https://stocknews.com/news/bngo-alks-gild-biib-should-you-watch-bionano-genomics-bngo-this-week/,2023-06-27 16:22:38,"Genomic testing equipment manufacturer Bionano Genomics, Inc. ( BNGO ) is gaining traction with its third-generation optical mapping solution, Saphyr, which offers advanced capabilities crucial for genome research.",BIIB,0.084722,0.207885,Somewhat-Bullish
GILD: 3 Biotech Stocks With Some Major Value in Them,https://stocknews.com/news/gild-biib-alks-rcus-dnli-3-biotech-stocks-with-some-major-value-in-them/,2023-06-27 12:14:56,The biotech sector assumes a crucial role in propelling the advancement of healthcare by spearheading the creation of innovative therapies and technologies aimed at addressing unmet medical requirements.,BIIB,0.232439,0.087244,Neutral
"Amyotrophic Lateral Sclerosis Treatment Market to Reach US$ 594.1 Million in 2031, Expanding at a CAGR of 5.5%: TMR Report",https://www.benzinga.com/pressreleases/23/06/g33011292/amyotrophic-lateral-sclerosis-treatment-market-to-reach-us-594-1-million-in-2031-expanding-at-a-ca,2023-06-26 17:30:00,"Wilmington, Delaware, United States, June 26, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - In 2022, the global industry was estimated to be worth $594.1 million. It is expected to increase at a 5.5% CAGR from 2023 to 2031, reaching more than US$ 958.2 million by the end of 2031.",BIIB,0.042271,0.074033,Neutral
Biogen shareholders back Susan Langer as director,https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-shareholders-back-susan-langer-director-2023-06-26/,2023-06-26 17:07:00,"June 26 ( Reuters ) - Biogen ( BIIB.O ) shareholders elected former company executive Susan Langer as a director on Monday, weeks after her romantic partner, Alex Denner, vacated the seat and the board nominated her to replace him. Langer, 32, had served in various roles at the biotech ...",BIIB,0.720339,0.026645,Neutral
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?,https://www.fool.com/investing/2023/06/23/is-this-a-sign-that-biogens-leqembi-could-obtain/,2023-06-23 11:30:00,The catalyst many Biogen investors have been waiting for may soon arrive.,BIIB,0.627549,0.300025,Somewhat-Bullish
Medicare offers details on reimbursement for new Alzheimer's drugs,https://www.reuters.com/business/healthcare-pharmaceuticals/medicare-offers-details-reimbursement-new-alzheimers-drugs-2023-06-22/,2023-06-22 20:39:00,"CHICAGO, June 22 ( Reuters ) - The U.S. Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai Co Ltd ( 4523.T ) and Biogen Inc's ( BIIB.O ) new Alzheimer's drug Leqembi, should it win traditional U.S. approval as expected by ...",BIIB,0.072655,0.188676,Somewhat-Bullish
Alleged Industrial Espionage Makes an Interesting Story,https://www.fool.com/investing/2023/06/21/alleged-industrial-espionage-makes-an-interesting/,2023-06-22 01:09:00,We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.,BIIB,0.009932,0.057189,Neutral
GILD: 3 Biotech Stocks Every Investor Wants,https://stocknews.com/news/gild-biib-alks-3-biotech-stocks-every-investor-wants/,2023-06-21 16:19:43,"The biotech sector is expanding due to innovations and robust demand. Furthermore, the biotech sector enjoys inelastic demand for its products and services and is relatively stable in the face of economic uncertainty.",BIIB,0.152258,0.083183,Neutral
"Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote ""FOR"" All Seven of the Company's Highly Qualified Director Nominees - Alkermes  ( NASDAQ:ALKS ) ",https://www.benzinga.com/pressreleases/23/06/n32943919/independent-proxy-advisory-firm-glass-lewis-recommends-alkermes-shareholders-vote-for-all-seven-of,2023-06-21 12:00:00,"Supports Alkermes' Existing Board and Notes Strong Positive Momentum Shares Board's Belief that Sarissa's Nominees Would Not Be Additive to the Board Notes Alkermes Board is ""sufficiently independent, qualified and capable to oversee the Company""",BIIB,0.0362,-0.011842,Neutral
"Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote ""FOR"" All Seven of the Company's Highly Qualified Director Nominees",https://www.prnewswire.com/news-releases/independent-proxy-advisory-firm-glass-lewis-recommends-alkermes-shareholders-vote-for-all-seven-of-the-companys-highly-qualified-director-nominees-301856284.html,2023-06-21 12:00:00,"Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote ""FOR"" All Seven of the ... PR ...",BIIB,0.028937,0.065277,Neutral
ISS recommends one of Sarissa's three nominees for Alkermes board,https://www.reuters.com/business/iss-recommends-one-sarissas-three-nominees-alkermes-board-2023-06-20/,2023-06-20 13:32:00,"NEW YORK, June 20 ( Reuters ) - Proxy advisory firm Institutional Investor Services urged Alkermes ( ALKS.O ) shareholders to elect one of three director candidates proposed by activist hedge fund Sarissa Capital, arguing more outside pressure on management is needed right now.",BIIB,0.323078,-0.014567,Neutral
Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board,https://www.prnewswire.com/news-releases/independent-proxy-advisory-firm-iss-recommends-alkermes-shareholders-vote-against-sarissa-employees-election-to-alkermes-board-301854859.html,2023-06-20 11:00:00,Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election ... PR ...,BIIB,0.077032,-0.011346,Neutral
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?,https://www.fool.com/investing/2023/07/09/biogen-just-milestone-why-isnt-stock-rising/,2023-07-09 10:00:00,Biogen shares are little changed year to date.,BIIB,0.693907,0.3581,Bullish
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know,https://www.cnbc.com/2023/07/08/leqembi-and-medicare-what-patients-and-doctors-should-know.html,2023-07-08 11:00:01,"Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.",BIIB,0.04583,0.0,Neutral
US Stocks Dip After Mixed Jobs Data,https://www.barrons.com/news/us-stocks-dip-after-mixed-jobs-data-da0d5c5b,2023-07-07 20:35:44,Wall Street stocks dipped Friday following data that showed slower hiring in the United States but which was seen as keeping the Federal Reserve on track to raise interest rates.,BIIB,0.18967,0.053266,Neutral
"Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets - BlackRock  ( NYSE:BLK ) , Citigroup  ( NYSE:C ) , JPMorgan Chase  ( NYSE:JPM ) , HDFC Bank  ( NYSE:HDB ) , America Movil  ( NYSE:AMX ) , Delta Air Lines  ( NYSE:DAL ) , UnitedHealth Group  ( NYSE:UNH ) , Microsoft  ( NASDAQ:MSFT ) , Tesla  ( NASDAQ:TSLA ) , Wells Fargo  ( NYSE:WFC ) , United Parcel Service  ( NYSE:UPS ) , Progressive  ( NYSE:PGR ) , Fastenal  ( NASDAQ:FAST ) , Amazon.com  ( NASDAQ:AMZN ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/markets/asia/23/07/33152597/mixed-jobs-data-fed-governors-want-more-interest-rate-hikes-us-china-spat-rattles-semiconductor-sect,2023-07-07 19:52:50,"The June jobs report released Friday showcased mixed data on the economy. The unemployment rate dropped from 3.7% to 3.6%, but job additions came in at 209,000, below economist expectations of 225,000. The figure is a sharp decline from May's 306,000 increase.",BIIB,0.12013,0.088734,Neutral
Factbox: Companies in Alzheimer's race after US nod for Eisai/Biogen drug,https://www.reuters.com/business/healthcare-pharmaceuticals/companies-alzheimers-race-after-us-nod-eisaibiogen-drug-2023-07-07/,2023-07-07 18:28:00,"July 7 ( Reuters ) - Eisai Co Ltd ( 4523.T ) and Biogen Inc's ( BIIB.O ) Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food and Drug Administration's standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past.",BIIB,0.443626,0.225038,Somewhat-Bullish
"If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/earnings/23/07/33151400/if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-4-900-today,2023-07-07 18:00:29,"Biogen BIIB has outperformed the market over the past 15 years by 2.33% on an annualized basis producing an average annual return of 11.25%. Currently, Biogen has a market capitalization of $40.28 billion.",BIIB,0.983605,0.387251,Bullish
Sales of Alzheimer's drug Leqembi may be slow initially but could pick up in 2024,https://www.cnbc.com/2023/07/07/alzheimers-drug-leqembi-sales-may-be-slow-at-first-analysts.html,2023-07-07 17:59:37,Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.,BIIB,0.0699,0.03343,Neutral
"Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33148410/expanded-medicare-coverage-for-biogen-eisais-leqembi-signals-a-turning-point-in-alz,2023-07-07 17:25:03,"The FDA approved a supplemental marketing application for Biogen Inc BIIB-Eisai Co Ltd ESALY supporting the traditional approval of Leqembi ( lecanemab-irmb ) , making it the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional ...",BIIB,0.540042,0.285406,Somewhat-Bullish
More Eisai/Biogen Alzheimer's drug approvals seen likely despite safety warning,https://www.reuters.com/business/healthcare-pharmaceuticals/more-eisaibiogen-alzheimers-drug-approvals-seen-likely-despite-safety-warning-2023-07-07/,2023-07-07 17:06:00,"July 7 ( Reuters ) - With U.S. approval of Eisai's ( 4523.T ) and Biogen's ( BIIB.O ) Alzheimer's drug Leqembi secured, Wall Street analysts said they expect other region's health regulators to follow suit even if they share similar concerns about a potentially severe side effect.",BIIB,0.151539,0.085725,Neutral
"Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more",https://www.cnbc.com/2023/07/07/stocks-making-the-biggest-moves-midday-rivian-levi-strauss-biogen-first-solar-and-more.html,2023-07-07 16:52:42,These are the stocks posting the largest moves in midday trading.,BIIB,0.130926,0.236595,Somewhat-Bullish
"FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline - Eli Lilly  ( NYSE:LLY ) , Biogen  ( NASDAQ:BIIB ) , Cassava Sciences  ( NASDAQ:SAVA ) ",https://www.benzinga.com/general/biotech/23/07/33149295/fda-approves-biogens-alzheimers-drug-here-are-other-companies-with-treatments-in-the-pipeline,2023-07-07 16:16:21,"The FDA fully approved Biogen Inc.'s BIIB Alzheimer's treatment Leqembi on Thursday, becoming the first Alzheimer's antibody treatment to reach full approval. Alzheimer's disease is a brain disease that leads to cognitive decline, impacting more than six million Americans according to the ...",BIIB,0.497391,0.094059,Neutral
"Stocks Pull Back As Yields Jump; Tesla, Meta In Focus: Weekly Review",https://www.investors.com/news/stock-market-rally-pulls-back-as-yields-jump-tesla-meta-in-focus/,2023-07-07 15:36:00,"Stocks Pull Back As Yields Jump. Tesla, Meta In Focus: Weekly Review Investor's Business Daily ...",BIIB,0.070935,0.14892,Neutral
Biogen's big Alzheimer's drug win fails to boost the stock as analysts see slow Leqembi rollout,https://www.marketwatch.com/story/biogens-big-alzheimers-drug-win-fails-to-boost-the-stock-as-analysts-see-slow-leqembi-rollout-1e94302c,2023-07-07 14:49:00,"Milestone Leqembi approval is ""a mixed bag,"" analysts say, given drug label's risk warnings and infusion-center bottlenecks.",BIIB,0.458708,0.129832,Neutral
Dow Jones Dips After Lukewarm Jobs Report; 2 Software Stocks Make Bullish Moves,https://www.investors.com/market-trend/stock-market-today/dow-jones-dips-lukewarm-jobs-report-software-leaders-dynatrace-datadog-make-bullish-moves/,2023-07-07 14:48:00,Dow Jones Dips After Lukewarm Jobs Report. 2 Software Stocks Make Bullish Moves Investor's Business Daily ...,BIIB,0.111747,0.252498,Somewhat-Bullish
"Biogen  ( BIIB ) , Eisai Get Full FDA Nod for Leqembi in Alzheimer's",https://www.zacks.com/stock/news/2118140/biogen-biib-eisai-get-full-fda-nod-for-leqembi-in-alzheimers,2023-07-07 13:51:00,"Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.",BIIB,0.241684,0.167178,Somewhat-Bullish
Top 10 things to watch in the stock market Friday including a jobs shocker,https://www.cnbc.com/2023/07/07/top-10-things-to-watch-in-the-stock-market-friday-including-a-jobs-shocker.html,2023-07-07 13:15:34,Surprising jobs miss in June after Thursday's blowout ADP hiring number.,BIIB,0.092748,0.23397,Somewhat-Bullish
"Stocks making the biggest premarket moves: Levi Strauss, Biogen, Alibaba and more",https://www.cnbc.com/2023/07/07/stocks-making-the-biggest-premarket-moves-.html,2023-07-07 12:22:33,These are the stocks posting the largest moves in the premarket.,BIIB,0.207571,0.162165,Somewhat-Bullish
Futures: Jobs Data Looms; 7 Resilient Stocks,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobs-report-on-tap-meta-leads-resilient-stocks-as-threads-signups-soar/,2023-07-07 12:01:00,Dow Jones Futures: Jobs Report Looms Large As Yields Soar. Meta Leads 7 Resilient Stocks | Investor's Business Daily Investor's Business Daily ...,BIIB,0.070036,0.229579,Somewhat-Bullish
"The daily business briefing: July 7, 2023",https://theweek.com/briefing/business-briefing/1024836/the-daily-business-briefing-july-7-2023,2023-07-07 11:19:43,"MARK SCHIEFELBEIN / POOL / AFP via Getty Images The Food and Drug Administration on Thursday gave full approval to Leqembi, a drug that can slow the progression of Alzheimer's disease.",BIIB,0.054114,-0.008007,Neutral
"10 things you need to know today: July 7, 2023",https://theweek.com/briefing/daily-briefing/1024837/10-things-you-need-to-know-today-july-7-2023,2023-07-07 10:55:09,"The feud between Mark Zuckerberg and Elon Musk continues to escalate With Ukraine low on ammunition, the Biden administration is expected to announce on Friday that it will send the country cluster munitions as part of a weapons package worth $800 million, U.S. officials told CBS News on Thursday.",BIIB,0.034039,-0.00782,Neutral
"Why US Stock Futures Signal Weak Open On Friday - Eisai Co  ( OTC:ESAIY ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Costco Wholesale  ( NASDAQ:COST ) , SPDR S&P 500  ( ARCA:SPY ) , Biogen  ( NASDAQ:BIIB ) , Levi Strauss  ( NYSE:LEVI ) ",https://www.benzinga.com/news/earnings/23/07/33145327/stock-futures-dip-as-traders-eye-friday-jobs-report-analyst-says-q3-returns-hinge-more-on-this-cata,2023-07-07 10:52:56,"The market continues to be influenced by negative sentiment, as reflected in slightly lower stock futures early Friday. The June non-farm payrolls report, set to be released before the market opens, is expected to be a determining factor for today's trading direction.",BIIB,0.142989,0.262381,Somewhat-Bullish
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug,https://www.cnbc.com/2023/07/07/eisai-shares-tumble-despite-receiving-fda-greenlight.html,2023-07-07 10:00:07,Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval.,BIIB,0.089797,-0.007584,Neutral
"PWM, RIVN, META, TSLA, BIIB: Top 5 Trending Stocks - Meta Platforms  ( NASDAQ:META ) , Tesla  ( NASDAQ:TSLA ) , Prestige Wealth  ( NASDAQ:PWM ) , Rivian Automotive  ( NASDAQ:RIVN ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/markets/equities/23/07/33142132/top-5-trending-stocks-prestige-wealths-ipo-rivians-lawsuit-metas-new-platform-teslas-dip-and-bio,2023-07-07 00:27:34,"U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday. The Dow traded down 1.07 to 33,922.26 while the NASDAQ fell 0.82% to 13,679.04. The S&P 500 also fell, dropping 0.79% to 4,411.59.",BIIB,0.107978,-0.020156,Neutral
Tokyo Stocks Open Lower,https://www.barrons.com/news/tokyo-stocks-open-lower-41609f92,2023-07-07 00:16:51,"Tokyo stocks opened lower on Friday after falls on Wall Street as investors fretted over the prospect of more US interest rate hikes and the risk of recession. The benchmark Nikkei 225 index was down 0.88 percent, or 289.28 points, at 32,483.74 in early trade, while the broader Topix index ...",BIIB,0.110462,0.067461,Neutral
FDA Grants Traditional Approval for LEQEMBIÂ®  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease,https://www.globenewswire.com/news-release/2023/07/07/2700886/0/en/FDA-Grants-Traditional-Approval-for-LEQEMBI-lecanemab-irmb-for-the-Treatment-of-Alzheimer-s-Disease.html,2023-07-07 00:00:00,The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer's disease ...,BIIB,0.142371,0.062395,Neutral
US government approves Alzheimer's drug to slow cognitive decline,https://www.aljazeera.com/news/2023/7/6/us-government-approves-alzheimers-drug-to-slow-cognitive-decline,2023-07-06 23:34:27,"Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.",BIIB,0.054857,0.0,Neutral
"FDA approves Alzheimer's treatment Leqembi, clearing the way for Medicare coverage",https://www.marketwatch.com/story/fda-approves-biogen-and-eisai-alzheimers-treatment-leqembi-56e3acd7,2023-07-06 21:51:00,"Despite Medicare coverage, drug may remain out of reach for many patients, policy experts say ...",BIIB,0.7887,0.456167,Bullish
"FDA Grants Full Approval For Alzheimer's Drug, Despite Concerns",https://www.forbes.com/sites/brianbushard/2023/07/06/fda-grants-full-approval-for-alzheimers-drug-despite-concerns/,2023-07-06 21:30:31,"Leqembi costs $26,000 per year before insurance.",BIIB,0.166743,0.020737,Neutral
FDA Has Approved The Anti-Alzheimer's Drug Leqembi. What You Need To Know,https://www.forbes.com/sites/howardgleckman/2023/07/06/fda-has-approved-the-anti-alzheimers-drug-leqembi-what-you-need-to-know/,2023-07-06 21:25:20,"What You Need To Know The Food and Drug Administration (FDA) has granted final approval to the anti-Alzheimer's drug lecanamab, marked as Leqembi by drugmakers Eisai a...",BIIB,0.045396,0.152111,Somewhat-Bullish
Futures: Jobs Data Due; Elon Musk Rips 'Cheating' Threads,https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-with-jobs-report-due-meta-threads-has-record-launch-elon-musk-decries-cheating/,2023-07-06 21:16:00,Dow Jones Falls With Jobs Report Due. Meta's Threads Has Record Launch As Elon Musk Decries 'Cheating ... Investor's Business Daily ...,BIIB,0.074848,0.254359,Somewhat-Bullish
What's Going On With Biogen  ( BIIB )  Stock After Hours - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/general/biotech/23/07/33140561/whats-going-on-with-biogen-stock-thursday,2023-07-06 21:08:22,Biogen Inc BIIB shares were flat in Thursday's after-hours session after falling marginally by 0.31% to $284.99 during regular trading. The U.S.,BIIB,0.669956,0.162442,Somewhat-Bullish
US FDA grants standard approval of Eisai/Biogen Alzheimer's drug,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-grants-standard-approval-eisaibiogen-alzheimers-drug-2023-07-06/,2023-07-06 21:03:00,"LOS ANGELES, July 6 ( Reuters ) - The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai ( 4523.T ) and Biogen's ( BIIB.O ) Leqembi for patients with Alzheimer's disease, clearing the way for wider insurance coverage of the drug.",BIIB,0.058472,-0.224018,Somewhat-Bearish
Alzheimer's drug Leqembi has full FDA approval now and that means Medicare will pay for it,https://apnews.com/article/alzheimers-drug-fda-approval-medicare-leqembi-a9c8b770aa1868a59889143c3bc9d127,2023-07-06 20:50:00,"WASHINGTON ( AP ) - U.S. officials granted full approval to a on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.",BIIB,0.059935,0.0,Neutral
New Federal Decisions Make Alzheimer's Drug Leqembi Widely Accessible,https://www.nytimes.com/2023/07/06/health/alzheimers-leqembi-medicare.html,2023-07-06 20:48:30,"The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.",BIIB,0.022643,0.023273,Neutral
"FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage",https://www.cnbc.com/2023/07/06/fda-approves-alzheimers-drug-leqembi-from-eisai-biogen.html,2023-07-06 20:44:19,"Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.",BIIB,0.081276,0.100389,Neutral
Biogen's Make-Or-Break Moment In Alzheimer's Treatment Is Here,https://www.investors.com/news/technology/biogen-stock-faces-a-pivotal-test-as-fda-mulls-alzheimers-treatment/,2023-07-06 14:27:00,Biogen Stock Faces A Pivotal Test As FDA Mulls Alzheimer's Treatment | Investor's Business Daily Investor's Business Daily ...,BIIB,0.747807,0.394391,Bullish
NeuroSense CEO Provides Q2 2023 Update,https://www.prnewswire.com/news-releases/neurosense-ceo-provides-q2-2023-update-301871106.html,2023-07-06 12:30:00,"CAMBRIDGE, Mass., July 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( Nasdaq: NRSN ) ( ""NeuroSense"" ) , a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company's clinical and operational developments ...",BIIB,0.115787,0.068844,Neutral
Biosimilar BYOOVIZâ¢ now reimbursed in Quebec to treat serious retinal disorders,https://www.newswire.ca/news-releases/biosimilar-byooviz-tm-now-reimbursed-in-quebec-to-treat-serious-retinal-disorders-808170767.html,2023-07-06 11:00:00,â¢ First provincial listing of anti-VEGF ranibizumab biosimilar brings cost-effective new option to patients and helps support healthcare system sustainability,BIIB,0.382925,0.461703,Bullish
First Alzheimer's drug to slow disease progression expected to get full FDA approval,https://www.cnn.com/2023/07/06/health/leqembi-alzheimers-fda-approval-medicare/index.html,2023-07-06 10:47:00,"The US Food and Drug Administration is expected to decide on Thursday whether to grant traditional approval to the Alzheimer's drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease.",BIIB,0.035293,0.064528,Neutral
FDA weighs first full approval for experimental Alzheimer's drug,https://www.axios.com/2023/07/06/leqembi-fda-expected-approval-alzheimers,2023-07-06 03:38:05,The Food and Drug Administration is set to decide today whether to make a drug shown to have modest success delaying Alzheimer's disease widely available to the public - or whether cost and safety concerns justify limiting its availability.,BIIB,0.089129,0.082905,Neutral
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,2023-07-03 21:01:00,Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the ... PR ...,BIIB,0.040795,0.143852,Neutral
COREVITASÂ® VANTAGEÂ® SIMULATIONS WINS AWARD FOR BEST USE OF INNOVATION,https://www.prnewswire.com/news-releases/corevitas-vantage-simulations-wins-award-for-best-use-of-innovation-301869174.html,2023-07-03 18:00:00,"WALTHAM, Mass., July 3, 2023 /PRNewswire/ -- CorEvitas, LLC, the gold-standard provider of real-world evidence solutions for the life sciences industry, today announced that it has received the 2023 BOBI ( Best of Business Intelligence ) Award for Best Use of Innovation from the British ...",BIIB,0.230782,0.46967,Bullish
"Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment - Ionis Pharmaceuticals  ( NASDAQ:IONS ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33094946/biogen-reports-new-spinraza-data-in-atrophy-patients-after-incomplete-response-to-n,2023-07-03 12:36:09,Biogen Inc BIIB announced new Spinraza ( nusinersen ) data that were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA.,BIIB,0.502207,0.470579,Bullish
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth,https://www.globenewswire.com/news-release/2023/07/03/2698382/0/en/Bionomics-Announces-Key-Leadership-Updates-to-Drive-U-S-Focused-Transformation-and-Next-Stage-of-Strategic-Growth.html,2023-07-03 10:00:00,"ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 ( GLOBE NEWSWIRE ) -- Bionomics Limited ( Nasdaq: BNOX | ASX: BNO ) ( Bionomics or Company ) , a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from ...",BIIB,0.036869,0.086244,Neutral
New data highlight potential benefit of SPINRAZAÂ®  ( nusinersen )  in infants and toddlers with unmet medical needs after gene therapy,https://www.prnewswire.com/news-releases/new-data-highlight-potential-benefit-of-spinraza-nusinersen-in-infants-and-toddlers-with-unmet-medical-needs-after-gene-therapy-301868324.html,2023-06-30 20:08:00,New data highlight potential benefit of SPINRAZAÂ® ( nusinersen ) in infants and toddlers with unmet medical needs after ... PR ...,BIIB,0.135921,0.147846,Neutral
"New Data at Cure SMA Highlight Potential Benefit of SPINRAZAÂ®  ( nusinersen )  in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy - Ionis Pharmaceuticals  ( NASDAQ:IONS ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/pressreleases/23/06/g33084807/new-data-at-cure-sma-highlight-potential-benefit-of-spinraza-nusinersen-in-infants-and-toddlers-wi,2023-06-30 20:06:00,Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after ZolgensmaÂ® ( onasemnogene abeparvovec ) Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience,BIIB,0.244518,0.271476,Somewhat-Bullish
New Data at Cure SMA Highlight Potential Benefit of SPINRAZAÂ®  ( nusinersen )  in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy,https://www.globenewswire.com/news-release/2023/06/30/2698081/0/en/New-Data-at-Cure-SMA-Highlight-Potential-Benefit-of-SPINRAZA-nusinersen-in-Infants-and-Toddlers-with-Unmet-Clinical-Needs-After-Gene-Therapy.html,2023-06-30 20:06:00,"CAMBRIDGE, Mass., June 30, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced new SPINRAZAÂ® ( nusinersen ) data aimed at answering critical questions for the spinal muscular atrophy ( SMA ) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by ...",BIIB,0.234401,0.295735,Somewhat-Bullish
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference  ( AAIC )  2023,https://markets.businessinsider.com/news/stocks/eisai-presents-latest-analysis-of-lecanemab-s-effect-on-biomarker-changes-and-subcutaneous-dosing-at-the-alzheimer-s-association-international-conference-aaic-2023-1032460519,2023-07-19 23:30:00,Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference ...,BIIB,0.171485,0.038924,Neutral
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference  ( AAIC )  2023,https://www.globenewswire.com/news-release/2023/07/19/2707815/0/en/Eisai-Presents-Latest-Analysis-of-Lecanemab-s-Effect-on-Biomarker-Changes-and-Subcutaneous-Dosing-at-The-Alzheimer-s-Association-International-Conference-AAIC-2023.html,2023-07-19 23:30:00,"Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer's disease ...",BIIB,0.152258,0.046701,Neutral
What Is the Nasdaq?,https://www.kiplinger.com/investing/stocks/what-is-the-nasdaq,2023-07-19 20:28:04,"""The Nasdaq"" is a term market participants hear several times a day, but what exactly is ""the Nasdaq""? Typically, when an investor says ""the Nasdaq,"" they're referring to the Nasdaq Composite, or IXIC. This is an index that tracks the performance of the Nasdaq Stock Market, an electronic platform ...",BIIB,0.089797,0.086968,Neutral
"Tesla On Tap: ""Mega-cap"" Reporting Season Gets Underway After Close With EV Giant's Earnings - Apple  ( NASDAQ:AAPL ) , Albertsons Companies  ( NYSE:ACI ) ",https://www.benzinga.com/markets/23/07/33291567/tesla-on-tap-mega-cap-reporting-season-gets-underway-after-close-with-ev-giants-earnings,2023-07-19 19:36:45,"( Wednesday market open ) Major indexes ride into Tesla's TSLA earnings later today on a long winning streak that carried stocks to new 15-month highs yesterday. Hopes for an economic ""soft landing"" based on recent positive data drove gains. Investors appear to expect more positive news after ...",BIIB,0.038811,0.071259,Neutral
Biogen  ( BIIB )  to Report Q2 Earnings: Here's What to Expect,https://www.zacks.com/stock/news/2123856/biogen-biib-to-report-q2-earnings-heres-what-to-expect,2023-07-19 14:56:00,"Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.",BIIB,0.327366,0.280062,Somewhat-Bullish
GSK  ( GSK )  Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release,https://www.zacks.com/stock/news/2123708/gsk-gsk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q2-release,2023-07-19 14:01:46,Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BIIB,0.176502,-0.001433,Neutral
Is Biogen Stock a Buy Now?,https://www.fool.com/investing/2023/07/19/is-biogen-stock-a-buy-now/,2023-07-19 12:30:00,The biotech hasn't been the best investment recently.,BIIB,0.499254,0.275555,Somewhat-Bullish
Biotech and Biopharma Executive Eliana Clark Joins Culture Biosciences' Advisory Board,https://www.benzinga.com/pressreleases/23/07/g33281046/biotech-and-biopharma-executive-eliana-clark-joins-culture-biosciences-advisory-board,2023-07-19 10:39:41,"SAN FRANCISCO, July 19, 2023 ( GLOBE NEWSWIRE ) -- Culture Biosciences is excited to welcome Eliana Clark, PhD, Executive Vice President and Chief Technical Officer at Intellia Therapeutics, Inc., to the company's Advisory Board.",BIIB,0.05833,0.028026,Neutral
Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030,https://www.fool.com/investing/2023/07/19/prediction-company-will-be-a-biotech-giant-by-2030/,2023-07-19 09:30:00,You might want to get in on this story right now.,BIIB,0.164656,0.160826,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2123266/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know,2023-07-18 21:50:20,"In the latest trading session, Biogen Inc. (BIIB) closed at $276.17, marking a -0.8% move from the previous day.",BIIB,0.624172,0.310732,Somewhat-Bullish
The Fight Against Alzheimer Goes Beyond Plaque. Tangles Are a Target Too.,https://www.barrons.com/articles/alzheimer-prothea-plaque-tau-tangles-1ab2626a,2023-07-18 21:36:00,"Keep your eyes on tau, not just amyloid-beta, as the world of medical research takes on Alzheimer's disease. A rivalry between Eli Lilly and the team of Biogen and Eisai Pharmaceuticals was the main event at this week's international conference of the Alzheimer's Association in Amsterdam.",BIIB,0.445569,0.174965,Somewhat-Bullish
"A new treatment for Alzheimer's offers hope-but raises questions, too",https://www.economist.com/science-and-technology/2023/07/18/a-new-treatment-for-alzheimers-offers-hope-but-raises-questions-too,2023-07-18 18:35:44,"F the search for a drug to treat Alzheimer's disease had seemed a costly wild-goose chase. Then, in 2021, a drug called aducanumab received regulatory approval in America. A second, lecanemab, got the nod in January this year.",BIIB,0.126119,-0.005879,Neutral
Alzheimer's Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off.,https://www.barrons.com/articles/alzheimers-drugs-competition-lilly-biogen-4cdc6c6,2023-07-18 18:13:00,"After two years of false starts and regulatory stumbles, two huge biopharma companies are getting ready for a showdown over the market for new Alzheimer's disease therapies. Billions of dollars in sales hang in the balance.",BIIB,0.241924,0.22259,Somewhat-Bullish
"Subdued Tone: Major Indexes Waver Despite Earnings Beats by Bank of America, Morgan Stanley - American Express  ( NYSE:AXP ) , American Airlines Group  ( NASDAQ:AAL ) ",https://www.benzinga.com/markets/23/07/33272167/subdued-tone-major-indexes-waver-despite-earnings-beats-by-bank-of-america-morgan-stanley,2023-07-18 17:57:32,"( Tuesday market open ) The morning kicks off with more big banks beating analysts' earnings expectations, but major indexes were barely changed in premarket trading. Retail Sales-an important barometer of consumer health-rose less than expected in June.",BIIB,0.039944,0.07154,Neutral
Lilly's  ( LLY )  Donanemab Slows Alzheimer's Disease Progression,https://www.zacks.com/stock/news/2123179/lillys-lly-donanemab-slows-alzheimers-disease-progression,2023-07-18 15:30:00,Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.,BIIB,0.143987,0.164116,Somewhat-Bullish
Earnings Preview: Biogen Inc.  ( BIIB )  Q2 Earnings Expected to Decline,https://www.zacks.com/stock/news/2122901/earnings-preview-biogen-inc-biib-q2-earnings-expected-to-decline,2023-07-18 14:01:22,Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BIIB,0.299478,-0.024572,Neutral
Virtualware  ( EPA:MLVIR )  Announces record-breaking First-Half 2023 Results: VR SaaS Business Line Records Steady 208% Growth,https://www.globenewswire.com/news-release/2023/07/18/2706087/0/en/Virtualware-EPA-MLVIR-Announces-record-breaking-First-Half-2023-Results-VR-SaaS-Business-Line-Records-Steady-208-Growth.html,2023-07-18 05:57:00,"BILBAO, Spain, July 18, 2023 ( GLOBE NEWSWIRE ) -- Virtualware ( EPA:MLVIR ) , a pioneering VR company employing a SaaS business model, today announced record-breaking H1 2023 financial results, just three months after it went public in Euronext Access Paris.",BIIB,0.052801,0.098632,Neutral
"Treating Alzheimer's Very Early Offers Better Hope of Slowing Decline, Study Finds",https://www.nytimes.com/2023/07/17/health/alzheimers-drug-donanemab.html,2023-07-17 14:18:51,"A trial of donanemab, an experimental drug, found it modestly slowed the worsening of memory and thinking and worked better in patients at earlier stages and those under 75.",BIIB,0.027828,-0.18346,Somewhat-Bearish
Second Alzheimer's drug to slow disease's progression may be approved in the US this year,https://www.cnn.com/2023/07/17/health/second-alzheimers-drug-to-slow-disease-may-be-approved-this-year/index.html,2023-07-17 14:15:00,"The full approval this month of the Alzheimer's drug Leqembi marked a historic shift in the treatment of the disease: For the first time, doctors have a medicine to prescribe that has been proven to slow the loss of memory and ability to do daily tasks that Alzheimer's brings.",BIIB,0.043579,0.057612,Neutral
Should You Buy the Dip With Biogen Stock Right Now?,https://www.fool.com/investing/2023/07/17/should-you-buy-the-dip-with-biogen-stock-right-now/,2023-07-17 13:45:00,"It's expected to grow, but things might not work out precisely as planned.",BIIB,0.213988,0.079119,Neutral
These 2 Numbers Should Scare Every Biogen Shareholder,https://www.fool.com/investing/2023/07/16/numbers-should-scare-every-biogen-shareholder/,2023-07-16 11:15:00,There are a couple of pieces of evidence that Biogen's long-term strategy isn't working.,BIIB,0.222327,0.152752,Somewhat-Bullish
Acumen's Alzheimer's drug passes initial safety test,https://www.reuters.com/business/healthcare-pharmaceuticals/acumens-alzheimers-drug-passes-initial-safety-test-2023-07-16/,2023-07-16 06:04:13,"CHICAGO, July 16 ( Reuters ) - An experimental Alzheimer's disease drug developed by Acumen Pharmaceuticals ( ABOS.O ) targeting a novel form of the toxic protein beta amyloid in the brain passed an early safety test and will advance to a larger trial, the company said on Sunday.",BIIB,0.126119,0.017125,Neutral
Novartis  ( NVS )  to Report Q2 Earnings: Is a Beat in Store?,https://www.zacks.com/stock/news/2121531/novartis-nvs-to-report-q2-earnings-is-a-beat-in-store,2023-07-14 15:29:00,"When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.",BIIB,0.13873,0.072651,Neutral
"Puzzles And Games Cut Dementia Risk-But Socializing With Friends And Family Barely Helps, Study Finds",https://www.forbes.com/sites/maryroeloffs/2023/07/14/puzzles-and-games-cut-dementia-risk-but-socializing-with-friends-and-family-barely-helps-study-finds/,2023-07-14 15:01:18,"A new study says activities that involve competition, require problem solving or learning a new skill can stave off dementia in older adults, a new study says.",BIIB,0.07446,-0.141254,Neutral
"Progressive Supranuclear Palsy Market Growing at a CAGR of 27.7% During the Study Period  ( 2019-2032 ) , Assesses DelveInsight",https://www.prnewswire.com/news-releases/progressive-supranuclear-palsy-market-growing-at-a-cagr-of-27-7-during-the-study-period-20192032-assesses-delveinsight-301876550.html,2023-07-13 21:01:00,"Progressive Supranuclear Palsy Market Growing at a CAGR of 27.7% During the Study Period ( 2019-2032 ) , Assesses ... PR ...",BIIB,0.027731,0.096866,Neutral
Column: New Alzheimer's drug holds promise but adds cost pressures for Medicare,https://www.reuters.com/markets/europe/new-alzheimers-drug-holds-promise-adds-cost-pressures-medicare-2023-07-13/,2023-07-13 15:41:00,"July 13 ( Reuters ) - Federal officials made a splash last week by giving the green light to an expensive new drug that holds promise of slowing the advance of Alzheimer's disease. If this sounds like deja vu, you are not wrong.",BIIB,0.039614,-0.045816,Neutral
"Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment",https://www.zacks.com/stock/news/2120702/biotech-stock-roundup-biib-eisais-drug-update-nvax-gains-on-deal-amendment,2023-07-13 13:22:00,Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.,BIIB,0.115416,0.228499,Somewhat-Bullish
Why Isn't Biogen Stock Soaring After This Major FDA Approval?,https://www.fool.com/investing/2023/07/13/why-isnt-biogen-stock-soaring-after-this-major-fda/,2023-07-13 12:15:00,Is the stock a good contrarian buy?,BIIB,0.364275,0.092217,Neutral
Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2120242/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know,2023-07-12 21:50:18,"Biogen Inc. (BIIB) closed the most recent trading day at $277.41, moving -0.87% from the previous trading session.",BIIB,0.663374,0.277382,Somewhat-Bullish
BIIB: 3 Biotech Stocks to Acquire in July,https://stocknews.com/news/biib-alks-thtx-3-biotech-stocks-to-acquire-in-july/,2023-07-12 18:27:40,"The biotech industry is poised for substantial expansion due to growing new drug formulations, the rising prevalence of personalized medicine, and several government initiatives and funding in the space.",BIIB,0.27838,0.342506,Somewhat-Bullish
P/E Ratio Insights for Biogen - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/07/33201740/pe-ratio-insights-for-biogen,2023-07-12 16:16:05,"In the current market session, Biogen Inc. BIIB share price is at $280.50, after a 0.24% increase. Moreover, over the past month, the stock fell by 6.52%, but in the past year, spiked by 30.88%.",BIIB,0.405651,0.0,Neutral
Why Biogen Inc.  ( BIIB )  is Poised to Beat Earnings Estimates Again,https://www.zacks.com/stock/news/2120090/why-biogen-inc-biib-is-poised-to-beat-earnings-estimates-again,2023-07-12 16:10:12,Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,BIIB,0.410505,0.414748,Bullish
"Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy",https://www.globenewswire.com/news-release/2023/07/12/2703461/20739/en/Ultragenyx-Appoints-Howard-Horn-as-Chief-Financial-Officer-and-Executive-Vice-President-Corporate-Strategy.html,2023-07-12 12:00:00,"NOVATO, Calif., July 12, 2023 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive ...",BIIB,0.077593,0.047914,Neutral
Should iShares Morningstar Mid-Cap Value ETF  ( IMCV )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2119612/should-ishares-morningstar-mid-cap-value-etf-imcv-be-on-your-investing-radar,2023-07-12 10:20:07,Style Box ETF report for ...,BIIB,0.123526,0.068619,Neutral
Ionis  ( IONS )  Posts Encouraging Data From Amyloidosis Drug Study,https://www.zacks.com/stock/news/2119263/ionis-ions-posts-encouraging-data-from-amyloidosis-drug-study,2023-07-11 13:40:00,"Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).",BIIB,0.422661,0.227425,Somewhat-Bullish
Prothena  ( PRTA )  Alzheimer's Disease Drug Licensed by BMY,https://www.zacks.com/stock/news/2119204/prothena-prta-alzheimers-disease-drug-licensed-by-bmy,2023-07-11 12:59:00,"Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.",BIIB,0.144275,0.355965,Bullish
Eisai exec who helped steer Alzheimer's drug approval to retire in July,https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-exec-who-helped-steer-alzheimers-drug-approval-retire-july-2023-07-11/,2023-07-11 07:15:00,"[1/2] A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering from Alzheimer's disease at the Memory Centre at the Department of Readaptation and Geriatrics of the University Hospital ( HUG ) , in Geneva, Switzerland, June 6, 2023.",BIIB,0.159569,0.020879,Neutral
Biogen  ( BIIB )  Stock Down Despite FDA Nod to Alzheimer's Drug,https://www.zacks.com/stock/news/2118733/biogen-biib-stock-down-despite-fda-nod-to-alzheimers-drug,2023-07-10 15:22:00,Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.,BIIB,0.219312,0.133484,Neutral
Icahn Enterprises shares jump on loan agreement and other stocks on the move,https://www.marketwatch.com/story/icahn-enterprises-shares-jump-on-report-of-loan-agreement-and-other-stocks-on-the-move-ae6968af,2023-07-10 14:07:00,"Icahn Enterprises, Alibaba and Northern Trust are stocks on the move.",BIIB,0.190417,0.196592,Somewhat-Bullish
FDA Approves New Alzheimer's Drug But Creators Biogen And Eisai Stock Slides,https://www.forbes.com/sites/qai/2023/07/10/fda-approves-new-alzheimers-drug-but-creators-biogen-and-eisai-stock-slides/,2023-07-10 12:00:00,Eisai saw its stock fall 4.67% on the news and Biogen was down 2.07%.,BIIB,0.141935,0.085657,Neutral
Newly approved Alzheimer's drug may not work as well on women,https://www.axios.com/2023/07/11/leqembi-azheimers-drug-women-men-efficacy,2023-07-10 10:37:55,Some experts are questioning whether a newly approved Alzheimer's drug was shown in clinical trials to be less effective on women - even though the FDA didn't flag any such concerns when it was authorized last week.,BIIB,0.043499,0.142862,Neutral
Biden's inside voice,https://www.axios.com/2023/07/10/bidens-inside-voice,2023-07-10 09:45:00,"Maybe you've noticed President Biden sometimes whispering in public settings - especially when answering questions from reporters. But behind closed doors, he's been known to take the volume up a notch. â¢ And, CVS and Walgreens get into the clinical trials business.",BIIB,0.023464,0.070641,Neutral
Wall Street ends week higher on US soft landing hopes,https://www.moneycontrol.com/news/business/markets/wall-street-ends-week-higher-on-us-soft-landing-hopes-11055541.html,2023-07-29 03:27:36,"The Dow Jones Industrial Average rose 176.37 points, or 0.5%, to 35,459.09, the SP 500 gained 44.76 points, or 0.99%, to 4,582.17 and the Nasdaq Composite added 266.55 points, or 1.9%, to 14,316.66.",BIIB,0.055751,0.122889,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SURF, RETA, INPX",https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-surf-reta-inpx-301888529.html,2023-07-28 20:46:00,"NEW YORK, July 28, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to Coherus BioSciences, Inc.",BIIB,0.175859,0.118146,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc.  ( Nasdaq - RETA ) , Talaris Therapeutics, Inc.  ( Nasdaq - TALS ) , InpixonÂ®  ( Nasdaq - INPX ) , Amedisys, Inc.  ( Nasdaq - AMED ) ",https://www.benzinga.com/pressreleases/23/07/g33448233/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-reata-pharmac,2023-07-28 18:21:02,"BALA CYNWYD, Pa., July 28, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BIIB,0.235823,0.210602,Somewhat-Bullish
Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering,https://www.marketwatch.com/story/biogen-agrees-to-acquire-reata-pharmaceuticals-for-7-3-billion-in-cash-e0a6135,2023-07-28 18:12:00,Biogen's all-cash deal is a rare-disease play.,BIIB,0.779232,0.381337,Bullish
"Stock Market Rallies Amid Earnings Wave, Fed Hike: Weekly Review",https://www.investors.com/news/stock-market-rallies-amid-huge-earnings-fed-rate-hike-inflation-data-weekly-review/,2023-07-28 18:06:00,"The stock market rally advanced amid a massive wave of earnings reports, a new Fed rate hike and tame inflation data, though the Dow Jones ended a long winning streak. Microsoft ( MSFT ) guidance disappointed, hitting many related stocks.",BIIB,0.028023,0.19241,Somewhat-Bullish
Stock Market Finishing Week On Strong Note; Chip Stock Leads The Dow,https://www.investors.com/market-trend/stock-market-today/stock-market-finishing-week-on-strong-note-intel-leads-dow/,2023-07-28 17:50:00,Stock Market Finishing Week On Strong Note. Chip Stock Leads The Dow Investor's Business Daily ...,BIIB,0.204072,0.397128,Bullish
"Moore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firm - Denbury  ( NYSE:DEN ) , Inpixon  ( NASDAQ:INPX ) ",https://www.benzinga.com/pressreleases/23/07/g33446821/moore-kuehn-encourages-reta-tals-inpx-and-den-investors-to-contact-law-firm,2023-07-28 16:57:12,"NEW YORK, July 28, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.",BIIB,0.110462,0.212618,Somewhat-Bullish
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33444357/reatas-acquisition-fits-biogens-strategy-despite-high-cost-analyst-says-high-level-,2023-07-28 15:56:17,"Earlier today, Biogen Inc BIIB agreed to acquire Reata Pharmaceuticals Inc RETA for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.",BIIB,0.718897,0.314394,Somewhat-Bullish
"Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals - Reata Pharmaceuticals  ( NASDAQ:RETA ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/m-a/23/07/33444844/health-care-company-biogen-announces-acquisition-of-reata-pharmaceuticals,2023-07-28 15:10:07,"Biogen BIIB has announced an acquisition of Reata Pharmaceuticals RETA that is expected to be completed in Q4 of 2023. Under the terms of the agreement, Biogen has agreed to give Reata Pharmaceuticals $7.30 billion in cash in exchange for RETA stock.",BIIB,0.538389,0.036618,Neutral
AstraZeneca strikes $1 billion deal for Pfizer rare-disease gene therapies,https://www.marketwatch.com/story/astrazeneca-strikes-1-billion-deal-for-pfizer-rare-disease-gene-therapies-705d2fc5,2023-07-28 15:00:00,Stock gains 5% after AstraZeneca's second-quarter results top analyst expectations.,BIIB,0.199037,0.167833,Somewhat-Bullish
"Dow Jones Rally Sparked By Surging Intel Stock; Nasdaq 100 Leaders Include Tesla, Dexcom, KLAC",https://www.investors.com/market-trend/stock-market-today/dow-jones-rally-sparked-by-surging-intel-stock-nasdaq-100-leaders-tesla-tsla-dexcom-dxcm-klacs/,2023-07-28 14:50:00,"Dow Jones Rally Sparked By Surging Intel Stock. Nasdaq 100 Leaders Include Tesla, Dexcom, KLAC Investor's Business Daily ...",BIIB,0.104683,0.15005,Somewhat-Bullish
Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition,https://www.forbes.com/sites/maryroeloffs/2023/07/28/biogen-looks-to-bulk-up-rare-disease-portfolio-with-73-billion-acquisition/,2023-07-28 13:45:22,Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.,BIIB,0.783955,0.191166,Somewhat-Bullish
Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals,https://www.investors.com/news/technology/biogen-stock-biogen-announces-7-3-billion-acquisition-of-reata-pharmaceuticals/,2023-07-28 13:34:00,"Biogen ( BIIB ) announced Friday it has agreed to acquire Reata Pharmaceuticals ( RETA ) for about $7.3 billion, boosting the biopharmaceutical company's drug offerings for serious neurological diseases. Reata stock surged early as Biogen stock slid Friday.",BIIB,0.917354,0.299614,Somewhat-Bullish
The Investing Club's top 10 things to watch in the stock market Friday,https://www.cnbc.com/2023/07/28/the-investing-clubs-top-10-things-to-watch-in-the-stock-market-friday.html,2023-07-28 13:27:56,We're watching the bond market Friday after Thursday's spike in yields triggered a late-day reversal for equities.,BIIB,0.125789,0.219384,Somewhat-Bullish
"Why Reata Pharmaceuticals  ( RETA )  Stock Is Trading Higher Premarket Today - Reata Pharmaceuticals  ( NASDAQ:RETA ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/07/33440534/biogen-bolsters-rare-disease-portfolio-agrees-to-buy-reata-pharmaceuticals-with-enterprise-value-,2023-07-28 13:07:49,"Biogen Inc BIIB has agreed to acquire Reata Pharmaceuticals Inc RETA for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.",BIIB,0.849318,0.587963,Bullish
Market Rebounds With Inflation Data Due; 5 Earnings Winners,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-rebounds-inflation-data-5-earnings-winners/,2023-07-28 12:09:00,Dow Jones Futures: Market Rally Set To Rebound With Inflation Data Due. 5 Earnings Winners Investor's Business Daily ...,BIIB,0.105449,0.053918,Neutral
Biogen to bulk up rare disease treatments with $7 billion Reata acquisition,https://apnews.com/article/biogen-reata-acquisition-98308231d2e704171ea44ac6a32637c6,2023-07-28 12:07:00,Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimer's treatment developer said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year.,BIIB,0.647216,0.295113,Somewhat-Bullish
Biogen to Buy Reata Pharmaceuticals in $7.3 Billion Deal,https://www.wsj.com/articles/biogen-to-buy-reata-pharmaceuticals-in-7-3-billion-deal-512adde2,2023-07-28 12:03:00,The deal would bolster the biotech company's portfolio of treatments for neuromuscular and rare diseases.,BIIB,0.967875,0.252802,Somewhat-Bullish
"Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and more",https://www.cnbc.com/2023/07/28/stocks-making-the-biggest-moves-premarket-intc-roku-pg-.html,2023-07-28 11:56:16,These are the stocks posting the largest moves in premarket trading.,BIIB,0.098456,0.189304,Somewhat-Bullish
Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio,https://www.reuters.com/markets/deals/biogen-buy-reata-65-bln-bulk-up-rare-disease-portfolio-2023-07-28/,2023-07-28 11:21:40,"July 28 ( Reuters ) - Biogen ( BIIB.O ) said it would buy biotech firm Reata Pharmaceuticals ( RETA.O ) for roughly $6.5 billion to expand its presence in the rare disease drugs market. Biogen will pay $172.50 per share in cash, which represents a 58.9% premium to Reata's last closing price.",BIIB,0.9545,0.141564,Neutral
"Biogen to Acquire Reata Pharmaceuticals - Reata Pharmaceuticals  ( NASDAQ:RETA ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/pressreleases/23/07/g33439516/biogen-to-acquire-reata-pharmaceuticals,2023-07-28 11:05:44,"SKYCLARYSÂ® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical need",BIIB,0.359592,0.207274,Somewhat-Bullish
Biogen to Acquire Reata Pharmaceuticals,https://www.globenewswire.com/news-release/2023/07/28/2713028/0/en/Biogen-to-Acquire-Reata-Pharmaceuticals.html,2023-07-28 11:05:00,"CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) and Reata Pharmaceuticals, Inc. ( Nasdaq: RETA ) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in ...",BIIB,0.395324,0.252143,Somewhat-Bullish
"Virtualware  ( MLVIR )  launches VIROO 2.4, the new version of its Virtual Reality as a service  ( VRaaS )  platform",https://www.globenewswire.com/news-release/2023/07/28/2712895/0/en/Virtualware-MLVIR-launches-VIROO-2-4-the-new-version-of-its-Virtual-Reality-as-a-service-VRaaS-platform.html,2023-07-28 06:38:00,"BILBAO, July 28, 2023 - Spanish publicly traded company, Virtualware ( EPA:MLVIR ) , one of the leaders in virtual reality, announced today the release of the new version 2.4 of its VRaaS platfom, VIROO, which incorporates, among other capabilities, Mixed Reality ( MR ) and VR CAVEs integration ...",BIIB,0.076847,0.100195,Neutral
Biogen  ( NASDAQ:BIIB )  Rating Lowered to Buy at StockNews.com,https://www.defenseworld.net/2023/07/28/biogen-nasdaqbiib-rating-lowered-to-buy-at-stocknews-com.html,2023-07-28 05:02:51,"Biogen ( NASDAQ:BIIB - Get Free Report ) was downgraded by StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a research note issued on Wednesday. Other equities analysts have also issued research reports about the stock.",BIIB,0.827318,0.387918,Bullish
"Multiple Sclerosis Market Size and Share to Grow Significantly, Assesses DelveInsight | Leading Companies - Roche, Atara, Immunic, Celgene, Anokion SA, Sanofi, Actelion, Biogen, Genzyme, ImStem, Rho, Bristol-Myers Squibb",https://www.prnewswire.com/news-releases/multiple-sclerosis-market-size-and-share-to-grow-significantly-assesses-delveinsight--leading-companies---roche-atara-immunic-celgene-anokion-sa-sanofi-actelion-biogen-genzyme-imstem-rho-bristol-myers-squibb-301887032.html,2023-07-27 21:01:00,"Multiple Sclerosis Market Size and Share to Grow Significantly, Assesses DelveInsight | Leading Companies - Roche ... PR ...",BIIB,0.044182,0.088537,Neutral
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO,https://www.fool.com/investing/2023/07/27/biogen-11-words-from-ceo/,2023-07-27 10:00:00,"Biogen shares have stagnated in recent years, but the company has a plan to change that.",BIIB,0.583426,0.268134,Somewhat-Bullish
"Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and Company, Janssen, Merck, BioVie, Biogen, Vivoryon, Sage, Alnylam, BioXcel, EIP, Otsuka, Alector, Transposon",https://www.prnewswire.com/news-releases/dementia-market-to-grow-rapidly-estimates-delveinsight--key-companies-active-in-the-market---pfizer-eli-lilly-and-company-janssen-merck-biovie-biogen-vivoryon-sage-alnylam-bioxcel-eip-otsuka-alector-transposon-301885979.html,2023-07-26 21:01:00,"Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and ... PR ...",BIIB,0.071357,0.077488,Neutral
Fed Staff No Longer Predict Recession As Inflation Cools,https://www.forbes.com/sites/brianbushard/2023/07/26/fed-staff-no-longer-predict-recession-as-inflation-cools/,2023-07-26 19:59:58,"Federal Reserve Chair Jerome Powell said the ""resiliency"" of the economy prompted the Fed to no longer forecast a looming recession.",BIIB,0.080728,-0.066322,Neutral
Why Sage Therapeutics Stock Is Tumbling Today,https://www.fool.com/investing/2023/07/26/why-sage-therapeutics-stock-is-tumbling-today/,2023-07-26 19:46:00,A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.,BIIB,0.337811,-0.325964,Somewhat-Bearish
"Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More",https://www.zacks.com/stock/news/2128013/biotech-stock-roundup-biib-gsks-q2-earnings-kod-faces-setback-more,2023-07-26 14:08:00,Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.,BIIB,0.116536,0.027736,Neutral
"Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It - Could This Rising Company Have The Answer? - Tiziana Life Sciences  ( NASDAQ:TLSA ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/07/33390126/neuroinflammation-a-key-indicator-for-alzheimers-but-current-treatments-show-little-success-in-re,2023-07-26 12:05:46,"There have been several accelerated approvals granted to treatments for patients with Alzheimer's disease ( AD ) by the Food and Drug Administration ( FDA ) in recent months, and there are several treatments also in development.",BIIB,0.234307,-0.170296,Somewhat-Bearish
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,https://www.benzinga.com/pressreleases/23/07/g33389178/monte-rosa-therapeutics-appoints-dr-anthony-m-manning-to-board-of-directors,2023-07-26 11:30:00,"BOSTON, July 26, 2023 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.",BIIB,0.069495,0.074263,Neutral
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors,https://www.globenewswire.com/news-release/2023/07/26/2711202/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Anthony-M-Manning-to-Board-of-Directors.html,2023-07-26 11:30:00,"BOSTON, July 26, 2023 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. ( NASDAQ: GLUE ) , a clinical stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.",BIIB,0.046006,0.072788,Neutral
"Pharma Giant GSK Beats Second-Quarter Goals On Growth In Vaccines, General Medicines",https://www.investors.com/news/technology/gsk-stock-vaccine-sales-drive-q2-beat/,2023-07-26 11:02:00,GSK Stock: Vaccine Sales Drive Q2 Beat Investor's Business Daily ...,BIIB,0.102888,0.08308,Neutral
Alkermes plc Reports Second Quarter 2023 Financial Results,https://www.prnewswire.com/news-releases/alkermes-plc-reports-second-quarter-2023-financial-results-301885734.html,2023-07-26 11:00:00,- Second Quarter Revenues of $617.4 Million Reflect Strong Performance of Proprietary Product Portfolio and Reinstatement of Long-Acting INVEGAÂ® Product Royalties - - Net Sales of Proprietary Products Increased Approximately 21% Year-Over-Year - - Prevailed in Janssen Arbitration.,BIIB,0.01682,-0.035366,Neutral
Why Biogen Stock Got Sick Today,https://www.fool.com/investing/2023/07/25/why-biogen-stock-got-sick-today/,2023-07-25 22:09:46,"While the company has won approval for a promising drug, it's cutting costs in the wake of that regulatory green light.",BIIB,0.605266,0.241668,Somewhat-Bullish
Biogen  ( BIIB )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/07/25/biogen-biib-q2-2023-earnings-call-transcript/,2023-07-25 19:30:45,"BIIB earnings call for the period ending June 30, 2023.",BIIB,0.071333,0.102025,Neutral
"Stocks making the biggest moves midday: Spotify, RTX, General Electric and more",https://www.cnbc.com/2023/07/25/stocks-making-the-biggest-moves-midday-spot-rtx-ge.html,2023-07-25 16:16:51,These are the stocks posting the largest moves in midday trading.,BIIB,0.070105,-0.007099,Neutral
"Biogen to cut 1,000 jobs as focus turns to Alzheimer's drug Leqembi launch",https://www.foxbusiness.com/economy/biogen-cut-1000-jobs-focus-turns-alzheimers-drug-leqembi-launch,2023-07-25 15:58:17,"Biogen said it expects to eliminate roughly 1,000 positions to save money ahead of launching a new drug to treat Alzheimer's disease.",BIIB,0.733479,0.436648,Bullish
"Biogen  ( BIIB )  Beats on Q2 Earnings & Sales, Announces Job Cuts",https://www.zacks.com/stock/news/2127098/biogen-biib-beats-on-q2-earnings-sales-announces-job-cuts,2023-07-25 15:21:00,Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.,BIIB,0.228073,-0.05759,Neutral
"Biogen to slash 1,000 jobs as it looks to save $700 million",https://www.marketwatch.com/story/biogen-tops-earnings-estimates-and-says-it-will-shift-resources-to-higher-value-areas-8d6f9f2d,2023-07-25 14:44:00,"Biotech giant's cost-cutting effort comes amid the launch of its Alzheimer's treatment, Leqembi.",BIIB,0.56217,0.357617,Bullish
"Top Stories Tuesday, July 25: Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years - Apple  ( NASDAQ:AAPL ) , American Airlines Group  ( NASDAQ:AAL ) ",https://www.benzinga.com/news/23/07/33370617/ron-desantis-escapes-car-accident-unhurt-en-route-to-campaign-event-tiktok-takes-on-twitter-analysts,2023-07-25 14:26:24,The campaign for Republican presidential contender and Florida Gov. Ron DeSantis said the candidate and a few of his team members were involved in a vehicular accident on their way to a campaign event on Tuesday. DeSantis and his staff emerged unscathed from the incident.,BIIB,0.060541,-0.107004,Neutral
"2023 Layoff Tracker: Biogen Cuts 1,000 Employees",https://www.forbes.com/sites/brianbushard/2023/07/25/2023-layoff-tracker-biogen-cuts-1000-employees/,2023-07-25 14:19:07,"Second quarter layoffs continue apace after more than 136,000 employees were cut by major U.S. companies in the first quarter of 2023.",BIIB,0.261117,-0.482704,Bearish
Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs,https://www.wsj.com/articles/biogen-to-cut-roughly-11-of-workforce-to-focus-on-big-return-drugs-145b3f23,2023-07-25 13:26:00,The biotech cited the launch of Alzheimer's drug Leqembi as part of its new focus.,BIIB,0.947069,-0.196935,Somewhat-Bearish
Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable,https://www.investors.com/news/technology/biogen-stock-alzheimers-drug-not-yet-profitable-as-company-tops-earnings-views/,2023-07-25 13:24:00,Biogen Stock: Alzheimer's Drug Not Yet Profitable As Company Tops Earnings Views Investor's Business Daily ...,BIIB,0.729556,0.066848,Neutral
"Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch",https://www.cnbc.com/2023/07/25/biogen-to-cut-1000-jobs-as-company-prepares-for-leqembi-launch-.html,2023-07-25 12:39:48,"Biogen, in its second-quarter earnings report, said the plan will result in $700 million in net operating expense savings by 2025.",BIIB,0.585052,0.255851,Somewhat-Bullish
"Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area ( s ) , Layoff 1K Staff - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/07/33365698/biogen-q2-earnings-tops-expectations-shift-resources-to-higher-value-area-s-layoff-1k-staff,2023-07-25 12:36:40,"Biogen Inc BIIB posted Q2 FY23 sales of $2.46 billion, beating the consensus of $2.37 billion, down 5% Y/Y and 3% at constant currency ( CC ) . Multiple sclerosis revenue of $1.21 billion decreased by 15% ( down 14% CC ) . Multiple sclerosis drug Tysabri sales are down to $483.1 million from ...",BIIB,0.628066,-0.090416,Neutral
Biogen Inc.  ( BIIB )  Tops Q2 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2126717/biogen-inc-biib-tops-q2-earnings-and-revenue-estimates,2023-07-25 12:25:07,"Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",BIIB,0.405651,0.175573,Somewhat-Bullish
"Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting' - Alaska Air Gr  ( NYSE:ALK ) , Alphabet  ( NASDAQ:GOOG ) , Alphabet  ( NASDAQ:GOOGL ) , Kimberly-Clark  ( NYSE:KMB ) , Teladoc Health  ( NYSE:TDOC ) , Spotify Technology  ( NYSE:SPOT ) , Verizon Communications  ( NYSE:VZ ) , General Motors  ( NYSE:GM ) , 3M  ( NYSE:MMM ) , Snap  ( NYSE:SNAP ) , Dow  ( NYSE:DOW ) , F5  ( NASDAQ:FFIV ) , Microsoft  ( NASDAQ:MSFT ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Visa  ( NYSE:V ) , SPDR S&P 500  ( ARCA:SPY ) , General Electric  ( NYSE:GE ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/earnings/23/07/33365504/nasdaq-futures-rise-ahead-of-microsoft-alphabet-earnings-analyst-warns-of-volatility-from-feds-mess,2023-07-25 11:41:00,"Stock futures indicate a positive start on Tuesday, driven by strong earnings momentum. However, concerns loom over overbought small-cap stocks. Investors are keeping an eye on the Federal Reserve's two-day rate-setting meeting, which begins today.",BIIB,0.106541,0.0,Neutral
"Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace",https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-cut-1000-jobs-save-costs-alzheimers-drug-launch-gathers-pace-2023-07-25/,2023-07-25 11:07:00,Biogen to cut 1000 jobs to save costs as Alzheimer's drug launch gathers pace ...,BIIB,0.443626,0.209619,Somewhat-Bullish
Dow futures lackluster after scorching rally; Big Tech earnings in focus,https://www.reuters.com/markets/us/dow-futures-lackluster-after-scorching-rally-big-tech-earnings-focus-2023-07-25/,2023-07-25 09:57:00,Dow futures lackluster after scorching rally. Big Tech earnings in focus ...,BIIB,0.118647,0.0,Neutral
"All Eyes On Biogen's Alzheimer's Drug, Big Potential Payday, Ahead Of Earnings",https://www.investors.com/news/technology/biogen-stock-all-eyes-are-on-alzheimers-drug-big-potential-payday-ahead-of-earnings/,2023-07-24 21:46:00,"Biogen ( BIIB ) reports second-quarter financials Tuesday, with analysts expecting both profit and revenue to fall as all eyes are on the company's recently fully approved Alzheimer's drug, Leqembi.",BIIB,0.778056,0.193697,Somewhat-Bullish
3 Top ETFs to Buy Right Now,https://www.fool.com/investing/2023/07/24/3-top-etfs-to-buy-right-now/,2023-07-24 21:45:00,These three exchange-traded funds could be winning plays for patient investors.,BIIB,0.07423,0.039438,Neutral
"Brace For Action: Big Week Ahead Includes Fed Meeting, Heavy Earnings And Data Calendar - Apple  ( NASDAQ:AAPL ) , FedEx  ( NYSE:FDX ) ",https://www.benzinga.com/markets/23/07/33349594/brace-for-action-big-week-ahead-includes-fed-meeting-heavy-earnings-and-data-calendar,2023-07-24 16:07:03,"( Monday market open ) The week ahead has something for everyone, including a Federal Reserve meeting and reports from roughly 30% of all S&P 500Â® companies. Most of the action starts tomorrow, and trading was subdued in premarket hours Monday as investors awaited the excitement to come.",BIIB,0.042011,0.072014,Neutral
Better Big Biotech Buy: Vertex vs. Biogen,https://www.fool.com/investing/2023/07/24/better-big-biotech-buy-vertex-vs-biogen/,2023-07-24 14:09:27,These companies have a track record of billion-dollar earnings.,BIIB,0.592095,0.391347,Bullish
"Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors",https://www.globenewswire.com/news-release/2023/07/24/2709506/0/en/Capricor-Therapeutics-Announces-Appointment-of-Philip-J-Gotwals-Ph-D-to-its-Board-of-Directors.html,2023-07-24 12:30:00,"SAN DIEGO, July 24, 2023 ( GLOBE NEWSWIRE ) -- Capricor Therapeutics ( NASDAQ: CAPR ) , a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment ...",BIIB,0.03878,0.029033,Neutral
Biotech wins fail to move stock indicators ahead of earnings,https://www.financialexpress.com/healthcare/news-healthcare/biotech-wins-fail-to-move-stock-indicators-ahead-of-earnings/3184760/,2023-07-24 10:35:25,Biotech has had a pretty good year between a flurry of deals and approvals of new drugs for vexing diseases such as Alzheimer's. Yet that isn't showing up in stock performance. Two closely watched indicators lag far behind the overall market.,BIIB,0.057215,0.0,Neutral
Lilly Joins Biogen as Alzheimer's Drugs Finally Emerge,https://www.barrons.com/articles/lilly-joins-biogen-as-alzheimers-drugs-finally-emerge-c5a3235f,2023-07-22 00:03:00,"After years of false starts and regulatory stumbles, Alzheimer's therapies have suddenly emerged. Earlier this month, Biogen and Japanese partner Eisai received full approval for Leqembi, which, significantly, Medicare will pay for.",BIIB,0.546745,0.044252,Neutral
"Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades' - Goldman Sachs Gr  ( NYSE:GS ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/07/33318021/goldman-sachs-charles-schwab-and-this-healthcare-stock-on-cnbcs-final-trades,2023-07-21 13:34:23,"On CNBC's ""Halftime Report Final Trades,"" Joshua Brown of Ritholtz Wealth Management named Biogen Inc. BIIB as the 4th cheapest stock in the whole Health Care Select Sector SPDR Fund XLV. The company is scheduled to report quarterly earnings next week.",BIIB,0.501398,0.503842,Bullish
"Treatments for Alzheimer's, finally",https://www.ft.com/content/49ab3e87-aefd-43bf-9e64-dc34daffa559,2023-07-21 04:00:38,"This is an audio transcript of the FT News Briefing podcast episode: 'Treatments for Alzheimer's, finally' Good morning from the Financial Times. Today is Friday, July 21st. And this is your FT News Briefing.",BIIB,0.033703,0.135516,Neutral
"Win Streak Threatened: Tesla, Netflix Results Bring Pressure as Housing, Leading Indicators Data Awaited - American Express  ( NYSE:AXP ) , American Airlines Group  ( NASDAQ:AAL ) ",https://www.benzinga.com/news/earnings/23/07/33307492/win-streak-threatened-tesla-netflix-results-bring-pressure-as-housing-leading-indicators-data-await,2023-07-20 15:51:29,"( Thursday market open ) Pressure surfaced early Thursday as investors assessed yesterday's results from Tesla TSLA and Netflix NFLX. The Nasdaq ( COMP ) fell sharply in premarket trading, but the Dow Jones Industrial Average ( $DJI ) and its eight-session winning streak remained in the green.",BIIB,0.040899,0.071765,Neutral
 ( BIIB )  - Analyzing Biogen's Short Interest - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/07/33305393/biib-analyzing-biogens-short-interest,2023-07-20 14:30:23,"Biogen's BIIB short percent of float has fallen 6.9% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 1.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.03 days to cover their ...",BIIB,0.224903,0.085754,Neutral
"Ischemic Stroke Market is Likely to Increase at a Steady Growth Rate, Examines DelveInsight | Key Companies Working in Market - Roche, Acticor Biotech, Genentech, Mallinckrodt, AbbVie, Janssen, Bristol Myers Squibb, Bayer",https://www.prnewswire.com/news-releases/ischemic-stroke-market-is-likely-to-increase-at-a-steady-growth-rate-examines-delveinsight--key-companies-working-in-market---roche-acticor-biotech-genentech-mallinckrodt-abbvie-janssen-bristol-myers-squibb-bayer-301895355.html,2023-08-08 21:01:00,"Ischemic Stroke Market is Likely to Increase at a Steady Growth Rate, Examines DelveInsight | Key Companies ... PR ...",BIIB,0.049221,0.012825,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation  ( Nasdaq - SATS ) , Sovos Brands, Inc.  ( Nasdaq - SOVO ) , Reata Pharmaceuticals, Inc.  ( Nasdaq - RETA ) , Amedisys, Inc.  ( Nasdaq - AMED ) ",https://www.benzinga.com/pressreleases/23/08/g33644967/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-echostar-corp,2023-08-08 20:33:58,"BALA CYNWYD, Pa., Aug. 08, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BIIB,0.232069,0.208011,Somewhat-Bullish
Looking Into Biogen's Recent Short Interest - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/08/33628115/looking-into-biogens-recent-short-interest,2023-08-08 13:00:32,"Biogen's BIIB short percent of float has risen 24.07% since its last report. The company recently reported that it has 2.57 million shares sold short, which is 2.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.29 days to cover their ...",BIIB,0.224903,0.158881,Somewhat-Bullish
Is Sage Therapeutics a Contrarian Buy?,https://www.fool.com/investing/2023/08/08/is-sage-therapeutics-a-contrarian-buy/,2023-08-08 13:00:00,A regulatory setback weighed heavily on the drugmaker's shares Monday.,BIIB,0.244109,-0.046036,Neutral
"DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday - Axsome Therapeutics  ( NASDAQ:AXSM ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/earnings/23/08/33624476/draftkings-to-rally-over-38-here-are-10-other-analyst-forecasts-for-tuesday,2023-08-08 11:43:36,"Piper Sandler raised the price target for Chegg, Inc. CHGG from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market trading. Atlantic Equities cut Biogen Inc. BIIB price target from $282 to $275.",BIIB,0.28442,0.006401,Neutral
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - PACW, INPX, AMNB, RETA",https://www.benzinga.com/pressreleases/23/08/g33610103/alert-the-m-a-class-action-firm-continues-investigating-the-merger-pacw-inpx-amnb-reta,2023-08-07 21:00:00,"NEW YORK, Aug. 07, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...",BIIB,0.069495,0.121224,Neutral
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead - Sage Therapeutics  ( NASDAQ:SAGE ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33604705/what-more-can-support-biogensages-zuranolone-resubmission-analysts-see-uncertain-ro,2023-08-07 17:44:05,The FDA approved Sage Therapeutics Inc SAGE and Biogen Inc's BIIB Zurzuvae ( zuranolone ) 50 mg for adults with postpartum depression ( PPD ) but issued a Complete Response Letter for the New Drug Application for zuranolone for major depressive disorder.,BIIB,0.363388,-0.144019,Neutral
"FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says - Axsome Therapeutics  ( NASDAQ:AXSM ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33601230/fdas-rejection-of-sagebiogens-zuranolone-boosts-prospects-for-axsomes-auvelity-anal,2023-08-07 16:06:56,"Axsome Therapeutics Inc AXSM reported Q2 sales of $46.7 million, beating the consensus of $40.19 million. The company reported a Q2 EPS loss of $ ( 1.54 ) , missing the consensus of $ ( 1.24 ) .",BIIB,0.261117,-0.372647,Bearish
Why Sage Therapeutics Stock Is Crashing Today,https://www.fool.com/investing/2023/08/07/why-sage-therapeutics-stock-is-crashing-today/,2023-08-07 15:44:32,Sage's regulatory win wasn't enough to offset an even bigger regulatory loss.,BIIB,0.386875,-0.159288,Somewhat-Bearish
Stock Market Glad To Start A New Week; Warren Buffett Berkshire Stock Rises,https://www.investors.com/market-trend/stock-market-today/stock-market-glad-to-start-a-new-week-warren-buffett-stock-rises-on-profit-news/,2023-08-07 14:59:00,Stock Market Glad To Start A New Week. Warren Buffett Berkshire Stock Rises Investor's Business Daily ...,BIIB,0.169676,-0.237489,Somewhat-Bearish
Stock Market Glad To Start A New Week; Warren Buffett Berkshire Stock Rises,https://www.investors.com/research/stock-market-glad-to-start-a-new-week-warren-buffett-stock-rises-on-profit-news/,2023-08-07 14:59:00,Stock Market Glad To Start A New Week. Warren Buffett Berkshire Stock Rises Investor's Business Daily ...,BIIB,0.169676,-0.237489,Somewhat-Bearish
Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug,https://www.cnbc.com/2023/08/07/sage-therapeutics-plunges-after-fda-decision-on-depression-drug.html,2023-08-07 14:52:26,"The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder.",BIIB,0.342487,-0.19103,Somewhat-Bearish
Sage Therapeutics' stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder,https://www.marketwatch.com/story/sage-therapeutics-stock-craters-49-after-fda-approves-zuranolone-for-postpartum-depression-but-not-major-depressive-disorder-2648cefa,2023-08-07 14:46:00,"The good news on postpartum depression was offset by disappointment about major depressive disorder, which would be a far greater opportunity.",BIIB,0.321673,0.162009,Somewhat-Bullish
"Top Stories Monday, Aug 7: PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories - Apple  ( NASDAQ:AAPL ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/markets/cryptocurrency/23/08/33602277/paypal-unveils-usd-backed-stablecoin-trucking-firm-yellow-corp-files-for-bankruptcy-fda-ap,2023-08-07 14:34:22,"In a significant move to bolster the adoption of digital tokens for transactions, PayPal Holdings Inc PYPL announced Monday the launch of a new U.S. dollar-denominated stablecoin. The digital coin, issued by Paxos Trust Co., is underpinned by U.S. dollar deposits, short-term Treasuries, and other ...",BIIB,0.085629,-0.034944,Neutral
Pharma Earnings Reports Are Moving The Markets And AI Shakes Up The Emerging Tech Space - AI Newsletter August 5th,https://www.forbes.com/sites/qai/2023/08/07/pharma-earnings-reports-are-moving-the-markets-and-ai-shakes-up-the-emerging-tech-spaceforbes-ai-newsletter-august-5th/,2023-08-07 14:16:24,"Subscribe to the Forbes AI newsletter to stay in the loop and get AI-backed investing insights, the latest news and more delivered directly to your inbox every weekend.",BIIB,0.087027,0.033382,Neutral
Why This Biotech Lost Half Its Value On An FDA Approval,https://www.investors.com/news/technology/sage-stock-why-the-biotech-lost-half-its-value-after-the-fda-approved-its-depression-drug/,2023-08-07 13:20:00,Sage Stock: Why The Biotech Lost Half Its Value After The FDA Approved Its Depression Drug Investor's Business Daily ...,BIIB,0.382925,-0.067054,Neutral
"Sage Therapeutics and Biogen Stocks Are Falling - What's Going On? - Sage Therapeutics  ( NASDAQ:SAGE ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/08/33595528/fda-approves-sage-therapeuticsbiogens-zuranolone-for-one-type-of-depression-rejects-for-another,2023-08-07 12:57:48,"The FDA approved Sage Therapeutics Inc SAGE and Biogen Inc's BIIB Zurzuvae ( zuranolone ) 50 mg for adults with postpartum depression ( PPD ) . Zurzuvae is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD.",BIIB,0.519739,0.065282,Neutral
Lupin Pharmaceuticals Just Recalled Two Birth Control Pills - Did It Affect The Stock?,https://www.forbes.com/sites/qai/2023/08/07/lupin-pharmaceuticals-just-recalled-two-birth-control-pillsdid-it-affect-the-stock/,2023-08-07 12:19:59,"Despite the news, Lupin's share price rose 4% on earnings results and has increased 47% in ...",BIIB,0.067064,0.105488,Neutral
"Biogen, Sage face uphill battle with postpartum depression pill",https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-sage-face-uphill-battle-with-postpartum-depression-pill-2023-08-07/,2023-08-07 11:35:00,"Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo",BIIB,0.541149,-0.118908,Neutral
Major US health systems expect to offer Alzheimer's drug Leqembi in a few months,https://www.reuters.com/business/healthcare-pharmaceuticals/major-us-health-systems-expect-offer-alzheimers-drug-leqembi-few-months-2023-08-07/,2023-08-07 10:16:00,"The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File photo",BIIB,0.101582,-0.022781,Neutral
Retirees' Biggest Social Security News of the Year Is Less Than 10 Weeks Away,https://www.fool.com/retirement/2023/08/07/retirees-biggest-social-security-news-of-the-year/,2023-08-07 10:00:00,You'll soon find out how much fizz is in your Social Security COLA for 2024.,BIIB,0.069294,-0.058183,Neutral
"Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA - EQRx  ( NASDAQ:EQRX ) , New Relic  ( NYSE:NEWR ) ",https://www.benzinga.com/pressreleases/23/08/g33589244/lifshitz-law-pllc-announces-investigations-of-eqrx-rvmd-newr-and-reta,2023-08-06 00:13:00,"NEW YORK, Aug. 05, 2023 ( GLOBE NEWSWIRE ) -- Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc.",BIIB,0.084423,0.037647,Neutral
What To Know About Zuranolone-The First FDA-Approved Oral Pill For Postpartum Depression,https://www.forbes.com/sites/tylerroush/2023/08/05/what-to-know-about-zuranolone-the-first-fda-approved-oral-pill-for-postpartum-depression/,2023-08-05 18:26:34,About one in seven women experience postpartum depression after giving birth.,BIIB,0.084722,-0.040967,Neutral
FDA approves first postpartum depression pill in the US,https://www.cnn.com/2023/08/04/health/fda-approves-first-postpartum-depression-pill-in-the-us/index.html,2023-08-05 15:56:00,"The US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression - making it the first FDA-approved oral pill in the United States specifically for postpartum depression, a serious mental illness that can develop in about 1 in 7 new mothers ...",BIIB,0.044718,-0.016001,Neutral
3 Fantastic Growth Stocks to Buy in August,https://www.fool.com/investing/2023/08/05/3-fantastic-growth-stocks-to-buy-in-august/,2023-08-05 10:55:00,These stocks could be poised to soar.,BIIB,0.044469,0.167724,Somewhat-Bullish
US approves first pill to treat postpartum depression,https://www.aljazeera.com/news/2023/8/5/us-approves-first-pill-to-treat-postpartum-depression,2023-08-05 06:47:26,"Zurzuvae is expected to be commercially available later this year. Health regulators in the United States have approved the first pill to treat postpartum depression, offering a lifeline to the as many as one in seven new mothers who suffer from the condition each year.",BIIB,0.468029,0.015338,Neutral
"FDA Approves ZURZUVAEâ¢  ( zuranolone ) , the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder - Sage Therapeutics  ( NASDAQ:SAGE ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/pressreleases/23/08/g33585905/fda-approves-zurzuvae-zuranolone-the-first-and-only-oral-treatment-approved-for-women-with-postpar,2023-08-05 02:41:32,Postpartum depression ( PPD ) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45,BIIB,0.113181,0.078266,Neutral
"FDA Approves ZURZUVAEâ¢  ( zuranolone ) , the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder",https://www.globenewswire.com/news-release/2023/08/05/2719329/0/en/FDA-Approves-ZURZUVAE-zuranolone-the-First-and-Only-Oral-Treatment-Approved-for-Women-with-Postpartum-Depression-and-Issues-a-Complete-Response-Letter-for-Major-Depressive-Disorder.html,2023-08-05 02:41:00,Postpartum depression ( PPD ) approval based on results from two Phase 3 clinical trials. in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day ...,BIIB,0.099528,0.059654,Neutral
FDA approves first-ever pill for postpartum depression in new mothers,https://www.marketwatch.com/story/fda-approves-first-ever-pillfor-postpartum-depression-in-new-mothers-185ecf81,2023-08-04 23:40:00,Biogen and Sage Therapeutics are behind the first FDA-approved pill for treating postpartum depression.,BIIB,0.294682,-0.004313,Neutral
US FDA approves Biogen-Sage Therapeutics pill for clinical depression,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-biogen-sage-therapeutics-pill-clinical-depression-2023-08-04/,2023-08-04 23:11:00,"Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo/File Photo Aug 4 ( Reuters ) - The U.S.",BIIB,0.388879,0.109144,Neutral
"For the First Time, There's a Pill for Postpartum Depression",https://www.nytimes.com/2023/08/04/health/postpartum-depression-pill-fda.html,2023-08-04 23:03:01,"Because the pill works faster than other antidepressants and is taken for only two weeks, it may encourage more treatment of the debilitating condition.",BIIB,0.02241,-0.000889,Neutral
"The Biotech Game Is Changing. Watch for Disruptions, Says RBC.",https://www.barrons.com/articles/biotech-stocks-changing-regulation-disruption-1b4b3ee,2023-08-04 20:33:00,"Disruptions in Biotech Could Shake Up the Stocks. Watch Out, Says ...",BIIB,0.31006,-0.034473,Neutral
BIIB: 3 Biotech Stocks Smart Money Is After,https://stocknews.com/news/biib-cdtx-thtx-3-biotech-stocks-smart-money-is-after/,2023-08-04 19:40:44,"The biotech industry is at the cutting edge of modern healthcare and spearheads it by developing ground-breaking therapies and technologies that cater to underserved or previously unserved markets, thereby increasing the size of the pie for the healthcare industry.",BIIB,0.250902,0.236751,Somewhat-Bullish
Bioprocess Validation Market to grow at a CAGR of 11.39% from 2022 to 2027|Increasing demand for ... - PR Newswire,https://www.prnewswire.com/news-releases/bioprocess-validation-market-to-grow-at-a-cagr-of-11-39-from-2022-to-2027increasing-demand-for-biopharmaceuticals-to-boost-market-growth---technavio-301892736.html,2023-08-04 15:15:00,Bioprocess Validation Market to grow at a CAGR of 11.39% from 2022 to 2027|Increasing demand for ... PR ...,BIIB,0.062191,0.120072,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, EQRX, DFFN - EQRx  ( NASDAQ:EQRX ) , Diffusion Pharmaceuticals  ( NASDAQ:DFFN ) ",https://www.benzinga.com/pressreleases/23/08/g33542241/shareholder-investigation-halper-sadeh-llc-investigates-reta-eqrx-dffn,2023-08-03 10:23:21,"NEW YORK, Aug. 03, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Reata Pharmaceuticals, Inc.",BIIB,0.165031,0.105018,Neutral
Biogen Unusual Options Activity For August 02 - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/markets/options/23/08/33530285/biogen-unusual-options-activity-for-august-02,2023-08-02 19:31:26,"A whale with a lot of money to spend has taken a noticeably bullish stance on Biogen. Looking at options history for Biogen BIIB we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations ...",BIIB,0.807885,0.147251,Neutral
Virtualware partners with AdvanSoft to introduce VIROO in Malaysia,https://www.globenewswire.com/news-release/2023/08/02/2717130/0/en/Virtualware-partners-with-AdvanSoft-to-introduce-VIROO-in-Malaysia.html,2023-08-02 16:00:00,"Bilbao, Spain, 18 August.- Spanish technology company Virtualware ( EPA: MLVIR ) , one of the European leaders in the virtual reality industry, has signed a partnership agreement with AdvanSoft Sdn Bhd to boost VIROO's presence in Malaysia.",BIIB,0.045396,0.097424,Neutral
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.,https://www.fool.com/investing/2023/08/01/biogens-just-made-its-biggest-acquisition-heres-wh/,2023-08-01 09:45:00,Biogen also recently announced a plan to cut costs and focus investment on high-growth areas.,BIIB,0.58463,0.464328,Bullish
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - AMNB, RETA, PACW, INPX",https://www.benzinga.com/pressreleases/23/07/g33481779/alert-the-m-a-class-action-firm-continues-investigating-the-merger-amnb-reta-pacw-inpx,2023-07-31 21:41:30,"NEW YORK, July 31, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...",BIIB,0.069495,0.121224,Neutral
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/earnings/23/07/33480589/heres-how-much-you-would-have-made-owning-biogen-stock-in-the-last-15-years,2023-07-31 21:00:41,"Biogen BIIB has outperformed the market over the past 15 years by 3.6% on an annualized basis producing an average annual return of 12.44%. Currently, Biogen has a market capitalization of $39.13 billion.",BIIB,0.983605,0.387251,Bullish
Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer's disease,https://www.marketwatch.com/story/quest-diagnostics-launches-first-at-home-blood-test-to-assess-risk-of-developing-alzheimers-disease-20cd3639,2023-07-31 15:27:00,A simple test can detect the brain protein beta amyloid that is linked to the progression of Alzheimer's disease.,BIIB,0.191929,0.191759,Somewhat-Bullish
"Rising Stars, Falling Trends: July's Industry ETF Winners and Losers - Invesco Solar ETF  ( ARCA:TAN ) , Deere  ( NYSE:DE ) , SLB  ( NYSE:SLB ) , Archer-Daniels Midland  ( NYSE:ADM ) , Mueller Industries  ( NYSE:MLI ) , Amgen  ( NASDAQ:AMGN ) , Ferguson  ( NYSE:FERG ) , Vanguard Real Estate ETF  ( ARCA:VNQ ) , VanEck Gold Miners ETF  ( ARCA:GDX ) , SPDR S&P 500  ( ARCA:SPY ) , American Tower  ( NYSE:AMT ) , SMA Solar Tech  ( OTC:SMTGF ) , VanEck Oil Services ETF  ( ARCA:OIH ) , VanEck Semiconductor ETF  ( NASDAQ:SMH ) , Taiwan Semiconductor  ( NYSE:TSM ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Antero Resources  ( NYSE:AR ) , First Solar  ( NASDAQ:FSLR ) , SPDR S&P Oil & Gas Explor & Product  ( ARCA:XOP ) , Biogen  ( NASDAQ:BIIB ) , SPDR S&P Regional Banking ETF  ( ARCA:KRE ) , Enphase Energy  ( NASDAQ:ENPH ) , Broadcom  ( NASDAQ:AVGO ) , Western Alliance  ( NYSE:WAL ) , CoStar Gr  ( NASDAQ:CSGP ) , iShares Biotechnology ETF  ( NASDAQ:IBB ) , Prologis  ( NYSE:PLD ) , Waters  ( NYSE:WAT ) , Ovintiv  ( NYSE:OVV ) , Danaher  ( NYSE:DHR ) , Invesco Water Resources ETF  ( NASDAQ:PHO ) , U.S. Global Jets ETF  ( ARCA:JETS ) , Lam Research  ( NASDAQ:LRCX ) , Zoetis  ( NYSE:ZTS ) , SM Energy  ( NYSE:SM ) , SPDR Dow Jones Industrial Average ETF  ( ARCA:DIA ) , iShares Russell 2000 ETF  ( ARCA:IWM ) , NVIDIA  ( NASDAQ:NVDA ) , Zions Bancorp  ( NASDAQ:ZION ) , Apellis Pharmaceuticals  ( NASDAQ:APLS ) , Crown Castle  ( NYSE:CCI ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) , Southwest Airlines  ( NYSE:LUV ) , VanEck Agribusiness ETF  ( ARCA:MOO ) , Pinnacle Finl Partners  ( NASDAQ:PNFP ) , Delta Air Lines  ( NYSE:DAL ) , Ecolab  ( NYSE:ECL ) , APA  ( NASDAQ:APA ) , Halliburton  ( NYSE:HAL ) , SolarEdge Technologies  ( NASDAQ:SEDG ) , Valmont Industries  ( NYSE:VMI ) , Intel  ( NASDAQ:INTC ) ",https://www.benzinga.com/markets/equities/23/07/33471902/rising-stars-falling-trends-julys-industry-etf-winners-and-losers,2023-07-31 14:59:22,"As July comes to an end, it's time to take a look at the best- and worst-performing industry ETFs for the month. Among the largest ETFs that represent major U.S. stock indices, the SPDR S&P 500 ETF Trust SPY returned 3.1% in July, marking its fifth consecutive month of gains.",BIIB,0.110209,0.049137,Neutral
"Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More",https://www.zacks.com/stock/news/2129900/drug-biotech-stocks-q2-earnings-due-on-aug-1-pfe-mrk-more,2023-07-31 13:58:00,"Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1.",BIIB,0.087185,0.141037,Neutral
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen,https://www.fool.com/investing/2023/07/31/better-alzheimers-drug-stock-eli-lilly-vs-biogen/,2023-07-31 11:45:00,"By 2024, their medicines will likely be competing on the market, and one might win.",BIIB,0.431371,0.20737,Somewhat-Bullish
Quest Diagnostics launches Alzheimer's blood test for consumers,https://www.reuters.com/business/healthcare-pharmaceuticals/quest-diagnostics-launches-alzheimers-blood-test-consumers-2023-07-31/,2023-07-31 11:10:00,"CHICAGO, July 31 ( Reuters ) - Quest Diagnostics ( DGX.N ) on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein which can appear years before dementia symptoms arise.",BIIB,0.127456,0.030949,Neutral
"Biogen's New Boss Is Delivering, but Stock Isn't Pricing It in Yet",https://www.wsj.com/articles/biogens-new-boss-is-delivering-but-stock-isnt-pricing-it-in-yet-2ad9ceb6,2023-07-31 11:00:00,"The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street's skepticism presents an opportunity.",BIIB,0.922387,0.050543,Neutral
Could This Stock Be the Next Biotech Buyout?,https://www.fool.com/investing/2023/07/31/a-buyout-deal-pushed-reata-higher-could-these-be-n/,2023-07-31 10:13:00,"A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next.",BIIB,0.231884,0.082913,Neutral
Robert W. Baird Remains a Hold on Gilead Sciences  ( GILD ) ,https://markets.businessinsider.com/news/stocks/robert-w-baird-remains-a-hold-on-gilead-sciences-gild-1032494585,2023-07-31 09:45:15,Robert W. Baird Remains a Hold on Gilead Sciences (GILD) - Markets Insider ...,BIIB,0.148731,0.135159,Neutral
Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks,https://www.reuters.com/business/healthcare-pharmaceuticals/promising-new-alzheimers-drugs-may-benefit-whites-more-than-blacks-2023-07-31/,2023-07-31 09:04:00,"[1/5] Barrington and Vickie Riley pose at the Emory University Brain Health Center in Atlanta, Georgia, U.S., July 12, 2023. The Riley's, who have been married more than 35 years, participated in the Charlie and Harriet Shaffer Cognitive Empowerment Program. Barrington Riley has mild cognitive...",BIIB,0.049784,-0.039896,Neutral
A Double Whammy That Could Reduce Your Social Security Increase in 2024,https://www.fool.com/retirement/2023/07/30/a-double-whammy-that-could-reduce-your-social-secu/,2023-07-30 11:00:00,There's also a third potential whammy to consider.,BIIB,0.067919,-0.061138,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc.  ( Nasdaq - FRGI ) , Veritiv Corporation  ( NYSE - VRTV ) , New Relic, Inc.  ( NYSE - NEWR ) , Reata Pharmaceuticals, Inc.  ( Nasdaq - RETA ) ",https://www.benzinga.com/pressreleases/23/08/g33900603/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-fiesta-restau,2023-08-17 19:29:23,"BALA CYNWYD, Pa., Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BIIB,0.255641,0.224143,Somewhat-Bullish
Is Invesco Dynamic Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2137310/is-invesco-dynamic-biotechnology-genome-etf-pbe-a-strong-etf-right-now,2023-08-17 10:20:07,Smart Beta ETF report for ...,BIIB,0.118064,0.06168,Neutral
Virtualware partners with VRLOGIC to leverage its VR CAVEs business with VIROO.,https://www.globenewswire.com/news-release/2023/08/17/2727034/0/en/Virtualware-partners-with-VRLOGIC-to-leverage-its-VR-CAVEs-business-with-VIROO.html,2023-08-17 09:51:00,"Spanish technology company Virtualware ( EPA: MLVIR ) , one of the European leaders in the virtual reality industry, recently signed a partnership agreement with the German company VRLOGIC GmbH to leverage its VR CAVEs business with VIROO.",BIIB,0.049732,0.098234,Neutral
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update,https://www.prnewswire.com/il/news-releases/neurosense-announces-second-quarter-2023-financial-results-and-provides-business-update-301902486.html,2023-08-16 13:00:00,"CAMBRIDGE, Mass., Aug. 16, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( NASDAQ: NRSN ) ( ""NeuroSense"" ) , a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2023 and provided a business update.",BIIB,0.064973,0.056318,Neutral
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update,https://www.prnewswire.com/news-releases/neurosense-announces-second-quarter-2023-financial-results-and-provides-business-update-301902486.html,2023-08-16 13:00:00,"CAMBRIDGE, Mass., Aug. 16, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( NASDAQ: NRSN ) ( ""NeuroSense"" ) , a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2023 and provided a business update.",BIIB,0.064973,0.056318,Neutral
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - PRDS, CIR, RETA, AMNB",https://www.benzinga.com/pressreleases/23/08/g33849414/alert-the-m-a-class-action-firm-continues-investigating-the-merger-prds-cir-reta-amnb,2023-08-14 22:00:00,"NEW YORK, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...",BIIB,0.067158,0.120888,Neutral
"If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/earnings/23/08/33837974/if-you-invested-100-in-this-stock-15-years-ago-you-would-have-500-today,2023-08-14 16:00:27,"Biogen BIIB has outperformed the market over the past 15 years by 3.21% on an annualized basis producing an average annual return of 11.96%. Currently, Biogen has a market capitalization of $39.45 billion.",BIIB,0.983605,0.387251,Bullish
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates,https://www.zacks.com/stock/news/2136103/3-biotech-stocks-poised-to-beat-q2-earnings-estimates,2023-08-14 11:15:00,"We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.",BIIB,0.042496,0.136604,Neutral
"Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management - Medicenna Therapeutics  ( NASDAQ:MDNA ) ",https://www.benzinga.com/pressreleases/23/08/g33825888/medicenna-establishes-boston-presence-appoints-brent-meadows-as-chief-business-officer-and-bolster,2023-08-14 11:00:25,"Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent. Brent Meadows, MBA, joins as Chief Business Officer ( CBO ) , bringing over 25 years of large pharma and biotech experience and a track record of multiple high-value transactions in ...",BIIB,0.029728,0.040437,Neutral
"Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management",https://www.globenewswire.com/news-release/2023/08/14/2724250/0/en/Medicenna-Establishes-Boston-Presence-Appoints-Brent-Meadows-as-Chief-Business-Officer-and-Bolsters-Management.html,2023-08-14 11:00:00,"TORONTO and HOUSTON, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- Medicenna Therapeutics Corp. ( ""Medicenna"" or ""the Company"" ) ( NASDAQ: MDNA TSX: MDNA ) , a clinical-stage immunotherapy company, announced today the appointment of Brent Meadows, MBA, as its Chief Business Officer ( ""CBO"" ) , as part of ...",BIIB,0.035983,0.041706,Neutral
Insight: What happens when a $2 million gene therapy is not enough,https://www.reuters.com/business/healthcare-pharmaceuticals/what-happens-when-2-million-gene-therapy-is-not-enough-2023-08-12/,2023-08-12 09:05:00,"[1/5] Elizabeth Kutschke spends time at the park with her 2-year-old son, Ben, who was diagnosed with spinal muscular atrophy, an inherited disorder which is the leading genetic cause of death in infancy globally and leaves children too weak to walk, talk, swallow or even breathe, in Oak Park,...",BIIB,0.020146,0.035661,Neutral
Why Shares of Sage Therapeutics Slumped This Week,https://www.fool.com/investing/2023/08/11/why-shares-of-sage-therapeutics-slumped-this-week/,2023-08-11 15:23:53,The company got bad news from the FDA and saw increased losses.,BIIB,0.13459,-0.123342,Neutral
"Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News",https://www.zacks.com/stock/news/2135802/biotech-stock-roundup-sage-grtx-plunge-on-setback-regn-to-buy-dbtx-more-news,2023-08-11 14:34:00,Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.,BIIB,0.119235,-0.041673,Neutral
2 Beaten-Down Stocks That Still Aren't Worth Buying,https://www.fool.com/investing/2023/08/11/2-beaten-down-stocks-that-still-arent-worth-buying/,2023-08-11 12:50:00,These companies aren't bargains at all.,BIIB,0.056011,-0.111,Neutral
Denali  ( DNLI )  Q2 Earnings Beat on Higher Collaboration Revenues,https://www.zacks.com/stock/news/2135288/denali-dnli-q2-earnings-beat-on-higher-collaboration-revenues,2023-08-10 16:02:00,Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.,BIIB,0.434349,0.180364,Somewhat-Bullish
"Ionis  ( IONS )  Q2 Loss Narrows Y/Y, Sales Surpass Estimates",https://www.zacks.com/stock/news/2135191/ionis-ions-q2-loss-narrows-yy-sales-surpass-estimates,2023-08-10 15:31:00,Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.,BIIB,0.297404,0.056876,Neutral
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?,https://www.fool.com/investing/2023/08/10/could-6-point-5-billion-acquisition-help-biogen/,2023-08-10 13:00:00,The company's rare disease portfolio may soon get an upgrade.,BIIB,0.461699,0.006151,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, AEL, NLTX, RETA - NexTier Oilfield  ( NYSE:NEX ) , American Equity Inv  ( NYSE:AEL ) ",https://www.benzinga.com/pressreleases/23/08/g33688724/shareholder-investigation-halper-sadeh-llc-investigates-nex-ael-nltx-reta,2023-08-10 00:57:16,"NEW YORK, Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: NexTier Oilfield Solutions Inc.",BIIB,0.116348,0.087101,Neutral
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection,https://www.fool.com/investing/2023/08/09/more-alzheimers-treatments-are-coming-this-company/,2023-08-09 13:53:00,"Alzheimer's is a huge problem, and earlier detection could make a big difference.",BIIB,0.069697,0.209286,Somewhat-Bullish
"With an Acquisition on the Way, Is Biogen Stock a Buy?",https://www.fool.com/investing/2023/08/09/with-an-acquisition-on-the-way-is-biogen-stock-a/,2023-08-09 12:30:00,Can the biotech finally get back in the good graces of investors?,BIIB,0.582526,0.310217,Somewhat-Bullish
Eli Lilly Has Tentpoles In Weight Loss And Alzheimer's; But Is It A Buy?,https://www.investors.com/news/technology/eli-lilly-stock-buy-now/,2023-08-09 12:00:00,Eli Lilly Has Tentpoles In Weight Loss And Alzheimer's. But Is It A Buy? Investor's Business Daily ...,BIIB,0.079304,0.218136,Somewhat-Bullish
"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide",https://www.forbes.com/sites/qai/2023/08/09/novavax-earnings-call-reveals-surprise-profit-but-stocks-still-slide/,2023-08-09 11:14:56,"It's not the only vaccine producer struggling to get by, but Novavax looked terminal earlier this year by its own admission.",BIIB,0.033703,-0.052441,Neutral
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/09/2721423/0/en/BiomX-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-08-09 10:30:00,Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates ...,BIIB,0.023579,0.032015,Neutral
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - SCU, AMNB, NEWR, RETA",https://www.benzinga.com/pressreleases/23/08/g34080066/alert-the-m-a-class-action-firm-continues-investigating-the-merger-scu-amnb-newr-reta,2023-08-28 21:51:05,"NEW YORK, Aug. 28, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...",BIIB,0.068896,0.121133,Neutral
Novartis'  ( NVS )  Sandoz Gets FDA Nod for Tysabri's Biosimilar,https://www.zacks.com/stock/news/2141397/novartis-nvs-sandoz-gets-fda-nod-for-tysabris-biosimilar,2023-08-28 14:57:00,"Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.",BIIB,0.229149,0.06697,Neutral
Wall Street Thinks This Tiny Biotech Company Could Soar Soon,https://www.fool.com/investing/2023/08/28/wall-street-thinks-this-tiny-biotech-company-could/,2023-08-28 12:30:00,An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.,BIIB,0.055621,0.022997,Neutral
Multiple sclerosis market in the US to Grow by USD 3.95 billion from 2021 to 2026 | Rising prevalence of multiple ... - PR Newswire,https://www.prnewswire.com/news-releases/multiple-sclerosis-market-in-the-us-to-grow-by-usd-3-95-billion-from-2021-to-2026--rising-prevalence-of-multiple-sclerosis-will-drive-growth---technavio-301909378.html,2023-08-26 00:30:00,Multiple sclerosis market in the US to Grow by USD 3.95 billion from 2021 to 2026 | Rising prevalence of multiple ... PR ...,BIIB,0.178021,0.217977,Somewhat-Bullish
"Sandoz receives FDA approval for TyrukoÂ®  ( natalizumab-sztn ) , first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis",https://www.globenewswire.com/news-release/2023/08/25/2731654/0/en/Sandoz-receives-FDA-approval-for-Tyruko-natalizumab-sztn-first-and-only-FDA-approved-biosimilar-for-relapsing-forms-of-multiple-sclerosis.html,2023-08-25 05:15:00,"Basel, August 25, 2023 - Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration ( FDA ) has approved its biosimilar TyrukoÂ® ( natalizumab-sztn ) , developed by Polpharma Biologics.",BIIB,0.024724,0.0,Neutral
Biogen Inc.  ( BIIB )  Down 0.2% Since Last Earnings Report: Can It Rebound?,https://www.zacks.com/stock/news/2140375/biogen-inc-biib-down-02-since-last-earnings-report-can-it-rebound,2023-08-24 15:30:41,Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BIIB,0.354572,0.154249,Somewhat-Bullish
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?,https://www.fool.com/investing/2023/08/24/is-sage-therapeutics-stock-in-trouble-dropping-50/,2023-08-24 09:10:00,The pharmaceutical company's growth prospects have taken a big hit.,BIIB,0.071784,-0.159745,Somewhat-Bearish
These Are The 5 Best Stocks Of The Year,https://www.investors.com/research/here-are-best-performing-stocks-of-2023-with-gains-as-high-as-345/,2023-08-22 12:00:00,Best Stocks: These Are The Top 5 Of The Year Investor's Business Daily ...,BIIB,0.176717,0.162786,Somewhat-Bullish
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - AMNB, RETA, CIR, PRDS",https://www.benzinga.com/pressreleases/23/08/g33974061/alert-the-m-a-class-action-firm-continues-investigating-the-merger-amnb-reta-cir-prds,2023-08-21 21:35:21,"NEW YORK, Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...",BIIB,0.067158,0.120888,Neutral
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html,2023-08-21 21:01:00,"The medical second opinion market is expanding rapidly due to the increasing frequency of malignancies, infectious diseases, genetic diseases, cardiovascular diseases, hematological diseases, orthopedic diseases, and other diseases around the world.",BIIB,0.048671,0.037506,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Earthstone Energy, Inc.  ( NYSE - ESTE ) , Fiesta Restaurant Group, Inc.  ( Nasdaq - FRGI ) , Veritiv Corporation  ( NYSE - VRTV ) , Reata Pharmaceuticals, Inc.  ( Nasdaq - RETA ) ",https://www.benzinga.com/pressreleases/23/08/g33964496/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-earthstone-en,2023-08-21 14:27:45,"BALA CYNWYD, Pa., Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BIIB,0.226301,0.20402,Somewhat-Bullish
Bethany L. Sensenig Joins Supernus' Board of Directors,https://www.globenewswire.com/news-release/2023/08/21/2728720/19871/en/Bethany-L-Sensenig-Joins-Supernus-Board-of-Directors.html,2023-08-21 13:00:00,"ROCKVILLE, Md., Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today that Bethany L.",BIIB,0.128135,-0.003533,Neutral
Japan health ministry panel recommends approval of Alzheimer's treatment Leqembi,https://www.reuters.com/business/healthcare-pharmaceuticals/japan-health-ministry-panel-recommends-approval-alzheimers-treatment-leqembi-2023-08-21/,2023-08-21 12:54:00,Japan health ministry panel recommends approval of Alzheimer's treatment ...,BIIB,0.269776,0.271837,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, AEL, PRDS, CELL - American Equity Inv  ( NYSE:AEL ) , PhenomeX  ( NASDAQ:CELL ) ",https://www.benzinga.com/pressreleases/23/08/g33953862/shareholder-investigation-halper-sadeh-llc-investigates-reta-ael-prds-cell,2023-08-20 19:40:13,"NEW YORK, Aug. 20, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Reata Pharmaceuticals, Inc.",BIIB,0.10607,0.084268,Neutral
"SAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm",https://www.prnewswire.com/news-releases/sage-investigation-notice-robbins-geller-rudman--dowd-llp-announces-investigation-into-sage-therapeutics-inc-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information-to-contact-the-firm-301904886.html,2023-08-19 18:15:00,SAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage ... PR ...,BIIB,0.084423,-0.115848,Neutral
"Top Analyst Reports for Humana, Cintas & Biogen",https://www.zacks.com/research-daily/2146023/top-analyst-reports-for-humana-cintas-biogen,2023-09-07 21:17:00,"Today's Research Daily features new research reports on 16 major stocks, including Humana Inc. (HUM), Cintas Corporation (CTAS) and Biogen Inc. (BIIB).",BIIB,0.195025,0.276419,Somewhat-Bullish
Prothena  ( PRTA )  Skyrockets 88.7% in 12 Months: Here's Why,https://www.zacks.com/stock/news/2146171/prothena-prta-skyrockets-887-in-12-months-heres-why,2023-09-07 16:00:00,Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.,BIIB,0.102231,0.289694,Somewhat-Bullish
Why Is Denali Therapeutics Inc.  ( DNLI )  Down 0.1% Since Last Earnings Report?,https://www.zacks.com/stock/news/2146141/why-is-denali-therapeutics-inc-dnli-down-01-since-last-earnings-report,2023-09-07 15:30:49,Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BIIB,0.080728,0.25985,Somewhat-Bullish
Should BNY Mellon US Mid Cap Core Equity ETF  ( BKMC )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2145779/should-bny-mellon-us-mid-cap-core-equity-etf-bkmc-be-on-your-investing-radar,2023-09-07 10:20:05,Style Box ETF report for ...,BIIB,0.128135,0.060442,Neutral
Biogen Inc.  ( BIIB )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2145683/biogen-inc-biib-dips-more-than-broader-markets-what-you-should-know,2023-09-06 21:50:21,"Biogen Inc. (BIIB) closed at $263.72 in the latest trading session, marking a -0.97% move from the prior day.",BIIB,0.665097,0.096533,Neutral
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst - Denali Therapeutics  ( NASDAQ:DNLI ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34287817/denali-therapeutics-breakthrough-blood-brain-barrier-platform-a-game-changer-in-neu,2023-09-06 18:45:28,B Riley Securities initiated coverage on Denali Therapeutics Inc DNLI with a Buy rating and a price target of $38.,BIIB,0.29234,-0.189865,Somewhat-Bearish
Jim Cramer's top 10 things to watch in the stock market Wednesday,https://www.cnbc.com/2023/09/06/jim-cramers-top-10-things-to-watch-in-the-stock-market-wednesday-.html,2023-09-06 13:08:22,"Equities are lower in premarket trading Wednesday, while Arm Holdings' roadshow ahead of a planned initial public offering is impressive.",BIIB,0.136113,0.0,Neutral
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - NEWR, AMNB, DBTX, RETA",https://www.benzinga.com/pressreleases/23/09/g34257451/alert-the-m-a-class-action-firm-continues-investigating-the-merger-newr-amnb-dbtx-reta,2023-09-05 23:46:11,"NEW YORK, Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...",BIIB,0.067919,0.120992,Neutral
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring,https://www.fool.com/investing/2023/09/05/competing-in-these-3-markets-could-send-eli-lilly/,2023-09-05 14:00:00,Each market presents the opportunity for multiple catalysts as well as more sales.,BIIB,0.053749,0.0,Neutral
Biogen's  ( BIIB )  Stock Outperforms Industry YTD: Here's Why,https://www.zacks.com/stock/news/2144831/biogens-biib-stock-outperforms-industry-ytd-heres-why,2023-09-05 13:40:00,"While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.",BIIB,0.531326,0.229629,Somewhat-Bullish
5 Stock Buys With Fat Profit Margins,https://www.forbes.com/sites/johndorfman/2023/09/04/livent-snapon-5-stock-buys-with-fat-profit-margins/,2023-09-05 00:06:17,"These stocks have large profit margins, which can be a sign that a company has a unique product or is significantly ahead of its competitors.",BIIB,0.055881,0.142267,Neutral
"Big Companies-From CVS To Yellow Corp.-Laid Off More Than 65,000 This Summer",https://www.forbes.com/sites/brianbushard/2023/09/04/big-companies-from-cvs-to-yellow-corp-laid-off-more-than-65000-this-summer/,2023-09-04 19:30:11,"The biggest layoffs this summer came at Yellow Corp., CVS Health, KPMG, Biogen and Binance.",BIIB,0.061473,-0.114068,Neutral
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/earnings/23/09/34213020/1000-invested-in-biogen-15-years-ago-would-be-worth-this-much-today,2023-09-04 18:30:22,"Biogen BIIB has outperformed the market over the past 15 years by 3.91% on an annualized basis producing an average annual return of 12.94%. Currently, Biogen has a market capitalization of $38.69 billion.",BIIB,0.983605,0.387251,Bullish
Neuromyelitis Optica Spectrum Disorder Market to grow by USD 173.48 million from 2022 to 2027 | The growing ... - PR Newswire,https://www.prnewswire.com/news-releases/neuromyelitis-optica-spectrum-disorder-market-to-grow-by-usd-173-48-million-from-2022-to-2027--the-growing-geriatric-population-drives-growth---technavio-301915605.html,2023-09-01 22:45:00,Neuromyelitis Optica Spectrum Disorder Market to grow by USD 173.48 million from 2022 to 2027 | The growing ... PR ...,BIIB,0.047185,0.0,Neutral
Sage Therapeutics  ( SAGE )  Plunges 46% in a Month: Here's Why,https://www.zacks.com/stock/news/2143923/sage-therapeutics-sage-plunges-46-in-a-month-heres-why,2023-09-01 17:27:00,"The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.",BIIB,0.21258,0.121483,Neutral
Anti-rheumatic Market to Grow Exponentially by 2029- Brandessence Market Research,https://www.prnewswire.com/news-releases/anti-rheumatic-market-to-grow-exponentially-by-2029--brandessence-market-research-301915970.html,2023-09-01 14:34:00,"LONDON, Sept. 1, 2023 /PRNewswire/ -- Rheumatoid arthritis ( RA ) is a highly prevalent auto-immune ailment. This disease predominantly affects our joints, mainly that of hands and feet. It occurs when the immune system begins attacking the healthy tissues.",BIIB,0.027382,0.060193,Neutral
5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects,https://www.zacks.com/commentary/2143430/5-biotech-stocks-to-buy-as-new-drug-approvals-drive-industry-prospects,2023-09-01 13:18:00,"New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.",BIIB,0.024372,0.055127,Neutral
 ( BIIB )  - Analyzing Biogen's Short Interest - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/09/34171679/biib-analyzing-biogens-short-interest,2023-09-01 13:15:20,"Biogen's BIIB short percent of float has fallen 11.61% since its last report. The company recently reported that it has 3.03 million shares sold short, which is 2.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.1 days to cover their ...",BIIB,0.224903,0.085754,Neutral
Biogen Inc.  ( BIIB )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2143281/biogen-inc-biib-gains-as-market-dips-what-you-should-know,2023-08-31 21:45:17,"Biogen Inc. (BIIB) closed the most recent trading day at $267.36, moving +0.07% from the previous trading session.",BIIB,0.606946,0.233452,Somewhat-Bullish
"Sage, Struggling With Depression Flop, Cuts Workforce By 40%",https://www.investors.com/news/technology/sage-stock-could-a-workforce-cut-lift-its-depression/,2023-08-31 15:10:00,Sage Stock: Could A Workforce Cut Lift Its Depression? Investor's Business Daily ...,BIIB,0.429845,-0.069269,Neutral
Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2142663/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know,2023-08-30 21:50:19,"Biogen Inc. (BIIB) closed the most recent trading day at $267.18, moving -0.31% from the previous trading session.",BIIB,0.606946,0.241862,Somewhat-Bullish
Blood test for Parkinson's disease promising in early study,https://www.reuters.com/business/healthcare-pharmaceuticals/blood-test-parkinsons-disease-promising-early-study-2023-08-30/,2023-08-30 18:12:00,"Aug 30 ( Reuters ) - An experimental blood test that detected Parkinson's disease in a preliminary study could become the first specific tool for diagnosing the devastating neurodegenerative condition, researchers said on Wednesday.",BIIB,0.113062,0.0,Neutral
"Albert Maasland, Former CAB and Saxo Bank UK CEO, joins Virtualware's International Advisory Board",https://www.globenewswire.com/news-release/2023/08/30/2734030/0/en/Albert-Maasland-Former-CAB-and-Saxo-Bank-UK-CEO-joins-Virtualware-s-International-Advisory-Board.html,2023-08-30 06:00:00,"London and Bilbao, Spain, August 30, 2023.- Spanish Virtual Reality company Virtualware ( MLVIR.PA ) has appointed Albert C. Maasland, former CEO of Crown Agents Bank and former CEO of Saxo Bank UK, to its International Advisory Board, in a decision that will reinforce the company's position as a ...",BIIB,0.051774,0.114497,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, AMED, RETA, SURF - Amedisys  ( NASDAQ:AMED ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g34097085/shareholder-investigation-halper-sadeh-llc-investigates-dbtx-amed-reta-surf,2023-08-29 16:34:52,"NEW YORK, Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Decibel Therapeutics, Inc.",BIIB,0.129516,0.091303,Neutral
"Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm - Amedisys  ( NASDAQ:AMED ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g34095921/moore-kuehn-encourages-amed-dbtx-reta-and-surf-investors-to-contact-law-firm,2023-08-29 15:47:47,"NEW YORK, Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.",BIIB,0.107978,0.210957,Somewhat-Bullish
Roche's  ( RHHBY )  Evrysdi Gets Label Expansion in EU for Newborns,https://www.zacks.com/stock/news/2142071/roches-rhhby-evrysdi-gets-label-expansion-in-eu-for-newborns,2023-08-29 15:39:00,"Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.",BIIB,0.229149,0.163422,Somewhat-Bullish
Better Buy: Biogen vs. Eli Lilly,https://www.fool.com/investing/2023/08/29/better-buy-biogen-vs-eli-lilly/,2023-08-29 14:07:00,This battle of biotech giants has a clear winner.,BIIB,0.608634,0.207174,Somewhat-Bullish
Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity,https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-google-cloud-partner-to-build-next-generation-ai-platform-for-biological-engineering-and-biosecurity-301912283.html,2023-08-29 12:00:00,Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and ... PR ...,BIIB,0.039353,0.153924,Somewhat-Bullish
Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity - Ginkgo Bioworks Holdings  ( NYSE:DNA ) ,https://www.benzinga.com/pressreleases/23/08/n34086282/ginkgo-bioworks-and-google-cloud-partner-to-build-next-generation-ai-platform-for-biological-engin,2023-08-29 12:00:00,"Ginkgo and Google Cloud enter strategic five-year cloud and AI partnership Ginkgo to pioneer new large language models for biological engineering applications, powered by Google Cloud's Vertex AI platform",BIIB,0.027164,0.147098,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CPRI, RETA - Capri Holdings  ( NYSE:CPRI ) , American National  ( NASDAQ:AMNB ) ",https://www.benzinga.com/pressreleases/23/09/g34633215/shareholder-investigation-halper-sadeh-llc-investigates-amnb-cpri-reta,2023-09-15 21:44:01,"NEW YORK, Sept. 15, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: American National Bankshares Inc.",BIIB,0.155451,0.101048,Neutral
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/earnings/23/09/34624241/100-invested-in-biogen-15-years-ago-would-be-worth-this-much-today,2023-09-15 17:30:25,"Biogen BIIB has outperformed the market over the past 15 years by 3.36% on an annualized basis producing an average annual return of 12.4%. Currently, Biogen has a market capitalization of $37.04 billion.",BIIB,0.983605,0.387251,Bullish
Biogen Inc.  ( BIIB )  Stock Moves -0.19%: What You Should Know,https://www.zacks.com/stock/news/2148040/biogen-inc-biib-stock-moves--019-what-you-should-know,2023-09-12 21:50:17,"In the latest trading session, Biogen Inc. (BIIB) closed at $258.44, marking a -0.19% move from the previous day.",BIIB,0.658245,0.103347,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - VRTV, HCCI, RETA, ACER",https://www.benzinga.com/pressreleases/23/09/g34500168/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-vrtv-hcci-reta-acer,2023-09-12 18:02:53,"NEW YORK, Sept. 12, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...",BIIB,0.067919,0.120992,Neutral
Sitting Around For Too Many Hours Can Boost Your Dementia Risk-Here's What Researchers Recommend,https://www.forbes.com/sites/willskipworth/2023/09/12/sitting-around-for-too-many-hours-can-boost-your-dementia-risk-heres-what-researchers-recommend/,2023-09-12 15:00:00,A new study found that people with too much sedentary time have an increased risk of developing dementia.,BIIB,0.051999,0.029997,Neutral
REGN: 3 Biotech Gainers to Consider,https://stocknews.com/news/regn-biib-regn-reta-3-biotech-gainers-to-consider/,2023-09-11 16:47:19,"The biotech industry is well-positioned to thrive, owing to inelastic demand, rapid advancements, and government initiatives. So, quality biotech stocks Regeneron Pharmaceuticals, Inc. ( REGN ) , Biogen Inc. ( BIIB ) , and United Therapeutics Corporation ( UTHR ) could be worth buying.",BIIB,0.236684,0.142313,Neutral
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer - Madrigal Pharmaceuticals  ( NASDAQ:MDGL ) ,https://www.benzinga.com/pressreleases/23/09/g34434144/madrigal-pharmaceuticals-appoints-bill-sibold-as-chief-executive-officer,2023-09-11 11:00:00,"CONSHOHOCKEN, Pa., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. MDGL, a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis ( NASH ) , today announced that Bill Sibold has succeeded Paul Friedman, M.D., as Chief Executive ...",BIIB,0.042953,0.057112,Neutral
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?,https://www.fool.com/investing/2023/09/09/does-biogens-latest-15-billion-dollar-move-make-it/,2023-09-09 11:45:00,"Buying a biotech is a good move, but it might not be enough to entice investors.",BIIB,0.365166,0.267121,Somewhat-Bullish
Alector  ( ALEC )  Up 7% on Finishing Enrolment in Alzheimer Study,https://www.zacks.com/stock/news/2146781/alector-alec-up-7-on-finishing-enrolment-in-alzheimer-study,2023-09-08 16:10:00,Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.,BIIB,0.179788,0.168865,Somewhat-Bullish
Why Is Ionis Pharmaceuticals  ( IONS )  Up 1.4% Since Last Earnings Report?,https://www.zacks.com/stock/news/2146705/why-is-ionis-pharmaceuticals-ions-up-14-since-last-earnings-report,2023-09-08 15:30:27,Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BIIB,0.147818,0.021972,Neutral
"Scientists Finally Discover Why Exercise Cuts Alzheimer's Risk, Study Says",https://www.forbes.com/sites/willskipworth/2023/09/08/scientists-finally-discover-why-exercise-cuts-alzheimers-risk-study-says/,2023-09-08 15:00:00,Researchers have identified a hormone called irisin that reduces a protein widely believed to cause Alzheimer's disease-more proof that the best known way to combat the disease is by staying active.,BIIB,0.07887,-0.002055,Neutral
"The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group",https://www.zacks.com/stock/news/2146643/the-zacks-analyst-blog-highlights-humana-cintas-biogen-royal-caribbean-cruises-and-markel-group,2023-09-08 13:24:00,"Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group are part of the Zacks top Analyst Blog.",BIIB,0.341857,0.23324,Somewhat-Bullish
Intercept Pharmaceuticals  ( ICPT )  Surges on Acquisition Deal,https://www.zacks.com/stock/news/2156244/intercept-pharmaceuticals-icpt-surges-on-acquisition-deal,2023-09-27 14:02:00,Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.,BIIB,0.202932,0.194798,Somewhat-Bullish
"Ionis  ( IONS )  Meets Rare Disease Drug Study Goal, Stock Up 8.5%",https://www.zacks.com/stock/news/2156308/ionis-ions-meets-rare-disease-drug-study-goal-stock-up-85,2023-09-27 13:58:00,"Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.",BIIB,0.3796,0.222398,Somewhat-Bullish
Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of Directors,https://www.prnewswire.com/news-releases/chroma-medicine-strengthens-leadership-with-the-appointment-of-biotech-business-leader-michael-a-kelly-to-its-board-of-directors-301939429.html,2023-09-27 11:00:00,Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its ... PR ...,BIIB,0.089462,0.005256,Neutral
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder,https://www.investors.com/news/technology/ionis-stock-ionis-stock-gains-olezarsen-body-fat/,2023-09-26 15:54:00,"Ionis Pharmaceuticals ( IONS ) on Tuesday said Olezarsen, an experimental drug in late-stage patient trials, succeeded in reducing abnormally high levels of body fat in patients with a rare genetic disorder. Ionis stock broke out on the news.",BIIB,0.388879,-0.17433,Somewhat-Bearish
"Biogen Completes Acquisition of Reata Pharmaceuticals - Reata Pharmaceuticals  ( NASDAQ:RETA ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/pressreleases/23/09/g34906129/biogen-completes-acquisition-of-reata-pharmaceuticals,2023-09-26 12:59:54,"Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYSÂ® ( omaveloxolone ) , the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc.",BIIB,0.259037,0.15009,Somewhat-Bullish
"Eisai's Alzheimer's drug wins approval in Japan, following US",https://www.financialexpress.com/healthcare/pharma-healthcare/eisais-alzheimers-drug-wins-approval-in-japan-following-us/3255107/,2023-09-26 07:01:06,Eisai Co.'s breakthrough Alzheimer's disease drug won clearance from Japanese regulators after the medicine was fully cleared in the US in July.,BIIB,0.126119,-0.031089,Neutral
"After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen",https://apnews.com/article/japan-alzheimers-drug-eisai-approved-f866aeb9dd3591d1dd9e41d265115b5f,2023-09-26 06:19:00,"After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen The Associated Press ...",BIIB,0.118064,0.179402,Somewhat-Bullish
"Sandoz receives European Commission approval for TyrukoÂ®  ( natalizumab ) , first and only biosimilar for multiple sclerosis in Europe",https://www.globenewswire.com/news-release/2023/09/26/2749144/0/en/Sandoz-receives-European-Commission-approval-for-Tyruko-natalizumab-first-and-only-biosimilar-for-multiple-sclerosis-in-Europe.html,2023-09-26 05:15:00,"Basel, September 26, 2023 - Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Commission ( EC ) granted marketing authorization for the first and only biosimilar TyrukoÂ® ( natalizumab ) , developed by Polpharma Biologics.",BIIB,0.033052,0.0,Neutral
Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2155109/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know,2023-09-25 21:50:19,"In the latest trading session, Biogen Inc. (BIIB) closed at $255.02, marking a -1.03% move from the previous day.",BIIB,0.593715,0.286564,Somewhat-Bullish
"Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/09/34861916/japans-regulatory-authority-approves-biogeneisais-alzheimer-treatment-leqembi,2023-09-25 14:41:44,"Eisai Co Ltd ESALY ESALF and Biogen Inc BIIB announced that humanized anti-soluble aggregated amyloid-beta ( AÎ² ) monoclonal antibody Leqembi Intravenous Infusion ( 200 mg, 500mg, lecanemab ) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild ...",BIIB,0.364275,0.10874,Neutral
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer - Editas Medicine  ( NASDAQ:EDIT ) ,https://www.benzinga.com/pressreleases/23/09/g34863723/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-,2023-09-25 13:00:00,"CAMBRIDGE, Mass., Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Editas Medicine, Inc. EDIT, a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer.",BIIB,0.130571,0.136534,Neutral
Japan approves Alzheimer treatment Leqembi by Eisai and Biogen,https://www.reuters.com/business/healthcare-pharmaceuticals/japan-approves-alzheimer-treatment-leqembi-by-eisai-biogen-2023-09-25/,2023-09-25 05:16:00,"The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS /File Photo Acquire Licensing Rights",BIIB,0.224903,0.184366,Somewhat-Bullish
LEQEMBIÂ® Intravenous Infusion  ( Lecanemab )  Approved for the Treatment of Alzheimer's Disease in Japan - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/09/g34847116/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-japan,2023-09-25 05:02:57,"TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"" ) and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.",BIIB,0.18602,0.053692,Neutral
"Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG",https://www.prnewswire.com/news-releases/chronic-lower-back-pain-market-to-showcase-tremendous-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---eli-lilly-camurus-braeburn-inc-scilex-holding-mesoblast-limited-anges-mg-301934365.html,2023-09-21 21:01:00,"Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to ... PR ...",BIIB,0.02275,0.014186,Neutral
"Here's a rapid-fire update on all 35 stocks in the Club's portfolio, including a new buy",https://www.cnbc.com/2023/09/21/rapid-fire-update-on-all-35-stocks-in-jim-cramers-club-portfolio.html,2023-09-21 19:22:59,Jim Cramer ran through all 35 Club stocks during our September Monthly Meeting on Thursday.,BIIB,0.039844,0.086994,Neutral
 ( BIIB )  - Analyzing Biogen's Short Interest - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/09/34764319/biib-analyzing-biogens-short-interest,2023-09-20 14:15:20,"Biogen's BIIB short percent of float has risen 3.39% since its last report. The company recently reported that it has 3.14 million shares sold short, which is 2.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.06 days to cover their ...",BIIB,0.224903,0.158881,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2152141/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know,2023-09-18 21:50:20,"In the latest trading session, Biogen Inc. (BIIB) closed at $253.30, marking a -0.58% move from the previous day.",BIIB,0.617188,0.296886,Somewhat-Bullish
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DBTX, RETA, VRTV, HCCI",https://www.benzinga.com/pressreleases/23/09/g34702887/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-dbtx-reta-vrtv-hcci,2023-09-18 20:59:47,"NEW YORK, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...",BIIB,0.067727,0.120965,Neutral
Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... - PR Newswire,https://www.prnewswire.com/news-releases/large-molecule-injectable-drugs-market-to-grow-by-usd-191-45-billion-from-2022-2027--north-america-to-account-for-45-of-market-growth---technavio-301929312.html,2023-09-18 08:35:00,Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... PR ...,BIIB,0.052685,0.0,Neutral
Here's The Point This Obesity-Focused Stock Of The Day Becomes Actionable,https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-the-point-at-which-this-ibd-stock-of-the-day-could-become-actionable-again/,2023-10-06 16:37:00,Eli Lilly Stock: The Point At Which This IBD Stock Of The Day Could ... Investor's Business Daily ...,BIIB,0.087027,0.066449,Neutral
"An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8 - VanEck Gold Miners ETF  ( ARCA:GDX ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/23/10/35109444/an-oversold-gold-miner-with-strong-fundamentals-its-relative-strength-index-is-below-20-and-its-piot,2023-10-05 13:58:03,"On Zero Hedge on Monday, contributing editor ""Quoth The Raven"" suggested ""paying urgent attention to gold miners"": As everybody knows, one of my favorite assets on the board right now for buying is gold miners.",BIIB,0.152499,0.062346,Neutral
Public reimbursement for biosimilar BYOOVIZâ¢ to treat serious retinal disorders now secured in four provinces and two national benefits programs,https://www.newswire.ca/news-releases/public-reimbursement-for-biosimilar-byooviz-tm-to-treat-serious-retinal-disorders-now-secured-in-four-provinces-and-two-national-benefits-programs-817633984.html,2023-10-04 11:00:00,Public reimbursement for biosimilar BYOOVIZâ¢ to treat serious retinal disorders now secured in four provinces and two ... Canada ...,BIIB,0.436009,0.557652,Bullish
How Much Will Your Medicare Part B Premiums Increase Next Year?,https://www.fool.com/retirement/2023/10/04/how-much-medicare-part-b-premiums-increase/,2023-10-04 09:30:00,"Part B premiums declined this year, but don't expect such good news for 2024.",BIIB,0.062926,-0.131082,Neutral
"$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,800 Today - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/earnings/23/10/35064710/1000-invested-in-this-stock-20-years-ago-would-be-worth-7-800-today,2023-10-03 14:00:26,"Biogen BIIB has outperformed the market over the past 20 years by 3.54% on an annualized basis producing an average annual return of 10.81%. Currently, Biogen has a market capitalization of $36.49 billion.",BIIB,0.983605,0.387251,Bullish
Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2158859/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know,2023-10-02 21:50:19,"Biogen Inc. (BIIB) closed at $252.86 in the latest trading session, marking a -1.61% move from the prior day.",BIIB,0.554916,0.214534,Somewhat-Bullish
"Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Working to Develop Therapies - Vanda, Kyowa Kirin, Sage, Athira, Aptinyx, CogState, AgeneBio",https://www.prnewswire.com/news-releases/parkinsons-disease-psychosis-market-is-likely-to-increase-at-a-steady-growth-rate-by-2032-estimates-delveinsight--key-companies-working-to-develop-therapies---vanda-kyowa-kirin-sage-athira-aptinyx-cogstate-agenebio-301941331.html,2023-10-02 21:01:00,"Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight ... PR ...",BIIB,0.027508,0.032597,Neutral
"FDA Approves Biogen's TOFIDENCEâ¢  ( tocilizumab-bavi ) , a Biosimilar Referencing ACTEMRAÂ®",https://www.globenewswire.com/news-release/2023/09/29/2752273/0/en/FDA-Approves-Biogen-s-TOFIDENCE-tocilizumab-bavi-a-Biosimilar-Referencing-ACTEMRA.html,2023-09-29 20:06:00,"CAMBRIDGE, Mass., Sept. 29, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced that the U.S. Food and Drug Administration ( FDA ) has approved TOFIDENCE ( tocilizumab-bavi ) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous ...",BIIB,0.341699,0.225364,Somewhat-Bullish
"FDA Approves Biogen's TOFIDENCEâ¢  ( tocilizumab-bavi ) , a Biosimilar Referencing ACTEMRAÂ® - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/pressreleases/23/09/g35011402/fda-approves-biogens-tofidence-tocilizumab-bavi-a-biosimilar-referencing-actemra,2023-09-29 20:06:00,"TOFIDENCE ( BIIB800 ) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 ( GLOBE NEWSWIRE ...",BIIB,0.321135,0.173813,Somewhat-Bullish
Suven Pharma gets a new board as Advent International completes stake buy,https://www.business-standard.com/companies/news/suven-pharma-gets-a-new-board-as-advent-international-completes-stake-buy-123092901342_1.html,2023-09-29 16:31:18,"As US-based private equity ( PE ) firm Advent International completed the acquisition of a majority stake in Hyderabad-based Suven Pharma, it announced a change in the pharma company's board.",BIIB,0.079921,0.029415,Neutral
Sangamo Therapeutics 10% Owner Sold $3.00M In Company Stock - Sangamo Therapeutics  ( NASDAQ:SGMO ) ,https://www.benzinga.com/news/23/09/35004871/sangamo-therapeutics-10-owner-sold-3-00m-in-company-stock,2023-09-29 15:01:45,"BIOGEN INC, 10% Owner at Sangamo Therapeutics SGMO, reported a large insider sell on September 28, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that INC sold 6,000,000 shares of Sangamo Therapeutics.",BIIB,0.129516,0.0,Neutral
Virtualware's VIROO capabilities shown at NATO Exercise,https://www.globenewswire.com/news-release/2023/09/29/2751745/0/en/Virtualware-s-VIROO-capabilities-shown-at-NATO-Exercise.html,2023-09-29 05:39:00,"Bilbao, Spain, September 29.- Virtualware ( EPA: MLVIR ) , the European leader in the virtual reality industry, has participated at the NATO Air Operation exercise focused on chemical, biological, radiological, and nuclear ( CBRN ) Def interoperability to present the VR training project for the ...",BIIB,0.045396,0.113299,Neutral
Is Biogen Stock a Buy Now?,https://www.fool.com/investing/2023/09/28/is-biogen-stock-a-buy-now/,2023-09-28 14:07:00,"It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.",BIIB,0.501398,0.072025,Neutral
Ionis  ( IONS )  Inks New Deal With Roche to Develop Novel RNA Drugs,https://www.zacks.com/stock/news/2157174/ionis-ions-inks-new-deal-with-roche-to-develop-novel-rna-drugs,2023-09-28 14:06:00,"Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.",BIIB,0.382088,0.203331,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Falls More Steeply Than Broader Market: What Investors Need to Know,https://www.zacks.com/stock/news/2167530/biogen-inc-biib-falls-more-steeply-than-broader-market-what-investors-need-to-know,2023-10-17 21:50:20,"In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day.",BIIB,0.520477,0.1729,Somewhat-Bullish
"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech",https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html,2023-10-16 21:01:00,"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period ( 2019-2032 ) , Assesses ... PR ...",BIIB,0.025845,-0.023726,Neutral
Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/10/35270983/inquiry-into-biogens-competitor-dynamics-in-biotechnology-industry,2023-10-16 16:00:46,"In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Biogen BIIB alongside its primary competitors in ...",BIIB,0.47672,0.242597,Somewhat-Bullish
"Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/government/23/10/35245698/improved-alzheimers-diagnosis-access-cms-expands-amyloid-pet-scan-usage,2023-10-13 19:10:42,"The U.S. Centers for Medicare and Medicaid Services has revised its policy permitting multiple uses of amyloid positron emission tomography ( PET ) scans, a non-invasive brain scan crucial for identifying amyloid plaques, a telltale sign of Alzheimer's.",BIIB,0.254307,0.182864,Somewhat-Bullish
Wall Street Analysts See a 25.44% Upside in Biogen Inc.  ( BIIB ) : Can the Stock Really Move This High?,https://www.zacks.com/stock/news/2165588/wall-street-analysts-see-a-2544-upside-in-biogen-inc-biib-can-the-stock-really-move-this-high,2023-10-13 13:55:05,"The mean of analysts' price targets for Biogen Inc. (BIIB) points to a 25.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.",BIIB,0.286864,0.368762,Bullish
GILD: How to Enhance Your Own Strategies with POWR Ratings,https://stocknews.com/news/gild-amgn-uthr-biib-regn-how-to-enhance-your-own-strategies-with-powr-ratings/,2023-10-12 16:29:47,"One thing Wall Street is never short of is ideas. Technical strategies, fundamental strategies, seasonal investing, and the list goes on and on and on.",BIIB,0.207868,0.139319,Neutral
"Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",https://www.benzinga.com/news/large-cap/23/10/35199963/is-there-a-blood-test-for-alzheimers-progress-underway-but-not-quite-ready,2023-10-11 18:27:04,"Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are in development, none are approved by regulators or insurance reimbursement.",BIIB,0.229149,0.0,Neutral
Will Biogen Inc.  ( BIIB )  Beat Estimates Again in Its Next Earnings Report?,https://www.zacks.com/stock/news/2164465/will-biogen-inc-biib-beat-estimates-again-in-its-next-earnings-report,2023-10-11 16:10:11,Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,BIIB,0.418689,0.518363,Bullish
Blood tests needed for widespread Alzheimer's diagnosis on the way,https://www.reuters.com/business/healthcare-pharmaceuticals/blood-tests-needed-widespread-alzheimers-diagnosis-way-2023-10-11/,2023-10-11 11:36:00,"[1/3] A view shows tests for patients suffering from Alzheimer's disease at the Memory Centre Department of Readaptation and Geriatrics of the University Hospital ( HUG ) , in Geneva, Switzerland, June 6, 2023. REUTERS/Denis Balibouse/File Photo Acquire Licensing Rights",BIIB,0.044469,-0.054621,Neutral
"LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/10/35164150/lumind-ceo-at-odds-with-neurologists-over-alzheimers-drugs-made-by-biogen-eli-lilly,2023-10-10 16:35:26,"Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd ESALY/ Biogen Inc's BIIB and Eli Lilly And Co's LLY. The former biotech executive is also hoping to include people with Down syndrome in Alzheimer's ...",BIIB,0.277433,0.033717,Neutral
"Mana.bio Advances AI-Based Lipid Nanoparticle  ( LNP )  Platform to Accelerate ""Programmable Drug Delivery"" for RNA and Gene Therapies",https://www.prnewswire.com/news-releases/manabio-advances-ai-based-lipid-nanoparticle-lnp-platform-to-accelerate-programmable-drug-delivery-for-rna-and-gene-therapies-301952340.html,2023-10-10 16:30:00,"Mana.bio Advances AI-Based Lipid Nanoparticle ( LNP ) Platform to Accelerate ""Programmable Drug Delivery"" for RNA ... PR ...",BIIB,0.03443,0.083694,Neutral
"Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer - Medicenna Therapeutics  ( NASDAQ:MDNA ) ",https://www.benzinga.com/pressreleases/23/10/g35158239/medicenna-therapeutics-appoints-humphrey-gardner-m-d-as-chief-medical-officer,2023-10-10 11:07:53,"TORONTO and HOUSTON, Oct. 10, 2023 ( GLOBE NEWSWIRE ) -- Medicenna Therapeutics Corp. ( ""Medicenna"" or the ""Company"" ) MDNAMDNA, a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical ...",BIIB,0.051111,0.00497,Neutral
"Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer",https://www.globenewswire.com/news-release/2023/10/10/2757337/0/en/Medicenna-Therapeutics-Appoints-Humphrey-Gardner-M-D-as-Chief-Medical-Officer.html,2023-10-10 11:07:00,Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic institutions Dr. Gardner brings over 30 years of experience leading clinical development to ...,BIIB,0.051774,0.004975,Neutral
New Equity Research Report Recommends 'Buy' Rating for Virtualware  ( EPA:MLVIR )  with â¬10 Price Target,https://www.globenewswire.com/news-release/2023/10/10/2757117/0/en/New-Equity-Research-Report-Recommends-Buy-Rating-for-Virtualware-EPA-MLVIR-with-10-Price-Target.html,2023-10-10 05:45:00,"New York and Bilbao, Spain, 10, October.- Litchfield Hills Research initiated coverage of Virtualware ( ENXTPA: MLVIR ) with a 'Buy' rating and â¬10 ( $10.56 ) price target, according to an equity research report published and distributed Monday.",BIIB,0.047278,0.097811,Neutral
Biogen Inc.  ( BIIB )  Advances But Underperforms Market: Key Facts,https://www.zacks.com/stock/news/2162963/biogen-inc-biib-advances-but-underperforms-market-key-facts,2023-10-09 21:50:20,"In the most recent trading session, Biogen Inc. (BIIB) closed at $264.21, indicating a +0.36% shift from the previous trading day.",BIIB,0.584103,0.336573,Somewhat-Bullish
Bristol Myers  ( BMY )  to Acquire Mirati Therapeutics for $5.8 B,https://www.zacks.com/stock/news/2162756/bristol-myers-bmy-to-acquire-mirati-therapeutics-for-58-b,2023-10-09 14:24:00,"Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.",BIIB,0.137148,0.151625,Somewhat-Bullish
"LANGaware Strengthens Advisory Board with Michel Vounatsos, Former Biogen CEO and Strategic Visionary",https://www.prnewswire.com/news-releases/langaware-strengthens-advisory-board-with-michel-vounatsos-former-biogen-ceo-and-strategic-visionary-301950283.html,2023-10-09 12:00:00,"NEW YORK, Oct. 9, 2023 /PRNewswire/ -- LANGaware, a pioneering tech company at the forefront of AI-driven cognitive and mental health diagnostics, is delighted to announce the appointment of Michel Vounatsos to their advisory board.",BIIB,0.157483,0.108438,Neutral
FDA Approves TOFIDENCEâ¢  ( tocilizumab-bavi )  a Biosimilar of ACTEMRAÂ® developed by Bio-Thera Solutions,https://www.prnewswire.com/news-releases/fda-approves-tofidence-tocilizumab-bavi-a-biosimilar-of-actemra-developed-by-bio-thera-solutions-301950199.html,2023-10-08 08:45:00,"â¢ TOFIDENCE is Bio-Thera's first product approved by USFDA. â¢ TOFIDENCE is the first monoclonal antibody drug researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in â¢ TOFIDENCE is the first biosimilar to Actemra approved by USFDA",BIIB,0.1491,0.104231,Neutral
Why Biogen's Alzheimer's Treatment Results Sent Its Rival Crashing 15%,https://www.investors.com/news/technology/biogen-stock-drags-rival-prothena-down-on-mixed-alzheimers-treatment-results/,2023-10-26 18:27:00,Biogen Stock Drags Rival Prothena Down 15% On Mixed ... Investor's Business Daily ...,BIIB,0.493442,0.055496,Neutral
CRISPR  ( CRSP )  to Report Q3 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2172563/crispr-crsp-to-report-q3-earnings-whats-in-the-cards,2023-10-26 12:22:00,"Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.",BIIB,0.244723,-0.027788,Neutral
Eli Lilly  ( LLY )  to Report Q3 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2172391/eli-lilly-lly-to-report-q3-earnings-whats-in-the-cards,2023-10-26 11:40:00,"On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.",BIIB,0.216473,-0.026882,Neutral
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study,https://www.cnbc.com/2023/10/25/alzheimers-drug-leqembi-shows-promise-as-injection.html,2023-10-25 22:45:26,Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.,BIIB,0.214304,0.236084,Somewhat-Bullish
"Injected version of Eisai/Biogen Alzheimer's drug effective, side effects higher",https://www.reuters.com/business/healthcare-pharmaceuticals/injected-version-eisaibiogen-alzheimers-drug-effective-side-effects-higher-2023-10-25/,2023-10-25 21:30:00,"The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File Photo Acquire Licensing Rights",BIIB,0.075635,0.108141,Neutral
Biogen and Eisai release new Alzheimer's drug data that may support wider uptake,https://www.marketwatch.com/story/biogen-and-eisai-release-new-alzheimers-drug-data-that-may-support-wider-uptake-40d2d151,2023-10-25 21:28:00,Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.,BIIB,0.524949,0.059391,Neutral
Eisai Presents New LEQEMBIÂ®  ( lecanemab-irmb )  Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease  ( CTAD )  Conference - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/10/g35427706/eisai-presents-new-leqembi-lecanemab-irmb-investigational-subcutaneous-formulation-interim-study-r,2023-10-25 21:26:00,"TOKYO and CAMBRIDGE, England, Oct. 25, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"" ) and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.",BIIB,0.119876,0.032771,Neutral
Eisai Presents New LEQEMBIÂ®  ( lecanemab-irmb )  Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease  ( CTAD )  Conference,https://www.globenewswire.com/news-release/2023/10/25/2767024/0/en/Eisai-Presents-New-LEQEMBI-lecanemab-irmb-Investigational-Subcutaneous-Formulation-Interim-Study-Results-and-Clinical-Improvement-Data-in-Earlier-Stages-of-Early-Alzheimer-s-Diseas.html,2023-10-25 21:26:00,"Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics ( AUC ) 11% Higher, And Similar ARIA Rates To IV ...",BIIB,0.109165,0.04029,Neutral
Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/markets/equities/23/10/35419274/biogen-says-new-data-shows-promise-for-potential-new-generation-of-treatments-in-early-alzheimer,2023-10-25 16:20:08,"Biogen Inc. BIIB reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide ( ASO ) therapy targeting tau, in mild Alzheimer's disease ( AD ) .",BIIB,0.574235,0.147322,Neutral
New Data from Biogen's Investigational Antisense Oligonucleotide  ( ASO )  Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease,https://www.globenewswire.com/news-release/2023/10/25/2766721/0/en/New-Data-from-Biogen-s-Investigational-Antisense-Oligonucleotide-ASO-Targeting-Tau-Shows-Promise-for-Potential-New-Generation-of-Treatments-in-Early-Alzheimer-s-Disease.html,2023-10-25 14:51:00,"CAMBRIDGE, Mass., Oct. 25, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide ( ASO ) therapy targeting tau, in mild Alzheimer's disease ( AD ) .",BIIB,0.27704,0.090909,Neutral
Stocks to own ahead of a rally that this $15 billion fund house says is coming soon,https://www.marketwatch.com/story/stocks-to-own-ahead-of-a-rally-that-this-15-billion-fund-house-says-is-coming-soon-adffe026,2023-10-25 12:07:00,"Sit Investment Associates, Roger Sit, says a short sharp recession is coming, along with a stock rally and lots of opportunities to own names across the board.",BIIB,0.071784,-0.052264,Neutral
Amgen  ( AMGN )  to Report Q3 Earnings: Will It Beat Estimates?,https://www.zacks.com/stock/news/2171289/amgen-amgn-to-report-q3-earnings-will-it-beat-estimates,2023-10-25 11:26:00,"Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.",BIIB,0.272181,0.036737,Neutral
"An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week - Stitch Fix  ( NASDAQ:SFIX ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/markets/penny-stocks/23/10/35399377/an-oversold-small-cap-industrial-that-insiders-are-buying-ahead-of-earnings-this-week,2023-10-24 16:41:30,"In a post last month, we wrote about the power of RSI ( Relative Strength Index ) as a technical indicator ( Relative Strength Index ) in relation to Stitch Fix, Inc. SFIX A technical indicator to keep in mind for earnings trades. https://t.co/g6zISKkVmc$BIG $SFIX",BIIB,0.196344,0.109088,Neutral
Pharma Stock News - InMed Pharmaceuticals Inc.'s  ( NASDAQ: INM )  INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies,https://www.investorideas.com/news/2023/biotech/10241NASDAQ-INM.asp,2023-10-24 14:50:24,Pharma Stock News - InMed Pharmaceuticals Inc.'s ( NASDAQ: INM ... ...,BIIB,0.031159,-0.10684,Neutral
Pfizer  ( PFE )  to Report Q3 Earnings: Here's What to Expect,https://www.zacks.com/stock/news/2170681/pfizer-pfe-to-report-q3-earnings-heres-what-to-expect,2023-10-24 11:39:00,"Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.",BIIB,0.234911,0.032619,Neutral
Here's Why Biogen Inc.  ( BIIB )  Fell More Than Broader Market,https://www.zacks.com/stock/news/2170464/heres-why-biogen-inc-biib-fell-more-than-broader-market,2023-10-23 21:50:19,"The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close.",BIIB,0.519002,0.272314,Somewhat-Bullish
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug,https://www.reuters.com/business/healthcare-pharmaceuticals/roche-settles-us-patent-lawsuit-against-biogen-over-blockbuster-arthritis-drug-2023-10-23/,2023-10-23 19:27:00,"The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing Rights",BIIB,0.507107,-0.025708,Neutral
What's in Store for Bristol-Myers  ( BMY )  in Q3 Earnings?,https://www.zacks.com/stock/news/2170140/whats-in-store-for-bristol-myers-bmy-in-q3-earnings,2023-10-23 12:47:00,Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.,BIIB,0.150592,0.046863,Neutral
Merck  ( MRK )  to Report Q3 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2170134/merck-mrk-to-report-q3-earnings-whats-in-the-cards,2023-10-23 11:25:00,"Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.",BIIB,0.256179,-0.02884,Neutral
StockNews.com Initiates Coverage on Sangamo Therapeutics  ( NASDAQ:SGMO ) ,https://www.defenseworld.net/2023/10/22/stocknews-com-initiates-coverage-on-sangamo-therapeutics-nasdaqsgmo.html,2023-10-22 05:43:24,StockNews.com Initiates Coverage on Sangamo Therapeutics ... Defense World ...,BIIB,0.051111,0.160402,Somewhat-Bullish
Novartis  ( NVS )  to Report Q3 Earnings: What's in the Offing?,https://www.zacks.com/stock/news/2169736/novartis-nvs-to-report-q3-earnings-whats-in-the-offing,2023-10-20 14:20:00,"Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.",BIIB,0.130689,0.0516,Neutral
"Anti-obesity drugs are an investable ""fountain of youth"" for baby boomers",https://www.investorideas.com/news/2023/biotech/10191RichardMills-Anti-Obesity-Drugs.asp,2023-10-19 18:23:25,"Anti-obesity drugs are an investable ""fountain of youth"" for baby ... ...",BIIB,0.026815,0.036404,Neutral
Sage's  ( SAGE )  Huntington's Disease Drug Gets FDA's Orphan Tag,https://www.zacks.com/stock/news/2169138/sages-sage-huntingtons-disease-drug-gets-fdas-orphan-tag,2023-10-19 16:16:00,The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.,BIIB,0.231884,0.102378,Neutral
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease  ( CTAD )  2023 Meeting - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/10/g35326238/biogen-to-present-new-data-at-the-clinical-trials-on-alzheimers-disease-ctad-2023-meeting,2023-10-19 11:30:00,Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer's disease Additional late-breaking presentations from the CLARITY AD study explore predictive biomarkers and novel subcutaneous administration of LEQEMBIÂ® ( lecanemab-irmb ),BIIB,0.349665,0.092957,Neutral
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease  ( CTAD )  2023 Meeting,https://www.globenewswire.com/news-release/2023/10/19/2763066/0/en/Biogen-to-Present-New-Data-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-2023-Meeting.html,2023-10-19 11:30:00,"CAMBRIDGE, Mass., Oct. 19, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) will present new data from its Alzheimer's disease portfolio at the upcoming Clinical Trials on Alzheimer's Disease ( CTAD ) meeting taking place October 24-27 in Boston, Mass.",BIIB,0.326499,0.111515,Neutral
$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/10/35318992/1000-invested-in-biogen-20-years-ago-would-be-worth-this-much-today,2023-10-18 21:00:33,"Biogen BIIB has outperformed the market over the past 20 years by 3.66% on an annualized basis producing an average annual return of 11.04%. Currently, Biogen has a market capitalization of $38.16 billion.",BIIB,0.983605,0.387251,Bullish
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates,https://www.zacks.com/stock/news/2168288/5-biotech-stocks-set-to-outpace-q3-earnings-estimates,2023-10-18 15:20:00,"Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.",BIIB,0.353418,0.115454,Neutral
3 Struggling Stocks Investors Shouldn't Buy on the Dip,https://www.fool.com/investing/2023/10/18/3-struggling-stocks-investors-shouldnt-buy-on-the/,2023-10-18 12:23:00,These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.,BIIB,0.350564,-0.025926,Neutral
Looking Into Biogen's Recent Short Interest - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/11/35626255/looking-into-biogens-recent-short-interest,2023-11-06 18:00:26,"Biogen's BIIB short percent of float has fallen 7.62% since its last report. The company recently reported that it has 2.64 million shares sold short, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.95 days to cover their ...",BIIB,0.224903,0.085754,Neutral
Countdown to Biogen Inc.  ( BIIB )  Q3 Earnings: A Look at Estimates Beyond Revenue and EPS,https://www.zacks.com/stock/news/2179432/countdown-to-biogen-inc-biib-q3-earnings-a-look-at-estimates-beyond-revenue-and-eps,2023-11-06 17:02:00,"Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",BIIB,0.319725,0.041567,Neutral
Eli Lilly chief scientific officer 'extremely optimistic' that major new Alzheimer's breakthrough is coming,https://www.marketwatch.com/story/eli-lilly-chief-scientific-officer-extremely-optimistic-that-major-new-alzheimers-breakthrough-is-coming-79003fcc,2023-11-06 16:05:00,"Dr. Daniel Skovronsky believes a big leap in Alzheimer's disease treatment may be just around the corner-and that an overlooked class of medicines could become the GLP-1 drugs of the future. If he's right, Eli Lilly & Co.'s LLY, remarkable winning streak won't fizzle any time soon.",BIIB,0.075754,0.013501,Neutral
Biogen  ( BIIB )  to Report Q3 Earnings: Will It Beat Estimates?,https://www.zacks.com/stock/news/2179003/biogen-biib-to-report-q3-earnings-will-it-beat-estimates,2023-11-06 13:26:00,"Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.",BIIB,0.348103,0.222584,Somewhat-Bullish
Biogen Appoints Monish Patolawala to its Board of Directors - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/11/g35617358/biogen-appoints-monish-patolawala-to-its-board-of-directors,2023-11-06 12:30:00,"CAMBRIDGE, Mass., Nov. 06, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company ( ""3M"" ) , to the Company's Board of Directors ( the ""Board"" ) , effective January 1, 2024.",BIIB,0.288138,0.240823,Somewhat-Bullish
Futures edge up on rate cut hopes; Fed speakers awaited,https://www.reuters.com/markets/us/futures-edge-up-rate-cut-hopes-fed-speakers-awaited-2023-11-06/,2023-11-06 11:03:00,Futures edge up on rate cut hopes. Fed speakers awaited ...,BIIB,0.085629,0.0,Neutral
Here's how America's economy could begin to weaken | Business,https://edition.cnn.com/2023/11/05/business/stocks-week-ahead-how-us-economy-weakens/index.html,2023-11-05 12:30:00,Here's how America's economy could begin to weaken CNN International ...,BIIB,0.030064,-0.051893,Neutral
Here's how America's economy could begin to weaken | Business,https://www.cnn.com/2023/11/05/business/stocks-week-ahead-how-us-economy-weakens/index.html,2023-11-05 12:30:00,Here's how America's economy could begin to weaken ...,BIIB,0.030064,-0.051893,Neutral
"Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... - PR Newswire",https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-to-account-for-39-of-market-growth--technavio-301976707.html,2023-11-03 22:35:00,"Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... PR ...",BIIB,0.074692,0.0,Neutral
"Mild Jobs Report Puts More Pressure On Falling Yields as Stocks On Pace For Best Week In A Year - Apple  ( NASDAQ:AAPL ) , Walt Disney  ( NYSE:DIS ) ",https://www.benzinga.com/markets/23/11/35597954/mild-jobs-report-puts-more-pressure-on-falling-yields-as-stocks-on-pace-for-best-week-in-a-year,2023-11-03 17:45:16,"( Friday market open ) A mild October U.S. jobs report Friday doesn't appear likely to dent recent market optimism about interest rates. The benchmark 10-year Treasury note yield fell another 10 basis points immediately after the data, potentially loosening pressure on stocks.",BIIB,0.042048,-0.185859,Somewhat-Bearish
"Ionis  ( IONS )  Q3 Loss Wider Than Expected, Sales Beat Estimates",https://www.zacks.com/stock/news/2178101/ionis-ions-q3-loss-wider-than-expected-sales-beat-estimates,2023-11-03 13:44:00,Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.,BIIB,0.300088,0.116073,Neutral
Editas Medicine Announces Third Quarter 2023 Results and Business Updates,https://www.globenewswire.com/news-release/2023/11/03/2773078/0/en/Editas-Medicine-Announces-Third-Quarter-2023-Results-and-Business-Updates.html,2023-11-03 11:00:00,Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology ( ASH ) Annual Meeting and in a ...,BIIB,0.053035,0.065926,Neutral
Take Five: You  ( may )  have arrived at your destination,https://www.reuters.com/business/take-five/global-markets-themes-graphic-2023-11-03/,2023-11-03 08:38:00,"LONDON, Nov 3 ( Reuters ) - Next week will have plenty to keep financial market traders and investors busy, including whether the Federal Reserve really has hit peak rates, another possible rate rise in Australia, a batch of European bank earnings and the continuing conflict in Gaza.",BIIB,0.046006,0.068571,Neutral
"Treasuries, Stocks Extend Gains Following Fed Meeting as Apple, Jobs Report Loom - ConocoPhillips  ( NYSE:COP ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/markets/23/11/35571776/treasuries-stocks-extend-gains-following-fed-meeting-as-apple-jobs-report-loom,2023-11-02 17:40:43,"( Thursday market open ) The World Series is over, but Wall Street remains in the thick of this week's triple play of a Fed meeting, Apple ( NASDAQ: AAPL ) earnings and Friday's October jobs report. So far, stocks are building up a lead as worries lessen about future Federal Reserve rate hikes.",BIIB,0.045353,-0.187044,Somewhat-Bearish
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/11/35546123/heres-how-much-you-would-have-made-owning-biogen-stock-in-the-last-15-years,2023-11-01 18:30:16,"Biogen BIIB has outperformed the market over the past 15 years by 1.68% on an annualized basis producing an average annual return of 12.42%. Currently, Biogen has a market capitalization of $34.40 billion.",BIIB,0.983605,0.387251,Bullish
"Fed in Sight: Rate Pause Widely Expected As Market Warily Watches Rising Yields, Dollar - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",https://www.benzinga.com/markets/23/11/35545121/fed-in-sight-rate-pause-widely-expected-as-market-warily-watches-rising-yields-dollar,2023-11-01 17:52:29,"( Wednesday market open ) November dawns after major indexes finished October with consecutive gains for the first time in two weeks. Stocks lost ground in premarket trading Wednesday, however, as investors awaited results from today's Federal Reserve meeting that's widely expected to bring a ...",BIIB,0.043698,-0.186486,Somewhat-Bearish
Biogen Inc.  ( BIIB )  Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release,https://www.zacks.com/stock/news/2176407/biogen-inc-biib-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release,2023-11-01 14:01:19,Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BIIB,0.259267,0.13811,Neutral
"Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer",https://www.globenewswire.com/news-release/2023/11/01/2771019/0/en/Sensei-Biotherapeutics-Appoints-Stephanie-Krebs-MS-MBA-as-Chief-Business-Officer.html,2023-11-01 11:30:00,"BOSTON, Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc. ( Nasdaq: SNSE ) , a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief ...",BIIB,0.043898,0.103483,Neutral
"Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer - Sensei Biotherapeutics  ( NASDAQ:SNSE ) ",https://www.benzinga.com/pressreleases/23/11/g35533717/sensei-biotherapeutics-appoints-stephanie-krebs-ms-mba-as-chief-business-officer,2023-11-01 11:30:00,"BOSTON, Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc. SNSE, a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business ...",BIIB,0.042647,0.102191,Neutral
Sangamo Therapeutics  ( NASDAQ:SGMO )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/11/01/sangamo-therapeutics-nasdaqsgmo-coverage-initiated-by-analysts-at-stocknews-com.html,2023-11-01 08:30:45,Sangamo Therapeutics ( NASDAQ:SGMO ) Coverage Initiated by ... Defense World ...,BIIB,0.049939,0.128204,Neutral
Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2175072/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now,2023-10-31 10:20:05,Smart Beta ETF report for ...,BIIB,0.117486,0.060435,Neutral
Biogen Inc.  ( BIIB )  Rises But Trails Market: What Investors Should Know,https://www.zacks.com/stock/news/2174831/biogen-inc-biib-rises-but-trails-market-what-investors-should-know,2023-10-30 21:45:20,"The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close.",BIIB,0.45825,0.110032,Neutral
Assessing Biogen's Performance Against Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/10/35494535/assessing-biogens-performance-against-competitors-in-biotechnology-industry,2023-10-30 16:00:46,"Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delve into an extensive industry comparison, evaluating Biogen BIIB in comparison to its major ...",BIIB,0.462743,0.185643,Somewhat-Bullish
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/11/35836598/heres-how-much-1000-invested-in-biogen-20-years-ago-would-be-worth-today,2023-11-16 20:00:16,"Biogen BIIB has outperformed the market over the past 20 years by 2.35% on an annualized basis producing an average annual return of 9.84%. Currently, Biogen has a market capitalization of $33.56 billion.",BIIB,0.983605,0.387251,Bullish
Is The Alzheimer's Drug Leqembi Eligible For Medicare Coverage?,https://www.forbes.com/health/medicare/leqembi-medicare/,2023-11-16 12:59:21,Medicare Coverage For Leqembi: What To Know - Forbes Health Forbes ...,BIIB,0.143415,0.206992,Somewhat-Bullish
Eli Lilly plans new 2 billion euro German plant,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-plans-new-2-bln-euro-german-plant-source-2023-11-16/,2023-11-16 11:25:00,Eli Lilly plans single-digit billion dollar new German plant ...,BIIB,0.078611,0.0,Neutral
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/11/35780726/industry-comparison-evaluating-biogen-against-competitors-in-biotechnology-industry,2023-11-14 16:00:19,"In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Biogen BIIB alongside its primary competitors in ...",BIIB,0.554751,0.141136,Neutral
Ionis  ( IONS )  Early-Stage Genetic Disorder Data Shows Promise,https://www.zacks.com/stock/news/2183312/ionis-ions-early-stage-genetic-disorder-data-shows-promise,2023-11-13 14:46:00,"Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.",BIIB,0.420083,0.216924,Somewhat-Bullish
Nereid Therapeutics Appoints Michael Kauffman as CEO,https://www.prnewswire.com/news-releases/nereid-therapeutics-appoints-michael-kauffman-as-ceo-301986045.html,2023-11-13 13:00:00,"Seasoned industry executive with decades of success in drug discovery, development, regulatory approvals and commercialization will lead Nereid's work to advance multiple programs towards the clinic",BIIB,0.063763,0.040012,Neutral
Fosun Pharma to deliver China-made surgical robots in key medical milestone,https://www.scmp.com/business/china-business/article/3241245/fosun-pharma-prepares-deliver-da-vinci-surgical-robots-make-advanced-medical-treatment-affordable,2023-11-12 08:14:06,The Fosun Group is looking to make another major leap in the healthcare industry as it prepares to deliver locally-made surgical robots to hospitals.,BIIB,0.056943,0.082934,Neutral
Biogen  ( NASDAQ:BIIB )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/11/12/biogen-nasdaqbiib-stock-rating-lowered-by-stocknews-com.html,2023-11-12 06:54:44,"Biogen ( NASDAQ:BIIB - Get Free Report ) was downgraded by StockNews.com from a ""buy"" rating to a ""hold"" rating in a note issued to investors on Friday. BIIB has been the subject of several other reports.",BIIB,0.873767,0.400757,Bullish
Sangamo Therapeutics  ( NASDAQ:SGMO )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/11/12/sangamo-therapeutics-nasdaqsgmo-coverage-initiated-at-stocknews-com.html,2023-11-12 06:34:46,Sangamo Therapeutics ( NASDAQ:SGMO ) Coverage Initiated at ... Defense World ...,BIIB,0.054114,0.127763,Neutral
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome,https://www.prnewswire.com/news-releases/ionis-shares-positive-clinical-update-from-ongoing-trial-of-ion582-for-angelman-syndrome-301985239.html,2023-11-11 16:30:00,"â¢ Part 1 of HALOS trial evaluating ION582 has completed enrollment with results expected in mid-2024 â¢ ION582 has been generally well tolerated at all dose levels, and participants are continuing to Part 2, the long-term extension portion of the study",BIIB,0.081691,0.096292,Neutral
Market Rally Pauses As Yields Rebound: Weekly Review,https://www.investors.com/news/stock-market-rally-pauses-as-yields-rebound-datadog-affirm-among-earnings-winners-weekly-review/,2023-11-10 12:00:00,"The stock market rally saw the Dow Jones, S&P 500 and Nasdaq snap long win streaks, slashing or erasing weekly gains. The Russell 2000 tumbled amid weak breadth. Earnings generally remained positive.",BIIB,0.070036,0.006148,Neutral
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?,https://www.fool.com/investing/2023/11/10/the-alzheimers-drug-market-is-heating-up-should-yo/,2023-11-10 11:50:00,"The real competitive battle is about to begin, and it will last a long time.",BIIB,0.235823,0.097212,Neutral
These Analysts Revise Their Forecasts On Biogen After Q3 Results - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/earnings/23/11/35708707/these-analysts-revise-their-forecasts-on-biogen-after-q3-results,2023-11-09 18:49:50,"Biogen Inc BIIB reported better-than-expected third-quarter earnings. Biogen posted quarterly sales of $2.53 billion, beating the consensus of $2.39 billion, up 1% Y/Y and 3% at constant currency ( CC ) . Adjusted EPS of $4.36, down 9%, beating the consensus of $3.97.",BIIB,0.976726,-0.159635,Somewhat-Bearish
"Stock Market News for Nov 9, 2023",https://www.zacks.com/stock/news/2181656/stock-market-news-for-nov-9-2023,2023-11-09 14:30:00,"U.S. stock closed mostly higher on Wednesday, with the S&P 500 and Nasdaq extending their longest winning streak in more than two years as investors weighed comments from Federal Reserve officials on future interest rates path.",BIIB,0.213048,0.167923,Somewhat-Bullish
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates,https://www.zacks.com/stock/news/2181433/4-biotech-stocks-likely-to-outpace-q3-earnings-estimates,2023-11-09 12:05:00,"Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.",BIIB,0.041394,0.096085,Neutral
TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS,https://www.newswire.ca/news-releases/treefrog-therapeutics-reinforces-executive-committee-with-three-new-members-801014367.html,2023-11-09 10:32:00,"Jaime Arango, Chief Financial Officer, Jens SchrÃ¶der as Chief Medical Officer and Rachel Mooney, Chief Communications Officer",BIIB,0.102888,0.077031,Neutral
Biogen  ( BIIB )  Q3 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/11/08/biogen-biib-q3-2023-earnings-call-transcript/,2023-11-08 19:15:20,"BIIB earnings call for the period ending September 30, 2023.",BIIB,0.047296,0.101222,Neutral
"Sage Therapeutics  ( SAGE )  Q3 Earnings Lag Estimates, Down 5%",https://www.zacks.com/stock/news/2181116/sage-therapeutics-sage-q3-earnings-lag-estimates-down-5,2023-11-08 18:11:00,"Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.",BIIB,0.252463,0.161541,Somewhat-Bullish
"Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/11/35673203/biogen-revises-annual-forecast-as-reata-m-a-and-alzheimers-drug-expenses-hit-bottomline-stock-sli,2023-11-08 17:43:20,"Biogen Inc BIIB posted Q3 FY23 sales of $2.53 billion, beating the consensus of $2.39 billion, up 1% Y/Y and 3% at constant currency ( CC ) . Adjusted EPS of $4.36, down 9%, beating the consensus of $3.97. Multiple sclerosis revenue of $1.16 billion decreased by 14% ( down 12% CC ) .",BIIB,0.755086,0.00399,Neutral
Earnings Data Deluge,https://www.zacks.com/stock/news/2180976/earnings-data-deluge,2023-11-08 16:00:00,"Pre-market indices are gamely climbing again this morning, after starting early-morning trading in the red. Currently, the Dow is +45 points, the S&P 500 +5, the market-leading Nasdaq +6 and even the small-cap Russell 2000 is in the green, +0.4 points.",BIIB,0.160099,0.21827,Somewhat-Bullish
"Pre-Markets Keep Streak Alive; RL, BIIB Beat",https://www.zacks.com/stock/news/2180968/pre-markets-keep-streak-alive-rl-biib-beat,2023-11-08 15:42:00,"The Dow rides its longest winning streak since July of this year, while the S&P and Nasdaq are enjoying their strongest moves since 2021.",BIIB,0.15697,0.215609,Somewhat-Bullish
"Biogen  ( BIIB )  Beats on Q3 Earnings & Sales, Cuts EPS View",https://www.zacks.com/stock/news/2180965/biogen-biib-beats-on-q3-earnings-sales-cuts-eps-view,2023-11-08 15:31:00,Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.,BIIB,0.308891,0.198618,Somewhat-Bullish
"Ranking the biggest winners, and losers, in the current economy",https://www.businessinsider.com/news-today-november-8-economy-rankings-boomers-gen-z-millennials-2023-11,2023-11-08 13:00:00,"The latest news, headlines, and business stories for November 8 - Business Insider ...",BIIB,0.030524,-0.047548,Neutral
Futures subdued ahead of Powell's remarks,https://www.reuters.com/markets/us/futures-take-breather-ahead-powell-remarks-2023-11-08/,2023-11-08 12:47:00,"A trader works on the floor at the New York Stock Exchange ( NYSE ) in New York City, U.S., October 27, 2023. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights",BIIB,0.077094,0.148013,Neutral
"S&P 500, Nasdaq Set For Muted Open Today: What's Moving Stock Futures? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/23/11/35669834/us-stocks-set-to-open-flat-after-hot-7-day-rally-traders-sharpen-focus-on-powells-speech-disney-ear,2023-11-08 12:12:10,"Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell's speech for insights into possible rate cuts. Media earnings, including Walt Disney Co. DIS, take center stage in the earnings ...",BIIB,0.080728,0.0,Neutral
Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment,https://www.marketwatch.com/story/biogen-quarterly-results-top-estimates-despite-complex-launch-of-new-alzheimers-treatment-3b16535c,2023-11-08 12:10:00,"Company focuses on new products in Alzheimer's, postpartum depression as multiple sclerosis product revenues decline ...",BIIB,0.669671,0.273489,Somewhat-Bullish
Biogen cuts annual profit forecast on persistent higher costs,https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-cuts-annual-profit-forecast-persistent-higher-costs-2023-11-08/,2023-11-08 12:03:00,"Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration Acquire Licensing Rights",BIIB,0.755086,0.063556,Neutral
Biogen Cuts Profit Outlook As Leqembi Expenses Mount,https://www.investors.com/news/technology/biogen-stock-biogen-earnings-q3-2023/,2023-11-08 12:00:00,"Biogen Stock: Drugmaker Tops Earnings Views, But Cuts Profit Guide Investor's Business Daily ...",BIIB,0.725935,0.295705,Somewhat-Bullish
Just turned 50? Here's where Howard Marks suggests investing for the next 10 years.,https://www.marketwatch.com/story/just-turned-50-heres-where-howard-marks-suggests-investing-for-the-next-10-years-d3e489ef,2023-11-08 11:49:00,"From Hong Kong, Oaktree's Howard Marks and some other top investors discuss where a 50-year old might want to put money for the next decade.",BIIB,0.07104,-0.104564,Neutral
Should You Invest in the Invesco Biotechnology & Genome ETF  ( PBE ) ?,https://www.zacks.com/stock/news/2180608/should-you-invest-in-the-invesco-biotechnology-genome-etf-pbe,2023-11-08 11:20:04,Sector ETF report for ...,BIIB,0.129168,0.070052,Neutral
"New postpartum depression drug gets almost $16,000 price tag, raising questions about access",https://www.cnn.com/2023/11/07/health/postpartum-depression-drug-price-tag/index.html,2023-11-07 23:50:35,"A newly approved medication to treat postpartum depression will cost $15,900 per 14-day course, before insurance, when it reaches the market later this year, raising concerns among doctors and researchers that some patients may have trouble paying for the drug.",BIIB,0.105449,0.04818,Neutral
Sentiment Check: Market Under Pressure as Positive Feelings Dip Following Hawkish Remarks from Fed Official,https://www.benzinga.com/markets/23/11/35661550/sentiment-check-market-under-pressure-as-positive-feelings-dip-following-hawkish-remarks-from-fed-of,2023-11-07 22:08:39,"( Tuesday market open ) ) Five Federal Reserve officials are speaking today, but words from another Fed policymaker yesterday helped lead to early losses on Wall Street. Stocks fell in premarket trading on ideas that the battle against inflation may not be won and rate hikes may not be over.",BIIB,0.042421,-0.161099,Somewhat-Bearish
BIIB: Biogen  ( BIIB )  Earnings Spotlight: Is the Biotech Stock a Buy or Sell?,https://stocknews.com/news/biib-gild-jazz-alks-biogen-biib-earnings-spotlight-is-the-biotech-stock-a-buy/,2023-11-07 17:02:10,BIIB: Biogen ( BIIB ) Earnings Spotlight: Is the Biotech Stock a Buy or ... ...,BIIB,0.526355,0.189417,Somewhat-Bullish
Eisai expects Alzheimer's drug to rake in revenue of $66.5 mln by March,https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-expects-alzheimers-drug-rake-revenue-665-mln-by-march-2023-11-07/,2023-11-07 14:11:00,"The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato/File Photo Acquire Licensing Rights",BIIB,0.451494,0.553956,Bullish
"Biogen-Sage Therapeutics postpartum depression pill priced at $15,900",https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-sage-therapeutics-postpartum-depression-pill-priced-15900-2023-11-07/,2023-11-07 13:51:00,Biogen-Sage Therapeutics postpartum depression pill priced at ...,BIIB,0.436009,-0.052356,Neutral
Why Biogen  ( BIIB )  Might Surprise This Earnings Season,https://www.zacks.com/stock/news/2179917/why-biogen-biib-might-surprise-this-earnings-season,2023-11-07 13:32:00,Biogen (BIIB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,BIIB,0.906257,0.608664,Bullish
"Wall Street extends winning streak; eyes Fed speakers, Treasury auctions",https://www.moneycontrol.com/news/business/markets/wall-street-extends-winning-streak-eyes-fed-speakers-treasury-auctions-11680071.html,2023-11-07 00:48:42,"Equities last week posted their biggest weekly percentage gain in about a year, as a weaker-than-expected U.S. payrolls report on Friday sent Treasury yields lower on the view the Fed was done hiking interest rates and could start cutting them next year.",BIIB,0.068306,0.0,Neutral
Sangamo Therapeutics  ( NASDAQ:SGMO )  Now Covered by Analysts at StockNews.com,https://www.defenseworld.net/2023/11/26/sangamo-therapeutics-nasdaqsgmo-now-covered-by-analysts-at-stocknews-com-2.html,2023-11-26 08:14:48,Sangamo Therapeutics ( NASDAQ:SGMO ) Now Covered by Analysts ... Defense World ...,BIIB,0.049939,0.105246,Neutral
"Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals",https://www.zacks.com/stock/news/2188966/zacks-industry-outlook-highlights-gilead-sciences-crispr-therapeutics-acadia-pharmaceuticals-dynavax-and-ligand-pharmaceuticals,2023-11-24 14:10:00,"Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.",BIIB,0.021388,0.138084,Neutral
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright,https://www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright,2023-11-22 13:07:00,"New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.",BIIB,0.022326,0.061954,Neutral
"Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/23/11/35901610/alzheimers-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-o,2023-11-21 20:16:25,Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins ( white matter ) from the brain have sparked a renewed interest in developing vaccines to combat this memory-robbing disease.,BIIB,0.229149,-0.07556,Neutral
Sangamo Therapeutics  ( NASDAQ:SGMO )  Now Covered by Analysts at StockNews.com,https://www.defenseworld.net/2023/11/18/sangamo-therapeutics-nasdaqsgmo-now-covered-by-analysts-at-stocknews-com.html,2023-11-18 08:16:44,Sangamo Therapeutics ( NASDAQ:SGMO ) Now Covered by Analysts ... Defense World ...,BIIB,0.058188,0.12399,Neutral
Prothena  ( PRTA )  Pipeline Shows Promise in a Tough AD Market,https://www.zacks.com/stock/news/2186212/prothena-prta-pipeline-shows-promise-in-a-tough-ad-market,2023-11-17 18:35:00,"Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.",BIIB,0.122269,-0.093569,Neutral
Exclusive: Manufacturer Lonza says it will not fill obesity drug syringes,https://www.reuters.com/business/healthcare-pharmaceuticals/manufacturer-lonza-says-it-will-not-fill-obesity-drug-syringes-2023-11-17/,2023-11-17 13:49:00,"The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing Rights",BIIB,0.056143,0.0659,Neutral
The War In Alzheimer's Treatment Is Just Beginning,https://www.investors.com/news/technology/biotech-stocks-the-war-in-alzheimers-treatment-is-just-beginning-why-there-is-still-hope/,2023-11-17 13:15:00,Biotech Stocks: The Race For An Alzheimer's Cure Takes Off Investor's Business Daily ...,BIIB,0.21806,0.140978,Neutral
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints,https://www.prnewswire.com/news-releases/neurosenses-phase-2b-als-trial-achieves-primary-safety-and-tolerability--secondary-clinical-efficacy-endpoints-302005837.html,2023-12-05 13:00:00,"CAMBRIDGE, Mass., Dec. 5, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( Nasdaq: NRSN ) ( ""NeuroSense"" ) , a company developing treatments for severe neurodegenerative diseases, today reported that it met its primary safety and tolerability endpoints and achieved secondary clinical efficacy ...",BIIB,0.101797,-0.046828,Neutral
"NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023",https://www.prnewswire.com/news-releases/neurosense-to-report-phase-2b-als-topline-primary-safety-and-tolerability--secondary-clinical-efficacy-endpoints-on-december-5-2023-302005044.html,2023-12-04 21:01:00,NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints ... PR ...,BIIB,0.043421,-0.037602,Neutral
Sangamo Therapeutics  ( NASDAQ:SGMO )  Earns Sell Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/12/04/sangamo-therapeutics-nasdaqsgmo-earns-sell-rating-from-analysts-at-stocknews-com.html,2023-12-04 06:24:44,Sangamo Therapeutics ( NASDAQ:SGMO ) Earns Sell Rating from ... Defense World ...,BIIB,0.05339,0.150707,Somewhat-Bullish
Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive ... - PR Newswire,https://www.prnewswire.com/news-releases/neuromuscular-disease-therapeutics-market-size-to-grow-by-usd-65-13-billion-from-2022-2027-aquestive-therapeutics-inc-bausch-health-companies-inc-biogen-inc-and-more-among-the-major-companies-in-the-market--technavio-302002042.html,2023-12-01 18:30:00,Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive ... PR ...,BIIB,0.059636,0.014995,Neutral
Annovis Bio  ( ANVS )  Stock Surges 38% in a Month: Here's Why,https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-heres-why,2023-12-01 16:12:00,Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.,BIIB,0.142565,0.146836,Neutral
"Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... - PR Newswire",https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-613-9-million-from-2022-to-2027--growing-research-in-gene-therapy-for-cvds-and-orphan-diseases-is-the-major-market-trend--technavio-302002646.html,2023-12-01 07:35:00,"Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... PR ...",BIIB,0.048523,0.017903,Neutral
"Codexis to Host Virtual KOL Event on its ECO Synthesisâ¢ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023 - Codexis  ( NASDAQ:CDXS ) ",https://www.benzinga.com/pressreleases/23/11/g35989473/codexis-to-host-virtual-kol-event-on-its-eco-synthesis-platform-and-the-future-of-rnai-therapeutic,2023-11-28 21:05:24,"REDWOOD CITY, Calif., Nov. 28, 2023 ( GLOBE NEWSWIRE ) -- Codexis, Inc.",BIIB,0.02849,0.073265,Neutral
"Codexis to Host Virtual KOL Event on its ECO Synthesisâ¢ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023",https://www.globenewswire.com/news-release/2023/11/28/2787362/24825/en/Codexis-to-Host-Virtual-KOL-Event-on-its-ECO-Synthesis-Platform-and-the-Future-of-RNAi-Therapeutics-Manufacturing-on-December-8-2023.html,2023-11-28 21:05:00,"REDWOOD CITY, Calif., Nov. 28, 2023 ( GLOBE NEWSWIRE ) -- Codexis, Inc. ( NASDAQ: CDXS ) , a leading enzyme engineering company, today announced it will host a virtual key opinion leader ( KOL ) event focused on its Enzyme-Catalyzed Oligonucleotide ( ECO ) Synthesisâ¢ platform and the broader RNA ...",BIIB,0.028972,0.073454,Neutral
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/11/35982754/comparative-study-biogen-and-industry-competitors-in-biotechnology-industry,2023-11-28 16:00:18,"In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices.",BIIB,0.516883,0.167844,Somewhat-Bullish
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update,https://www.prnewswire.com/il/news-releases/neurosense-announces-third-quarter-2023-financial-results-and-provides-business-update-301999234.html,2023-11-28 13:45:00,"â¢ Topline clinical secondary efficacy results and primary safety endpoints from Phase ALS trial ( PARADIGM ) expected in early â¢ Patients who completed the 18-month PARADIGM trial, including the 6-month double-blind study plus the 12-month open label extension, have requested to continue ...",BIIB,0.022202,0.151982,Somewhat-Bullish
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update,https://www.prnewswire.com/news-releases/neurosense-announces-third-quarter-2023-financial-results-and-provides-business-update-301999234.html,2023-11-28 13:45:00,"â¢ Topline clinical secondary efficacy results and primary safety endpoints from Phase ALS trial ( PARADIGM ) expected in early â¢ Patients who completed the 18-month PARADIGM trial, including the 6-month double-blind study plus the 12-month open label extension, have requested to continue ...",BIIB,0.022202,0.151982,Somewhat-Bullish
"Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer",https://www.globenewswire.com/news-release/2023/11/27/2786524/0/en/Terns-Pharmaceuticals-Mourns-the-Loss-of-Senthil-Sundaram-Former-Chief-Executive-Officer.html,2023-11-27 21:05:00,"FOSTER CITY, Calif., Nov. 27, 2023 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( ""Terns"" or the ""Company"" ) ( Nasdaq: TERN ) , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious oncologic and metabolic diseases, today ...",BIIB,0.146025,0.049104,Neutral
"Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer - Terns Pharma  ( NASDAQ:TERN ) ",https://www.benzinga.com/pressreleases/23/11/g35968012/terns-pharmaceuticals-mourns-the-loss-of-senthil-sundaram-former-chief-executive-officer,2023-11-27 21:05:00,"FOSTER CITY, Calif., Nov. 27, 2023 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( ""Terns"" or the ""Company"" ) TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious oncologic and metabolic diseases, today announced that ...",BIIB,0.139669,0.047874,Neutral
"Virtualware Appoints John A. Cunningham, COO of VRARA and Former Unity Executive, to International Advisory Board for U.S. Expansion Drive",https://www.globenewswire.com/news-release/2023/11/27/2785842/0/en/Virtualware-Appoints-John-A-Cunningham-COO-of-VRARA-and-Former-Unity-Executive-to-International-Advisory-Board-for-U-S-Expansion-Drive.html,2023-11-27 06:45:00,"BILBAO, Spain and MIAMI, November 27, 2023.- Virtualware, a European leader in Virtual Reality solutions, has appointed VR and AR industry leader John A. Cunningham to its International Advisory Board in a move that marks a significant step in Virtualware's U.S. market expansion.",BIIB,0.042122,0.103523,Neutral
BioNTX Celebrates Resilience and Innovation in North Texas Biosciences Ecosystem,https://www.prnewswire.com/news-releases/biontx-celebrates-resilience-and-innovation-in-north-texas-biosciences-ecosystem-302017055.html,2023-12-15 19:38:00,"DALLAS, Dec. 15, 2023 /PRNewswire/ -- BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success.",BIIB,0.205807,0.240955,Somewhat-Bullish
"CHMP Issues Positive Opinion for Biogen's SKYCLARYSÂ®  ( omaveloxolone ) , the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/pressreleases/23/12/g36257323/chmp-issues-positive-opinion-for-biogens-skyclarys-omaveloxolone-the-first-therapy-to-treat-friedr,2023-12-15 14:05:25,"Friedreich's ataxia is a genetic, debilitating and life-shortening neuromuscular disease1 Milestone highlights Biogen's growing portfolio in rare diseases and focus on addressing unmet needs of patients living with neuromuscular diseases CAMBRIDGE, Mass., Dec. 15, 2023 ( GLOBE NEWSWIRE ) -- ...",BIIB,0.259382,0.080298,Neutral
"CHMP Issues Positive Opinion for Biogen's SKYCLARYSÂ®  ( omaveloxolone ) , the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease",https://www.globenewswire.com/news-release/2023/12/15/2797103/0/en/CHMP-Issues-Positive-Opinion-for-Biogen-s-SKYCLARYS-omaveloxolone-the-First-Therapy-to-Treat-Friedreich-s-Ataxia-a-Rare-Neurodegenerative-Disease.html,2023-12-15 14:05:00,"CAMBRIDGE, Mass., Dec. 15, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) recommended marketing authorization for SKYCLARYSÂ® ( omaveloxolone ) for the treatment of Friedreich's ...",BIIB,0.22792,0.091747,Neutral
"5 Things to know for Dec. 15: Israel, Vaccines, European Union, Storms, Train collision",https://www.cnn.com/2023/12/15/us/5-things-to-know-for-dec-15-israel-vaccines-european-union-storms-train-collision/index.html,2023-12-15 11:40:00,Some of America's legacy airlines are hiring aggressively and adjusting flight schedules to accommodate staffing shortages as they prepare to to fly around 2.8 million passengers a day during the end-of-year holiday rush. Here's what else you need to know to Get Up to Speed and On with Your Day.,BIIB,0.040899,0.028801,Neutral
"First postpartum depression pill now available in the US, drugmakers say",https://www.cnn.com/2023/12/14/health/postpartum-depression-pill-zurzuvae/index.html,2023-12-15 04:04:00,"The first oral pill approved in the United States to treat postpartum depression is now available by prescription, according to the drugmakers. The US Food and Drug Administration approved the therapy, called Zurzuvae, in August.",BIIB,0.104228,0.130792,Neutral
"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire",https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html,2023-12-14 22:15:00,"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... PR ...",BIIB,0.078099,0.0,Neutral
"ZURZUVAEâ¢  ( zuranolone )  CIV, a Landmark Oral Treatment for Women with Postpartum Depression  ( PPD ) , is Now Available in the U.S. - Sage Therapeutics  ( NASDAQ:SAGE ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/pressreleases/23/12/g36232867/zurzuvae-zuranolone-civ-a-landmark-oral-treatment-for-women-with-postpartum-depression-ppd-is-now-,2023-12-14 11:30:00,"ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD ...",BIIB,0.14333,0.052345,Neutral
"ZURZUVAEâ¢  ( zuranolone )  CIV, a Landmark Oral Treatment for Women with Postpartum Depression  ( PPD ) , is Now Available in the U.S.",https://www.globenewswire.com/news-release/2023/12/14/2796102/0/en/ZURZUVAE-zuranolone-CIV-a-Landmark-Oral-Treatment-for-Women-with-Postpartum-Depression-PPD-is-Now-Available-in-the-U-S.html,2023-12-14 11:30:00,"ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD ...",BIIB,0.130926,0.061208,Neutral
"U.S. Neurologists Eagerly Await Promising Oral Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement",https://www.benzinga.com/pressreleases/23/12/g36222947/u-s-neurologists-eagerly-await-promising-oral-brutons-tyrosine-kinase-inhibitors-in-multiple-scler,2023-12-13 19:03:51,"Exton, PA, Dec. 13, 2023 ( GLOBE NEWSWIRE ) -- Several clinical trials are underway for Bruton's tyrosine kinase inhibitors ( BTKi ) targeting relapsing and progressive multiple sclerosis ( RMS/PPMS ) .",BIIB,0.052455,-0.013,Neutral
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/12/36218811/industry-comparison-evaluating-biogen-against-competitors-in-biotechnology-industry,2023-12-13 16:00:49,"In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating Biogen BIIB in relation to its major competitors in the ...",BIIB,0.572601,0.193461,Somewhat-Bullish
Eisai to launch Alzheimer's drug Leqembi in Japan on Dec 20,https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-launch-alzheimers-drug-leqembi-japan-dec-20-2023-12-13/,2023-12-13 08:53:00,Eisai to launch Alzheimer's drug Leqembi in Japan on Dec ...,BIIB,0.192694,0.136769,Neutral
"The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity",https://www.zacks.com/stock/news/2196695/the-zacks-analyst-blog-highlights-biogen-prothena-ac-immunes-and-vaxxinity,2023-12-12 14:10:00,"Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.",BIIB,0.170878,0.131235,Neutral
"Vanqua Bio Advances Clinical Candidate for Parkinson's Disease, Expands Leadership Team to Support Further Development",https://www.benzinga.com/pressreleases/23/12/g36194201/vanqua-bio-advances-clinical-candidate-for-parkinsons-disease-expands-leadership-team-to-support-f,2023-12-12 12:30:00,"CHICAGO, Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase ( GCase ) , will enter clinical development in the first quarter of 2024, with an initial ...",BIIB,0.047092,0.094795,Neutral
Sangamo Therapeutics  ( NASDAQ:SGMO )  Research Coverage Started at StockNews.com,https://www.defenseworld.net/2023/12/12/sangamo-therapeutics-nasdaqsgmo-research-coverage-started-at-stocknews-com.html,2023-12-12 06:20:45,"Equities research analysts at StockNews.com began coverage on shares of Sangamo Therapeutics ( NASDAQ:SGMO - Get Free Report ) in a note issued to investors on Tuesday. The brokerage set a ""sell"" rating on the biopharmaceutical company's stock.",BIIB,0.055621,0.105872,Neutral
"$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,200 Today - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/23/12/36185858/1000-invested-in-this-stock-20-years-ago-would-be-worth-7-200-today,2023-12-11 21:30:52,"Biogen BIIB has outperformed the market over the past 20 years by 2.89% on an annualized basis producing an average annual return of 10.34%. Currently, Biogen has a market capitalization of $35.73 billion.",BIIB,0.983605,0.387251,Bullish
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus,https://www.zacks.com/stock/news/2196083/alzheimers-disease-space-evolves-in-2023-stocks-in-focus,2023-12-11 14:06:00,"The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.",BIIB,0.136888,0.191134,Somewhat-Bullish
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs - BioXcel Therapeutics  ( NASDAQ:BTAI ) ,https://www.benzinga.com/pressreleases/23/12/g36173480/bioxcel-therapeutics-strengthens-clinical-development-leadership-to-advance-late-stage-programs,2023-12-11 12:00:00,"Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of Directors NEW HAVEN, Conn., Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- BioXcel Therapeutics, Inc.",BIIB,0.025761,0.072552,Neutral
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond,https://www.fool.com/investing/2023/12/09/2-popular-stocks-to-avoid-like-the-plague-in-2024/,2023-12-09 18:52:00,These stocks aren't worth the risk.,BIIB,0.193465,0.008012,Neutral
Why Is Biogen Inc.  ( BIIB )  Up 6.4% Since Last Earnings Report?,https://www.zacks.com/stock/news/2195589/why-is-biogen-inc-biib-up-64-since-last-earnings-report,2023-12-08 16:30:42,Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BIIB,0.355164,0.134467,Neutral
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?,https://www.fool.com/investing/2023/12/08/abbvies-on-an-acquisition-binge-could-your-favorit/,2023-12-08 10:38:00,Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.,BIIB,0.051551,0.18687,Somewhat-Bullish
"Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights",https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html,2023-12-08 07:14:00,"BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.",BIIB,0.028833,0.001897,Neutral
"If You Invested $100 In This Stock 20 Years Ago, You Would Have $800 Today - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/23/12/36389293/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-800-today,2023-12-26 19:00:27,"Biogen BIIB has outperformed the market over the past 20 years by 3.19% on an annualized basis producing an average annual return of 10.72%. Currently, Biogen has a market capitalization of $37.79 billion.",BIIB,0.983605,0.387251,Bullish
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day,https://www.zacks.com/stock/news/2202108/fluor-corporation-and-align-technology-have-been-highlighted-as-zacks-bull-and-bear-of-the-day,2023-12-26 13:45:00,Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.,BIIB,0.071075,0.042296,Neutral
"Recap 2023: From postpartum depression to Alzheimer's disease, here are some crucial USFDA approvals this year",https://www.financialexpress.com/healthcare/pharma-healthcare/recap-2023-from-postpartum-depression-to-alzheimers-disease-here-are-some-crucial-usfda-approvals-this-year/3347615/,2023-12-26 08:11:11,"The United States Food and Drug Administration ( FDA ) approves a wide range of innovative drugs and products that play a crucial role in improved patient outcomes. Based on the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new ...",BIIB,0.080188,0.168534,Somewhat-Bullish
Where To Invest Your 401 ( K ) ,https://www.kiplinger.com/retirement/401ks/where-to-invest-your-401k,2023-12-25 17:00:13,"These days, 401 ( k ) plans make it relatively easy to save for retirement, but the task of figuring out which funds to invest in is still tricky. A good target-date fund is an easy box to check - and most plans offer one. Low-cost index funds are another no-brainer.",BIIB,0.042196,0.160021,Somewhat-Bullish
Could Ginkgo Bioworks Stock Help You Become a Millionaire?,https://www.fool.com/investing/2023/12/24/could-ginkgo-bioworks-stock-help-you-become-a-mill/,2023-12-24 13:10:00,"It's easy to see a way for this to be a huge business in the future, but the path ahead of it is by no means a smooth one.",BIIB,0.064797,0.086356,Neutral
Bristol Myers  ( BMY )  to Buy Karuna Therapeutics for $14B,https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b,2023-12-22 16:13:00,"Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.",BIIB,0.066047,0.0,Neutral
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024,https://www.zacks.com/stock/news/2201572/3-beaten-down-biotech-stocks-to-buy-for-a-turnaround-in-2024,2023-12-22 14:46:00,"Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.",BIIB,0.132855,0.050293,Neutral
"Ionis  ( IONS ) , AstraZeneca's Eplontersen Receives FDA Nod",https://www.zacks.com/stock/news/2201529/ionis-ions-astrazenecas-eplontersen-receives-fda-nod,2023-12-22 14:34:00,FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.,BIIB,0.387674,0.139475,Neutral
Postpartum Depression Market Size Is Expected To Reach A Value Of $36.9 Billion By 2028 At A CAGR Of 32% As Per The Business Research Company's Postpartum Depression Global Market Report 2024,https://www.benzinga.com/pressreleases/23/12/g36347132/postpartum-depression-market-size-is-expected-to-reach-a-value-of-36-9-billion-by-2028-at-a-cagr-o,2023-12-21 16:30:00,"LONDON, Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Postpartum Depression Global Market Report 2024, the postpartum depression market has witnessed exponential growth, surging from $9.17 billion in 2023 to a projected $12.15 billion in 2024, showcasing a remarkable ...",BIIB,0.052685,-0.066055,Neutral
Looking Into Biogen's Recent Short Interest - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/short-sellers/23/12/36344473/looking-into-biogens-recent-short-interest,2023-12-21 14:45:21,"Biogen's BIIB short percent of float has risen 7.8% since its last report. The company recently reported that it has 2.83 million shares sold short, which is 2.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.12 days to cover their ...",BIIB,0.224903,0.158881,Somewhat-Bullish
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.,https://www.fool.com/investing/2023/12/21/looking-to-invest-in-next-big-craze-like-ozempic/,2023-12-21 14:30:00,Diabetes and weight-loss drugs won't be the hottest category of medicines forever.,BIIB,0.049322,0.052428,Neutral
"Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma",https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html,2023-12-20 12:00:01,"Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.",BIIB,0.08091,0.05643,Neutral
Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors - PR Newswire,https://www.prnewswire.com/news-releases/deka-biosciences-adds-industry-veterans-to-its-executive-leadership-team-and-board-of-directors-302019378.html,2023-12-19 19:09:00,Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors PR ...,BIIB,0.044386,-0.022424,Neutral
Ionis  ( IONS )  Out Licenses Europe Rights for HAE Drug to Otsuka,https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka,2023-12-19 15:45:00,"Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.",BIIB,0.423843,0.161527,Somewhat-Bullish
Centralized Marketing Authorizations of Generic Versions of TECFIDERAÂ® are Revoked by the European Commission - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/pressreleases/23/12/g36300699/centralized-marketing-authorizations-of-generic-versions-of-tecfidera-are-revoked-by-the-european-,2023-12-19 12:30:21,"CAMBRIDGE, Mass., Dec. 19, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen's product TECFIDERAÂ® ( dimethyl fumarate ) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.",BIIB,0.536645,0.160579,Somewhat-Bullish
Biogen's  ( BIIB )  Rare Disease Drug Skyclarys Gets CHMP Nod in EU,https://www.zacks.com/stock/news/2199443/biogens-biib-rare-disease-drug-skyclarys-gets-chmp-nod-in-eu,2023-12-18 14:57:00,Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.,BIIB,0.315975,-0.027516,Neutral
3 Biotech Stocks Most Wall Street Analysts Are Bullish About,https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about,2023-12-18 14:01:00,"Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.",BIIB,0.037563,0.058359,Neutral
IBD Stock Of The Day: The Buying Opportunity In Weight Loss,https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-lingers-in-a-buy-zone-after-snagging-two-obesity-deals/,2024-01-05 18:01:00,Novo Nordisk Stock Lingers In Buy Zone After Snagging Two Obesity Deals Investor's Business Daily ...,BIIB,0.060388,0.337437,Somewhat-Bullish
This Top 10% Stock Is Playing A Game Of Whiplash,https://www.investors.com/news/technology/kymr-stock-whiplash-shares-surge-then-topple-after-275-million-offering/,2024-01-05 15:16:00,"KYMR Stock Whiplash: Shares Surge, Then Topple After $275 Million Offering Investor's Business Daily ...",BIIB,0.081276,0.345837,Somewhat-Bullish
It's Been An Abysmal Two Years. But Biotech Is Looking Up.,https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/,2024-01-05 14:00:00,"Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...",BIIB,0.059429,0.106048,Neutral
Stran & Company Appoints Ian Thomas Wall as Chief Information Officer,https://www.globenewswire.com/news-release/2024/01/04/2804023/0/en/Stran-Company-Appoints-Ian-Thomas-Wall-as-Chief-Information-Officer.html,2024-01-04 14:00:00,"Quincy, MA, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Stran & Company, Inc. ( ""Stran"" or the ""Company"" ) ( NASDAQ: SWAG. SWAGW ) , a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, announces that it has appointed Ian Thomas Wall ...",BIIB,0.04794,0.073616,Neutral
Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.,https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets,2024-01-04 12:30:00,"Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarketsâ¢.",BIIB,0.079392,0.0,Neutral
Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform - PR Newswire,https://www.prnewswire.com/news-releases/ginkgo-bioworks-completes-program-with-biogen-to-boost-productivity-of-gene-therapy-manufacturing-platform-302025717.html,2024-01-04 12:00:00,Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform PR ...,BIIB,0.096283,0.159307,Somewhat-Bullish
POTENTIAL BREAKTHROUGH FOR ALZHEIMER'S TREATMENT: FOCUSED ULTRASOUND COMBINED WITH MONOCLONAL ANTIBODIES MAY SLOW DISEASE PROGRESSION,https://www.newswire.ca/news-releases/potential-breakthrough-for-alzheimer-s-treatment-focused-ultrasound-combined-with-monoclonal-antibodies-may-slow-disease-progression-839028810.html,2024-01-04 12:00:00,POTENTIAL BREAKTHROUGH FOR ALZHEIMER'S TREATMENT: FOCUSED ULTRASOUND COMBINED WITH ... Canada ...,BIIB,0.046452,0.0,Neutral
Biogen  ( NASDAQ:BIIB )  Upgraded to Buy by StockNews.com,https://www.defenseworld.net/2024/01/04/biogen-nasdaqbiib-upgraded-to-buy-by-stocknews-com.html,2024-01-04 07:52:42,StockNews.com upgraded shares of Biogen ( NASDAQ:BIIB - Free Report ) from a hold rating to a buy rating in a report released on Wednesday morning. BIIB has been the topic of several other research reports.,BIIB,0.805954,0.453307,Bullish
Biogen Inc.  ( BIIB )  Sees a More Significant Dip Than Broader Market: Some Facts to Know,https://www.zacks.com/stock/news/2205288/biogen-inc-biib-sees-a-more-significant-dip-than-broader-market-some-facts-to-know,2024-01-03 22:50:20,"In the latest trading session, Biogen Inc. (BIIB) closed at $263.43, marking a -1.6% move from the previous day.",BIIB,0.573651,0.283813,Somewhat-Bullish
Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2204768/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now,2024-01-03 11:20:07,Smart Beta ETF report for ...,BIIB,0.116631,0.066983,Neutral
"Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/12/36394374/upward-trajectory-for-biotechpharma-m-a-sector-trends-towards-pre-pandemic-levels-forecasts-posit,2023-12-29 12:04:52,"According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&A deals in Q3 2023. PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: ...",BIIB,0.16171,0.332796,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Stock Declines While Market Improves: Some Information for Investors,https://www.zacks.com/stock/news/2203359/biogen-inc-biib-stock-declines-while-market-improves-some-information-for-investors,2023-12-28 22:50:20,"The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close.",BIIB,0.531019,0.241213,Somewhat-Bullish
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement,https://www.prnewswire.com/news-releases/neurosense-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requirement-302022851.html,2023-12-27 22:00:00,"CAMBRIDGE, Mass., Dec. 27, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( Nasdaq: NRSN ) ( ""NeuroSense"" or the ""Company"" ) , a company developing treatments for severe neurodegenerative diseases, today announced that it has received a notification from the Listing Qualifications Department ...",BIIB,0.067919,-0.024226,Neutral
Understanding Biogen's Position In Biotechnology Industry Compared To Competitors - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/23/12/36399366/understanding-biogens-position-in-biotechnology-industry-compared-to-competitors,2023-12-27 16:00:39,"In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Biogen BIIB and its primary competitors in the Biotechnology industry.",BIIB,0.571381,0.12016,Neutral
"BIIB, ZTS, EXAS: Which ""Strong Buy"" Healthcare Stock is Best?",https://markets.businessinsider.com/news/stocks/biib-zts-exas-which-strong-buy-healthcare-stock-is-best-1032965194,2024-01-13 22:24:08,"In 2023, the only thing nearly as hot as generative AI technologies like ChatGPT were GLP-1 injections ( weight-loss drugs like Ozempic ) . GLP-1 may not be the most significant healthcare breakthrough of all time, but it certainly represents one of its most profitable in a while.",BIIB,0.31583,0.198498,Somewhat-Bullish
"Gene Therapy Global Market is Projected to Grow at a CAGR of ~19% by 2028, Predicts DelveInsight",https://www.prnewswire.com/news-releases/gene-therapy-global-market-is-projected-to-grow-at-a-cagr-of-19-by-2028-predicts-delveinsight-302033381.html,2024-01-12 22:01:00,"LAS VEGAS, Jan. 12, 2024 /PRNewswire/ -- DelveInsight's Gene Therapy Market Insights report provides the current and forecast market analysis, individual leading gene therapy companies' market shares, challenges, gene therapy market drivers, barriers, trends, and key market gene therapy ...",BIIB,0.030369,0.0,Neutral
"How Interest Rates Matter In Possible DocuSign, Software Buyouts",https://www.investors.com/news/technology/how-interest-rates-matter-in-possible-docusign-software-buyouts/,2024-01-12 19:52:00,"DocuSign's ( DOCU ) possible sale to a private equity firm could be a precursor to more deals but perhaps not at big premiums, said an Evercore ISI analyst. DOCU stock rose for a second day in a row amid reports it could be acquired.",BIIB,0.103331,0.364434,Bullish
Here's Why Regeneron Just Hit A Record High - Again,https://www.investors.com/news/technology/regn-stock-hits-a-record-high-again-as-it-tacks-on-new-wins/,2024-01-12 18:22:00,REGN Stock Hits A Record High - Again - As It Tacks On New Wins Investor's Business Daily ...,BIIB,0.06211,0.337735,Somewhat-Bullish
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/24/01/36615264/evolving-landscape-for-alzheimers-blood-tests-gains-momentum-amid-inaccuracy-concerns,2024-01-12 18:17:14,"A new era in Alzheimer's diagnosis is on the horizon as Dr. Suzanne Schindler and her team at Washington University School of Medicine pioneered blood tests capable of detecting sticky amyloid plaques, a key Alzheimer's indicator.",BIIB,0.155954,0.252164,Somewhat-Bullish
"Shift4 Wins Price Target Hikes From Truist, Goldman Sachs",https://www.investors.com/research/ibd-stock-of-the-day/four-stock-shift4-wins-price-target-hikes-from-truist-goldman-sachs/,2024-01-12 17:25:00,"Shift4 Payments ( FOUR ) is the IBD Stock Of The Day as the financial technology company wins price target hikes for FOUR stock. On the stock market today, FOUR stock rose around 1% to 75.69. Shift4 stock has gained about 2% in 2024. FOUR stock has climbed 25% over the past 52 weeks.",BIIB,0.062761,0.337867,Somewhat-Bullish
GigaCloud Stock Takes A Breather After A Big Run Of More Than 200%,https://www.investors.com/news/technology/gct-stock/,2024-01-11 20:42:00,GCT Stock: How GigaCloud Expanded Into Large Parcel E-Commerce Investor's Business Daily ...,BIIB,0.058188,0.337168,Somewhat-Bullish
"$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,100 Today - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/24/01/36601102/1000-invested-in-this-stock-20-years-ago-would-be-worth-6-100-today,2024-01-11 20:31:15,"Biogen BIIB has outperformed the market over the past 20 years by 2.08% on an annualized basis producing an average annual return of 9.48%. Currently, Biogen has a market capitalization of $36.66 billion.",BIIB,0.983605,0.387251,Bullish
C4  ( CCCC )  Up 6% on Restructuring Plan to Curb Cash Burn,https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn,2024-01-11 16:44:00,The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.,BIIB,0.054236,0.052814,Neutral
Salesforce Upgraded On Software Price Increase Boost,https://www.investors.com/news/technology/crm-stock-salesforce-stock-upgraded-on-price-increase-boost/,2024-01-11 15:41:00,CRM Stock: Salesforce Upgraded On Price Increase Boost Investor's Business Daily ...,BIIB,0.142565,0.413891,Bullish
"Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments - Ginkgo Bioworks Holdings  ( NYSE:DNA ) ",https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36580897/analyst-assesses-cell-programming-focused-ginkgo-bioworks-positioning-amid-revenue-,2024-01-10 19:29:43,"Wednesday, Ginkgo Bioworks Holdings Inc DNA released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million. Preliminary cell engineering and biosecurity revenue are expected to be within the disclosed guidance range of $145 million-$150 million and up ...",BIIB,0.241684,0.0,Neutral
Prothena's  ( PRTA )  Update on Pipeline Progress Disappoints,https://www.zacks.com/stock/news/2208432/prothenas-prta-update-on-pipeline-progress-disappoints,2024-01-10 17:06:00,"Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.",BIIB,0.113329,-0.02735,Neutral
Comparing Biogen With Industry Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ,https://www.benzinga.com/news/24/01/36578930/comparing-biogen-with-industry-competitors-in-biotechnology-industry,2024-01-10 16:00:38,"In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Biogen BIIB and its primary competitors in the Biotechnology industry.",BIIB,0.529659,0.082668,Neutral
What Buying Juniper Networks Means For HPE Stock,https://www.investors.com/news/technology/what-buying-juniper-networks-means-for-hpe-stock/,2024-01-10 15:56:00,"Hewlett Packard Enterprise's ( HPE ) $14 billion all-cash acquisition of Juniper Networks ( JNPR ) will shake-up the computer networking market, giving Cisco Systems ( CSCO ) and others a more formidable rival, analysts say.",BIIB,0.058903,0.337242,Somewhat-Bullish
Biotech Continues Its 225% Winning Streak With A Sales Beat,https://www.investors.com/news/technology/tgtx-stock-continues-its-surge-after-ms-drug-crushes-sales-estimates/,2024-01-10 14:33:00,TGTX Stock Continues Its 225% Surge After MS Drug Crushes Sales Estimates Investor's Business Daily ...,BIIB,0.137671,0.406953,Bullish
Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference,https://www.prnewswire.com/news-releases/ginkgo-bioworks-provides-business-updates-at-jp-morgan-healthcare-conference-302031259.html,2024-01-10 12:35:00,"Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business",BIIB,0.027476,0.096738,Neutral
"Drug Discovery Informatics Market Set to Surge at 10.9% CAGR, to Reach USD 6.8 billion by 2031 | Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/01/g36571592/drug-discovery-informatics-market-set-to-surge-at-10-9-cagr-to-reach-usd-6-8-billion-by-2031-trans,2024-01-10 09:06:42,"Wilmington, Delaware, United States, Jan. 10, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global drug discovery informatics market is estimated to flourish at a CAGR of 10.9% from 2023 to 2031.",BIIB,0.064449,0.289891,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Registers a Bigger Fall Than the Market: Important Facts to Note,https://www.zacks.com/stock/news/2207796/biogen-inc-biib-registers-a-bigger-fall-than-the-market-important-facts-to-note,2024-01-09 22:50:20,"In the latest trading session, Biogen Inc. (BIIB) closed at $255.84, marking a -0.83% move from the previous day.",BIIB,0.5633,0.281167,Somewhat-Bullish
China approves Alzheimer's drug Leqembi developed by Eisai and Biogen,https://www.scmp.com/news/china/science/article/3247845/china-joins-us-and-japan-approving-alzheimers-drug-leqembi-developed-eisai-and-biogen,2024-01-09 22:00:16,"China has approved the sale of Leqembi, an antibody that has shown to slow progression of the disease for people in the early stages of Alzheimer's. The drug will be launched in the third quarter.",BIIB,0.09186,0.055046,Neutral
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines - C4 Therapeutics  ( NASDAQ:CCCC ) ,https://www.benzinga.com/pressreleases/24/01/g36565423/c4-therapeutics-announces-2024-priorities-and-extended-cash-runway-to-advance-portfolio-of-targete,2024-01-09 21:01:00,"Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research Efforts Results in Workforce Reduction of Approximately 30%",BIIB,0.025514,0.050263,Neutral
Palo Alto Networks Pushes AI-Driven Cybersecurity Automation,https://www.investors.com/research/ibd-stock-of-the-day/panw-stock-palo-alto-networks-pushes-ai-driven-cybersecurity-automation/,2024-01-09 20:14:00,"Palo Alto Networks ( PANW ) is the IBD Stock of the Day as the cybersecurity leader's shares bounce off the 10-week moving average and forge a new entry point. PANW stock jumped 111% in 2023, a move that has some analysts questioning its valuation. On the stock market today, shares rose 3.6% to ...",BIIB,0.04583,0.335683,Somewhat-Bullish
Top-Notch Biotech Soars - Again - On Rumored Novartis Buyout,https://www.investors.com/news/technology/cytk-stock-rockets-as-novartis-reportedly-nears-a-buyout-deal/,2024-01-08 19:12:00,CYTK Stock Rockets As Novartis Reportedly Nears A Buyout Deal Investor's Business Daily ...,BIIB,0.186738,0.480646,Bullish
How To Buy Hot And Promising - But Uncertain - Biotech Stocks,https://www.investors.com/research/how-to-find-the-best-stocks-to-buy/xbi-etf-how-to-buy-hot-and-promising-but-uncertain-biotech-stocks/,2024-01-08 17:34:00,"A mix of choppy or nonexistent earnings alongside the promise of game-changing breakthroughs make biotech stocks a challenge for investors. The SPDR S&P Biotech ETF ( XBI ) , now on the IBD Leaderboard watchlist, offers an alternative to betting on a single biotech name.",BIIB,0.246999,0.430266,Bullish
Regeneron Slumps As Its Biggest Moneymaker Falls Short,https://www.investors.com/news/technology/regn-stock-slumps-as-us-eylea-sales-disappoint-exel-stock-slammed-on-guidance/,2024-01-08 14:51:00,"REGN Stock Slumps As U.S. Eylea Sales Disappoint, EXEL Stock Slammed On Guidance Investor's Business Daily ...",BIIB,0.172097,0.458082,Bullish
Two Biotechs Roughly Double After Snagging Splashy Takeover Deals,https://www.investors.com/news/technology/amam-stock-harp-stock-catapult-after-snagging-jnj-merck-buyouts/,2024-01-08 14:19:00,"AMAM Stock, HARP Stock Catapult After Snagging J&J, Merck Buyouts Investor's Business Daily ...",BIIB,0.114682,0.37702,Bullish
Is Beleaguered Big Pharma Merck Finally Staging A Comeback?,https://www.investors.com/news/technology/merck-stock-is-it-finally-time-for-this-2023-laggard-to-stage-a-comeback/,2024-01-08 14:00:05,Merck Stock: Is It Finally Time For This 2023 Laggard To Stage A Comeback? Investor's Business Daily ...,BIIB,0.058903,0.337242,Somewhat-Bullish
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases - Denali Therapeutics  ( NASDAQ:DNLI ) ,https://www.benzinga.com/pressreleases/24/01/g36531655/denali-therapeutics-announces-key-anticipated-2024-milestones-and-priorities-to-further-advance-it,2024-01-08 13:00:00,"Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readiness Advance broad clinical-stage portfolio of seven therapeutic product candidates across neurodegeneration ( ALS, Parkinson's disease, MS, FTD-GRN ) , lysosomal storage disease ( MPS II, MPS ...",BIIB,0.076455,0.0479,Neutral
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases,https://www.prnewswire.com/news-releases/ionis-poised-for-continued-momentum-in-2024-with-product-launches-and-key-advances-in-robust-pipeline-of-investigational-medicines-for-serious-diseases-302028429.html,2024-01-08 12:03:00,Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of ... PR ...,BIIB,0.038468,0.0,Neutral
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 - Caribou Biosciences  ( NASDAQ:CRBU ) ,https://www.benzinga.com/pressreleases/24/01/g36525999/caribou-biosciences-appoints-tim-kelly-as-chief-technology-officer-and-highlights-multiple-clinica,2024-01-07 16:00:00,-- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrolling ...,BIIB,0.015054,0.093924,Neutral
"AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday - Covenant Logistics Gr  ( NASDAQ:CVLG ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/news/24/01/36777733/at-t-to-rally-around-44-here-are-10-top-analyst-forecasts-for-thursday,2024-01-25 12:42:44,"Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised ResMed Inc. RMD price target from $180 to $215. Needham analyst Mike Matson maintained a Buy ...",BIIB,0.245339,-0.122041,Neutral
"Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36766392/slow-market-penetration-for-biogens-another-alzheimers-drug-ubs-highlights-risks-fo,2024-01-24 19:55:14,"UBS has downgraded Biogen Inc BIIB, noting inflection for its second Alzheimer's drug Leqembi ( lecanemab ) will take longer than anticipated.",BIIB,0.586747,0.128726,Neutral
Stock Of The Day Lilly Is In A Buy Zone. And It's Not Related To Obesity.,https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-rallies-into-buy-zone-on-surprising-results-in-treating-deafness/,2024-01-24 17:12:00,Eli Lilly Stock Rallies Into Buy Zone On Surprising Results In Treating Deafness Investor's Business Daily ...,BIIB,0.101367,-0.043919,Neutral
"Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More",https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more,2024-01-24 15:42:00,Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.,BIIB,0.045139,0.087207,Neutral
"Virtualware Reports  ( MLVIR.PA )  Record â¬4.52 Million Revenue in 2023, a 40% Surge from Previous Year",https://www.globenewswire.com/news-release/2024/01/24/2814776/0/en/Virtualware-Reports-MLVIR-PA-Record-4-52-Million-Revenue-in-2023-a-40-Surge-from-Previous-Year.html,2024-01-24 07:10:00,"Bilbao, January 24 - European Virtual Reality company Virtualware ( MLVIR.PA ) ( EPA:MLVIR ) , reported record total revenues of â¬4.52 million in 2023, 40% more than in the previous year, just nine months after its IPO on Euronext Access Paris.",BIIB,0.039033,0.074235,Neutral
Biogen Inc.  ( BIIB )  Rises Higher Than Market: Key Facts,https://www.zacks.com/stock/news/2214591/biogen-inc-biib-rises-higher-than-market-key-facts,2024-01-23 22:50:20,"Biogen Inc. (BIIB) closed the most recent trading day at $251.68, moving +1.36% from the previous trading session.",BIIB,0.666827,0.288249,Somewhat-Bullish
"Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer",https://markets.businessinsider.com/news/stocks/alkeus-pharmaceuticals-appoints-seemi-khan-m-d-chief-medical-officer-1032987734,2024-01-23 13:30:00,"CAMBRIDGE, Mass., Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.",BIIB,0.081276,0.045765,Neutral
"Biogen  ( NASDAQ:BIIB )  Lifted to ""Buy"" at StockNews.com",https://www.defenseworld.net/2024/01/23/biogen-nasdaqbiib-lifted-to-buy-at-stocknews-com.html,2024-01-23 06:38:43,"Biogen ( NASDAQ:BIIB - Get Free Report ) was upgraded by stock analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a note issued to investors on Tuesday.",BIIB,0.832413,0.47097,Bullish
Highlights From the 2024 JPMorgan Health Care Conference,https://www.fool.com/investing/2024/01/22/highlights-from-the-2024-jpmorgan-health-care-conf/,2024-01-22 18:39:00,"Weight loss drugs are taking center spotlight, but other developing treatments could change how we live.",BIIB,0.009887,0.057158,Neutral
Is It Too Late to Buy Eli Lilly Stock?,https://www.fool.com/investing/2024/01/21/is-it-too-late-to-buy-crispr-therapeutics-stock/,2024-01-21 15:30:00,Eli Lilly is now the most valuable healthcare stock in the world.,BIIB,0.055109,0.080989,Neutral
"These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street",https://www.fool.com/investing/2024/01/18/these-could-be-the-biggest-nasdaq-100-winners-in-2/,2024-01-18 10:50:00,Nice gains could be on the way for three stocks if analysts are right.,BIIB,0.475618,0.338854,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Stock Moves -0.37%: What You Should Know,https://www.zacks.com/stock/news/2211737/biogen-inc-biib-stock-moves--037-what-you-should-know,2024-01-17 22:50:19,"Biogen Inc. (BIIB) closed the most recent trading day at $245.27, moving -0.37% from the previous trading session.",BIIB,0.684485,0.195683,Somewhat-Bullish
DoubleVerify Digital Ad Tools Scale Up At Meta Platforms,https://www.investors.com/research/ibd-stock-of-the-day/dv-stock-doubleverify-meta-platform-digital-ad-partnership-goes-live/,2024-01-17 17:23:00,"DoubleVerify ( DV ) is the IBD Stock of the Day as the specialist in digital advertising verification forges an entry point from a cup-with-handle base. Bank of America and BMO Capital Markets recently initiated coverage of DV stock with buy and outperform ratings, respectively.",BIIB,0.050465,0.336707,Somewhat-Bullish
"Alzheimer's Disease Diagnostics & Treatment Market Revenues to Reach US$11.9 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Persistence Market Research",https://www.benzinga.com/pressreleases/24/01/g36655498/alzheimers-disease-diagnostics-treatment-market-revenues-to-reach-us-11-9-billion-by-2030-market-s,2024-01-17 10:00:00,"New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global market for Alzheimer's disease diagnostics and treatment is projected to experience a compound annual growth rate ( CAGR ) of 8.9%, reaching a value of US$11.9 billion by the end of 2030, up from US$6.5 billion ...",BIIB,0.111877,0.14894,Neutral
Gitlab Profitability On Fast Track Amid Market Share Gains,https://www.investors.com/research/ibd-stock-of-the-day/gtlb-stock-gitlab-profitability-on-fast-track-amid-market-share-gains/,2024-01-16 20:19:00,"Gitlab ( GTLB ) is the IBD Stock Of The Day as the company emerges as a strong player in a fast-growing software market and GTLB stock inflects to consistent quarterly profits. Founded in 2014, GitLab helps customers develop software and deploy new applications in a secure process.",BIIB,0.049732,0.336595,Somewhat-Bullish
Biogen Inc.  ( BIIB )  Stock Drops Despite Market Gains: Important Facts to Note,https://www.zacks.com/stock/news/2220558/biogen-inc-biib-stock-drops-despite-market-gains-important-facts-to-note,2024-02-02 22:45:21,"In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $243.72, denoting a -1.66% change from the preceding trading day.",BIIB,0.620664,0.300605,Somewhat-Bullish
Biogen  ( BIIB )  to Stop Selling Alzheimer's Disease Drug Aduhelm,https://www.zacks.com/stock/news/2219643/biogen-biib-to-stop-selling-alzheimers-disease-drug-aduhelm,2024-02-01 15:27:00,"Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.",BIIB,0.507331,0.178458,Somewhat-Bullish
InnovationRx: Show Me The Healthcare Savings,https://www.forbes.com/sites/katiejennings/2024/02/01/innovationrx-welltheory-healthcare-savings/,2024-02-01 15:00:12,"InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. here were a whopping two healthtech startups that hit billion-dollar valuations in 2023, compared to 52 unicorns minted during the two years prior, according to a PitchBook analysis.",BIIB,0.041323,0.233516,Somewhat-Bullish
"Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal",https://www.zacks.com/stock/news/2219523/biotech-stock-roundup-gsks-q4-results-vrtx-gains-on-update-tsvt-up-on-regn-deal,2024-02-01 14:45:00,Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.,BIIB,0.305871,-0.045602,Neutral
Biogen discontinues Alzheimer's drug Aduhelm - .com,https://www.upi.com/Health_News/2024/01/31/Biogen-discontinues-Aduhelm/1831706726311/,2024-01-31 19:15:27,Biogen discontinues Alzheimer's drug Aduhelm UPI News ...,BIIB,0.38588,-0.094722,Neutral
"Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/24/01/36871446/biogen-gives-up-on-aduhelm-efforts-after-two-years-of-controversial-fda-accelerated-approval-for-,2024-01-31 17:10:21,Biogen Inc BIIB is pulling the plug on its Aduhelm Alzheimer's disease drug more than two years after the drug came into the limelight after receiving controversial FDA approval.,BIIB,0.754041,0.077887,Neutral
"Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments",https://www.cnbc.com/2024/01/31/biogen-drops-alzheimers-drug-aduhelm-to-focus-on-leqembi-others.html,2024-01-31 16:43:26,"Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was ""not related to any safety or efficacy concerns."" ...",BIIB,0.580018,-0.003493,Neutral
Biogen will stop selling its controversial Alzheimer's drug Aduhelm,https://apnews.com/article/biogen-alzheimer-aduhelm-dfb364a61e4e77da27fc055e826b9a49,2024-01-31 15:00:00,Biogen will shut down controversial Alzheimer's drug Aduhelm The Associated Press ...,BIIB,0.653386,0.229378,Somewhat-Bullish
Biogen drops controversial Alzheimer's drug,https://www.marketwatch.com/story/biogen-halts-development-of-controversial-alzheimers-drug-3e03858a,2024-01-31 13:59:00,"Biogen is halting the development and commercialization of the Alzheimer's drug Aduhelm, which drew intense scrutiny of its U.S. regulatory process due to concerns about whether its benefits outweighed its risks.",BIIB,0.712214,0.193001,Somewhat-Bullish
Biogen to Realign Resources for Alzheimer's Disease Franchise,https://www.globenewswire.com/news-release/2024/01/31/2821003/0/en/Biogen-to-Realign-Resources-for-Alzheimer-s-Disease-Franchise.html,2024-01-31 12:30:00,"CAMBRIDGE, Mass., Jan. 31, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced plans to reprioritize its resources in Alzheimer's disease ( AD ) , a strategic therapeutic area expected to drive near and long-term growth.",BIIB,0.533327,0.235505,Somewhat-Bullish
Council Post: How Pharma Can Borrow A Page From Digital Health Investors' Playbook,https://www.forbes.com/sites/forbestechcouncil/2024/01/31/how-pharma-can-borrow-a-page-from-digital-health-investors-playbook/,2024-01-31 11:00:00,How Pharma Can Borrow A Page From Digital Health Investors' Playbook Forbes ...,BIIB,0.057907,-0.098973,Neutral
"Sandoz launches first and only biosimilar for multiple sclerosis, TyrukoÂ®  ( natalizumab ) , in Germany",https://www.globenewswire.com/news-release/2024/01/31/2820708/0/en/Sandoz-launches-first-and-only-biosimilar-for-multiple-sclerosis-Tyruko-natalizumab-in-Germany.html,2024-01-31 06:00:00,Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...,BIIB,0.055621,0.0,Neutral
"Sandoz launches first and only biosimilar for multiple sclerosis, TyrukoÂ®  ( natalizumab ) , in Germany - SANDOZ GROUP AG S/ADR by Sandoz Group AG  ( OTC:SDZNY ) ",https://www.benzinga.com/pressreleases/24/01/g36860143/sandoz-launches-first-and-only-biosimilar-for-multiple-sclerosis-tyruko-natalizumab-in-germany,2024-01-31 06:00:00,Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules TyrukoÂ® approved for all indications of reference medicine TyrukoÂ® biosimilar to treat adults with highly active relapsing remitting multiple sclerosis ( RRMS ) Launch strengthens well-established Sandoz biosimilar ...,BIIB,0.049835,0.0,Neutral
Biogen Inc.  ( BIIB )  Laps the Stock Market: Here's Why,https://www.zacks.com/stock/news/2217474/biogen-inc-biib-laps-the-stock-market-heres-why,2024-01-29 22:50:18,"Biogen Inc. (BIIB) closed at $247.52 in the latest trading session, marking a +1.1% move from the prior day.",BIIB,0.556576,0.322246,Somewhat-Bullish
Breakthroughs in Alzheimer's Research Give Cause for Optimism,https://www.kiplinger.com/retirement/breakthroughs-in-alzheimers-research,2024-01-29 20:59:57,"When Kathleen Mangi asked her husband how he thought her sister was doing, James Mangi grew concerned.",BIIB,0.017194,0.113487,Neutral
Will Biogen Inc.  ( BIIB )  Beat Estimates Again in Its Next Earnings Report?,https://www.zacks.com/stock/news/2217370/will-biogen-inc-biib-beat-estimates-again-in-its-next-earnings-report,2024-01-29 17:10:10,Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,BIIB,0.414559,0.506915,Bullish
"NeuroSense's  ( NASDAQ: NRSN )  ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 - NeuroSense Therapeutics  ( NASDAQ:NRSN ) , Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/general/biotech/24/01/36823541/neurosenses-nasdaq-nrsn-als-drug-candidate-shows-promise-in-recent-phase-2b-trial-more-milestones,2024-01-29 13:30:16,Amyotrophic lateral sclerosis ( ALS ) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and ultimately death within two to five years from diagnosis.,BIIB,0.168785,-0.008358,Neutral
"Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... - PR Newswire",https://www.prnewswire.com/news-releases/dementia-and-movement-disorder-treatment-market-to-grow-by-usd-8-55-billion-market-share-trends-and-growth-analysis----technavio-302045378.html,2024-01-29 10:15:00,"Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... PR ...",BIIB,0.053509,0.125702,Neutral
Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarketsâ¢.,https://www.prnewswire.com/news-releases/regenerative-medicine-market-worth-49-0-billion--marketsandmarkets-302044495.html,2024-01-26 15:30:00,"CHICAGO, Jan. 26, 2024 /PRNewswire/ -- Regenerative Medicine Market in terms of revenue was estimated to be worth $16.0 billion in 2023 and is poised to reach $49.0 billion by 2028, growing at a CAGR of 25.1% from 2023 to 2028 according to a new report by MarketsandMarketsâ¢.",BIIB,0.073773,0.107998,Neutral
Denali's  ( DNLI )  Pipeline Progresses Despite Stiff Competition,https://www.zacks.com/stock/news/2216518/denalis-dnli-pipeline-progresses-despite-stiff-competition,2024-01-26 15:00:00,"Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.",BIIB,0.443626,0.060839,Neutral
